T1. Using a stratified approach in psychiatry – implications for treatment and the search for underlying mechanisms of mental illness

Martine Van Nierop, Ruud van Winkel, Inez Myin-Germeys, Jim Van Os, Margreet ten Have

Background: Previous work has shown that across different patient samples, patients exposed to childhood trauma are more likely to have co-occurrence of affective, anxious, and psychosis symptoms than non-traumatized patients. However, the clinical relevance of trauma-related admixture remains to be established. Furthermore, a possible underlying mechanism linking childhood trauma to psychopathology is not well understood.

Methods: We examined patients with mood disorder (n = 1260), anxiety disorder (n = 896) or psychotic disorder (n = 532) in terms of symptom profiles, quality of life (QOL) and social functioning. In a separate general population sample (n = 563), daily life stress sensitivity was investigated, using the Experience Sampling Method (ESM).

Results: Mood disorder patients exposed to childhood trauma and with an admixture of affective, anxious and psychosis symptoms (Trauma+/ADM+) had a lower QOL (B -12.6, 95% CI -17.7 to -7.5, P < 0.001), more help-seeking behaviour (Odds Ratio (OR) 2.5, 95% CI 1.1 to 5.7, P = 0.031), and higher prevalence of substance use disorders (OR 7.8, 95% CI 1.1 to 58.0, P = 0.044), compared with patients without a trauma history and symptom admixture (Trauma-/ADM-). Similar results were found in patients with an anxiety disorder. Traumatized patients with a psychotic disorder and admixture of symptoms showed lower QOL (B -0.6, 95% CI -0.9 to -0.4, P < 0.001), higher prevalence of drug disorders (OR 2.2, 95% CI 1.2 to 3.9, P = 0.008), and lower global assessment of functioning (B -12.8, 95% CI -17.1 to -8.5, P < 0.001) than Trauma-/ADM- patients. Individuals from the general population who had experienced trauma and have co-occurring (subclinical) symptoms showed an increased emotional reactivity to daily life hassles (B 0.09, 95% CI 0.02 to 0.15, P = 0.008), compared with Trauma-/ADM- individuals.

Discussion: Using a stratification approach, based on trauma exposure and symptom profiles, uncovers a clinically meaningful subgroup of patients who are more treatment-resistant. Additional trauma-treatment may be beneficial, even in patients who are not suffering from clear posttraumatic stress symptoms. Increased daily life stress sensitivity may be the underlying mechanism trough which some, but not all, individuals who are exposed to trauma develop psychopathology. In future studies attempting to find underlying biological or psychological mechanisms in mental illness, utilizing a stratification approach based on environmental exposure and symptom phenotype, rather than on diagnostic category, may be necessary.

T2. Relationship between clozapine induced EEG abnormalities and the serum concentration of clozapine in Japanese patients with schizophrenia

Yuka Kikuchi, Wataru Sato, Yukiko Akamine, Takashi Kanbayashi, Tetsuo Shimizu

Background: Clozapine-induced electroencephalography (EEG) abnormalities are common. It has been reported that clozapine-induced EEG abnormalities occur in a dose-dependent manner and correlate with the serum concentration of clozapine (C-CLZ). However, the opposing results were also reported. The objective of this study is to investigate the relationship between serum level of clozapine and EEG abnormalities.

Methods: Twenty-eight patients were recruited in this study, but five patients were excluded because clozapine was discontinued before post-treatment EEG measurement or measurement of C-CLZ. Ultimately, 23 patients (6 males, 17 females) with an average age of 35 years were enrolled. The subjects were divided into EEG normal and abnormal group. C-CLZ and the serum concentration of metabolite of clozapine (N-CLZ) were measured. The correlation between C-CLZ and daily dose of CLZ (D-CLZ), N-CLZ and D-CLZ were evaluated in each group. C-CLZ per D-CLZ (C/D), N-CLZ per D-CLZ (N/D) and the ratio of C-CLZ to N-CLZ (C/N) were compared between the two groups.

Results: 74 serum levels were measured. All patients had normal baseline EEGs, and 10 patients later showed EEG abnormalities. There was a significant correlation between C-CLZ and D-CLZ (EEG normal: rs 0.58, P < 0.01, EEG abnormal: rs 0.56, P < 0.01) and between N-CLZ and D-CLZ (EEG normal: rs 0.53, P < 0.01, EEG abnormal: rs 0.57, P < 0.01). There were no significant differences between the EEG normal and EEG abnormal groups in C/D, N/D, C/N.

Discussion: It has been reported that clozapine-induced EEG abnormalities occur in a dose-dependent manner and correlate with the serum level of clozapine. (Welch et al. 1994, Freudenreich et al. 1997, Haring et al. 1994). However, Centorrino et al. (2002) did not find a relationship between dose and EEG abnormalities. Goyal et al. (2011) reported EEG abnormalities in 61.9% of patients received clozapine at a dose of 100 mg or less. Haring et al described EEG abnormalities in 52% of patients and reported that these were dependent on plasma levels; they also determined that dose was not statistically related to EEG abnormalities.

In this study, there was a moderate correlation between C-CLZ and D-CLZ and between N-CLZ and D-CLZ. On the other hand, there were no significant difference between EEG abnormal and EEG normal group in C/D, N/D and C/N. These results indicates that EEG abnormalities may occur independently of dose of clozapine or the serum level of clozapine.

T3. Extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study

Qi-Jing Bo, Xian-Bin Li, An-Ning Li, Zhi-Min Wang, Xin Ma, Chuan-Yue Wang

Background: The risperidone maintenance treatment in schizophrenia (RMTS) study was designed to identify the duration of maintenance treatment required with the initial therapeutic dose, in constant to a reduced dose. The current study investigated extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study.
symptoms (EPS) in different risperidone maintenance treatment paradigms over one year. 

Methods: Clinically stabilized patients with schizophrenia (N = 374) were randomized to a no-dose-reduction group and 4-week and 26-week reduction groups, in which the dose was gradually reduced to 50% over 8 weeks and maintained. EPS were assessed at baseline and every two months, followed by every two months. The Simpson-Angus Scale of Extrapyramidal Symptoms (SAS)-Chinese version assessed EPS severity. Data were analyzed via a generalized Linear Mixed Model (GLMM).

Results: The frequency of EPS at baseline was 23.2%, 20.0%, and 21.3% in the 4-week, 26-week, and no-dose-reduction groups, respectively. Risperidone dose, positive symptoms, and disorganized thoughts at baseline predicted development and maintenance of EPS. The GLMM indicated the significant decrease in EPS was maintained, and different trajectories occurred over time across groups. In the 235 patients who continued treatment after 1-year, the incidence of EPS decreased to 4.1%, 2.8%, and 10.0% in the 4-week, 26-week, and no-dose-reduction groups, respectively, whereas the numbers of dropouts because of intolerable EPS were not significantly different (4.8%, 6.7%, and 6.2%, respectively).

Discussion: These novel findings indicate that EPS were tolerable and differentially decreased depending on the dose paradigm during the one-year treatment period. Future studies should implement a GLMM to investigate antipsychotic side effects during long-term treatment.

T4. Threshold of dopamine D2/3 receptor occupancy for hyperprolactinemia in older patients with schizophrenia

Yusuke Iwata1, Shinichiro Nakajima2, Fernando Caravaggio2, Takefumi Suzuki2, Hiroyuki Uchida2, Eric Piltman1, Jun Ku Chung1, Wanna Mai1, Philip Gerretsen1, Bruce Pollock2, Benoit Mulsant2, David Mamo2, Ariel Graff-Guerrero1

1Centre for Addiction and Mental Health, 2Centre for Addiction and Mental Health, University of Toronto; 3Keio University School of Medicine; Inokashira Hospital; 4Keio University School of Medicine; Centre for Addiction and Mental Health

Background: Although hyperprolactinemia carries a long-term risk of morbidity, the threshold of dopamine D2/3 receptor (D2/3R) occupancy for hyperprolactinemia has not been investigated in older patients with schizophrenia. This study included 42 clinically stable outpatients with schizophrenia (DSM-IV) (mean ± SD age: 60.2 ± 6.7 years) taking olanzapine or risperidone. Subjects underwent [11C]-raclopride positron emission tomography (PET) scans to measure D2/3R occupancy before and after reducing their dose of antipsychotic by up to 40%. Blood samples were collected before each PET scan to measure prolactin (PRL) levels.

Methods: The present study was conducted in conjunction with a 12- to 24-week prospective PET study to examine the effects of antipsychotic dose reduction in older, stable patients with schizophrenia. Stepwise multiple regression analyses were performed to examine the effects of the following variables on PRL levels: age, gender, antipsychotics (olanzapine or risperidone), and D2/3R occupancy. To evaluate the D2/3R occupancy threshold for hyperprolactinemia in the population, Fischer’s exact tests were employed with increments of 1% between 60% and 70% D2/3R occupancy.

Results: PRL decreased following dose reduction (mean ± SD, 24.1 ± 30.2 to 17.2 ± 15.1, P < 0.001). 16 subjects showed hyperprolactinemia at baseline and 11 subjects still had hyperprolactinemia after dose reduction. PRL levels were associated with female gender (β = 0.32, P = 0.006, vs. male), antipsychotics (β = 0.23, P = 0.02), risperidone vs. olanzapine, and D2/3R occupancy (β = 0.23, P = 0.04). Those with D2/3R occupancy higher than 66% were more likely to have hyperprolactinemia than those with D2/3R occupancy lower than 66% (P = 0.03). Sensitivity, specificity, positive predictive value, and negative predictive value of this threshold were 0.44, 0.81, 0.78, and 0.48, respectively. We identified a D2/3R occupancy threshold for hyperprolactinemia of 66% in older patients with schizophrenia that is lower than that in younger patients (~73%).

Discussion: Our results suggest a higher sensitivity to antipsychotics in older patients. Thus, clinicians are advised to regularly monitor PRL levels and try to minimize exposure to antipsychotics while maintaining their clinical effectiveness in stable older patients with schizophrenia.

T5. Childhood neglect differentially affects psychotic patients in comparison to healthy siblings and controls

Nadja Marie1, Marina Mihaljevic2, Sanja Andric2, Tijana Mirjanic3

1University of Belgrade & Clinic for Psychiatry CCS; 2Clinic for Psychiatry CCS; 3Special Hospital for Psychiatric Disorders Kovin

Background: Life-threatening traumatic events (CT) encountered early in life may be mediated by affective dysregulation (distress proneness, i.e. negative emotionality) and reduced (pathological) defensive capacity (i.e. positive and negative symptoms). The confirmation that association between CT and psychosis has been apparent across subjects with different levels of psychosis risk was recently published and replicated, showing a true association rather than reporting bias, reverse causality, or passive gene-environment correlation. Literature is inconsistent if any sub-type of trauma in particular was associated with psychosis. We aimed to descriptively evaluate self-reports of childhood trauma, abuse and neglect in Serbian sample and to examine the correlation of abuse and neglect with neuroticism and psychotic symptoms in the cases vs. sibling and controls.

Methods: The study included Serbian clinical patient population-Pt (n = 52, age = 29.3 ± 6.0, male 59.6%, illness duration 62.8 ± 56.7 months), their healthy siblings-HS (n = 55, age = 28.6 ± 6.8, male 41.8%) and controls-C (n = 51, age = 29.8 ± 6.3, male 45.1%) and assessed cross-sectionally Childhood Trauma Questionnaire (CTQ, scores: total, abuse and neglect), neuroticism scale from Eysenck Personality Questionnaire-103 (EPQ-N) and Community Assessment of Psychic Experiences (CAPE, scores P and N). The data collection in Serbia was performed in collaboration with EU-GEI research network.

Results: The patients reported more EPQ-N, P and N (P = 0.000 in all comparisons with the other subgroups). Pt had more trauma than C (means: total CT 1.28 and 1.12, P = .001; abuse 1.12 and 1.00, P = .029; neglect 1.40 and 1.20, P = .005), while HS reported more neglect in comparison to C (means: 1.20 and 1.12, P = .020) and less abuse in comparison to patients (1.07 and 1.13, P = .05). Pt and HS had the same levels of neglect (mean 1.40, both). Positive significant correlation between childhood trauma, distress proneness and psychosis proneness was confirmed in all sub-samples. However, positive significant correlation between neglect and two aforementioned domains was evident only in non-patient population. In Pt, the neglect in childhood was associated neither with present levels of neuroticism, nor with positive/negative symptoms (r = .108; r = .221 and r = .215, respectively).

Discussion: Evidence that childhood exposure to both sub-types of trauma is the highest in the patients with schizophrenia is consistent with the similar studies from other countries, while the finding that patients’ reaction to neglect is different in comparison to general population is unexpected finding. Possibility that there are specific underlying mechanisms which alter sensitivity towards neglect in subjects at highest risk for psychosis deserves further attention, firstly the consideration of disorganized symptom dimension and related domains.

T6. Immigration and community mental health services: an example of an effective outreach drug treatment program

Fran Calvo-García1, Cristina Giralt-Vázquez2

1Institut d’Assistència Sanitària

Background: The prevalence of mental health problems on homeless population, especially drug abuse disorders, is higher than the general population. In the other hand, some surveys have shown that the access to drug treatment of immigration-population with drug-abuse problems in Spain is lower than natives. This characteristic: to be homeless-immigrant in Spain, are risk factors of drug-abuse and conversely that requires outreach programs and street-work interdisciplinary teams. The objective of this survey is to describe the effect on immigration homeless population of a qualitative outreach intervention addressed to motivate the introduction of drug treatment in public-ambulatory drug-services.
Methods: This is a survey was made in the city of Girona (Catalonia, Spain), with about 100,000 people in a region of a 39 km2. There’s only one homeless public shelter in the city, and only one mental health and addictions institution. These characteristics made the city special for to investigate the homeless. The design of the survey was observational, transversal and analytic. Measurement of location and dispersion were need for to compare means (depending on normality) there were used. There were analysed two samples. First of all, we used the data since 2010 until 2014 (included) about all the homeless population of Girona (n = 737) in these years to contextualize the phenomenon. We compare this population with some sociodemographic characteristics to contextualize differences among origin. In a second step, we had analysed severity of dependence using the Severity Dependence Scale (SDS) on a representative experimental sample of 154 homeless during the year 2014 (cut-off point indicating presence of dependence for alcohol and cocaine (\( \geq 4 \)), cannabis (\( \geq 4 \)), and heroin (\( \geq 5 \)). We compare the results of SDS to the treatment doing for the subjects (immigrants or not) to compare the access to the public services. Also, we compared this population with some sociodemographic characteristics to contextualize differences and we described the effect of the street-work outreach intervention.

Results: About the homeless population of Girona (n = 737): The gender distribution was 613 males (83.2%) and 123 females (16.7%). The median of age was 44 years old (Z of K.S. = 8.45, \( P < .001 \)), without significant differences among genders (men = 45, women = 42, U Mann-Whitney = .072). Immigration establishment was in 51.3% of the sample (n = 326), 20.5% from Maghreb, (n = 75). Immigrant featured more mental health diagnoses (\( X^2 = 25.1, df = 1, P < .001 \)), especially psychotic disorders (\( X^2 = 4.8, df = 1, P = .049 \)) and more drug dependence diagnoses (\( X^2 = 18.5, df = 1, P = .033 \)) than native population. In consequence, immigrant population was registered more on the public mental health services than native population (\( X^2 = 46.3, df = 1, P < .001 \)). About the severity of dependence analysis (n = 154), the results of the SDS showed 51.2% of the sample (n = 79) obtained points higher than the cut-off punctuation. In addition, consulting the clinic expedient, it found 26.4% (36.4%) was registered. Therefore 23 subjects (14.8%) had dependence criteria and didn’t have contact with drug abuse services. Immigrants of the intervention group presented more treatment introductions than native population (\( X^2 = 11.4, df = 1, P = .001 \)).

Discussion: The relationship among results of SDS and diagnose suggest a significant number of subjects with dependence was in treatment process and indicate the good results of the outreach street-work, especially the immigrant treatment results when we organize specific integration objectives and methodologies.

T8. Effect of brexpiprazole on weight and metabolic parameters: an analysis of short- and long-term trials in schizophrenia

Hans Eriksson1, Catherine Weiss2, Mary Hobart2, John Ouyang2, Emmanuelle Weiller1


Background: Approximately one-third of new cases of diabetes in patients with schizophrenia were seen in patients exposed to olanzapine, risperidone, or quetiapine in a US Veterans Health Administration cohort. Brexpiprazole is a serotonin-dopamine activity modulator that is a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors. Brexpiprazole was approved in July 2015 by the FDA for treatment of schizophrenia. Here we evaluate the effect of brexpiprazole on weight and metabolic parameters in patients with schizophrenia based on pooled data from two pivotal studies3,4 and pooled data from the open-label extension to these studies (NCT01397786) (data cut-off May 2015), and a phase 2, open-label extension study (NCT01649557).

Methods: In the two similarly designed pivotal studies, patients with acute schizophrenia were randomly assigned to fixed once-daily doses of brexpiprazole 2 mg, 4 mg or placebo for 6 weeks (an additional treatment group was included in each study [0.25 mg and 1.0 mg]; these doses were not presented). The long-term studies were open-label, 52-weeks, flexible-dose (1 to 4 mg/day and 1 to 6 mg/day) studies with brexpiprazole. The long-term studies enrolled de novo patients, patients who had completed one of the two pivotal studies, as well as patients who had completed a phase 2 study. We report how brexpiprazole affected fasting metabolic parameters including glucose and lipid metabolism-related laboratory measurements at Week 26 of the placebo-controlled studies and at Week 26 of the open-label studies. Results: In the short-term studies, mean change in weight from baseline to Week 6 was 1.7 (N = 253; 1.4 (N = 251), and 0.4 kg (N = 227)
Discussion: To our knowledge, this is the first examination of the interaction between FKBP5 variability with bullying on the expression of psychotic phenomena in daily life. The findings support and extend previous research indicating an interaction between FKBP5 SNPs and childhood trauma in the prediction of symptoms in several mental disorders. Consistent with the stress-sensitivity model of the positive dimension of psychosis, momentary stressors were associated with PLEs and paranoid experiences. Although genetic variability by itself did not moderate these associations, bullying exposure in carriers of the risk haplotype was associated with psychotic-like reactivity to social stress. The findings are consistent with the increasing relevance given to socially defeating schemas in the experience of reality distortion. Furthermore, they suggest that the interplay between bullying and FKBP5 variability plays a role in increasing the likelihood of psychotic-like reactivity to socially defeating appraisals in the real world.

T9. The interaction between bullying and FKBP5 haplotype on psychotic-like experiences and reactivity to stress: does it matter in real life?
Paula Cristóbal-Narváez\(^1\), Tamara Sheinbaum\(^1\), Araceli Rosa\(^2\), Sergi Ballespí\(^3\), Mercè Mitjavila\(^1\), Marta de Castro-Catalá\(^2\), Elionora Peña\(^3\), Thomas R. Kwapi\(^3\), Neus Barrantes-Vidal\(^1\)

\(^1\)Universitat Autònoma de Barcelona; \(^2\)Universitat de Barcelona; \(^3\)University of North Carolina at Greensboro

Background: Research indicates that exposure to psychosocial stressors, such as bullying, is associated with an increased risk for clinical and subclinical psychosis phenotypes. Bullying is a form of childhood adversity that may lead to feelings of social defeat. Evidence also suggests that daily life stressors play an important role in the expression of psychotic-like and paranoid symptoms. Individual variation in symptoms in response to stress is likely to be moderated by genetic variability. In particular, single nucleotide polymorphisms (SNPs) on the FKBP5 gene may moderate the association between momentary stress and psychotic-like symptoms. However, there are no studies investigating whether FKBP5 SNPs and bullying are associated with the real-world expression of symptoms. The present study used Experience Sampling Methodology to assess gene–momentary environment (GxE) interactions in daily life. Specifically, the study examined the impact of genetic variation in the FKBP5 gene, bullying, and their interaction (FKBP5 x bullying) on (i) levels of paranoid and psychotic-like experiences (PLEs); and (ii) paranoid and psychotic-like reactivity to different forms of momentary stress (situational and social stressors).

Methods: Two hundred and six nonclinical young adults were recruited for bullying with the Childhood Experiences of Care and Abuse. They were also prompted randomly eight times daily for one week to complete assessments of their current experiences, symptoms, and two types of stress appraisals: situational and social (being alone because people do not want to be with you). Participants were genotyped for the main FKBP5 SNPs (rs3800373, rs9296158 and rs1360780) reported in previous studies. Analyses were conducted with the haplotype derived from these three SNPs.

Results: Bullying, but not FKBP5 haplotype, was associated with PLEs. Neither was associated with paranoia. However, the GxE interaction indicated that bullying was associated with increased paranoia and PLEs for participants with the risk haplotype but not for those with the non-risk haplotype. In addition, bullying moderated the association of situational, but not social stress with paranoia. The risk haplotype did not moderate the associations of situational or social stress with symptoms. The GxE interaction indicated that the association between social stress and PLEs was significantly increased by exposure to bullying in participants with the risk haplotype, but not for those with the non-risk haplotype.

References:

T10. Mismatch negativity and P3A amplitude in young adolescents with first episode psychosis: a comparison with attention-deficit/hyperactivity disorder
Jacob Rydkjaer\(^1\), Jens Richardt Jepsen\(^2\), Anne Katrine Pagsberg\(^3\), Birgitte Fagerlund\(^1\), Birte Glenthoj\(^1\), Bob Oranje\(^\text{a}\)

\(^1\)CINS; \(^2\)Karolinska; \(^3\)National Institute for Health and Welfare; \(^\text{a}\)University of Copenhagen

Background: Deficient mismatch negativity (MMN) has been proposed as a candidate biomarker in schizophrenia and may therefore be potentially useful in early identification and intervention in early onset psychosis. In this study we explored whether deficits in the automatic orienting and reorienting responses, measured as MMN and P3a amplitude, are present in young adolescents with first episode psychosis and whether findings are specific for psychosis compared to young adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).

Methods: MMN and P3a amplitude were assessed in young adolescents (age 12-17 years) with either first episode psychosis (N = 27) or with ADHD (N = 28) and age and gender matched healthy controls (N = 43). The MMN paradigm consisted of a four-tone auditory oddball task with deviant stimuli based on frequency, duration and their combination.

Results: The results showed significantly less MMN in patients with psychosis compared to healthy controls in response to frequency deviants. A trend level difference between these two groups was seen in MMN elicited by duration deviants. MMN amplitudes in the group of patients with ADHD were not significantly different from patients with psychosis or healthy controls. No significant group differences were found on P3a amplitude.

Discussion: In conclusion, young adolescents with first episode psychosis showed impaired MMN compared to healthy controls while intermediate and overlapping levels of MMN were observed in adolescents with ADHD. The findings suggest that young FEP patients already exhibit preattentive deficits that are characteristic of schizophrenia albeit expressed on a continuum shared with other neuropsychiatric disorders.
T12. Associations of neonatal markers of inflammation and risk of autism spectrum disorders

Christina Dalman*, Brian K Lee1, Renee Gardner2, Håkan Karlsson1

1Karolinska Institute; 2Drexel University

Background: Animal models indicate that early life immune disturbances can influence neurodevelopmental outcomes relevant to autism. While prenatal exposures such as maternal infection are implicated in the etiology of autism, the role of perinatal immune exposures is less clear.

We here aimed to measure acute phase proteins in neonatal dried blood spots, as markers of neonatal inflammation, and determine associations with later risk of autism.

Methods: We performed a case-control study of 779 autism cases and 1,050 control born 1998-2000 in Sweden, with case ascertainment as of December 2011. Blood spots were collected from a central biobank. Nine acute phase proteins were measured using a magnetic bead-based multiplex panel: α2 microglobulin, C-reactive protein, haptoglobin, serum amyloid P, procalcitonin, ferritin, tissue plasminogen activator, fibrinogen, and serum amyloid A. We examined logistic regression models of the inflammatory markers adjusted for total protein content, sex of child, maternal age, and birth year. Inflammatory markers were individually examined, as well as combined into an inflammation index score based on ridge regression coefficients.

Results: All acute phase proteins were moderately to highly correlated, ranging from Spearman correlations of 0.31 (fibrinogen and C-reactive protein) to 0.79 (ferritin and α2 microglobulin). Higher levels of 6 of the 9 acute phase proteins were individually associated with increased risk of autism. Per doubling of acute phase protein concentration, adjusted individual odds ratios ranged from 1.05, 95% CI: 0.94-1.17 (procalcitonin) to 1.15, 95% CI: 1.03-1.28 (tissue plasminogen activator). A 15D increase in the inflammation index score was associated with a 19% increase in odds of autism, OR: 1.19, 95% CI 1.07-1.33.

Discussion: Because acute phase proteins are not thought to cross the placenta, the results suggest that the perinatal innate immune system may influence later risk of autism.

T13. Episodic memory impairments are associated with functional alterations within the memory network in schizophrenia

Viola Oertel*, Michael Stäblein2, Denisa Ghinea3, Helena Storchak1, Dominik Kraft1, Christian Knöchel1, Andreas Reif2

1University Frankfurt; 2University Hospital Frankfurt

Background: Schizophrenia (SZ) is a severe mental disease that is associated various with cognitive deficits. For instance, episodic memory deficits are commonly found in- and are therefore characteristic for schizophrenia. In this study, we used a face-name-association task in order to elucidate the biological underpinnings of episodic memory function in SZ.

Methods: 32 healthy subjects, 34 SZ patients and 30 first-degree relatives underwent T2-weighted fMRI assessments on a 3 Tesla Siemens Magnetom Scanner while a face-name-association task was presented. An anatomical t1 weighted scan was acquired using the 3D-MDEFT sequence. The groups were matched for age, gender and years of education. In order to evaluate cognitive performance we tested participants on the multiple-choice-word comprehension test, a test for verbal intelligence, and the MATRICS Consensus Cognitive Battery which considers seven cognitive domains. Additionally, we assessed current psychopathology in patients using the PANSS.

The functional pattern of the three groups were analyzed in a statistical group comparisons. Additionally, we performed correlation analysis between individual psychopathology, accuracy and reaction time of the face-name association task and the beta scores of the functional brain pattern. Results: SZ patients showed a significantly lower response accuracy and a significant increase of reaction time during the retrieval of Face-Name-Pairs compared to controls. We also observed slightly lower accuracy in relatives compared with controls. However, this contrast did not reach statistical significance. During retrieval, schizophrenia patients displayed significant altered neuronal activation patterns within the episodic memory network when compared with functional activation in the control group. The relatives’ functional activation pattern during retrieval was comparable to that of the patient group, indicating altered functional response during retrieval of face-name pairs. Impaired performance in various cognitive domains, predominantly in the memory, were significantly associated with altered functional activation within the memory network. However, individual psychopathology did not correlate to the neuronal activation during the encoding or retrieval of face-name pairs.

Discussion: Both the accuracy of memory performance as well as the functional activation pattern during retrieval revealed alterations in SZ patients, and to a lesser degree, in relatives of schizophrenia patients. The results are subsequently meant to be integrated in a comprehensive model of memory function that is of interest for the treatment of cognitive symptoms in SZ, as persistent cognitive impairment may hamper full rehabilitation.
to at least two antipsychotic drugs trial with adequate dose and length. Despite recent advances in the development of new antipsychotic medications, up to 20-30% of SCZ patients still report disabling treatment-resistant symptoms. TRS patients may constitute a specific neurobiological profile due its pharmacological distinct features. In general, neuroimaging studies report more severe abnormalities in TRS patients compared to non treatment-resistant schizophrenia (Non-TRS). The aim of this study was to evaluating white matter fiber tracts interconnecting brain regions between Non-TRS and TRS patients.

**Methods**: Diffusion MRI data were obtained on 44 TRS patients and 58 Non-TRS patients, collected on a Siemens 1.5T MRI scanner. Whole-brain analysis of fractional anisotropy (FA) was performed using tract-based spatial statistics (TBSS); TFCE (Threshold-Free Cluster Enhancement) was applied to find clusters, significance level was set at p less than 0.01. To investigate the potential confounding effect of age and gender on FA, we performed analyses investigating their effect, and found no significant correlation.

**Results**: No age, gender or duration of illness differences were observed between TRS and Non-TRS patients, respectively (35.09 y ± 8.75 vs 37.52y ± 11.52y); (40M/18F vs 28M/16F). There was a significant difference on age of onset between groups (20.89y ± 6.11y vs 23.97y ± 6.75y). A significant reduction in FA values was observed in several white matter tracts in TRS, mainly at the genu, body, and splenium of the corpus callosum (CC).

**Discussion**: This is the first study to compare white-matter integrity between TRS and Non-TRS patients. A previous study reported similar findings comparing TRS patients and healthy controls. Further studies will be required to replicate these results and to explore the significance of white matter changes elsewhere in the brain in order to determine whether these changes occur before definition of TRS or are consequence of disease progression related to clozapine exposure.

**T15.** Post-mortem evidence for increased microglia activity in schizophrenia

Iris Sommer*1, Charissa Van Kesteren1, Rene Kahn1

1University Medical Centre Utrecht

**Background**: Although the precise pathogenesis of schizophrenia is unknown, genetic, biomarker and imaging studies suggest involvement of the immune system. It remains unsure whether the immune system is involved in the pathophysiology of all patients or just in a subgroup.

**Methods**: In this study we analyzed evidence from studies assessing immune-factors in post-mortem brains of schizophrenia patients and healthy controls. Thirty-nine studies were included, reporting on 665 patients and 628 controls. We divided these studies into those pertaining to cells and those assessing molecular parameters and meta-analyses were performed on both categories.

**Results**: Our pooled estimate on cellular level showed a significant increase in microglia (P = 0.0014) in the brains of schizophrenia patients compared to controls. Meta-regression on brain regions demonstrated this increase was most pronounced in the temporal cortex. Numbers of macroglia (astrocytes or oligodendrocytes) did not differ significantly. There was substantial heterogeneity of molecular parameters, therefore this category was divided into pro- and anti-inflammatory according to their association with increased or decreased activity of the immune system. A significant increase in the overall protein expression of the pro-inflammatory molecular components was observed.

**Discussion**: The significant increase in microglia density in postmortem brains of schizophrenia patients together with the increase in pro-inflammatory molecular markers observed in our meta-analysis strengthens the hypothesis that neuro-inflammation plays a role in the pathogenesis. A focus on this component of the pathogenesis may open up new strategies for effective prevention and treatment, for instance with immune-modulating drugs, stress or sleep modulation, exercise, food supplements or probiotics.

**T16.** A systematic review on the neural correlates of apathy within multiple patient populations, including schizophrenia

Claire Kos*1, Marie-Jose Van Tol2, Jan Bernard Marsman3, Henderikus Kneegtering4, Andre Aleman5

1Neuroimaging Center; 2Neuroimaging Center, University Medical Center Groningen; 3Univ Groningen; 4Lents and RGQc/NIC UMCG Groningen; 5University of Groningen, University Medical Center Groningen

**Background**: Apathy is a debilitating symptom present in many neuropsychiatric, neurodegenerative, and neurological disorders (Caiero et al., 2013; Theileritis et al., 2014; van Reekum et al., 2005). Apathy is commonly defined as a syndrome of diminished motivation that is persistent over time and which comprises a loss of goal-directed behavior, goal-directed and cognitive actions, and loss of expression of emotions (Marin, 2009). In schizophrenia, apathy is one of the core negative symptoms and the strongest predictor of poor cognitive, functional and occupational outcome, reduced medication compliance, increased caregiver burden, and diminished quality of life (Chase et al., 2011; Clark et al., 2011). Despite consistency in the diagnosis and phenomenology of apathy over various patient populations, the underlying neurobiology is unclear. The aim of this review is to provide insights into potential shared and unique neural correlates of apathy within separate patient groups.

**Methods**: Current neuroimaging literature (i.e. MRI, PET, SPECT and EEG research) on apathy in various patient populations (i.e. neurodegenerative, acquired brain injury, and psychiatric disorders) was gathered and reviewed. PubMed and Web of Knowledge databases were searched and a total of 99 articles, published between June 1990 and June 2014, were included. To visualize the results related to gray matter abnormalities, we constructed brain maps representing a selection of the imaging findings of the included articles in this review.

**Results**: Results suggest that structural abnormalities within fronto-striatal circuits are most consistently associated with apathy across the different pathological conditions, primarily involving mediodorsal prefrontal regions, the anterior cingulate cortex, and the mediodorsal basal ganglia. Of note, abnormalities within the inferior parietal cortex, a region previously not included in neuroanatomical models of apathy, was also found to be consistently associated with apathy. Furthermore, within neurodegenerative disorders and patients with acquired brain injury temporal regions were additionally associated with apathy. Results from functional studies suggest a disruption in reward anticipation and processing (measured with reward-related paradigms), and also report abnormalities within the fronto-striatal circuit. Of note, most of these functional studies were performed in schizophrenia patients.

**Discussion**: Our review suggests that the structural and functional neuroanatomy of apathy may be similar across different patient groups. However, the evidence of a rather selective use of either structural or functional neuroimaging methods and apathy measures within each patient group, a distinctive pathophysiology for apathy in different patient groups cannot be ruled out. The implication of a range of brain regions suggest that different routes towards apathy are possible, and that different population specific pathologies are associated with different types of apathy, as previously hypothesized by Levy & Dubois (2006). In order to increase our understanding of the etiology of apathy, we recommend a more diverse use of neuroimaging methods and a more detailed assessment on apathy across different pathology classes.

**T17.** Cognition and psychopathology in first episode of psychosis: are they related to inflammation?

Bibiana Cabrera Llorca*1, Miquel Bióque1, Rafael Penades2, Ana Gonzalez-Pinto3, Mara Parellada3, Julio Bobes4, Antonio Lobo5, Borja García-Bueno5, Juan Carlos Leza6, Miquel Bernardo7

1Barcelona Clinic Schizophrenia Unit, Hospital Clinic Barcelona; CIBERSAM; Barcelona Clinic Schizophrenia Unit, Hospital Clinic Barcelona; Universidad Complutense de Madrid; 2CIBERSAM, University of Oviedo; Institut Investigación Sanitaria Aragón; University of Zaragoza; CIBERSAM; CIBERSAM, Complutense University. Instituto de Investigación Hospital

**Background**: Cognitive deficits are present from the onset of psychosis and are considered a core feature of the disorder. Increasing evidence
suggests that cognitive function is associated with inflammatory processes. This study evaluated the association between cognition and inflammatory biomarkers in first episode of psychosis (FEP), in order to identify cognitive phenotypes from inflammatory expression profiles.

Methods: Case-control study of 92 FEP and 80 matched controls. Neurocognitive assessment, including verbal ability, sustained attention, verbal memory, working memory and executive function, was performed. The expression of pro- and anti-inflammatory mediators of a main inflammatory pathway related to stress was measured.

Results: FEP patients performed worse in all cognitive domains compared to controls and had higher expression of pro-inflammatory levels and lower expression of anti-inflammatory ones. In the FEP group, cognition and psychopathology were associated with inflammation. Hierarchical regression analysis showed that association between the anti-inflammatory prostaglandin 15d-PGJ2 and sustained attention on one hand, and COX-2 expression and executive function on the other, were statistically significant.

Discussion: 15d-PGJ2 plasma levels and COX-2 expression may be useful as biomarkers of cognition in FEP and would allow the stratification of patients based on these measures. The identification of subgroup of patients could be useful to guide treatment programs by providing tools to select a personalized treatment approach and would facilitate clinicians to monitor the course of cognitive impairment and therapeutic response. Determination of the inhibitory protein of the inflammatory transcription factor NFKB (IkBa) could be useful in early phases for assessing clinical severity.

T18. Response to clozapine treatment and neurotrophic factors level among schizophrenia patients
Amir Krivoy1, Eldar Hochman1, Hollander Sarah2, Weizman Abraham1, Michal Taler1
1Geha Mental Health Center; 2Tel Aviv University

Background: Clozapine is the only effective therapy for about 30% of schizophrenia patients otherwise refractory to anti-psychotics. However, not only it is associated with numerous side effects, some could be fatal, there is a substantial portion of this population who will not respond to clozapine. Therefore, there is an unmet need to find biomarkers for successful clozapine therapy. Neurotrophins, such as Brain Derived Neurotrophic Factor (BDNF), which are regulated by monoamines, including serotonin, are implicated in many psychiatric disorders. It was previously shown that serum BDNF levels tend to be low in schizophrenia patients in relation to healthy controls and that there might be an association between clozapine daily dose and the level of serum BDNF.

Methods: Blood samples of 86 chronic clozapine-treated schizophrenia patients were analyzed for serum neurotrophins in a cross-sectional design. Serum BDNF, Vascular Endothelial Growth Factor (VEGF), Neurotrophic Growth Factor (NGF) and Glial Derived Neurotrophic Factor (GDNF) were determined using standard ELISA kits. For each patient clozapine clinical responsiveness was determined using PSANSS and other clinical measures (both longitudinal from history records and current state).

Results: Our sample consisted of 49 (57%) responders (67.3% males, mean age 43.6 ± 10.4 years) and 37 (43%) non-responders (73% males, mean age 43.6 ± 10.7 years). There was a significant difference between groups on total-PSANSS (53.7 ± 13.7 vs. 85.2 ± 13.3, P < 0.0001, respectively). Responders had higher mean BDNF level than non-responders (2066 ± 814.4 pg per 1668 ± 820.7 pg, P < 0.05, respectively). There was no significant difference between responders and non-responders in mean VEGF, NGF and GDNF. VEGF was, however, significantly correlated with age (r = 0.23, P < 0.05). There was no significant correlation between the other neurotrophins and gender, age, clozapine daily dose or PSANSS

Discussion: Our findings suggest association between serum BDNF and response to clozapine among schizophrenia patients. Since BDNF readily crossed the blood-brain barrier, the serum levels may reflect brain levels, therefore supporting BDNF involvement in clozapine mechanism of action. Moreover, this might imply that patients with higher levels of BDNF tend to respond to clozapine, however this should be tested in a prospective longitudinal design and not cross-sectional as in our study. Based on these findings, we believe that there is a need to expand the search for other domains of clozapine activity as potential biomarkers for response. Eventually we believe it will enable us to construct a combined predictive model for clozapine response.

T19. Impairments in pre-attentive auditory processing and the cortical thickness of its structural correlates in schizophrenia
Jiyoon Seo1*, Minah Kim1, Kang Ik Cho1, June Sic Kim3, Tae Young Lee1, Jun Soo Kwon1
1Seoul National University

Background: The automatic auditory change detection response observed through the mismatch negativity (MMN) component of event-related potentials has been methodically studied in schizophrenia. MMN amplitude attenuation is a consistent finding in this population, and sustains interest of researchers with its potential in predicting conversion and reflecting disease progression after onset. Its generators are said to be localized in temporal, contributing to auditory perception and discrimination, and frontal, attention-switching, cortices. Studies of brain structure in schizophrenia have reported abnormalities in several areas, including those that are known as the generators of MMN. However, the potential relationship between MMN and the characteristics of related brain areas is unclear and warrants further exploration.

Methods: We conducted a magnetoencephalography study of MMN in 16 schizophrenic patients and 18 healthy control subjects. Through source reconstruction, we extracted whole-brain current source density (CSD) strengths using minimum norm estimation, and focused on areas previously reported as potential generators of MMN. We also went on to examine structural MRI using Freesurfer for surface-based cortical analysis of thickness and vertex-based GLM for group comparisons.

Results: Through extracting CSD values from MMN-relevant areas, we found significantly decreased CSD strengths of both temporal and frontal areas in patients compared to healthy subjects. Preliminary data will be presented on cortical thickness, as well as that with regard to CSD values in the two groups.

Discussion: The results will be discussed in terms of potential neuroanatomical underpinnings of MMN and how it may provide further insight on the nature of MMN deficits consistently observed in schizophrenia.

T20. Glutamate-related amino acids before and after 10 weeks of antipsychotic treatment in drug naive first-episode psychosis
Beyazit Garip1*, Hakan Kayir1
1Sinop Military Hospital; 2Gulhane Military Medical Academy

Background: The dysfunctions in glutamatergic neurotransmission and glutamate-related amino acids have been investigated in the pathophysiology of schizophrenia. Glutamine, glutamic acid, asparagine, proline and hydroxyproline are associated with glutamate metabolism and serine can be served as a neuromodulator by coactivating NMDA receptors. The aim of this study is to indicate the relationship between plasma glutamate-related amino acids levels and the severity of psychotic symptoms and treatment response in drug naive first episode psychotic patients before and after 10 weeks and 18-24 months follow-up periods.

Methods: Drug naive first episode psychotic patients (n = 41) were recruited to the study and followed up for 10 weeks. The blood samples were obtained before initiating the treatment and at the end of 10 weeks treatment. LC/MS/MS method was used to be able to measure plasma levels of these biological variables. To evaluate the psychotic symptoms, SANS, SAPS and BPRS inventories were applied before and after BPRS inventories. A decrease in BPRS score more than 40% was used to indicate treatment response. Healthy volunteers (n = 30) matched for age, sex and education levels were used as the control group. A long term follow-up was performed 36 of the patients by using the global assessment of functioning (GAF) score after 18-24 months from the acute episode.
Results: The plasma serine, asparagine, glutamine, glutamic acid, proline and hydroxyproline levels were significantly higher compared to healthy controls in the first-episode psychotic patients ($P < 0.0001$). After the treatment, plasma glutamic acid, proline and hydroxyproline levels were significantly increased ($P < 0.05$) while the asparagine level was decreased with the treatment ($P < 0.05$). The serine and glutamine levels remained similar ($P > 0.05$). The initial plasma glutamine levels were negatively correlated with the initial SAPS score ($r = -0.45$, $P < 0.01$) and the BPRS score evaluated at the end of 10 weeks ($r = -0.36$, $P < 0.05$). The initial plasma proline levels were negatively correlated with the SAPS score not only before the treatment but also at the end of the 10-week antipsychotic treatment ($r = -0.51$ and $r = -0.39$, respectively; $P < 0.05$). The initial plasma proline and hydroxyproline levels were both negatively correlated with the initial BPRS score ($r = -0.37$ and $r = -0.33$, $P < 0.05$). Moreover the serine and asparagine levels measured at 10th week were significantly correlated with the global assessment of functioning (GAF) scores obtained during the follow-up after 18-24 months ($r = 0.36$ and 0.38, respectively, $P < 0.05$). A linear regression analysis revealed that the asparagine was the main predictor for GAF score ($beta = 0.38$, $P < 0.05$). Depending on the partial correlation coefficients 14% of the variance in GAF score can be explained by a statistically valid model [$F(1,34) = 5.68; P < 0.05$].

Discussion: Glutamate-related amino acids may play an important role in the pathophysiology of first-episode psychosis. Their plasma levels were significantly correlated with the several symptom scales and they differentially changed with the treatment. Asparagine levels measured at the end of 10 weeks of antipsychotic treatment could be used as a predictive variable to estimate the long-term outcome.

T21. Aberrant tyrosine transport across plasma membrane - an endophenotype marker in schizophrenia

Lena Flyckt*1, Nikolaos Venizelos2

1Stockholm Centre F Psychiatric Research, 2Örebro University

Background: Studies of associations between biological markers, candidate genes and clinical characteristics such as symptoms and cognitive functioning may disentangle homogeneous subgroups in a heterogeneous disorder such as schizophrenia. Aberrant tyrosine transport across the cell membrane in patients with schizophrenia is a biological marker with bearing on the genetic susceptibility for schizophrenia. The aim of the present study was to investigate the occurrence of aberrant tyrosine transport across the fibroblast membrane in first-degree relatives to patients with schizophrenia to find indications of genetic transmission.

Methods: Twenty-three consecutively recruited patients with schizophrenia, both first-episode ($n = 10$) and chronic patients ($n = 13$), 23 mothers, 13 fathers and 10 controls entered the cross-sectional study. They were clinically characterized (diagnosis, PANSS, GAF, Sociodemographics, family history), underwent a neuropsychiatric investigation (WAIS-R NI) and skin biopsies were obtained for determination of tyrosine transport.

Results: A high and significant correlation was found between mothers and patients for the tyrosine kinetic parameter $Km$ ($r = -0.504$, $P = 0.024$). The correlations between the patient and the mother became even stronger when the analyses were confined to the 10 families with both parents included in the study ($r = -0.741$, $P = 0.014$). Mothers with a low $Km$ had worse cognitive functioning as compared to those with a high $Km$; a finding going in the same direction as in patients. Patients with low $Km$ ($n = 18$) performed worse than patient with high $Km$ ($n = 18$) and the healthy controls ($n = 51$).

Discussion: Aberrant tyrosine transport across plasma membrane may offer a biological marker that delineates a subgroup of patients with a heritable form of schizophrenia. A plausible mechanism is maternal inheritance for a subgroup of patients with low cognitive functioning.

T22. Structural brain correlates of stress reactivity in the at-risk mental state

Maria Cailem*1, Ulrich Reininghaus1, Lucia Valmaggia1, Barnaby Nelson2, Eva Velthorst1, Inez Myrin-Germey3, Craig Morgan1, Philip McGuire1, Matthew Kempton1, EU-GEI At Risk Study1

1Institute of Psychiatry, Psychology & Neuroscience, King’s College London; 2Oxygen Youth Health Research Centre; 3Academic Medical Center; 4KU Leuven

Background: Stress is thought to be a risk factor for psychosis, but the psychological and biological mechanisms underlying this association remain unclear. One psychological mechanism that is thought to be relevant is stress reactivity, characterised by intense emotional reactions and psychotic-like experiences in response to routine daily hassles and minor stressful experiences. This study investigated associations between stress reactivity and the volume of stress-related brain structures in people at clinical high risk for psychosis. It was hypothesized that the association between minor stressors and increased negative effect, positive affect and intensity of psychotic-like experiences would be stronger in those with smaller hippocampal and amygdala volume.

Methods: The Experience Sampling Method (ESM) was used to measure minor stressful experiences (event stress, social stress and activity stress), negative and positive affect and psychotic experiences in daily life. Structural MRI data was used to calculate the volume of the hippocampus and amygdala. In initial analyses on the association between volume of stress-related brain structures and elevated reactivity to minor stressors, linear mixed models were used to account for the multi-level structure of ESM data, treating multiple observations as nested within subjects.

Results: Smaller hippocampal volume was associated with: greater positive affective and negative affective reactivity to event stress; greater psychotic reactivity to activity stress; and greater negative affective reactivity to social stress. Smaller amygdala volume was associated with: greater positive affective, negative affective and psychotic reactivity to event stress; negative affective and psychotic reactivity to activity stress; and negative affective reactivity to social stress.

Discussion: Smaller volumes of two stress-related brain structures are markers for greater affective and psychotic reactivity to different forms of stress in people at clinical high risk for psychosis.

T23. Low serum nogo-a, UCH-I1 and α-synuclein levels in patients with schizophrenia compared to healthy controls

Omer Faruk Demirel*1, Ilhans Çetin2, Tank Sağlam2, Nazım Yıldız2, Alaattin Duran2

1Istanbul University, Cerrahpaşa Faculty of Medicine; 2Istanbul University

Background: Determining whether schizophrenia is a neurodegenerative illness with progressive structural changes in the brain after debut of the illness, or a neurodevelopmental disorder starting in early life, is of significant importance for understanding the pathophysiology of the illness and its treatments. Therefore, in this study we aimed to show the relation of neuromodulatory proteins with schizophrenia, and compared serum Nogo-A, UCH-L1 and α-synuclein levels of schizophrenia patients with healthy controls.

Methods: This study was performed in Psychotic Disorders Unit of Istanbul University, Cerrahpaşa Faculty of Medicine, department of psychiatry. 44 Patients with schizophrenia who is followed by psychiatric disorders unit, and 40 healthy control was included in this study. Socio-demographic form and PANSS was applied to patients, and sociodemographic form was applied to both groups. Fasting bloods were collected and Nogo-A, UCH-L1 and α-synuclein levels were measured by ELISA method.

Results: In study group, mean age onset of psychosis was 22.8 (±5.4), and mean number of hospitalization was 2.95 (±1.3). Serum Nogo-A, UCH-L1 and α-synuclein levels of the patients with schizophrenia were significantly lower than healthy controls.

Discussion: Serum levels of Nogo-A, UCH-L1 and α-synuclein in patients with schizophrenia was lower than healthy controls. Our study results supported the neurodevelopmental and neurodegenerative models for ethiopathogenesis of schizophrenia. As our
knowledge there is no study in the literature measuring serum levels of these molecules in patients with schizophrenia, therefore these preliminary study findings should be replicated by new researches.

T24. Mismatch negativity: alterations in nonclinical adults from the general population who report subclinical psychotic symptoms

Christian Döring1, Mario Müller2, Florence Hagenmüller1, Vladeta Ajdacic-Gross3, Helene Haker1, Wolfram Kawohl1, Wulf Rössler2, Karsten Heekeren1
1University of Zurich; 2University of Zurich; University of Sao Paulo

Background: Deficits of mismatch negativity (MMN) in schizophrenia and individuals at risk for psychosis have been replicated many times. Several studies have also demonstrated the occurrence of subclinical psychotic symptoms within the general population. However, none has yet investigated MMN in individuals from the general population who report subclinical psychotic symptoms.

Methods: The MMN to duration-, frequency-, and intensity deviants was recorded in 217 nonclinical individuals classified into a control group (n = 72) and three subclinical groups: paranoid (n = 44), psychotic (n = 51), and mixed paranoid-psychotic (n = 50). Amplitudes of MMN at frontocentral electrodes were referenced to average. Based on a three-source model of MMN generation, we conducted an MMN source analysis and compared the amplitudes of surface electrodes and sources among groups.

Results: Significant differences in MMN generation among the four groups were revealed at the frontal source for duration-deviant stimuli (P<0.01). We also detected a trend-level difference (P = 0.05) in MMN activity among those groups for frequency deviants at the frontal source.

Discussion: Individuals from the general population who report subclinical psychotic symptoms are a heterogeneous group. However, alterations already exist in their frontal MMN activity. This increased activity might be an indicator of more sensitive perception regarding changes in the environment for individuals with subclinical psychotic symptoms.

T25. Clinical and cognitive performance and the RS53576 SNP of the oxytocin receptor gene (OXTR) in recent onset psychosis and at risk mental state (ARMS) subjects

Vanessa Sanchez-Gistau1, Sara Arranz2, Montserrat Sole3, Angel Cabezas4, M. Jose Algora1, Javier Labad1, Elisabet Vilella6
1Early Intervention Service, Hospital Universitari Institut Pere Mata, IISP; Universitat Rovira i Virgili; CIBERSAM; 2Hospital Universitari Institut Pere Mata; 3Early Intervention Service, Hospital Universitari Institut Pere Mata; IISP; Universitat Rovira i Virgili; CIBERSAM; 4Early Intervention Service, Hospital Universitari Institut Pere Mata; 5Department of Mental Health, Corporació Sanitària i Universitària Parc Taulí, IDIPT, Sabadell, Barcelona; 6Hospital Universitari Institut Pere Mata; IISP; Universitat Rovira i Virgili; CIBERSAM

Background: There is an increasing interest in investigating the role of the central oxytocinergic system in the expression of psychotic disorders. In that sense, some studies have indicated a relationship between genetic variations in Oxtocine Receptor Gene (OXTR) and the risk of schizophrenia. OXTR SNP rs53576 has been shown as particularly promising candidate. However, inconclusive results in the risk of schizophrenia. OXTR SNP rs53576 has been shown as particularly promising candidate. Despite negative findings regarding the association of cognitive performance and social cognition and OXTR SNP rs53576, our results however are in accordance with previous findings indicating a relationship between the A-allele in 53576 and higher rates of psychopathology, specially positive symptoms and depressive symptoms. Therefore, the small sample size prevents us to make further conclusions, our results support the notion that specific variation in the OXTR gene might play a role in the clinical expression of patients with psychotic disorders.

T26. Dysregulated 14-3-3 family in schizophrenia

Ying Qing1, Liya Sun2, Chao Yang3, Jie Jiang4, Xuhan Yang1, Xiaowen Hu1, Donghong Cui1, Yifeng Xu1, Lin He1, Dongmei Han1, Chunting Wan1
1Shanghai Jiao Tong University

Background: The 14-3-3 family is implicated in the regulation of several key biological processes such as cell signaling, gene transcription, metabolism, neurodevelopment and apoptosis. In humans, there are several highly conserved members of this family expressed which are β, ε, γ, η, ζ, C and α. During the past two decades, this family has been found to be associated with schizophrenia by human genetic studies and postmortem gene expression studies. Linkage analysis studies identified SNPs of 14-3-3ε, 14-3-3η and 14-3-3C in various populations with schizophrenia and some postmortem studies reported altered mRNA expression levels of 14-3-3 family in different brain regions of patients with schizophrenia. To date, all of the studies published on the 14-3-3 family expression levels in schizophrenia were still focused on postmortem samples. Therefore, it is necessary to targetedly quantitate the 14-3-3 family expression at both transcript and translation levels in drug naïve first-episode patients with schizophrenia and to relate this family to disease status.

Methods: This study chose peripheral blood leukocytes as the clinical samples to targetedly investigate the mRNA and protein expression levels of the 14-3-3 family in drug naïve first-episode patients with schizophrenia and their matched controls by qRT-PCR and ultra performance liquid chromatography-multiple reaction monitoring mass spectrometry. PANSS ratings were completed through face-to-face interviews with trained raters. A Student’s t-test was performed to determined significant changes in mRNA or protein abundances. Pearson correlation analysis was performed to test the correlations between mRNA expression levels and protein expression levels and Spearman correlation analysis was performed to test the correlations between relative mRNA/protein expression and PANSS.
T28. Correlation between BDNF serum levels and basal clinical characteristics in first episode psychosis

Alba Toll, Anna Mané, Daniel Berge, Victor Pérez-Sola

Institut de Neuropsiquiatria i Addiccions, Hospital del Mar

**Background:** Brain-derived neurotrophic factor (BDNF) is the most widely distributed neurotrophin in the central nervous system and is highly expressed in the hippocampus and the prefrontal cortex, areas implicated in schizophrenia symptoms. Recent studies have found that BDNF levels were moderately reduced in schizophrenia samples, including drug naive and medicated patients, when compared with age-matched healthy controls. They also found an accelerated decrease with age, although they observed a high heterogeneity in BDNF levels between the different studies. Furthermore, their results could not support the greater decrease in men than in women that had previously been observed. The reasons for the heterogeneity in BDNF levels between different studies could be due in part by the fact that some patients were evaluated while on antipsychotic treatment. Atypical antipsychotics may increase, whereas treatment with conventional antipsychotics may decrease, peripheral BDNF levels. Moreover, they did not take into account illness characteristics, such as illness stage. Therefore, the aim of the present study is identify which factors may affect BDNF levels heterogeneity. We will study the relationship between clinical characteristic at baseline and BDNF serum levels at baseline in a sample of drug-naïve first episode psychosis.

**Methods:** 45 drug-naïve first episode psychosis patients were consecutively admitted to Hospital del Mar since January 2013 to April 2015 and entered the first episode programme of the institution. The included evaluation were sociodemographic and clinical data. Moreover we did fasting blood analysis to measure BDNF serum levels before the administration of antipsychotic treatment. We did a T student test to compare BDNF serum levels in relation to gender, cannabis use, tobacco use and diagnosis of affective psychosis. Furthermore we studied the correlation between BDNF serum levels and clinical variables at baseline using Pearson Correlation.

**Results:** The mean age at onset of illness was 24.71 years (ds = 5.758) and most of the subjects were male (64.3%). The BDNF serum levels at baseline did not show any correlation with clinical characteristics at baseline (age of onset, tobacco use and PANSS). Moreover, we did not find any differences in BDNF serum levels at baseline in relation to gender (56.75 ± 26.17 vs 57.11 ± 36.07, t = −0.034, P = 0.973), tobacco use (62.05 ± 29.13 vs 50.42 ± 27.64, t = 1.284, P = 0.207) and cannabis use (63.46 ± 33.78 vs 124.74 days and the most frequent diagnosis was Psychosis NOS (57.1%). The BDNF serum levels at baseline did not show any correlation with clinical characteristics at baseline (age of onset, tobacco use and PANSS). Moreover, we did not find any differences in BDNF serum levels at baseline in relation to gender (56.75 ± 26.17 vs 57.11 ± 36.07, t = −0.034, P = 0.973), tobacco use (62.05 ± 29.13 vs 50.42 ± 27.64, t = 1.284, P = 0.207) and cannabis use (63.46 ± 33.78 vs 124.74 days and the most frequent diagnosis was Psychosis NOS (57.1%). The BDNF serum levels at baseline did not show any correlation with clinical characteristics at baseline (age of onset, tobacco use and PANSS). Moreover, we did not find any differences in BDNF serum levels at baseline in relation to gender (56.75 ± 26.17 vs 57.11 ± 36.07, t = −0.034, P = 0.973), tobacco use (62.05 ± 29.13 vs 50.42 ± 27.64, t = 1.284, P = 0.207) and cannabis use (63.46 ± 33.78 vs 124.74 days and the most frequent diagnosis was Psychosis NOS (57.1%). The BDNF serum levels at baseline did not show any correlation with clinical characteristics at baseline (age of onset, tobacco use and PANSS). Moreover, we did not find any differences in BDNF serum levels at baseline in relation to gender (56.75 ± 26.17 vs 57.11 ± 36.07, t = −0.034, P = 0.973), tobacco use (62.05 ± 29.13 vs 50.42 ± 27.64, t = 1.284, P = 0.207) and cannabis use (63.46 ± 33.78 vs 124.74 days and the most frequent diagnosis was Psychosis NOS (57.1%). The BDNF serum levels at baseline did not show any correlation with clinical characteristics at baseline (age of onset, tobacco use and PANSS). Moreover, we did not find any differences in BDNF serum levels at baseline in relation to gender (56.75 ± 26.17 vs 57.11 ± 36.07, t = −0.034, P = 0.973), tobacco use (62.05 ± 29.13 vs 50.42 ± 27.64, t = 1.284, P = 0.207) and cannabis use (63.46 ± 33.78 vs 124.74 days and the most frequent diagnosis was Psychosis NOS (57.1%). The BDNF serum levels at baseline did not show any correlation with clinical characteristics at baseline (age of onset, tobacco use and PANSS). Furthermore, we studied the correlation between BDNF serum levels and clinical variables at baseline using Pearson Correlation.

**Discussion:** The mean age at onset of illness was 24.71 years (ds = 5.758) and most of the subjects were male (64.3%). The mean DUP was 124.74 days and the most frequent diagnosis was Psychosis NOS (57.1%). The BDNF serum levels at baseline did not show any correlation with clinical characteristics at baseline (age of onset, tobacco use and PANSS). Furthermore, we studied the correlation between BDNF serum levels and clinical variables at baseline using Pearson Correlation.
Although, it seems to be a tendency to have a higher BDNF levels in patients without tobacco and cannabis use, and affective psychosis. These results are in agreement with some recent studies which describe that acute cannabis use can initially increase, whereas chronic use can decrease, peripheral BDNF levels. In relation to tobacco use, it has been shown that nicotine use is associated with the alteration of BDNF levels in serum, and an association between smoking and the BDNF Val(66)Met polymorphism has also been found. But the effects of this association are still unclear. The hypothesis that FEP with affective psychosis have higher BDNF serum levels could be explained by the fact that patients with higher BDNF levels have a better prognosis, like patients with affective psychosis. However, more studies should be done to clarify the association between BDNF and clinical characteristics of schizophrenia.

T29. Platelet serotonin concentrations and depressive symptoms of schizophrenia

Vjekoslav Peitl1*, Ante Silic2, Draženka Ostoja2, Ana Kovak Mufić1, Danijel Crnković1, Dalibor Karlović1
1University Hospital Center Sestre Milosrdnice; 2Psychiatric Clinic Vrapženka Ostojić

Background: Depressive symptoms seem to be frequent in schizophrenia, but so far have received less attention than other symptom domains. Impaired serotonergic neurotransmission has been implicated in the pathogenesis of depression and schizophrenia. The objectives of this study were to investigate platelet serotonin concentrations in schizophrenic patients with and without depressive symptoms, as well as to investigate the association between platelet serotonin concentrations with symptoms of schizophrenia, mostly depressive symptoms.

Methods: A total of 364 patients were included in the study, 237 of which had significant depressive symptoms. Significant depressive symptoms were defined by the cut-off score of 7 or more on Calgary Depression Rating Scale (CDRS). Platelet serotonin concentrations were assessed by the enzyme-linked immunosorbent assay (ELISA).

Results: Prevalence of depression in patients with schizophrenia was 65.1%. Schizophrenic patients with depressive symptoms showed lower platelet serotonin concentrations compared to schizophrenic patients without depressive symptoms. An inverse correlation was found between platelet serotonin and depressive symptoms, with those symptoms being associated with lower platelet serotonin concentrations in patients with depressive symptoms (mean ± SD; 490.6 ± 401.2) compared to patients without depressive symptoms (mean ± SD; 660.7 ± 471.5).

Discussion: Depressive symptoms in schizophrenic patients may be associated with reduced concentrations of platelet serotonin.

T30. Is P300 an endophenotype for schizophrenia or a state marker of neurocognitive deficit? Evidence from inter-trial variability analysis

Minah Kim1*, Hanwoom Hong1, Ji-Hun Kim1, Tak Hyung Lee1, Tae Young Lee1, Sung Nyun Kim1, Youngja Lee1, Jun Soo Kwon1
1Seoul National University

Background: The P300 component, which reflects cognitive processes, is a candidate endophenotype for schizophrenia. However, the state-dependency of averaged P300 amplitudes has been an obstacle for defining P300 as a definitive endophenotype. Thus, we aimed to investigate whether P300 is a genetic vulnerability marker or a state-dependent marker through inter-trial variability analysis.

Methods: Forty-five patients with schizophrenia, thirty-two subjects with genetic high risk (GHR), and fifty-two healthy control (HC) subjects participated in P300, clinical symptoms, and neurocognitive function assessments. Both conventional averaging and inter-trial variability analysis were conducted for P300 and results were compared across groups using analysis of variance. Pearson’s correlation was performed to find the association between P300 inter-trial variability and measurements of current symptomatic, neurocognitive status.

Results: Average P300 amplitude at Pz was reduced in both GHR and schizophrenia groups compared with healthy control subjects. Meanwhile, P300 inter-trial variability was increased only in schizophrenia patients and was relatively preserved in subjects with GHR similar to that of HC subjects. Schizophrenia patients showed impaired performance in the measurements of executive function, attention, verbal memory, and verbal fluency. Furthermore, we found a significant relationship between neurocognitive performance results, which showed deficits in schizophrenia, and P300 inter-trial variability in schizophrenia patients.

Discussion: Increased inter-trial variability, owing to cognitive impairment, can make the averaged P300 seemingly state-dependent. From these results, we suggest that the P300 amplitude may be an endophenotype for schizophrenia, with inter-trial variability as a possible state marker for current cognitive deficits in schizophrenia.

T31. Examining the relationship between glutamate and auditory mismatch negativity (MMN) in antipsychotic-naive/free patients with schizophrenia: preliminary findings from an (1H-MRS-EEG study

Sri Mahavir Agarwal1*, Anushree Bose1, Hema Nawani1, Venkata Ram Shrivakumar1, Anekal Amaresha1, Boban Joseph1, Janardhanan Narayanaswamy1, Ganesan Venkataraman1
1National Institute of Mental Health and Neurosciences, Bangalore

Background: Mismatch negativity (MMN), an event-related potential (ERP) component elicited by the occurrence of an infrequent deviant stimulus in a series of standard stimuli, has been suggested to be associated with the excitatory glutamatergic neurotransmission. Although both glutamate and MMN are considered to be of high relevance to schizophrenia pathophysiology, the relationship between them has not been evaluated in schizophrenia patients. We report preliminary findings from a study examining whether in vivo glutamate concentration in the left temporoparietal junction (TPJ), a region implicated in the pathogenesis of auditory hallucinations, correlates with MMN amplitude in antipsychotic-naive and antipsychotic-free patients.

Methods: In vivo magnetic resonance spectroscopy (MRS) at a field strength of 3T was used to acquire single-voxel (2cm × 2cm × 2cm) spectra from the left TPJ of right-handed acutely symptomatic schizophrenia patients (N=12; 9 antipsychotic-naive; age = 32.7 ± 7.4 years, 7 male, duration of untreated psychosis (DUP): 30.6 ± 36.6 months; duration of illness 4.1 ± 3.9 years) and 10 healthy control (HC) subjects (age = 29.3 ± 6.8 years, 6 male, duration of illness 2.2 ± 1.6 years) [1]. All subjects were scanned using a 3T magnet. Twenty percent of subjects also took a 3mm bolus of L-Dopa, but this did not affect the findings. In vivo MRS was used to estimate the glutamate/creatine ratio (Glu/Cr) in subjects. The Cramer-Rao lower bound (CRLB) for glutamate and creatine was set at 20%. No subjects’ data exceeded the CRLB. The signal to noise ratio (SNR) for all subjects was ≥25. EEG data was analyzed using CURRY7, and MMN values from the lead with the strongest waveform across subjects were used for correlational analysis.

Results: Mean Glu/Cr among the subjects was 0.68 ± 0.05. Mean MMN amplitude was -3.97 ± 1.15. We found a significant positive correlation between Glu/Cr and MMN peak amplitude (r = 0.72, P = 0.04); higher glutamate level was associated with lower (less negative) MMN amplitude.

Discussion: To the best of our knowledge, this study reports, for the first time, the presence of an association between glutamate level and duration-MMN peak amplitude in schizophrenia patients. Our preliminary findings support the view that MMN is dependent on the glutamatergic neurotransmitter system. Given the importance of glutamate in information processing, cortical plasticity, and schizophrenia pathophysiology, our finding adds to the accumulating evidence supporting the role of MMN as a biomarker in schizophrenia.
T32. Interpersonal sensitivity, bullying and paranoid ideation among help-seeking adolescents and young adults.

Alice Masillo1, Lucia Vaimaggio2, Riccardo Saba1, Martina Brandizzi1, Nella Lo Cascio1, Juliana Fortes Lindau1, Ludovica Telesforo1, Paola Venturini3, Valentino Righetti1, Marco D'Alema1, Paolo Girardi1, Paolo Fiori Nastro1

1Sapienza University of Rome; 2Institute of Psychiatry, Psychology & Neuroscience, King's College London; 3Sapienza University of Rome; Sant'Andrea Hospital; 4Community Mental Health Service

Background: The effects of a negative interpersonal experience such as bullying in childhood and adolescence can be strong and long lasting. Bullying may be associated with paranoid ideation and suspiciousness. Individuals at high risk to develop psychosis reported significantly more experiences of bullying than healthy controls together with increased paranoid ideation in later life. Not many studies focused upon the possible correlation between pre-existing personality aspects and more severe psychological consequences of bullying. Interpersonal sensitivity (IS) is a personality trait defined as an extreme sensitivity to interpersonal interactions (i.e. subjects have the constant perception of self-deficiencies in relation to others and the feeling of having a bothersome core-self that needs to be hidden from others. IS is correlated to subtle suspiciousness and persecutory ideations. Therefore, having high level of IS may be a fertile ground upon which an adverse experience, as bullying, may produce the development of paranoid thoughts.

Methods: Data were collected in six Adult (AMHS) and Child and Adolescent Mental Health Services (CAMHS) located in one of the eight Local Health Districts of Rome, Italy, i.e. the Rome H area, between January 2012 and January 2015 as part of the early detection project “Liberiamo il Futuro” (LIF). The sample consisted of 147 adolescents and young adults selected after a screening phase (Prodromal Questionnaire 92 was used as screening instrument) and evaluated with the Structured Interview for Psychosis-risk Syndromes (SIPS). All participants were specifically asked if they had experienced either psychological bullying or physical bullying and completed the Interpersonal sensitivity measure (IPSM).

Results: Of the whole sample, 30 (20%) subjects had experienced psychological bullying or physical bullying at least once in the life. Performing a multiple regression, bullying was found to be an independent predictor of subtle paranoid ideation and suspiciousness (measured with the SIPS). However, IS was also found to be an independent predictor of subtle paranoid ideation; in particular two IPSM subscales, fragile inner-self and separation anxiety, resulted significantly correlated with paranoid ideation.

Discussion: Our results confirmed that bullying is a negative interpersonal experiences associated with paranoid ideation and suspiciousness. However, being overly sensitive and having negative beliefs about the self as fragile and vulnerable to threat also lead to a tendency to attribute experiences as externally caused and, in turn, facilitate the formation and maintenance of paranoid ideation (4). Conclusion: Having high level of IS may represent a predisposing factor for the developing of suspiciousness when facing a negative experience like bullying. Together with information and preventing campaigns about bullying into primary and secondary schools, assessing levels of interpersonal sensitivity and planning targeted psychotherapeutic interventions to fight potential difficulties in interpersonal relationships may be an important psychosis prevention action.

T33. Management of psychiatric symptoms in pediatric anti-NMDA receptor encephalitis: case report and systematic review

Sunny Tang1, Orna Alpert2

1University of Pennsylvania; 2Children’s Hospital of Philadelphia

Background: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune condition that causes serious psychiatric symptoms, prominently including psychosis, catatonia, and agitation. Nearly 40% of affected patients are in the pediatric age range, but few publications detail management of psychiatric symptoms for pediatric patients diagnosed with anti-NMDA receptor encephalitis. We present a systematic review of literature and an illustrative case report of a 1 7-year-old girl who presented with psychosis, agitation, and insomnia, and underwent treatment with olanzapine, clonazepam, and clonidine.

Methods: PUBMED was searched for all publications in the English language describing anti-NMDA encephalitis from 2007 to November 2015. Publications were included if they met all of the following criteria: 1) presented novel data, 2) reported treatment of psychiatric phenomena for one or more patients aged up to and including 18 years, and 3) full text was available. Thirty-four publications detailing 38 unique cases were included.

Results: Cases were 3 to 18 years of age and 66% female. The most commonly reported psychiatric symptoms were agitation (n=32, 84%), followed by psychosis (n=27, 71%), sleep disturbance (n=18, 47%), catatonia (n=17, 45%), mood disturbance (n=15, 40%), and anxiety (n=7, 18%). A total of 32 cases (84%) reported treatment with antipsychotic medications; first generation antipsychotics were used in 6 cases (16%), second generation antipsychotics were used in 15 cases (39%), and the antipsychotic was not specified in 4 cases (11%). The most common antipsychotics used were risperidone (n=16, 57%), haloperidol (n=10, 36%), and olanzapine (n=10, 36%). Benzodiazepines were used in 24 cases (63%), and lorazepam was most common (n=12, 55%). Some utilized medications including melatonin, clonidine, trazodone, anticholinergics, fluoxetine and zolpidem. A wide range of doses was reported. Additionally, non-pharmacologic interventions targeted at psychiatric symptoms were described in 11 cases, and electroconvulsive therapy (ECT) was administered in 5 cases. Significant adverse effects occurred, with neuroleptic malignant syndrome diagnosed with high probability in 4 cases (13%), and suspected in 5 additional cases (16%). Dystonia, rigidity, tremors, and bradykinesia were also linked to medication side effects. All reported adverse events occurred coincidentally with antipsychotic administration.

Discussion: Psychiatric symptoms in pediatric cases of anti-NMDA receptor encephalitis were frequently managed with antipsychotics and benzodiazepines. Though antipsychotic medication may be necessary to control agitation and psychosis, serious side effects are concerning. Unlike in delirium resulting from other causes, benzodiazepines do not seem to be contraindicated in altered mental status secondary to anti-NMDA receptor encephalitis. ECT may also be of utility and was well-tolerated in reported cases.

T34. Predicting the next three years: testing multivariate psychosis-risk outcome algorithms in an unselected adolescent psychiatric sample

Sebastian Therman1, Maija Lindgren1, Jaana Suvisaari1, Tyrone Cannon2

1National Institute for Health and Welfare; 2Yale University

Background: Several multivariate algorithms have been proposed for predicting psychosis among individuals at Clinical High Risk (CHR) for psychosis, as attempts to improve over current CHR criteria. These algorithms have typically been based on samples from specialized clinics, with a high base rate of transition to psychosis. In this study, we tested existing models in an unselected adolescent psychiatric sample, to determine the generalizability of previous findings to clinical practice. In addition, we generate our own exploratory model.

Methods: A total of 162 new psychiatric patients aged 15-18, of whom 59 fulfilled CHR criteria, underwent an extensive baseline assessment including the SIPS and a large neuropsychological battery. Clinical status 3 years after baseline was based on diagnoses in comprehensive national hospital registers and case reports. Previously published multivariate logistic regression algorithms for predicting transition to functional psychosis were ranked by model fit and, where appropriate, AUC. In secondary analyses, the prediction of psychiatric hospitalization in the CHR subsample was used as a proxy for determining how well the models predict deterioration of general functioning. In the corresponding exploratory analyses, all previously proposed predictors were entered in a regression analysis with a stepwise backward algorithm. All analyses were weighted to compensate for under-sampling of questionnaire screen negatives.
Background: For many years, self-reported schizotypy has been regarded as a nonclinical state of liability for schizophrenia. Its principal utility has been as a nonclinical window on mechanisms and processes that characterise the developmental course of schizophrenia. However, evidence emerging over the past five years suggests that features of self-reported schizotypy measured in non-help-seeking children and adolescents are strongly associated with general psychological distress, negative effect, and suicidal ideation and behaviour. I sought to test whether taxometric schizotypy classification during the early to mid teenage years predicted self-reported suicide-related thinking and behaviour two years later.

Methods: In the first phase of a two-phase study, n = 387 high-school pupils (12 to 16 years, M = 14.7 years; 35% male) were classified as schizotypal (n = 39) or non-schizotypal (n = 288) by taxometric analysis of self-reported psychotic and psychosis-like experiences. In the second phase approximately 2 years later (age M = 16.9 years), a subset of schizotypal (n = 16) and non-schizotypal (n = 31) group participants members participated in a comprehensive follow-up assessment during which they reported on passive and active suicidal ideation and suicide-related behaviour.

Results: Compared to the complement group, schizotypy was associated with higher odds of passive suicidal ideation (OR = 8.41, p = 0.01; 95% CI 1.65, 43.01) in analyses controlling for sex and Māori ethnic identity. In contrast, there was no evidence that schizotypy predicted active suicidal ideation (OR = 2.28, 95% CI 0.47, 11.16) or suicide-related behaviour (OR = 1.37, 95% CI 0.31, 6.09).

Discussion: Study findings suggest that schizotypy classification during early to mid teenage years predicts passive suicidal ideation up to two years later. In contrast, schizotypy did not predict more severe levels of suicidal ideation or behaviour over this period. Important study limitations include the rudimentary nature of the assessment of suicidality and the modest sample size.

T36. The discriminative value of the strauss and carper prognostic scale for prediction of clinical diagnosis in early onset psychosis

Raqel Vicente, Pilar Baos, Celso Arango*, Beatriz Payá, Angel del Rey-Mejías, Josefina Castro-Forníes, Ana Gonzalez-Pinto, Montse Graell, Dolores Moreno, Marta Rapado-Castro

1Hospital General Universitario Gregorio Marañón, 2Hospital Clínica I Universitari, 3Hospital de Sant Joan de Déu, 4Hospital Sant Joan de Déu Hospital Sant Joan de Déu Hospital Sant Joan de Déu

Background: Diagnostic stability in early-onset first episode psychosis (EOP) –wherein psychotic symptoms present before 18 years of age—is low due to differential diagnostic-related issues. Initial clinical presentation may be heterogeneous and unspecific, making it difficult to ascertain the diagnosis, with the most frequent change at this stage being to schizophrenia spectrum and to bipolar disorder (1). The Strauss and Carpenter Prognostic Scale (SCPS) is one of the most widely used questionnaires in outcome prediction research (2,3). The aim of the present study is to determine the discriminative value of the SCPS for predicting clinical diagnosis in subjects with a first episode of EOP.

Methods: A subsample of 57 EOP patients completed baseline assessment from the original CAFEPS sample (3). A total of 13 additional patients were included from an EOP inpatient psychiatry unit (4). Clinical diagnosis was determined at two years follow-up using the Spanish version of the K-SADS-PL. Premorbid adjustment and level of social and occupational functioning for the year prior to baseline assessment were determined using the SCPS. Binomial logistic regression analysis was used to predict clinical diagnoses (i.e. schizophrenia or bipolar disorder), based on premorbid adjustment and level of functioning at baseline (i.e. SCPS items). Backwards-stepwise regression analyses were conducted in order to further analyze the predictive value of SCPS items in clinical diagnosis.

Results: The logistic regression model was statistically significant (χ2 (20) = 60.834, P = 0.001). The model explained 67.5% (Nagelkerke R2) of the variance in clinical diagnosis and correctly classified 85.6% of cases with SCPS 3A, 11B, 12 and 13 items significantly predicting diagnosis. Results of a forward stepwise regression model revealed that item 11B predicted a significant amount (14.9%) of the variance in clinical diagnosis, even when variance for all other variables in the final model was accounted for (final model summary included 5 items from SCPS –i.e. 3A, 5, 11B, 12 and 13 – χ2(21) = 49.79 P < 0.001) and explained a total of 58.4% of the variance of clinical diagnosis.

Discussion: A model of 5 individual SCPS items at baseline was capable of predicting clinical diagnosis at 2 year follow up in patients with a first episode of EOP. These data demonstrate that individual SCPS items are capable of distinguishing clinical features in EOP, with potential clinical relevance to higher diagnostic accuracy at baseline. In particular, SCPS items assessing the average number of social relationships in the past year, longest period that any psychiatric symptoms persisted, presence of thought disorder, delusions, or hallucinations in the past year and presence of depression, hypomania or mania in the past year have predictive value for diagnosis of schizophrenia vs. bipolar disorder. Further research should focus on differentiating SCPS from other premorbid functioning scales in order to produce a more accurate predictive model aimed at increasing diagnostic precision at the time of the first presentation of psychotic symptoms in EOP.
We describe here the follow up results of a feasibility study of the under investigated.

Results: 82 PRS subjects (15.1 ± 1.8 years, range: 11-17 years; 41.7% males) and 37 HC (15.5 ± 1.5 years, range: 11-17 years; 35.1% males) were included. In the PRS sample, 78.9.5% met criterion 1 for inclusion. IQ matched HCs were also included. Exclusion criteria: 1st or 2nd degree family with a psychotic disorder; neurodevelopmental disorder r IQ < 70. The same assessment was performed in the HC sample.

Discussion: PRS subjects presented mainly attenuated positive symptoms (75% meeting a DSM-IV diagnosis), and almost half of them had family history of psychotic disorders. PRS subjects scored significantly higher in PRS than in HC. Number of stressful life events and their subjective affectation were also higher in PRS subjects than in HC (t = -3.617, p < 0.001; t = -4.187, p < 0.001). 75.8% of PRS vs. none HC subjects (x² = 0.501, P < 0.001) met DSM-IV criteria for a present diagnosis: mood disorder: 37.5%; OCD and other anxiety disorders: 15.7%; ADHD: 10.9%; ODD or conduct disorder: 6.3%, eating disorders: 1.6%. 58.2% of subjects met criteria for a second diagnosis. 94.7% of PRS received one type of treatment vs. 61.7% of HC (only psychological) (x² = 4.521, P < 0.001): 16.0% only psychological, 31% only pharmacological, 49.3% combined and 1.4% psychopedagogical. Regarding pharmacological treatment, 35.6% subjects took a selective serotonin reuptake inhibitor (SSRI) combined with an antipsychotic; 18.6% only antipsychotics; 13.6% only SSRIs and the rest, different types of drug combinations. 67.8% of subjects took more than one drug at the same time.

Discussion: PRS subjects presented mainly attenuated positive symptoms (75% meeting a DSM-IV diagnosis), and almost half of them had family history of psychotic disorders. PRS subjects scored higher than HC in all the psychopathological scales, including stress scores. The majority of PRS subjects received some type of treatment, mainly a combination of psychological and pharmacological one, being SSRIs altogether with antipsychotics the main prescribed medication.

T38. Transition to psychosis in children and adolescents at ultra high risk in Italian neuropsychiatry services: a follow-up study

Giulia Spada*, Silvia Molteni, Michela Tantardini, Federica Ferro, Matteo Chiappetti, Paolo Fusari-Poli, Umberto Balottin

1University of Pavia; 2King’s College London

Background: Identifying subjects at risk of developing psychosis has been shown as one of the main strategies to improve outcome in psychosis. The ultra-high risk (UHR) criteria are the most widely used to diagnose individuals in a putative prodromal phase. They detect attenuated psychotic symptoms (APS), brief limited intermittent psychotic symptoms (BLIPS), genetic risk and deterioration syndrome (GRD). A fourth experimental criteria, the attenuated negative symptoms (NEG), is being studied (Fusari-Poli, 2007).

However, some aspects of the UHR approach, such as its feasibility and reliability in specific groups such as children and adolescents, is under investigated.

We describe here the follow up results of a feasibility study of the first Italian service for early diagnosis and treatment of UHR children and adolescents.

Methods: In the setting of the Neuropsychiatric unit of the Neurological National Institute C. Mondino, Pavia, Italy we used the Comprehensive Assessment of At Risk Mental State (CAARMS) to determine if help-seeking patients met one of the UHR criteria (including the experimental one “NEG”) at baseline and we monitor the longitudinal outcome identifying subjects who had a transition to psychosis (DSM-IV diagnosis of any psychotic disorder).

Results: We present data from the 2 years follow-up of the feasibility study. 50 help seeking patients between 12 and 18 years old were included in our study (52% were male; mean age 15.6 y, 1.54 SD), 43 referred from the Neuropsychiatry ward, 5 from outpatient services, 2 from private practitioners. The socio-economic status was low in the majority of them (32/50; 64%). 22 of them met inclusion criteria for UHR (HR+: 4 GRD, 17 APS, 1 BLIPS), 9 of them met the NEG criteria only (HRNeg), 10 were already psychotic, and 9 were not at risk (HR-). 17 out of the 22 HR+ subjects also showed attenuated negative symptoms.

After an average follow-up of 685.82 days (292.53 SD) 6 subjects (19.35% of the total HR+ and HRNeg subgroup) developed psychosis (4 psychosis NOS, 1 schizoaffecitive disorder, 1 delusional disorder). 5 of them where HR+ at baseline. 1 of them was at risk only for the experimental criteria of the negative symptoms (HRNeg). All of the patients that made a transition met the NEG inclusion criteria at baseline. None of the HR- subjects had a transition to psychosis. The mean transition time was of 280.16 days. The longest transition time was of 631 days in the subject that was at risk at baseline only for negative symptoms.

Discussion: Our results show a transition rate in adolescents lower than the one available in literature in groups of adults. This underlines the need of longer follow-up in children and adolescents. We also hypothesize that the presence of attenuated negative symptoms plays an important role in the evolution to psychosis in specific groups such as children and adolescents. Further research on bigger samples is required to better understand the role of attenuated negative symptoms as inclusion criteria in the UHR approach.

T39. Psychosocial characteristics of voice hearing in Norwegian adolescents: a population-based study

Else-Marie Løberg*, Rolf Gjestad, Maj-Britt Posserud, Kristina Kompus, Astrid Johansen Lundervold

1Haukeland University Hospital; 2University of Oslo; 3University of Bergen

Background: Young people that are troubled by hearing non-existent voices may be at risk for psychosis. Thus, understanding the demographic, environmental and psychological characteristics and/or risk factors for voice hearing has clinical implications. In the present study we examine the influence of central psychosocial variables on the tendency to being troubled by voices.

Methods: A population-based cohort of Norwegian adolescents attending secondary education aged 16-18 (n = 10346) completed a web-based questionnaire (the “ung/hordaland”-survey) on mental health including psychosocial background variables. Being troubled by voices was assessed by using an item from the extended Launay-Slade Hallucinations Scale: “I have been troubled by hearing voices in my head”. Responses were given on 5-point scale. The adolescents were grouped into a not hearing voice and hearing voice group based on a score of 0-1 (“certainly does not apply to me” and 1 “possibly does not apply to me”) or 3-4 (“3 = possibly applies to me” and 4 = “certainly applies to me”), respectively. Adolescents answering 2 = “unsure” were excluded from the group analysis.

Previous findings have shown that 5.3% of the adolescents in this dataset are troubled by hearing voices (Kompus, Løberg, Posserud, Lundervold, 2015). 14 psychosocial variables from the web-based questionnaire were chosen based on previous studies, 7 of these were further derived by means of factor analyses to maximize validity.

Results: Levene’s test revealed that all but one of the variables had unequal variances. Therefore, F-tests not assuming equal variance were used in order to test group differences. All differences were statistically significant due to the large sample size, so effect sizes were calculated (Partial Eta2). The following effect sizes emerged presented by decreasing effect size: Experience of self-value, 0.37, Affective symptoms, 0.35, Self-harm, 0.28, Anxiety, 0.27, Dysregulation of activation, 0.27, Disruptability, 0.21, Family alienation, 0.19, Experience of trauma, 0.18, Self-efficacy, 0.14, Experience of bullying, 0.10, Social functioning, 0.06, Illicit drug use, 0.04, School grades, 0.04, and Days absent from school, 0.02.

Discussion: Medium – to large effects sizes were seen in relation to experience of self-value and trauma, affective and anxiety symptoms, dysregulation of activation and self-harm, disruptability and family alienation, suggesting differences in relation to both markers of sub- optimal mental health and environmental risk factors. Other variables, mainly related to school and social functioning did not differentiate the adolescents troubled by voices to the same extent. This could partly be explained by the inclusion route being via the adolescents’ schools. Since these psychosocial variables are interrelated, more
sophisticated analysis is needed to further entangle the unique direct and indirect effects on voice hearing.

**T40. Prevalence, clinical differences and impact of anxiety disorders on conversion to psychosis in youth at high risk of developing psychosis**

Espadas Marta1, Jordina Tor1, Marta Carulla1, Inmaculada Baeza2, Montserrat Dolz1*, Elena De la Serna3

1Hospital Sant Joan de Déu; 2Hospital Clinic Barcelona; 3Centro De Investigación Biomédica En Red De Salud Mental

**Background:** Comorbid diagnoses of anxiety are found in subjects at high risk for psychosis, also called Psychosis Risk Syndrome Subjects (PRSS). Social phobia was identified as the most prevalent diagnosis in PRSS. However, little is known about the role of anxiety in the transition to psychosis. Some studies found that anxiety would predate the onset of a bipolar or psychotic disorder. Nevertheless, it is still a controversial issue. The aim of this study is to investigate the prevalence of anxiety disorders at baseline, and the association with any attenuated symptom and with later transition to psychosis.

**Methods:** Prospective, naturalistic and multicentric study conducted in help-seeking child and adolescent population (age 10-17). Inclusion criteria: 1) Attenuated positive or negative symptoms in the previous 12 months; 2) Brief limited intermittent psychotic symptoms; 3) First or second degree relative with schizophrenia or schizotypal disorder plus impairment of functioning. Exclusion criteria: IQ < 70 and a diagnosis of neurodevelopmental disorder.

**Psychopathology** was assessed by The Semi-structured Interview for Prodromal Syndromes and scale of Prodromal Symptoms (SIPS/SOPS) and the semi-structured interview Kiddie-Sads-PL. SPSS 19.0 package was used to analyze data performance.

**Results:** A total of 89 PRSS (mean age 15,09 ± 1,72; 58,4% females) were recruited.10 patients had been experienced a full-blown psychotic illness. The 50% of converters (mean age 15,3 ± 1,75; 60% females) presented an anxiety disorder at baseline which met the DSM-IV-TR criteria (2 diagnosis of panic disorder, 1 social phobia, 2 general anxiety disorder, 3 obsessive-compulsive disorder (OCD), 1 phobia and 1 separation anxiety disorder). 20% of non converters (mean age 15,07 ± 1,73; 58,2% females) were diagnosed with an anxiety disorder (1 diagnostic of panic disorder, 5 social phobia, 2 general anxiety disorder, 2 diagnosis of OCD, 3 diagnosis of phobia, 2 separation anxiety disorder, 2 non specific anxiety disorder, 1 agoraphobia). There were no age (P = 0,693) nor gender (P = 0,915) differences between converters and non-converters. The transition to psychosis was associated with high rates of anxiety disorders (P = 0,037) and the diagnosis of anxiety was correlated to one attenuated negative symptom (N4 = emotional restriction (P = 0,039; r = 0,227). In patients with anxiety there was a trend to have more attenuated negative symptoms but this trend didn’t show significance (P = 0,069; r = 0,198)

**Discussion:** High rates of anxiety have been observed in patients with schizophrenia, psychotic disorders and PRRS. Differences in psychopathology seem to be the most important. Most of the anxiety reported high rates of anxiety in patients with severe attenuated psychotic symptoms, more specifically with attenuated positive symptoms like suspiciousness. However, we found this association in attenuated negative symptoms and in patients who fulfilled the transition to psychosis. Although more longitudinal studies in high-risk population are needed to clarify controversial issues, treatment of anxiety would be a challenge to delay the onset and severity of psychosis.

**T41. Adolescent trajectories of cognition and risk for psychosis**

Hannah Dickson1*, Alexis Cullen1, Rebecca Jones2, Abraham Reichenberg2, Ruth Roberts3, Sheilagh Hodgins4, Robin Morris1, Kristin Laurens5

1Institute of Psychiatry, Psychology and Neuroscience, Kings College London; 2London School of Hygiene and Tropical Medicine; 3Icahn School of Medicine at Mount Sinai; 4University of Montreal; 5University of New South Wales

**Background:** Impairments in multiple cognitive domains are apparent among youth who later develop schizophrenia, but it has been hypothesized that different impairments might follow distinct developmental courses from childhood into adolescence. The aim of the study was to examine developmental trajectories of cognitive growth during adolescence in youth at-risk for psychosis. The study design was a three-wave design with assessments at age 12, 14 and 16 years. The young people included were: age between 10 and 17 years, one or more of the criteria for PRS, as assessed by the SIPS interview, no diagnosis of psychotic disorder, autism spectrum disorder, neurological disease and / or mental retardation. We evaluate the subjects with the Kiddie-Sacks Scale (K-SADS-PL), the Hamilton Depression Rating Scale (HDRS) and the Structural Interview for Prodromal Syndromes (SIPS). Clinical data were available from baseline and 12 month follow-up. Data analysis was performed by SPSS 20.0 statistic program.

**Results:** A total of 34 PRS subjects were included. At 12 months follow up 10 PRS individuals had transitioned to psychosis (15,3 ± 1,75 years, range: 11,50-17,50 years; 60% females) and 24 PRS had not transitioned (15,58 ± 1,76 years, range: 11,50-17,50 years; 62,5% females) being the rate of transition to psychosis 29%. The lifetime and baseline prevalence of mood disorder evaluated with K-SADS-PL in PRS non-transitioned was respectively 30% and 40% while in PRS transitioned was respectively 42% and 54%. We found no differences in HDRS scores between PRS non-transitioned and transitioned to psychosis (P = 0,894). We found positive correlations between HDRS scores and the SOPS items. In PRS transitioned subjects: P1 (Unusual Thought Content/Delusional Ideas)
we modelled the effect of co-morbid neurodevelopmental disorders of unique antipsychotic medications prescribed in a 5 year observational study using electronic patient records. T43. Neurodevelopmental disorders and their impact on initial treatment failure in early onset psychosis: a historical cohort study using electronic patient records

Johnny Downs1, Suzannah Lechler1, Harry Dean1, Nicola Sears1, Rashmi Patel1, Hitesh Shetty1, Matthew Hotopf2, Tamsin Ford3, Celso Arango4, James MacCabe1, Richard Hayes1, Laura Pina-Camacho1

1Institute of Psychiatry, Psychology & Neuroscience, King’s College London; 2Maudsley BRC; 3University of Exeter; 4Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, IiSGM, CIBERSAM

Background: Neurodevelopmental disorders increase the risk of developing a psychotic disorder in childhood and are associated with poor clinical outcomes. However, little is known about the effect of neurodevelopmental co-morbidity on the response to antipsychotic medications. Using clinical data from a large electronic case register of child and adolescent mental health records, we sought to investigate whether initial treatment failure (ITF, defined as the initiation of a third trial of novel antipsychotic as a result of non-adherence, resistance and adverse effects to prior antipsychotic treatment) was associated with co-morbid autism spectrum disorders (ASD), attention-deficit hyperactivity disorders (ADHD) and intellectual disability (ID).

Methods: Data were obtained from a first episode psychosis cohort of 602 children (51% male), aged between 10 and 17, referred to inpatient and community based Child and Adolescent Mental Health services in South London, UK. Data for age, sex, ethnicity, adaptive function, co-morbid ICD-10 diagnoses at presentation and the number of unique antipsychotic medications prescribed in a 5 year observation period were extracted from electronic patient records using the Clinical Record Interactive Search system (CRIS). In this cohort study, we modelled the effect of co-morbid neurodevelopmental disorders on antipsychotic treatment failure over a 5-year period using Cox regression.

Results: Of the 602 children with first episode psychosis, 104 (17.3%) developed ITF within the follow up period. Of those children with ITF 9.6% (n = 10) had a persistently ineffective response to two consecutive trials different antipsychotics, 15.4% (n = 16) experienced persistently non tolerable adverse effects, 3% (n = 3) showed persistent non-adherence, and 78% (n = 77) showed a combination of these reasons. We identified a significant association between co-morbid ASD and developing ITF which persisted after controlling for potential confounders including socio-demographic factors, other co-morbid neurodevelopmental disorders (i.e. ADHD, ID) and markers of disease severity (adjusted hazard ratio(aHR) 2.10; 95% CI 1.13–3.92; p = 0.02). We found Black ethnic group was positively associated with ITF (aHR 1.87; 95% CI 1.04–3.38; p = 0.04) whilst adaptive function (as measured by the CGAS) at first presentation was inversely associated (aHR 0.98; 0.96–0.99; P = 0.02); we found no significant effect of ADHD or ID on ITF. F: Discussion: Children with psychosis and co-morbid ASD at first presentation are much less likely to have a straightforward response to antipsychotic medication. This suggests that psychosis within ASD may require different strategies in terms of treatment and clinical engagement than conventional approaches.

T44. Prediction of functional outcome in young patients with a recent-onset psychiatric disorder: beyond the traditional diagnostic classification system.

Amedeo Minichino1, Francesconi Marta1, Ricardo Carion1, Kristin Cadenhead2, Francesco Saverio Bersani1, Maurizio Parisi1, Santo Rullo1, Massimo Biondi1, Arturo Bevilacqua1, Roberto Delle Chiaie1

1Sapienza, University of Rome; 2Zucker Hillside Hospital; 3University of California, San Diego

Background: Poor functional outcome among patients with mental illness is not unique to psychotic disorders. Nevertheless, research on early predictors of functional outcome has primarily focused on individuals with an “at-risk mental state” (ARMS) for psychosis rather than across diagnostic groups in the early stages of psychiatric illness. We develop a multidimensional predictive model of functional outcome in young outpatients with the recent onset of psychiatric illness.

Methods: Prospective longitudinal study of consecutively screened non-psychotic outpatients (ages 17-35). Participants were interviewed with the Comprehensive Assessment of At Risk Mental States to assess ARMS status. Baseline demographic, clinical, neurocognitive, theory of mind, and neurological soft signs (NSS) measures were collected. The DRD1-rs4532 polymorphism was analyzed in a subgroup of participants. At 2-3 year follow-up, clinical and functioning data was collected. The Global Assessment of Functioning (GAF) scale was the primary outcome measure. A score higher or lower than 65 at follow-up defined the “Good” or “Poor” functional (PF) outcome subgroups, respectively. A binary logistic model was constructed to predict functional outcome in the entire sample using predictor variables generated within the following domains: demographic, clinical, ARMS, neurocognitive, theory of mind, NSS and functioning at baseline.

Results: 138 outpatients (53% male) participated at baseline then 116 agreed to clinical and functional follow-up assessment. 54.3% of patients experienced PF at follow-up. The final predictive model, with an accuracy of 79.7%, consisted of 3 variables: Attention, Avolition, and Motor-coordination; the addition of the DRD1-rs4532 polymorphism increased the accuracy to 81.9%. The model was independent of the ARMS status, the DSM diagnosis and psychotic conversion.

Discussion: Our results are the first to demonstrate that in a secondary mental health setting, a trans-diagnostic approach that takes into account specific neurocognitive, clinical, neurological, and genetic information, has the potential to identify those individuals with a common functional trajectory that is independent of diagnosis or ARMS status. Specific early therapeutic interventions that target modifiable risk factors and emphasize functional recovery in young psychiatric samples, independent of psychosis risk, is essential.

T45. Psychosis prediction in secondary mental health services. A broad, comprehensive approach to the “at risk mental state” syndrome.

Marta Francesconi1, Amedeo Minichino1, Kristin Cadenhead3, Ricardo Carion1, Arturo Bevilacqua1, Santo Rullo1, Maurizio Parisi1, Francesco Saverio Bersani1, Massimo Biondi1, Roberto Delle Chiaie1

1Sapienza, University of Rome; 2University of California, San Diego; 3Zucker Hillside Hospital

Background: Standardized criteria for detection of individuals “at risk mental state” (ARMS) for psychosis mainly rely on the expression of subsyndromal positive symptoms (SPS). SPS-based criteria may lack of specificity in detecting a real ARMS status when ARMS samples are characterized by high rates of comorbid psychiatric syndromes, such as those recruited in secondary mental health facilities.

Methods: 138 non-psychotic outpatients (aged 17-35) were recruited in secondary mental health services, with the aim of developing a predictive model of psychosis transition not relying on the SPS-based definition of psychosis risk and independent of psychiatric diagnoses.
Participants were interviewed with the Comprehensive Assessment of At Risk Mental States to assess ARMS status and followed up for up to 3 years (mean follow-up time, 2.3 years; SD = 0.9). Baseline demographic, clinical, cognitive, and Neurological Soft Signs (NSS) measures were collected. Cox regression was used to derive a risk index. Results: The conversion rate to psychosis was 21% for the overall sample, 34% for ARMS+ and 9% for ARMS-. The final predictor model, with a positive predictive validity of 75% consisted of three variables: visuospatial/constructional deficits, sensory integration and theory of mind abnormalities, and it cut across the ARMS and DSM-IV categories.

Discussion: To the best of our knowledge this is the first study to develop a predictive model of psychosis transition not relying on the SPS-based definition of risk. The use of the proposed predictive algorithm may enable a more selective recruitment in secondary mental health settings, potentially reducing duration of untreated psychosis and improving prognostic outcomes.

T46. The BDNF VAL66MET genotype regulates prepulse inhibition of acoustic startle, an endophenotype of schizophrenia: sensitivity to glucocorticoid stress hormone
Michael Notaras1, Rachel Hill1, Joseph Gogos2, Maarten van den Buuse3
1Florey Institute, University of Melbourne; 2Columbia University; 3La Trobe University

Background: Reduced expression of Brain-Derived Neurotrophic Factor (BDNF) has been implicated in the pathophysiology of schizophrenia. The BDNF Val66Met polymorphism, which results in deficient activity-dependent secretion of BDNF, has been reported to mediate stress sensitization and clinical features of schizophrenia, although clinical studies have been inconsistent (Notaras et al., Neuroscience and Biobehavioral Reviews 2015). Here we investigated whether chronic stress may be a factor that determines allele of risk within this disorder. The specific aim of the study was to investigate the effect of this polymorphism on Prepulse Inhibition (PPI), a translational model of sensorimotor gating which is disrupted in schizophrenia.

Methods: We utilized BDNFVal66Met mice genetically modified to carry a humanized BDNF transcript expressing the Val66Met polymorphism (hBDNFVal66Met) and studied the long-term effect of chronic corticosterone (CORT) exposure in these animals as a model of history of stress. PPI was measured using automated startle chambers which delivered startle pulses and prepulse-pulse combinations and recorded the animals’ startle responses. PPI was assessed at both 100mscc and 30msc inter-stimulus intervals (ISI).

Results: Analysis of PPI at the commonly used 100mscc ISI identified that, irrespective of CORT treatment, the hBDNFVal/Met genotype was associated with significantly reduced PPI. In contrast, PPI was not different in hBDNFMet/Met mice compared to the hBDNFVal/Val genotype. At the 30mscc ISI, a significant genotype x CORT interaction reflected that CORT treatment selectively disrupted sensorimotor gating of hBDNFVal/Met heterozygote mice but not hBDNFVal/Val or hBDNFMet/Met mice. Analysis of startle reactivity revealed a significant hBDNFVal66Met genotype x CORT x sex interaction, reflecting that chronic CORT reduced startle reactivity of hBDNFVal/Val male mice by 51%. However, ANCOVA suggested that this was independent of the effect of CORT and hBDNFVal66Met genotype on PPI.

Discussion: We provide the first robust evidence of a distinct BDNF ‘heterozygote disadvantage’ phenotype using the sensorimotor gating endophenotype of schizophrenia, and that a history of stress hormone exposure interacts with BDNF Val66Met genotype. These results extend our previous observations of selective CORT effects on fear extinction in the hBDNFMet/Met genotype (Notaras, Hill, Gogos and van den Buuse, Molecular Psychiatry in press). Overall, our studies therefore show that effects of the BDNF Val66Met polymorphism vary by behavioural paradigm and, potentially, clinical symptom domain.

T47. ARC/ARG3.1 genetic disruption in mice causes dopamine system alterations and neurobehavioral phenotypes related to schizophrenia
Francesco Papaleo1, Francesca Managò1, Kuan Wang2
1Istituto Italiano Di Tecnologia; 2NIMH

Background: Recent human genetic studies highlighted the post-synaptic Activity-regulated cytoskeleton-associated protein (Arc) complex as a convergence signal for several genes implicated in schizophrenia. However, the functional significance of Arc in schizophrenia-related neurobehavioral phenotypes and brain circuits is unknown.

Methods: We used genetically modified mice with targeted deletion of the Arc gene (Wang et al., 2006). A comprehensive behavioral assessment for functions that have been studied in rodents as relevant to schizophrenia. In addition, using a combination of ex vivo molecular assessments, in vivo microdialysis and electrical stimulation coupled with in vivo two-photon imaging we investigated the effects of Arc genetic disruption on different aspects of dopaminergic system functions.

Results: We demonstrated that genetic disruption of Arc in mice produces deficits in sensorimotor gating, social, and cognitive abilities, as well as altered locomotor/amphetamine responses consistent with schizophrenia-related phenotypes. Furthermore, genetic disruption of Arc led to reduced frontal cortical dopamine release and mesocortical circuit activation concomitant with increased postsynaptic D2 expression in the striatum.

Discussion: These findings identify a previously unexpected role of Arc in the regulation of dopaminergic neurotransmission and show that genetic disruption of Arc can lead to a hypoactive D2 receptor and upregulated mesostriatal D2 signaling with schizophrenia-related behavioral phenotypes. These results support the notion that Arc is a point of convergence for the pathophysiology of schizophrenia.

T48. Phase ii, double-blind, randomised, placebo-controlled study of adjunctive taurine in first-episode psychosis
Colin O’Donnell1, Kelly Allott2, Hok Pan Yuen3, Patrick D McGorry4
1Donegal Mental Health Service; 2Orygen, The National Centre of Excellence in Youth Mental Health

Background: Taurine is an inhibitory neuropeptidomulatory amino-acid in the central nervous system. Taurine activates GABA- and glycine-insensitive chloride channel and inhibits the NMDA receptor. It also functions as a neuroprotective agent and has a role in neural development and neurogenesis. The aim of this study was to determine the efficacy of adjunctive taurine in improving symptomology and cognition among patients with a DSM-IV first-episode psychotic disorder.

Methods: This was a randomised, double-blind, placebo-controlled trial (January 2007 and May 2009). Patients taking low dose antipsychotic medication were randomised to receive once-daily taurine 4 g or placebo for 12 weeks. One hundred and twenty one first-episode psychosis patients aged 18-25 years attending early intervention services in Melbourne, Australia consented to participate. The co-primary outcomes were: change in symptomatology (measured by the BPRS total) and change in cognition (measured by the MATRICS composite score) at 12 weeks. Secondary outcomes included tolerability and safety and additional clinical and functioning measures.

Results: Eighty six participants (n = 47 taurine; n = 39 placebo) were included in the final analysis. Taurine significantly improved sympto- matology measured by the BPRS total score (95% CI 1.8-8.5; P = 0.004) and psychotic subscale (95% CI 0.1-1.5; P = 0.026) when compared to placebo. Additionally, improvements were observed in depression (CDSS; 95% CI 0.1-3.0; P = 0.047) and global functioning (GAF; 95% CI 0.3-8.8; P = 0.04) scores. There was no group difference in composite cognitive score (95% CI -1.7-1.0; P = 0.582). A significant group difference was found on one safety and tolerability item: Psychic item 2 (Asthenia/Lassitude/Increased Fatigability) of the UKU, with the taurine group showing a more favourable outcome (P = 0.006).
Discussion: While adjunctive taurine did not improve cognition, it appears to improve psychopathology in patients early in the course of a first-episode psychosis who are also receiving low-dose antipsychotic treatment. The use of taurine warrants further investigation in larger randomised studies, particularly early in the course of psychosis.

T49. The effect of virtual reality exposure therapy on social participation in people with a psychotic disorder: a multi-site randomized controlled trial
Roos Pot-Kolder1, Roos Pot-Kolder*1, Wim Veling2, Mark Van der Gaag1
1VU University Amsterdam; 2University Medical Center Groningen

Background: Many patients with a psychotic disorder live a life of limited participation in society, even if their psychotic symptoms have been treated successfully. An important factor in sustaining social isolation is that social situations re activate experiences of social anxiety, ideas of reference and paranoid thoughts. The patient has learned to escape these situations, resulting in a short-term reduction in distress, which in turn strengthens the safety behavior and enhances avoidance and social withdrawal. However, exercises may break this vicious circle. Virtual Reality Exposure Therapy (VRET) is an evidence based treatment for several anxiety disorders. It has the potential to be an affordable and accessible form of treatment to enhance social participation and wellbeing for patients with a psychotic disorder and social withdrawal.

Methods: This study design is a single blind randomized clinical trial with three-months follow-up. VRET is compared to treatment as usual (http://www.controlled-trials.com/ISRCTN12929657). The VRET treatment consists of sixteen treatment sessions of sixty minutes each, within an eight-week timeframe. Social participation is measured with Ecological Momentary Assessments (EMA), before and at end of treatment, and at three months follow-up. Primary outcome is the subjective social participation. EMA-based measures include the time spent in the company of other people and the type of people spent time with. Subjective social participation is measured as momentary paranoia, perceived social threat and event stress as experienced in situations with other people.

Results: We finished the inclusion period of the study. One hundred and sixteen participants were included in the study. Follow-up is completed in December 2015. We will be able to present the main results of the study in April 2016 on the conference. Preliminary case reports suggest that many patients are able to reduce their safety behavior and participate more fully in daily life after VRET treatment.

Discussion: VRETBritain may be effective for improvement of social participation in patients with psychotic disorder.

T50. Correlation between functionality and symptom control in acute schizophrenia patients
Tian mei Si1, Hua Fei Lu2, Li Li Zhang2, Fu Feng2, Jian Min Zhuo2, Shangli Cai2
1National Clinical Research Center for Mental Disorders, Peking University Institute
2University of Basel Psychiatric Clinics, Center for Gender Research and Early Detection

Background: The treatment goals for patients with schizophrenia include not only eliminating symptoms, but also maximizing quality of life and adaptive functionality. PANSS (Positive and Negative Syndrome Scale) and PSP (Personal and Social Performance scale) were reliable tools for the evaluation of symptoms and functionality in the acute and stable stage of schizophrenia. In the previous studies, there was significant correlation between functionality and symptom in maintenance phase, while few studies focused on the correlation in acute phase. We aimed to investigate the correlation between function and symptom, and explore the factors which are associated with functionality in acute phase of schizophrenia.

Methods: An 8-week, open-labelled, single-arm and multi-center study was conducted to evaluate the effects of flexible-dose paliperidone extended release (ER) tablets in treating acutely patients with schizophrenia in China. A total of 608 patients with schizophrenia were enrolled, and 602 subjects were included in the Full Analysis Set (FAS), and the PANSS total score of each patient was ≥ 70 at baseline. Subjects would be required to be hospitalized within the first 7 days after the study initiation. Follow-up visits were scheduled at Weeks 2, 4, and 8 (endpoint). PANSS, PSP, CGI-S (Clinical Global Impression - Severity Scale), treatment satisfaction, sleep quality and daytime drowsiness were assessed at every visit point. This is a post hoc analysis of the study, focused on the correlation between functionality and symptom management in acute schizophrenia patients, and the factors associated with functionality. Logistic regression analysis and Pearson correlation analysis were applied.

Results: There were 602 subjects (FAS) included in the analysis. PSP total scores increased and PANSS total scores decreased gradually during the study. PSP and PANSS total scores were negatively correlated at all visits (P < 0.0001). In the 495 subjects with PANSS reduction ≥ 30% at endpoint, the percentage of subjects with PSP change from baseline ≥ 10 increased gradually (from 39.19% at Week 1 to 92.12% at Week 8). In the 103 subjects with PANSS reduction < 30% at endpoint, most of them had PSP score change from baseline < 10 (from 81.55% at week 1 to 76.7% at week 8). In the subjects with PSP total scores change ≥ 10 at endpoint compared with baseline, the percentage of subjects with PANSS reduction ≥ 30% increase gradually (from 38.3% at week 1 to 95% at week 2). In the 118 subjects with change in PSP total scores < 10 at endpoint compared with baseline, most of them have PANSS reduction < 30% (66.95% at endpoint). At week 1, subjects with PSP total score change ≥ 10 has higher possibility to get better symptom control in the endpoint, compare with those subjects with PSP total scores < 10 (OR = 2.85, 95%CI = 1.68-4.84). The association is more remarkable at endpoint (OR = 38.48, 95%CI = 21.84-67.49). The factors which influenced the changes of PSP total score at endpoint included disease duration, PANSS total scores at baseline and endpoint, and the PANSS subscale scores, treatment satisfaction, sleep quality and daytime drowsiness at endpoint.

Discussion: PSP total scores and PANSS total scores were significantly correlated in acute phase.

References:
1. American Psychiatric Association steering committee on practice guidelines; Practice guideline for the Treatment of Patients With Schizophrenia, Second Edition

T51. Associations of negative symptoms and psychosocial functioning in patients at risk for psychosis
Katharina Beck1, Katharina Beck*1, Christina Andreaou2, Erich Studerus2, Stephanie Menghini-Müller1, Laura Egloff3, Anita Riecher-Rössler4
1University of Basel Psychiatric Clinics, Center for Gender Research and Early Detection; 2University Hospital of Psychiatry Basel; 3University of Basel Psychiatric Clinics, Center for Gender Research and Early Detection; University Psychiatric Clinics (UPK); 4Center for Gender Research and Early Detection

Background: Impairment of psychosocial functioning in patients with psychosis is common and related to various factors such as symptoms and neurocognition. Recent research suggests that these impairments precede the onset of frank psychosis and are already present in patients with an at risk mental state (ARMS) for psychosis. Furthermore, they seem to persist independent of later transition to psychosis and despite of preventive treatments. Identifying relevant factors that impact psychosocial functioning is crucial to a broader understanding of ARMS and the development of suitable intervention strategies. In patients with psychotic disorders, main negative symptoms seem to affect psychosocial functioning. Negative symptoms are also experienced by ARMS patients and have been repeatedly associated with impaired psychosocial functioning. However, recent research suggests that this may partly be due to an overlap of measures of negative symptoms and psychosocial functioning.

Aim of the present study was to assess the association between negative symptoms and psychosocial functioning, disentangling this conceptual overlap. Based on the few studies available so far, it was
hypothesized that negative symptoms predict poor psychosocial functioning in ARMS even after correction for confounding characteristics.

Methods: Data of 57 patients with ARMS for psychosis who participated in the early detection of psychosis (FEPSY) study were analyzed. Negative psychosocial functioning included the Global Assessment of Functioning (GAF) and occupational status. Negative symptoms were assessed by the Scale for the Assessment of Negative Symptoms (SANS), which includes both subscales that overlap with functioning measures (subscales with conceptual overlap; COS) and subscales that do not (conceptually distinct subscales; CDS). Hierarchical regression analyses were conducted to evaluate the distinct contribution of the different negative symptom subscales in predicting psychosocial functioning while controlling for education and neurocognition (composite score).

Results: Negative symptoms were significantly correlated with poorer psychosocial functioning. CDS contributed independently to psychosocial functioning. After controlling for education (ΔR² = .122, p = .008) and neurocognition (ΔR² = .229, p = .008), CDS (ΔR² = .274, p = .030) and COS (ΔR² = .475, p = .006) contributed independently to the prediction of psychosocial functioning. The complete model explained 40% of the variance (Adj. R² = .400, p = .000).

Discussion: These results support the notion of negative symptoms directly affecting psychosocial functioning above the impact of neurocognition, confirming findings by previous studies. This effect seems to not only be due to construct similarities between negative symptoms and functioning, as negative symptom domains without conceptual overlap were also significant predictors of psychosocial functioning. This emphasizes the relevance and impact of negative symptoms in patients with ARMS. Thus, interventions targeting the reduction of negative symptoms could be the key to improving psychosocial functioning in these patients.

References:

TS5. Gender differences in the symptomatology of patients at-risk for psychosis - results from the EU-GEI study

Stephanie Menghini-Müller*, Erich Studerus², Ulrike Heitz³, Laura Egloff³, Sarah Ittig³, EU-GEI Work Package 5*, Anita Riecher-Rössler²

1Psychiatric University Clinics Basel; 2University of Basel Psychiatric Clinics, Center for Gender Research and Early Detection; 3University of Basel Psychiatric Clinics, Center for Gender Research and Early Detection; University Psychiatric Clinics, EU-GEI

Background: Gender differences in symptomatology have been widely reported among chronic schizophrenia patients and partly also in first episode patients. However, many studies conducted in this area so far show inconsistent results, ranging from a higher impairment in specific symptoms observed in men to no gender differences regarding symptom presentation.1 The contradicting literature could be due to methodological inaccuracies or reflect the heterogeneity of the symptomatology. Furthermore, little is known about gender differences in patients with a so-called at-risk mental state (ARMS) for psychosis. The aim of this study was to test for potential gender differences in the baseline symptomatology of ARMS patients beyond possible effects of confounders (e.g. cannabis use).

Methods: The data analyzed in this study were collected within the multicenter European Gene-Environment Interactions (EU-GEI) study. Clinical symptoms were assessed in 342 ARMS patients (female, n = 151) using five observer-rated scales, namely, the expanded version of the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), the Comprehensive Assessment of At-Risk Mental State (CAARMS), the Montgomery-Åsberg Depression Rating Scale (MADRS), and the Young Mania Rating Scale (YMRS). Linear mixed effects models with a random intercept per center to account for clustering in the data were used to compare symptomatology at baseline between men and women. All P-values were fully corrected for multiple testing using the False Discovery Rate (FDR) procedure.

Results: There were no gender differences in demographic variables and psychiatric medication intake. However, men showed significantly higher rates of current cannabis use (P = 0.028) compared to women. With regard to symptomatology, when corrected for multiple testing, we found that ARMS men had significantly higher negative symptom scores (BPRS Negative Symptoms: P = 0.035, d = 0.418; SANS Affective Flattening: P = 0.035, d = 0.396; SANS Alogia: P = 0.035,

Elisabeth van der Stouwe*1, Bertine de Vries2, André Aleman1, Jooske van Busschbach1, Marieke Pijnenborg2

1University Medical Center Groningen; 2University of Groningen

Background: Individuals with a psychotic disorder are at an increased risk of becoming victim of a crime. Victimization can have a major impact on the lives of already vulnerable patients, and ultimately entails high costs for society (Choe, Teplin, & Abram, 2008). Research has revealed several factors (e.g. impaired social cognition, aggression regulation problems, assertiveness, self-stigma, self-esteem) to be associated with victimization in patients with a psychotic disorder. To address these risk factors, we developed a psychomotor resilience training with elements of kickboxing. In preparation of a multi-centre randomized controlled trial, we performed a feasibility study which aimed to (1) explore the willingness of patients to participate in an intervention including kickboxing, (2) evaluate the training protocol, (3) explore suitable outcome measures.

Methods: Twenty-four psychotic patients were recruited from the department of psychotic disorders of GGZ-Drenthe. Twenty weekly training sessions were provided by a psychomotor therapist and an expert by experience. Following every session the training protocol was evaluated by the trainers, psychologist and a martial arts expert. Victimization was determined with the crime victimization scale (IVM; Kamperman et al., 2014). Social behavior was assessed by means of a Dutch Social Functioning Inventory (IOA; Dam-Baggen & Kraaimaat, 1999), aggression regulation was assessed with a Dutch Self-expression and Control scale (ZECV; van Elderen, Verkes, Arkesteijn, & Korf, 1996). Differences pre- and post-intervention were determined by means of repeated measures analyses. After the intervention, participants were asked about subjective experiences with the training.

Results: Patients were willing to participate in the study; within six weeks 24 participants were recruited. At baseline, 58% of the participants reported that they had been victimized in the past five years. The training showed no effect on social behavior as measured with the IOA. Results reveal a marginal effect on control over internalization of aggression. After the intervention, participants had the idea that the training resulted in a decreased chance of victimization, more self-esteem, more empowerment, setting boundaries more easily and feeling safer outside.

Discussion: Patients were enthusiastic to participate in a study including an intervention with kickboxing techniques. Baseline results showed that victimization is a serious problem for these individuals. The IOA did not seem a suitable outcome measure to determine the effect on social behavior and will be replaced with another questionnaire in the RCT. The ZECV did seem a suitable outcome measure. Participants had the idea that the training had a positive effect on the risk factors of victimization. Following, we will test the efficacy of the training by means of a multicentre randomized controlled trial.

T55. Subjective experiences in psychosis early detection – factor structure of the Frankfurt complaint questionnaire

Martina Uttinger1, Erich Studer2, Sarah Ittig2, Ulrike Heitz2, Frauke Schultzze-Lutter3, Anita Riecher-Rössler2

1Psychiatric University Clinics Basel; 2University of Basel Psychiatric Clinics, Center for Gender Research and Early Detection; 3University Hospital of Child and Adolescent Psychiatry, University of Bern

Background: Patients suffering from schizophrenia are not only affected by positive symptoms but are also experiencing various disturbances, often already several years before the onset of frank psychosis1. Initially, these are often only subjectively experienced by patients themselves as deviations from their “normal” self, and were called basic symptoms. They can be assessed as a self-report with the Franklin Complaint Questionnaire (FCQ) which has been used in seven languages (German, English, French, Spanish, Italian, Japanese and Taiwanese). Although several studies have examined the factorial structure of the FCQ, results are still inconclusive. Besides the original four-factor-solution, one or two-factorial solutions have been suggested. Furthermore, all previous studies relied on exploratory factor analysis (EFA) and treated binary FCQ items as if they were continuous, which can severely bias the resulting factorial structure. The current study is the first to investigate the factorial structure of the FCQ using 1) confirmatory factor analysis (CFA), 2) categorical item methodology and 3) a combined sample of at-risk mental state (ARMS) for psychosis and first episode psychosis (FEP) patients.

Methods: The FCQ is a self-ratings questionnaire whose items were derived from interviews with schizophrenia patients. It contains 98 items and has a yes/no answer scale. A sample of 96 ARMS and 73 FEP patients participating in the prospective FePsy (Früherkennung von Psychosen) study2 in Basel, Switzerland was used to explore the factorial structure of the FCQ. The following previously proposed factorial solutions were compared using CFA: 1) the 10-factorial solution by Süßwold et al. 2) The EDF derived four-factorial solution of Süßwold et al. 3) the one factorial solution suggested by Yon et al. 4) the three factorial solution of Mass et al. and 5) the 24 item short version of Cuesta et al. All models were estimated using Bayesian methods. Models that were not too complex for the weighted least square estimator (WLSMV) (i.e. not more than 4 factors) were additionally estimated with WLSMV as it provides a larger variety of fit indices. Furthermore, we tested if any factors of the FCQ were able to predict transition to psychosis in our sample of ARMS patients using survival analysis.

Results: All tested models provided an acceptable fit to the data. The short version thereby seemed to fit best. Overall, the one factor solution proved to be the best fitting model. Predictive validities could not be found for any of the factors.

Discussion: The results of the present study suggest that the covariance between FCQ items is best explained by a single underlying latent factor. Our results using a sample of ARMS and FEP patients therefore seems to be in line with previous studies3. Compared to interviews assessing basic symptoms such as SPI-A or BSABS, predictive validities seem to be lower in this self-rating questionnaire. Therefore, future studies should compare the two methods of assessment item by item.

References:

Background: Brain derived neurotrophic factor (BDNF) is known to be involved in numerous cognitive processes. Peripheral BDNF levels in plasma and serum are used as in-vivo correlates of cortical BDNF. Since cognitive deficits are recognized as core feature of psychiatric disorders, preceding the onset of the illness (Pflueger, Gschwandtner, Stieglitz, & Riecher-Rössler, 2007), it is of utmost importance to investigate the relation between BDNF levels in emerging psychosis and their correlation with cognition to elucidate this matter. However, there are so far no studies investigating BDNF levels in individuals with an at-risk mental state (ARMS) for psychosis. The aims of the present study were hence the following: first to assess peripheral BDNF levels across different stages of potentially emerging psychosis, and second to investigate their association with cognitive performances. 

Methods: Plasma and serum BDNF levels were measured and correlated with neuropsychological performance in ARMS (n = 18), first episode psychosis (FEP; n = 6), and chronic schizophrenia patients (CS; n = 11) within the project “Vulnerability and Resilience Factors of Schizophrenia” funded by the Swiss National Foundation. Neuropsychological domains assessed were intelligence, verbal memory, working memory, attention and executive function.

Results: Plasma (P = .001) and serum (P < .001) BDNF levels differed significantly between groups and were highest in CS, intermediate in FEP and lowest in ARMS. Across all groups, plasma BDNF and verbal learning and memory were negatively correlated (r = -.361; P = .064), while a positive correlation was found between plasma BDNF and executive functioning (r = .356; P = .069), with both correlations being significantly predicted the outcome of the ToH task (P = .023; R² = .433).

Discussion: The low BDNF levels in ARMS compared to the other two groups were surprising, as based on the literature decreased levels with progression of the illness were expected. The low BDNF level in ARMS implies an important drop of this neurotrophin prior to the onset of the disorder. The associations of peripheral BDNF with neuropsychological performances preceding the onset of the disorder are so far inconsistent but could, if these findings are replicated, point towards a link of these variables. However, as this is the first study to investigate peripheral BDNF levels in ARMS and their correlation to neuropsychological performances, no firm conclusions can be drawn and more research is needed.

Reference:
was designed to extend these studies with a comprehensive multi-modal intervention (Plasticity-based Adaptive Cognitive Remediation, PACT) composed of auditory, visual, executive function, and social cognition exercises. A large multi-site trial was designed to assess the safety and efficacy of PACT for the treatment cognitive impairment in schizophrenia, and to evaluate the size, methodological rigor, and duration required for regulatory clearance as a medical device by the US Food and Drug Administration (FDA).

Methods: 150 patients with DSM-IV-TR diagnosed schizophrenia from 11 sites across the United States were enrolled into the trial based upon the MACTS guidelines for cognitive enhancement trials. Patients were stratified based upon baseline cognitive performance on the MACTS Consensus Cognitive Battery (MCCB), and randomized to receive treatment with 130 one-hour sessions of PACT or a control condition of video games 4-5 times per week over the course of 6 months. PACT is a set of eleven computerized cognitive training exercises designed to improve the speed and accuracy of information processing and neuromodulatory function. Each module involves an adaptive procedure to ensure learning, stimulus sets designed to generalize to real-world function, and a “game” wrapper that encourages controlled engagement of neuromodulatory systems. Treatment response was measured with two co-primary outcome measures: the MCCB for cognition, and the University of California, San Diego Performance Based Skills Assessment (UPSA-2) to measure functional capacity. Each outcome measure was analyzed separately using a random effects longitudinal linear model with subject as a random effect and the following fixed effects: site, treatment (PACT and control), week (week 0, 13 and 26), and treatment by week interaction. The primary contrast of interest was PACT versus control at Week 26.

Results: There were no significant differences between groups in demographic or clinical factors at baseline. Patients were aged 43+/−12 years of age, with MCCB composite scores of 29+/−13 and UPSA-2 scores of 87+/−15. Of the 75 patients randomized to each treatment group, 44 completed treatment with PACT while 58 completed treatment in the computer game condition (P=0.05). Use of field of view, but not auditory time order judgment, used as positive controls for target engagement, demonstrated significant improvement with PACT compared to the control condition. Changes in MCCB and UPSA-2 were small, and did not differ significantly between treatment groups.

Discussion: In contrast to previous studies assessing the effect of plasticity-based computerized cognitive remediation limited to the auditory system and verbal learning, the current larger study of a more comprehensive program consisting of exercises targeting auditory, visual, executive function, and social cognition did not demonstrate significant improvement in cognitive performance measures. Possible explanations include lack of target engagement, negative interference between auditory and visual training, and overall program efficacy. Additional analyses will focus on demographic and clinical measures that distinguished responders from non-responders, the relationship between “treatment engagement” markers and treatment response, and the reasons for the increased drop-out rate in patients randomized to the PACT intervention.

T59. Long-term safety and durability of effect of aripiprazole lauroxil in a one year schizophrenia extension study

Robert Risinger1, Aniele Stanford1, Yangchun Du1, Jacqueline Zummo1, Hassan Jamaal1, Chih-Chin Liu1, Amy Claxton1

1Alkermes, Inc.

Background: Aripiprazole lauroxil (AL; ARISTADA™, Alkermes, Inc.) is a long-acting injectable (LAI) antipsychotic is approved for the treatment of schizophrenia. We report on efficacy and safety outcomes from a 1-year extension study of long-term treatment with AL.

Methods: This 1-year AL treatment extension study enrolled subjects (n=478, safety population) from two sources: de novo subjects with chronic schizophrenia; and rollover subjects who had completed a double-blind, 12-week, placebo-controlled study. De novo subjects received monthly injections of AL 882 mg, and rollover (placebo or AL) subjects received monthly injection with either AL 441 mg or AL 882 mg depending on their assigned treatment in the preceding placebo-controlled study. Subjects who are first assigned to active AL also received daily oral aripiprazole (15 mg) for 3 weeks. The key primary and secondary objectives were to characterize the safety, and to evaluate the durability of therapeutic effect of AL during long-term treatment of subjects with stable schizophrenia.

Results: Of 478 (de novo = 242, rollover = 236) enrolled subjects, 462 had evaluable post-baseline data. At baseline, the mean (SD) age was 39 (12) years, 58% were male, 64% were white, 19% were black, 17% were Asian, and the mean (SD) PANSS total score was 61 (14). High proportions of subjects received ≥ 9 (76%) or > 13 injections (69%) of AL. Of the 110 and 368 patients enrolled in the 441 mg and 882 mg AL study arms, respectively, 32% of patients discontinued in each study arm. Drug-related adverse events were reported in 29 (26%) and 112 (30%) of subjects in the 441 and 882 mg AL arms. Treatment-emergent adverse events observed in ≥ 5% of subjects were insomnia (8%), and increased weight (5%). Serious drug-related adverse events were reported only in the 882 mg arm [3 subjects (< 1%)]. Overall incidence of Parkinsonism and akathisia based on the movement scale were 7% and 5%, respectively. The majority of patients (77%) gained ≤ 5 kg over 16 months, and, at any post-baseline visit, 88 subjects (18%) had a weight increase of ≥ 7%. Overall response (≥ 30% decrease in PANSS total score from baseline to Day 365 or, CGI-I of 2 or 1) was achieved by 51% of subjects at endpoint. Overall, the mean (SD) change from baseline in PANSS total score at study endpoint was -8 (10) and in CGI-S was -0.4 (0.7). The mean (SD) reduction in PANSS total for the placebo to 441 mg AL subject group was -19 (15) and the placebo to 882 mg AL subjects was -12 (12).

Discussion: Treatment of subjects with schizophrenia for ≥ 1 year with AL demonstrated continued safety and additional therapeutic effect. As most safety extension studies have the limitation of selecting for reduced drop-out, about half the study subjects were lost to follow-up. The low drop-out/high retention of this study supports the high overall safety and tolerability of AL for patients with schizophrenia. Further, the low proportion with weight gain supports the beneficial metabolic profile of the treatment with AL LAI. This study supports continued reduction in symptoms with maintenance AL with over half of completers meeting response criteria.

T60. The importance of vulnerability factors in at-risk mental state of psychosis individuals

Martina Papmeyer1, Irene Würsch2, Erich Studerus2, Rolf-Dieter Stieglitz2, Anita Riecher-Rössler2

1University Hospital of Psychiatry, University of Bern; 2University of Basel Psychiatric Clinics

Background: Stressors such as major life events or prevailing stress have been found to influence the onset and course of schizophrenic psychoses.1 They are thought to exert their effects by interacting with preexisting vulnerability indicators, leading to vicious circles which in turn provoke frank psychoses.2 Accordingly, the identification of indicators of heightened vulnerability for psychoses and relevant stressors may have important consequences to our understanding of the aetiology of these disorders. Various indicators of heightened vulnerability to psychosis and relevant stressors have been identified. However, it has scarcely been assessed prospectively to what extent these vulnerability factors are indeed more prevalent in individuals with an at-risk mental state (ARMS) for psychosis. Moreover, it remains largely unknown whether any of these contribute to the prediction of psychosis development in ARMS individuals.

Methods: In total, 28 healthy control subjects, 86 first-episode psychosis patients and 127 ARMS individuals were recruited as part of the prospective ‘Früherkennung von Psychosen’ (FePsy; English: early detection of psychosis) study.2 The relative frequencies of 13 distinct vulnerability factors for psychoses were compared between healthy control subjects, psychoses patients, those individuals with an ARMS with subsequent transition to psychosis (ARMS-T; n = 31) and those without subsequent transition (ARMS-NT; n = 55). Survival analyses were conducted to determine associations between time elapsed before transition to psychosis and vulnerability factors in all 127 ARMS individuals.

Results: The vulnerability factors “difficulties during school education or vocational training” and “difficulties during employment” were more commonly present in ARMS and first-episode psychosis
with post-mortem findings in patients with chronic schizophrenia. Possibly, reduced M1 availability is associated with cognitive impairments in psychotic patients.

T62. ALKS 3831 demonstrated equivalent antipsychotic efficacy while addressing weight gain: results from a phase 2, randomized, olanzapine-controlled study

Bernard Silverman*, Christoph Correll, Peter Weiden, Ying Jiang, Sanjeev Pathak, Lauren DiPietrillo, William Martin, Anjana Bose, Srdjan Stankovic, Elliot Ehrich

1Alkermes, Inc; 2The Zucker Hillside Hospital; 3University of Illinois at Chicago Medical Center, 4Alkermes, Inc.

**Background:** ALKS 3831 is a combination of olanzapine (OLZ) and samidorphan, designed to address weight gain seen with OLZ treatment.

**Methods:** After 1 week of OLZ lead-in, subjects were randomized (1:1:1:1) to once daily OLZ+placebo or ALKS 3831 (OLZ+ 5, 10, or 20 mg samidorphan) for 12 weeks. All subjects then received ALKS 3831 during a 12-week extension phase.

**Results:** Change in PANSS total score (primary endpoint) with ALKS 3831 was equivalent to OLZ alone (LS-mean difference (SE)=0.6±0.9 (95% CI -1.2, 2.5). ALKS 3831 treatment demonstrated significantly lower mean percent change in body weight from baseline in all study patients (FAS1, n=300) vs. OLZ of 31% and, of 51% (P < 0.05) in the subset of subjects with observed weight gain during OLZ lead-in (FAS2, n=195). Risk of ≥10% weight gain with OLZ alone was significantly greater than with ALKS 3831 (2.7 times. 95% CI: 1.1, 6.7; P=0.02) in FAS1 or in FAS2 (4.1 times. 95% CI: 1.4, 12.3; P=0.008).

**Discussion:** ALKS 3831 demonstrated efficacy equivalency to OLZ alone but also with consistent blockade of further OLZ-induced weight gain for up to 24 weeks. The safety profile of ALKS 3831 and OLZ were similar. These data suggest ALKS 3831 may be an important new treatment for schizophrenia.

T63. A phase 3 study to evaluate weight gain of ALKS 3831 compared to olanzapine in adults with schizophrenia

David McDonnell*, Sanjeev Pathak, Lauren DiPietrillo, Adam Simmons, Ying Jiang, Jacqueline Zummo, Hassan Jamal, Bernard Silverman

1Alkermes, Inc.

**Background:** An earlier Phase 1 study of ALKS 3831 (a combination of olanzapine and samidorphan) versus olanzapine alone in healthy volunteers demonstrated less weight gain in the ALKS 3831 treatment arm after 3 weeks. A subsequent Phase 2 study demonstrated similar efficacy and safety between olanzapine and ALKS 3831 treatments and significantly less weight gain in patients treated with ALKS 3831 compared to olanzapine over a 12-week period in patients with schizophrenia. The planned 24-week study, which is a part of the ENLIGHTEN study program, is designed to confirm and further evaluate these findings.

**Methods:** The proposed study is a two-arm, double-blind, active comparator controlled, multi-center study (planned n = 540) slated to begin enrollment in 2016. Inclusion criteria include both genders between 18 and 55 years of age (inclusive), non-obese defined as a body mass index (BMI) of 18.0 to 30.0 kg/m2, a DSM-5 diagnosis of schizophrenia, who can be treated on an outpatient basis defined as: no hospitalizations for acute exacerbations of schizophrenia within 6 months prior to the first follow-up visit, no current or past positive and Negative Syndrome (PANSS) total score of 50 to 90 (inclusive) and, Clinical Global Impression of Severity (CGI-S) score of ≤ 4. Exclusion criteria include diagnosis of additional psychiatric conditions, use of prohibited or contraindicated drugs and abnormal lab results during screening. After up to a 4-week screening
period, subjects will be randomized 1:1 to either olanzapine or ALKS 3831 treatment for 24 weeks. Active ingredients in once-daily oral doses will include ALKS 3831 10/10 (10 mg olanzapine/10 mg samidorphan) or 20/10 (20 mg olanzapine/10 mg samidorphan) or olanzapine (10 or 20 mg). The samidorphan dose was selected based upon results of the Phase 2 study that demonstrated a 10 mg dose was optimal for robust efficacy and safety of ALKS 3831. Adjustment of the olanzapine dose will be allowed up to week 4, then stay fixed for the remaining 20 weeks. In addition to PANS and CGI-S parameters, body weight, metabolic parameters (including fasting triglycerides, cholesterol, and glucose) and psychiatric symptoms will also be evaluated. Co-primary endpoints will be change in percent body fat and proportion of subjects with ≥10% weight gain from baseline to Week 24. Other endpoints include the Impact of Weight on Quality of Life –Lite Questionnaire (IWQOL-Lite) total score and change from baseline in EuroQol-SD (EQ-SD). Movement disorders, pharmaco kinetic, and pharmacodynamic parameters will also be measured.

Results: This is a new study.
Discussion: This is a new study.

T64. Safety, tolerability, and pharmacokinetics of single rising doses of BI 425809 given orally to healthy male volunteers: a partially randomised (within dose groups), single-blind, placebo-controlled, phase i study
Viktoria Moschetti1, Michael Desch2, Sophia Goetz2, Karl-Heinz Liesenfeld2, Sven Wind2, Glen Wunderlich3, Sun-Young A. Yum*1
1Boehringer Ingelheim Korea Ltd., 2Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, 3Boehringer Ingelheim Canada Ltd.

Background: BI 425809, a glycine transporter 1 (GlyT1) inhibitor, is a new chemical entity being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS) and Alzheimer’s disease. The objectives of this trial were to (1) examine safety and tolerability in healthy male volunteers (HV), (2) characterise the pharmacokinetic (PK) properties of BI 425809 after single dose, and (3) examine the relative bioavailability (BA) of tablet versus powder for reconstitution into oral solution (PFS).

Methods: This trial consisted of a partially randomised (within dose group), placebo-controlled, single-blind, single rising dose (SRD) part, followed by a randomised, open-label, crossover BA part. In the SRD part, HV were randomised in a 3:1 ratio (drug:placebo) to nine dose groups of BI 425809 (0.5, 1, 2, 5, 10, 25, 50, 100, 150 mg). In the BA part, 25 mg of PFS and tablet under fasted conditions were explored in a cross-over design. 83 HV (72 in SRD, 11 in BA) participated in the trial. The PK parameters, including Cmax and AUC, were characterised.

Results: This study included 243 patients who were ≥55 years old (n = 168 received lurasidone; n = 75 received placebo) and 1973 patients who were <55 years old (n = 1340 received lurasidone; n = 633 received placebo). Mean age was 60.4 years and 59.7 years in older and younger adult patients receiving lurasidone or placebo, respectively, and 37.6 years in younger patients (both treatment groups). The majority of patients were male in both the older (60%) and younger (72%) patient groups. The most common adverse events (≥5% of lurasidone-treated patients and at least twice the rate observed with patients receiving placebo) for lurasidone versus placebo were akathisia (10.1% vs 5.3%; number needed to harm [NNH] = 21) in older patients; and akathisia (13.3% vs 2.7%; NNH = 10), nausea (10.7% vs 5.5%; NNH = 20), somnolence (9.1% vs 3.8%; NNH = 19), and sedation (8.5% vs 3.6%; NNH = 21) in younger patients. In older patients, mean change in weight from baseline to Week 6 endpoint for lurasidone and placebo groups was -0.1 kg and -0.5 kg, respectively; median change from baseline was 0.0 mmol/L and -0.04 mmol/L, respectively, for total cholesterol; -0.07 mmol/L and -0.03 mmol/L, respectively, for triglycerides; and 0.17 mmol/L and -0.14 mmol/L, respectively, for glucose. In younger patients, mean change in weight from baseline to Week 6 endpoint for lurasidone and placebo groups was 0.5 kg and 0.0 kg, respectively; median change was -0.14 mmol/L and -0.18 mmol/L, respectively, for total cholesterol; -0.05 mmol/L and -0.08 mmol/L, respectively, for triglycerides; and 0.0 mg/dL and 0.06 mmol/L, respectively, for glucose.

Discussion: The safety profile of lurasidone was similar in older (≥55 years) and younger adult patients with schizophrenia. The most common adverse event observed with lurasidone in patients ≥55 years old was akathisia. In both older and younger patients, lurasidone was associated with minimal changes in weight, lipids, and glucose.

Sponsored by Sunovion Pharmaceuticals Inc.
ClinicalTrials.gov identifiers: NCT00044044; NCT00886343; NCT00549718; NCT00615433; NCT00711269; and NCT00790192. One study was completed prior to the requirement to register trials.

References
T66. Positive phase 3 clinical trial of ITI-007 for the treatment of schizophrenia: safety results from a randomized, double-blind, placebo-controlled trial

Cedric O’Gorman1, Kimberly Vanover1, Robert Davis1, Jelena Saillard1, Michal Weingart1, Sharon Mates1

1Intra-Cellular Therapies, Inc.

Background: ITI-007 is a first-in-class investigational new drug in clinical development for the treatment of schizophrenia. Through synergistic actions via serotonergic, dopaminergic and glutamatergic systems, ITI-007 represents a novel approach to the treatment of schizophrenia and other neuropsychiatric disorders. ITI-007 is a potent antagonist at 5-HT2A receptors, a mesolimbic/mesocortical dopamine phosphoprotein modulator (DPPM) with activity as a pre-synaptic partial agonist at 5-HT2A receptors, a mesolimbic glutamate GluN2B receptor phosphoprotein modulator and a serotonin reuptake inhibitor. Phase 2 clinical trial (ITI-007-005) data indicated that 60 mg ITI-007 was effective in reducing symptoms of schizophrenia with a safety and side effect profile similar to placebo (Lieberman et al., Biological Psychiatry, 2015 online ahead of print). In this trial, once-daily ITI-007 60 mg met the primary endpoint demonstrated efficacy with statistically significant improvement over placebo at Day 2 as measured by the PANSS total score (P = 0.022).

Results: In this trial, once-daily ITI-007 60 mg met the primary endpoint and demonstrated efficacy with statistically significant superior over placebo at Day 28 as measured by the PANSS total score (P = 0.022).

Discussion: These findings confirm and extend the positive results demonstrated at 60 mg in the Phase 2 study. Taken into context with data from another clinical trial (ITI-007-008) in which ITI-007 60 mg was associated with a mean of approximately 40% striatal dopamine D2 receptor occupancy using positron emission tomography (PET), ITI-007 demonstrated efficacy at relatively low striatal D2 receptor occupancy, lower than the occupancy range required by most other antipsychotic drugs. Unlike any existing schizophrenia treatment, this dopamine receptor phosphoprotein modulator, or DPPM, acts as a pre-synaptic partial agonist and post-synaptic antagonist at D2 receptors. This mechanism likely contributes to the favorable safety profile of ITI-007, with reduced risk for hyperprolactinemia, akathisia, extrapyramidal symptoms, and other motoric side effects. ITI-007 also lacks off-target pharmacological interactions that may contribute to cardiovascular and metabolic liability of other treatment options. As such, ITI-007 represents a novel approach to the treatment of schizophrenia.

T67. Yoga reduces the brain’s amplitude of low-frequency fluctuations in patients with early psychosis

Jingxia Jessie Lin1, Xujuan Geng2, Edwin H.M. Lee1, Sherry K.W. Chan1, Wing Chung Chang1, Christy L.M. Hui1, Michael Tse3, Cecilia L.W. Chan1, P.L. Khong2, William G. Honer4, Eric Y.H. Chen1

1HKU, 2State Key Lab of Brain & Cognitive Sciences, HKU, 3Institute of Human Performance, HKU, 4UBC

Background: Physical exercise attracted increasing attention for improving neurocognitive functioning in patients with psychotic disorders. However, there has been limited understanding of the neural mechanism of these effects. This study aimed to investigate the effects of aerobic exercise and yoga on cerebral spontaneous functional fluctuations in patients with early psychosis.

Methods: A total of 140 female patients with early psychosis were recruited and 124 received the allocated intervention in a randomized controlled study of 12 weeks of yoga or aerobic exercise compared with a wait-list group. 91 participants were scanned at baseline, and 72 had completed the scans at 12 weeks. The amplitudes of low-frequency functional (ALFF) fluctuations were compared among three groups, and the correlation between ALFF, cognition and clinical symptoms were examined.

Results: The ALFF decreased in the precuneus for the yoga group, and increased in the occipital cortex for the wait-list control group. These changes were correlated to the improvements of symptoms and working memory measured in all the participants.

Discussion: It is the first study to investigate the effects of yoga and aerobic exercise on brain function in patients with early psychosis. The results help to understand the possible neurobiological underpinnings for the cognitive and clinical improvements from yoga and aerobic exercise, and shed light on the application of exercise in clinical practice as a safe and convenient add-on treatment for psychoses.

T68. Can resting-state patterns predict aberrant salience in early psychosis spectrum?

Johanna Weiske1, Carlos Cabral2, Sebastian Von Saldern2, Maria Urquijo1, Joseph Kambeitz1, Nikolaos Koutsouliris1, Lana Kambeitz-Ilankovic1

1Ludwig-Maximilian-University; 2Psychiatric Hospital of the LMU, University Munich

Background: The theory of aberrant salience suggests that symptoms of psychosis arise from the incorrect assignment of salience to internal and external stimuli. Previous studies have shown that patients with recent onset psychosis (ROP) as well as patients with a clinical high risk for psychosis (CHR) exhibit aberrant salience. Fronto-striatal networks represent the neural basis of salience attribution and reward processing that is affected in psychosis and CHR patients.

The aim of this study was to use functional connectivity-based multivariate pattern analysis (MVPA) to classify good performance on a salience attribution task as measured by low implicit aberrant salience (low labS) and poor performance as measured by high implicit aberrant salience (high labS) in early psychosis spectrum (EPS) patients by applying a model generated in healthy controls (HCs).

Methods: HCs (n = 30), ROP (n = 16) and CHR (n = 18) patients underwent resting-state fMRI (RS-fMRI) and participated in the salience attribution test (SAT) outside the scanner as part of the PRONIA-study (Personalized Prognostic Tools for Early Psychosis Management). The two patient groups were combined into an EPS group (n = 34) because they showed no difference in SAT performance in previous studies. On the SAT, subjects had to perform a speeded response task while implicitly learning the relationship between cue-image categories and high or low reward contingency. labS was defined as the abnormal speeding of responses on task-irrelevant cue trials with a reward probability of 50%. Good SAT-performers (low labS) and poor SAT-performers (high labS) were identified via median split within each study group. MVPA was used to classify good vs. poor SAT performers in HCs by applying a L1-regularized L2-loss support vector machine. The model derived from this classification was then applied to EPS data.

Results: The classifier was able to differentiate between good and poor SAT-performers in HCs with a balanced accuracy of 80.0% (sensitivity and specificity: 80.0%). The discrimination between orbitofrontal and striatal, orbitofrontal and insula, globus pallidus and parietal, and caudate and temporal regions. In contrast, applying this model to EPS data yielded a lower classification performance of 50.0% (sensitivity: 52.9%, specificity: 47.1%).

Discussion: The high classification performance of 80.0% balanced accuracy was driven by differences in RS connectivities underlying reward processing and salience attribution in good HC relative to poor HC SAT-performers. The difficulties in applying the model to EPS patients could be due to altered brain functioning in EPS. Connectivity that were informative for the classification in HCs might be altered in EPS in such a way that they held no information for the classification of good vs. poor SAT-
performers. Another possible explanation could be the heterogeneity of the EPS group that contained CHR and ROP patients. To the best of our knowledge, this is the first study using RS connectivities to predict aberrant salience in good vs. poor performance across HC and EPS individuals. The high classification accuracy between distinguishing good vs. poor performers based on RS data in HC serves as a promising finding in the aberrant salience research domain and supports further investigations in EPS patients.

T69. The association between cognition and sub-domains of negative symptoms in schizophrenia
Zixu Yang1, Madeline Lim1, Bhing-Leet Tan1, Jimmy Lee1
1Institute of Mental Health, Singapore

Background: The relationship between negative symptoms and cognitive deficits in schizophrenia remains inconclusive and studies have presented conflicting results. Some studies found correlations (Addington et al., 1991; Bozikas et al., 2004) while some did not (Bagney et al., 2015). Bagney et al. (2015) conclude that there is no relationship between negative symptoms and cognition, and that the positive results previously found could have resulted from overlapping definitions of cognition and negative symptoms, or simply due to the instruments used. Therefore, it is worthy to re-examining this contentious relationship with refined measurement of both cognition and negative symptoms. To our best knowledge, no study has examined association of specific domains of negative symptoms (such as avolition, aloxia, and blunted affect) with cognition in schizophrenia and thus, the present study aims to fill this gap.

Methods: Forty participants (23 female and 17 male) diagnosed with schizophrenia were recruited for this study. The diagnosis of schizophrenia was ascertained with the Structured Clinical Interview for DSM-IV (SCID). Brief Assessment of Cognition in Schizophrenia (BACS; Keefe et al., 2004) was used to assess cognitive deficits as it is a reliable, comprehensive, and widely used neuropsychological battery to evaluate cognition in schizophrenia. The 16-item Negative Symptom Assessment (NSA-16; Axelrod, 1993) was used to assess the severity of negative symptoms as it outperforms the older scales such as the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987), in terms of better content validity and relying less on behaviors when scoring (Garcia-Portilla et al., 2015). Both the overall composite score and the five subscale scores of NSA-16 were used in the analysis.

Results: Participants had a mean age of 31.8 years (SD: 6.8; range: 20–49), and an average 13.8 years (SD: 2.9; range: 8.5–20) of education. Their mean age at illness onset was 22.8 years (SD: 6.5; range: 14–43 years), their mean duration of illness was 8.9 years (SD: 7.0; range: 1–24). Thirty-seven participants (92.5%) had never married, and 34 (85.0%) were Chinese, 6 (15.0%) were Malay or Indian. The BACS Z-scores were calculated with the age and gender adjusted using the Singapore Norm (Eng et al., 2013). The mean BACS composite Z-score was -1.66 (SD: 1.29; range -5.09–1.29) and mean overall composite NSA-16 score is 41.68 (SD: 8.49; range 25–66). The BACS composite Z-score had statistically significant negative associations with four domains of NSA, including communication dysfunction (r = -0.42, p = 0.007), dysfunction in sociality (r = -0.37, p = 0.019), motivational dysfunction (r = -0.41, p = 0.009), and reduced psychomotor activity (r = -0.36, p = 0.021) and with the overall composite score (r = -0.53, p < 0.001). A marginally significant association was also found for emotional/afffective dysfunction (r = -0.293, p = 0.066).

Discussion: An association between cognitive deficits and negative symptoms were found in this study – cognitive performance was worse as negative symptoms increased. Moreover, the association is rather general than specific to certain domains of negative symptoms, as almost all subscales of NSA-16 exhibited moderate correlations with BACS composite score. We surmise that the relationships amongst the different domains of negative symptoms and cognition may be more complex and inter-related; for example, both the cognitive impairments and motivational deficits may affect the communication which in turn affects the sociality, or the motivation may affect the cognitive performance as patients will not put their best efforts in the tasks. Further studies are needed to delineate the relationships between negative symptom sub-domains and cognition.

T70. Belief flexibility and delusions in psychosis: a systematic review
Chen Zhu1, Xiaiqi Sun1, Suzanne So1
1The Chinese University of Hong Kong

Background: Belief flexibility (BF) refers to the cognitive ability to "reflect on one's own beliefs, change them in the light of reflection and evidence, as well as generate and consider alternatives" (Garety et al., 2005, p. 374). As a measurable construct (Freeman et al., 2004; Moritz et al., 2006), BF is separable from delusional conviction and valid in its own right (So et al., 2012; Moritz et al., 2010). A negative reasoning bias in belief flexibility (i.e., belief inflexibility) has been found to be significantly associated with delusion severity (Garety et al., 2005; Hur et al., 2012), dimensions of delusions (e.g., conviction; So et al., 2012), and a poorer response to cognitive therapy for psychosis (Garety et al., 1997). Interventions targeting reasoning biases including BF have resulted in a reduction in delusions (Balzan et al., 2014; Ross et al., 2009; So et al., 2015). These studies have mainly adopted interview assessments (possibility of being mistaken, reaction to hypothetical contradiction, and generation of alternative explanations, Freeman et al., 2004). In recent years, there is an increase in the variety of BF measures by using experimental tasks (Woodward & Moritz, 2006; Kaliuzhna et al., 2012) and self-reports (van der Gaag et al., 2013). However, little is known about how BF measured by these tools relate to delusions. In light of the development of different measures for belief flexibility and delusions in each study, we conducted a systematic review to collate existing data to further delineate the relationship between BF and delusions. We addressed the following questions: 1) whether belief flexibility is associated with overall psychopathology of psychosis or with delusions specifically, 2) how strong the relationship between belief flexibility and severity of delusions is, and 3) how strong the relationship between belief flexibility and dimensions of delusions is.

Methods: This systematic review follows the PRISMA guideline ( Liberati et al, 2009). A systematic search for English literature using PsycINFO (1800 - 2015, present), PsyARTICLES, PubMed and MEDLINE (1946 - present) was conducted in late August, 2015. Empirical studies that investigated the relationship between belief flexibility and delusions (severity and/or dimensions) in at least one clinical sample were included. Meta-analysis was conducted using Comprehensive Meta-Analysis, Version 3.3.070 (CMA; Borenstein et al, 2014). For binary measures of BF (e.g., possibility of being mistaken), effect size was computed from means and standard deviations. For ordinal and continuous measures of BF (e.g., bias against disconfirmatory evidence), correlation coefficients were used for effect size aggregation.

Results: Preliminary analysis included 7 studies, out of which 4 studies measured BF by using interview assessments and 3 studies using experimental tasks. Overall, the effect sizes of association between BF and delusional severity ranged from 0.168 to 1.020, and the effect sizes of association between BF and delusional conviction ranged from 0.516 to 1.461.

Discussion: We are currently gathering original data from 15 authors, and will finalize the analysis in January 2016. In the final version, we will report Hedge's g, its 95% confidence interval, and the associated z and P values.

T71. Longitudinal change in neurocognition and its relation to symptomatic and functional changes over 2 years in individuals at clinical high-risk for psychosis
Ye Seul Shin1, So-Yeon Kim2, Tae Young Lee3, Ji-Won Hur4, Na Young Shin5, Sung Nyun Kim5, Min-Sup Shin5, Jun Soo Kwon5
1Seoul National University; 2Dukwang Women's University; 3SNU-MRC; 4Chung-Ang University; 5Seoul National University College of Medicine

Background: Negative symptoms and functional disability represent the core of schizophrenia and both are associated with cognitive...
impairments. We explored the course of cognitive change and its relation to symptomatic and functional changes in individuals at clinical high-risk (CHR) for psychosis to identify cognitive indicators of long-term course. Such attempts may offer insight into the pathological changes associated with the development of illness in the prodromal state.

**Methods:** Forty-seven CHR individuals completed neurocognitive, clinical, and functional assessments at baseline and 2-year follow-up; twenty-eight healthy controls were assessed for neurocognitive and functional measures at baseline and 2-year follow-up. The delta values of CHR individuals in neurocognitive, clinical, and functional domains were determined from differences between baseline and follow-up scores to estimate the degree of change.

**Results:** Although overall longitudinal cognitive performance of CHR individuals improved, the magnitude of improvement was not statistically different from that of normal controls at the group level. However, the individual data yielded two groups of CHR subjects showing opposite trajectories of cognitive change in semantic fluency (i.e., improvement or decline), which was significantly associated with changes in negative symptoms and functional measures. Moreover, the relationship between negative symptoms and functioning were more strengthened over time than baseline.

**Discussion:** Our findings show that semantic fluency seems to be a neurocognitive indicator reflecting clinical courses in CHR individuals. The longitudinal relationship of negative symptoms and functioning with semantic fluency may represent ongoing pathological processes in neural systems involving aberrant fronto-temporal interaction in the early phase of schizophrenia.

### T72. Prospective memory remains impaired two years after onset of schizophrenia


1 Castle Peak Hospital; 2 Castle Peak Hospital, Hong Kong Special Administrative Region; 3 Chinese Academy of Science; 4 Institute of Psychology, Chinese Academy of Science

**Background:** Prospective memory (PM) impairments have been found in patients with schizophrenia and their unaffected siblings. Evidence suggesting illness association and familiality supports that PM impairment may be an endophenotypic marker of schizophrenia. One previous study reported that PM remains impaired one year after the onset of schizophrenia. However, the long-term trajectory of PM impairment in schizophrenia remains unclear. Further longitudinal studies are needed to delineate the trait-like property of PM impairments in schizophrenia.

**Methods:** We recruited 57 patients with first-episode DSM-IV schizophrenia from an early psychosis clinic, and 97 healthy controls in the prodromal state. Patients were followed-up at four time-points for two years. Time- and event-based PM were assessed using a validated computer-based “dual-task” paradigm. Healthy controls were assessed at the baseline. We compared the 24-month trajectories of time- and event-based PM in patients with first-episode schizophrenia, using repeated measures ANOVA: Time Point (baseline, 6 month, 12 month, 24 month) x PM type (time-, event-based). We also compared the group differences in PM functions using univariate ANOVAs.

**Results:** All patients completed assessments at all time-points. At baseline, patients with first-episode schizophrenia exhibited impairments in time- (F(1,152) = 42.59, *P* < 0.001, corrected with Bonferroni adjustments) and event-based (F(1,152) = 48.24, *P* < 0.001, corrected with Bonferroni adjustments) PM, compared with controls. At 24 months, time-based (F(1,152) = 6.62, *P* = 0.022, corrected with Bonferroni adjustments) but not event-based (F(1,152) = 1.45, *P* = 0.462, corrected with Bonferroni adjustments) PM remained impaired in patients with first-episode schizophrenia. The Time Point main effect was significant (F(3,54) = 13.12, *P* < 0.001), suggesting that PM improved with time in patients with first-episode schizophrenia. The Time Point by PM type interaction showed a trend of significance (F(3,168) = 2.46, *P* = 0.078), suggesting that time-based PM impairment was stable, relative to event-based PM impairment.

**Discussion:** Our findings are generally consistent with previous results, and support that time-based PM remains impaired two years after the onset of schizophrenia. To our understanding, this study is one of the few longitudinal studies examining the trajectory of time- and event-based PM, using the longest follow-up duration and the largest sample of patients with first-episode schizophrenia. Our results add further evidence that supports PM impairments as possible endophenotypic marker of schizophrenia.

### T73. Trajectories of social cognition in schizophrenia and schizophrenia spectrum disorders

**Oleg Papsuev**, Maria Minyaycheva, Larisa Movina, Isaac Gurovich

1 Moscow Research Institute of Psychiatry

**Background:** Social cognition is considered as a main predictor of functional outcomes. New data has been published lately on dynamics of social and neurocognition during the course of schizophrenia. We would like to challenge the postulate that social cognition is stable phenomenon by evaluating social cognitive impairments in patients with first episode psychoses (FEP), chronic schizophrenia (CS) and schizophrenia-spectrum disorders (SSD).

**Methods:** In a cross-sectional study 71 patients with FEP, CS and SSD were assessed with a battery of clinical and social cognitive tests. Patients were assigned to four diagnostic groups: 1 - Schizoaffective disorder, 2 - Paranoid schizophrenia, 3 - Catatonic, Simple and Undifferentiated schizophrenia (mixed group with severe disorders), 4 - Schizotypal disorder. Three key social cognition domains were assessed: Emotion perception, Theory of Mind and Attributional style. Mann-Whitney analysis was performed for paired group comparisons, Kruskal-Wallis analysis was used for multiple groups comparisons.

**Results:** Patients with schizoaffective disorder and schizotypal disorder showed better scores in Hinting task (M = 18.9 SD = 1.3 and M = 18.3 SD = 1.8 respectively) than patients with paranoid schizophrenia and severe forms (M = 16.6 SD = 2.7 and M = 17.4 SD = 1.8 respectively (*P* = 0.003). Patients with FEP showed better results in Hinting task (18.1 ± 2.4) versus CS patients (17.4 ± 2.0) (*P* < 0.05). No differences in emotion perception (Ekman-60 task) among FEP and CS patients were detected. Patients with schizoaffective disorder showed better scores in emotional processing comparing to all forms of schizophrenia and schizotypal disorder patients (groups 1 to 4: M = 52.0 ± 4.2 vs. M = 46.6 ± 9.8, M = 47.4 ± 8.0, M = 47.0 ± 5.2, *P* < 0.05). No significant differences in attributional style were registered among all groups.

**Discussion:** Emotion perception and Theory of Mind domains show different level of impairment across FEP and CS patients and across different forms of schizophrenia and schizophrenia spectrum disorders. Emotion processing tends to be a more stable domain, Theory of Mind follows the prodigrent course of the disorder. Further longitudinal studies are needed to establish relations of social cognition domains to the course and severity of schizophrenia and schizophrenia spectrum disorders. Emotionality and capacity for empathy should be taken into account in future research.

### T74. Theory of mind impairment as a vulnerability marker for schizophrenia and its relation with schizotypal traits: a family based study.

**Maria Giralt**, Helena Palma-Gudiel, Salvador Miret, Jordi Soler, Claudia Prats, Lourdes Fañanás, Mar Fatjó-Vilas

1 Complex Assistencial en Salut Mental. Benito Menni. Sant Boi de Llobregat; 2 University of Barcelona; Centre for Biomedical Research Network on Mental Health (CIBERSAM); 3 Centre de Salut Mental de Lleida; Servei de Salut Mental i Addiccions, Hospital Santa Maria, Lleida. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM); 4 Universitat de Barcelona. Institut de Biomedicina de la Universitat de Barcelona (IBUB); 5 Universitat de Barcelona. Institut de Biomedicina de la Universitat de Barcelona (IBUB); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM); 6 University of Barcelona; Biomedicine Institute of the University of Barcelona (IBUB). Centre for Biomedical Research Network on Mental Health (CIBERSAM)

**Background:** The term theory of mind (ToM) refers to the capacity to infer one’s own and other persons’ mental states (beliefs, intentions, desires, emotions) and is a well-studied component of social
cognition. There are consistent evidences that ToM capabilities are impaired in schizophrenia (SZ) (S doorstep et al. 2007; Bora et al. 2009); however, whether it is a state dependent or trait remains controversial (de Achaval et al., 2010; Janssen et al. 2003). To date, studies investigating social cognition in unaffected relatives of patients with schizophrenia have shown inconsistent results (Lavoie et al. 2013) and how the schizotypal traits could moderate social cognition abilities remains unclear (Irani et al. 2006, Montag et al. 2012). We explored ToM in SZ patients, first degree relatives and healthy subjects in order to test whether deficits in ToM may be a putative endophenotypic marker of schizophrenia. We also investigated the role of SZ liability (i.e. schizotypy) as modifier of ToM deficits.

**Methods:** The sample consisted of 39 stable patients with a first episode of a schizophrenia-spectrum disorder (DSM-IV-TR), 82 healthy first degree relatives and 81 controls. ToM was assessed using the Hinting Task (HT, Corcoran et al. 1995) and schizotypy with the Schizotypal Personality Questionnaire-Brief (SPQ-B; Raine and Benishay 1995), which generates three dimensional scores: cognitive-perceptual, interpersonal and disorganization. We tested the effect of gender, age, years of education, IQ and family history on HT performance for each group. Only age and gender showed to have an effect so they were added as covariates in the following analyses.

**Results:** Comparison of HT performance between probands, first degree relatives and control groups (ANOVA test, adjusted for age, gender) showed a significant effect of group on HT total score (F = 9.34 P < 0.001). Post-hoc tests specified that patients performed significantly worse than relatives (P < 0.001) and controls (P < 0.001). High scores on SPQ-IP (F = 5.437, P = 0.023) and SPQ-CP (F = 5.144, P = 0.026) were related to worse ToM, in relatives but not in patients or controls.

**Discussion:** In our sample, ToM deficits are present in patients and not in relatives or controls. However, the observed influence of high levels of schizotypal traits suggests the link between ToM and schizophrenia liability, raising the possibility that ToM deficits could be candidate endophenotypes for schizophrenia.

**Supported by:** ERA-NET-NEURON-PIM2010ERN, CIBERSAM; Thanks to the Comissionat per a Universitats i Recerca del DIUE (2014SGR1636).

### T75. Uncovering the computational processes underlying motivational deficits in early schizophrenia

Gagan Fervaha*, Ofer Agid1, George Fousssias2, Hiroyoshi Takeuchi1, Ariel Graff-Guerrero2, Konstantine Zakzanis2, Gary Remington2,1Centre for Addiction and Mental Health (CAMH), and the University of Toronto; 1University of Toronto Scarborough

**Background:** Motivational deficits are a prevalent and persistent feature of schizophrenia, representing key determinants of outcome. Despite the known burden of this domain of psychopathology, the underlying mechanisms contributing to its clinical expression remain uncharacterized. Patients can theoretically manifest clinical amotivational symptoms in people with schizophrenia. There are consistent evidences that ToM capabilities are impaired in schizophrenia (SZ) (Sprong et al. 2007; Bora et al. 2009); however, whether it is a state dependent or trait remains controversial (de Achaval et al., 2010; Janssen et al. 2003). To date, studies investigating social cognition in unaffected relatives of patients with schizophrenia have shown inconsistent results (Lavoie et al. 2013) and how the schizotypal traits could moderate social cognition abilities remains unclear (Irani et al. 2006, Montag et al. 2012). We explored ToM in SZ patients, first degree relatives and healthy subjects in order to test whether deficits in ToM may be a putative endophenotypic marker of schizophrenia. We also investigated the role of SZ liability (i.e. schizotypy) as modifier of ToM deficits.

**Methods:** The sample consisted of 39 stable patients with a first episode of a schizophrenia-spectrum disorder (DSM-IV-TR), 82 healthy first degree relatives and 81 controls. ToM was assessed using the Hinting Task (HT, Corcoran et al. 1995) and schizotypy with the Schizotypal Personality Questionnaire-Brief (SPQ-B; Raine and Benishay 1995), which generates three dimensional scores: cognitive-perceptual, interpersonal and disorganization. We tested the effect of gender, age, years of education, IQ and family history on HT performance for each group. Only age and gender showed to have an effect so they were added as covariates in the following analyses.

**Results:** Comparison of HT performance between probands, first degree relatives and control groups (ANOVA test, adjusted for age, gender) showed a significant effect of group on HT total score (F = 9.34 P < 0.001). Post-hoc tests specified that patients performed significantly worse than relatives (P < 0.001) and controls (P < 0.001). High scores on SPQ-IP (F = 5.437, P = 0.023) and SPQ-CP (F = 5.144, P = 0.026) were related to worse ToM, in relatives but not in patients or controls.

**Discussion:** In our sample, ToM deficits are present in patients and not in relatives or controls. However, the observed influence of high levels of schizotypal traits suggests the link between ToM and schizophrenia liability, raising the possibility that ToM deficits could be candidate endophenotypes for schizophrenia.

**Supported by:** ERA-NET-NEURON-PIM2010ERN, CIBERSAM; Thanks to the Comissionat per a Universitats i Recerca del DIUE (2014SGR1636).

### T76. Encenicline increases the mats consisens cognit battery neurocognitive composite score in patients with schizophrenia

Andrew Ho1, Keith Neuchterlein2, Richard Keeffe3, Nancy Dgetluck1, Vicki Davis4, Ji Yu1, Dana Hilt1

1FORUM Pharmaceuticals; 2UCLA Center for Neurocognition and Emotion in Schizophrenia; 3Duke University Medical Center; 4NeuroCog Trials

**Background:** People with schizophrenia suffer from broad and significant cognitive impairment and perform ~1 to 1.5 standard deviations below normal controls. This degree of impairment is analogous to 15 IQ points. Encenicline is an alpha2 nicotinic acetylcholine receptor agonist and may improve cognition in people with schizophrenia. Subjects with schizophrenia from the US in the encenicline Phase 2B study were assessed with the MATRICS Consensus Cognitive Battery (MCCB), a 10-test battery assessing seven domains of cognition. As social cognition is distinct from neurocognition, the MCCB scoring software was updated in 2015 to support a new MCCB Neurocognitive Composite Score, calculated without the social cognition domain (MSCCIT). The new software made possible a new post hoc analysis.

**Methods:** Subjects with schizophrenia on a stable dose of atypical antipsychotics were randomized to receive encenicline 0.27 or 0.9 mg, or placebo, once daily for 12 weeks. Qualified raters assessed subjects with the MCCB at baseline, Day 44, and Day 84. To mirror the population of the ongoing Phase 3 studies, subjects aged < 50 years were included in this post hoc MCCB Neurocognitive Composite Score analysis (N = 104).

**Results:** Encenicline 0.27 and 0.9 mg were statistically superior to placebo at Day 84 as measured by the MCCB Neurocognitive Composite Score (P = 0.038 and P = 0.024, respectively). Effect sizes of the 0.27 and 0.9 mg groups were 0.55 and 0.57, respectively (number needed to treat ~ 4). There were no significant clinical or laboratory safety/tolerability findings.

**Discussion:** Re-analysis of the encenicline Phase 2B data using the recently published MCCB Neurocognitive Composite Score supports further development of encenicline for treatment of cognitive impairment in schizophrenia. Conclusive Phase 3 studies are currently ongoing.
T77. The goals for better work outcome in Japanese patients with schizophrenia: cut-off performances on measures of functional outcomes
Chika Sumiyoshi1, Philip D. Harvey2, Manabu Takaki3, Yuko Okahisa3, Taku Sato3, Ichiro Sora3, Keith H. Nuechterlein4, Kenneth L. Subotnik2, Torki Sumiyoshi1
1Fukushima University; 2University of Miami Miller School of Medicine; 3Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences of Medicine; 4Iwaki Meisei University; 5Kobe University; 6Semel Institute for Neuroscience and Human Behavior, University of California, 7Translational Medical Center, National Center of Neurology and Psychiatry

Background: Work outcome has an important implication for financial independence and better quality of life in patients with schizophrenia. Our previous study reports that the cognitive domains of learning and emotional management, and everyday/social functioning domains of independence and vocational functioning, were potential predictors for number of hours worked (Sumiyoshi et al., 2015). The aim of the current study was to provide cut-off points and cut-off performance scores on measures of these domains and on functional capacity to better predict work status.

Methods: Forty-five Japanese patients with schizophrenia were evaluated. Cognitive functioning and social functioning were assessed by the Japanese versions of the MATRICS Cognitive Consensus Battery (MCCB) and the Social Functioning Scale Individuals’ version modified for the MATRICS-PASS (Modified SFS for PASS). Functional capacity was assessed with the UCSD Performance-based Skills Assessment-Brief (UPSA-B). The total work hours for the most recent 3 months was dichotomized into either “better- or poorer-work” status by means of a median split (i.e. above and below the medians of the patients group). It was used as the dependent variables for the Receiver Operating Characteristic (ROC) curve analysis. Independent variables were a cognitive domain score consisting of Learning and Social Cognition (Emotional management task) in the MCCB, a social functioning domain score consisting of Independence and Vocational functioning in the Modified SFS, and the UPSA Total score. The area under the curve (AUC) was estimated as the index of sensitivity. The optimal cut-offs were determined in a manner to maximize the sum of sensitivity and specificity (Youden, 1950). Cut-off performance percentages on the measures were calculated by dividing cut-off points by the maximum score of each domain score and multiplying by 100.

Results: ROC analyses showed that the AUCs were 0.71 (95% CI: 0.55-0.87) for Learning/Emotional management, 0.78 (95% CI: 0.64-0.93) for the Independence/Vocational functioning, and 0.47 (0.30-0.65) for the UPSA total score. These results suggest that the former two scores elicited relatively good sensitivity to work status. The optimal cut-off points were determined as 153.4 for the Learning/Emotional management, 53.5 for the Independence/Vocational functioning, and 81.6 for the UPSA-B total score, corresponding to 76.7%, 60.8%, 81.6% cut-off performance, respectively.

Discussion: The cut-off performance of 60-70% in the Learning/Emotional management score and the Independence/Vocational functioning score is found to be an indicator of better vs. poor work status. In contrast to our finding, performance on the UPSA-B has been reported to elicit good sensitivity in prediction of work status (Mausbach et al, 2011). Further studies should investigate the contribution of this measure to the prediction for work outcome in patients with schizophrenia.

References:
1. Mausbach BT et al. Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia.

T78. Impact of the featural/configural processing of faces to the feeling of familiarity in schizophrenia
Delphine Pins1*, Alexandra Colin2, Sébastien Szaffarczyk1, Guillaume Vaiva1, Pierre Thomas1
1Univ. Lille, CNRS UMR 9193, Laboratoire de Sciences Cognitives et Sciences Affectives (SCALab), (CHU) de la Salpêtrière, 2Univ. Lille, CNRS UMR 9193, Laboratoire de Sciences Cognitives et Sciences Affectives (SCALab), Clinique de Psychiatrie, CURE

Background: Familiarity processing is a crucial aspect of recognition that provides the subjective experience of having already perceived a stimulus, regardless of the context in which it was previously encountered (Song et al., J. Neurosci, 2011). Familiarity disorders have been described in schizophrenia. A recent study showed a reduced familiarity threshold for faces in patients with schizophrenia compared to controls, suggesting a hyper-familiarity in patients (Horn et al., J. Psychiatr. Res., 2015). Yet, configural face processing seems to be impaired in schizophrenia, whereas featural face processing is preserved (Joshua et al., Schizophr. Res., 2009). It has then been suggested that the feeling of familiarity is based on predominant featural face processing in schizophrenia, in comparison to controls who analyze both configural and featural information. Face inversion paradigms selectively alter the configural face processing (Yin, J. Exp. Psychol., 1969). Assuming that face familiarity abnormalities in schizophrenia are related to a deficit of global information processing, the objective of this study was to show a smaller face inversion effect on the feeling of familiarity in patients compared to controls.

Methods: 15 patients with schizophrenia (DSM-IV criteria) and 15 controls, matched to the patients for gender and age, were recruited in the study. Stimuli were individually tailored for each participant and consisted of black and white images constructed from 3 photographs of familiar faces and 3 photographs of unfamiliar gender-matched faces. Familiar faces were those of people personally known by the participants. Stimuli were morphs of familiar and non familiar faces, including different levels of familiarity (from 5 to 95%, increments of 10%). Two inverted conditions were created: a classical face inversion (90° rotation of the whole face) and a Thatcher illusion face inversion (eyes and mouth orientations preserved). The 90 morphed images generated for each participant were presented individually, upright, inverted or with the Thatcher illusion, in a randomized order. Participants were asked to press a button each time they felt familiar with the face that was presented. After the completion of the task, participants were asked to specify the identity of the persons they considered to be familiar. First, the percentage of familiarity detection was calculated for each of the 10 levels of familiarity, for each participant. Then, a familiarity threshold was estimated from the psychometric function that estimated the percentage of familiarity detection according to the familiarity levels in the morph.

Results: Results showed a significant effect of the familiarity level on the percentage of familiarity detection, in both groups. Moreover, inverted conditions (classical and Thatcher) led to a lower performance compared to the upright condition, in both groups. Patients showed a significantly lower familiarity threshold compared to controls in the upright condition. Surprisingly face inversion effect was significantly higher in patients than controls. Nevertheless, the Thatcher illusion significantly increased the performances in comparison to classical inversion, in the patients group only.

Discussion: Our results confirm the hyper-familiarity observed in schizophrenia patients, for upright faces (Horn et al., J. Psychiatr Res., 2015). Nevertheless, face inversion leads to a hypo-familiarity in both groups. Both configural and featural information appear necessary to process face familiarity in schizophrenia patients. Nevertheless, restoring the featural information only (Thatcher illusion), partially improves the judgment in schizophrenia patient.
T79. Modeling difficulties in abstract thinking in psychosis; the importance of socio-developmental background

Akiah Berg1, Ingrid Melle2, Verena Zuber3, Carmen Simonsen1, Mari Nerhus4, Torill Ueland5, Ole A. Andreassen6, Kjetil Sundet1, Anja Vaskinn1

1University of Oslo; 2Centre for Psychosis Research, University of Oslo; 3European Molecular Biology Laboratory, 4NORMENT, 5RG Jelsén Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Norway; 6NORMENT, Oslo University Hospital; 7Oslo University Hospital; 8NORMENT KG Jelsén Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo; Division of Mental Health and Addiction, Oslo University Hospital

Background: Immigrants with psychosis show more difficulties in abstract thinking on the Positive and Negative Syndrome Scale (PANSS) compared to the majority population. In schizophrenia difficulties in abstract thinking are associated with neurocognition and insight into illness. These associations are presented as universal, implying that cognitive processes are fundamentally similar across countries and cultures. However, some research suggests that cognition is a dynamic interplay between biology, socioeconomic background and cultural values. In this study we aimed to assess if differences in socio-developmental background influence abstract thinking in patients with psychotic disorders, even in cases where all participants are educated within the same school system.

Methods: Participants (n = 174) were recruited from in and outpatient units in Oslo. Inclusion criteria were 17–65 years, IQ > 70, fluent in a Scandinavian language, full primary education in Norway and a DSM-IV diagnosis of psychotic or bipolar disorder. First- or second-generation immigrants (N = 58) were matched (1:2) with participants from the majority group by age (25, range 17–52), gender (45% female) and diagnosis (53% schizophrenia-spectrum, 35% bipolar disorder, 12% other psychosis). All participants completed a neurocognitive assessment and were interviewed with the PANSS. HDI for country of birth at year of birth was applied to all participants. This is a composite index measuring average achievement of a country based on three basic dimensions of human development; life expectancy, adult literacy and standard of living. Structural equation modelling was used to assess the model that best could explain variance found in abstract thinking.

Results: The model included a combination of the single indicators of PANSS item N5 abstract thinking and HDI, as well as latent variables assessed by principal component analysis for clinical factor (PANSS positive, negative and excited factor; items conceptual disorganization and poor attention) and neurocognitive factor (category fluency, category switching, digit span, and matrix reasoning). Both clinical and cognitive factor had a direct effect on abstract thinking (X2 difference = 32.081, df 8, p < .001). HDI did not however mediate this effect (X2 difference = 25.52, df 2, p < .001). The model with best fit (x2 = 96.591, df 33, p < .001) confirmed a significant indirect effect of socio-cultural background on abstract thinking through neurocognition, but not through clinical symptoms.

Discussion: Our findings suggest that the increased difficulties in abstract thinking previously found in immigrants with psychosis compared to a reference group is partially a consequence of differences in neurocognition and not psychosis pathology per se. Neurocognition however was influenced by participant’s socio-developmental background. This may explain some of the variance found in neurocognition in patients with psychosis. The HDI is here considered a more objective rating than typical categorization into immigrant groups and also encases in part socio-developmental history strengthening our findings. A limitation of this method, however, is that it does not reflect on cultural aspects such as beliefs, values, and traditions. However, we take into account the effect of different socio-economic status in ethnic minorities within nations. In conclusion, this study found that socio-developmental background influences difficulty in abstract thinking in psychosis by indirect effect through neurocognition suggesting that it be included as an important control variable in future studies of neurocognition in psychosis.

T80. Is cumulative life time depression positively linked to better cognition in schizophrenia?

Felicitas Meier1, Jennifer Engelen1, Bröhl Henrik1, Heinen Jessica1, Dietsche Bruno1, Danilowski Udo2, Kircher Tilo1, Krug Axel1

1Marburg University; 2Münster University

Background: It has consistently been shown in major depression (MD) that cumulative life time depression is negatively correlated with cognitive function. Conversely, in schizophrenia (SZ) life time depression has been related to more severe acute psychotic symptoms, but better cognitive functions (Chiappelli et al. 2014). In the current study we examined the influence of cumulative life time depression on episodic memory across patients with MD, SZ and healthy controls (HC).

Methods: Approximately 500 patients with SCID-confirmed diagnosis of major depression, schizophrenia, or schizophrenia affective disorder (SA) as well as an equal number of matched healthy controls were extensively phenotyped. The OPCRIT was used to operationalize cumulative life time depression: a score consisting of all items linked to depressive symptoms (e.g. duration of lifetime experienced depressive mood, dysphoria, sleep problems) was built. BDI and HAMD was integrated for state depression. To control for acute depressed symptomatology only remitted patients were included (HAMD < 8). During the fMRI task either a neutral face (encoding condition) or a scrambled picture (baseline) was presented. Participants were instructed to memorize the faces for later recognition as well as to indicate their sex via button press. Recognition phase familiar and non-familiar faces from the fMRI task and non-familiar faces were presented side by side; participants had to select the familiar face by button press. The groups’ neural responsivity in prefrontal areas and hippocampal formation were compared by a 3 x 2 ANOVA using a full factorial design with group (MD vs. SZ/SA vs. HC) and condition (baseline vs. encoding) as factors. The role of cumulative life time depression across the different groups is examined.

Results: We hypothesize both patient subgroups to exhibit decreased activity in lateral prefrontal regions and the hippocampal formation in contrast to HC. We further hypothesized that cumulative life time depression is positively linked to brain activity in these areas in SZ and negatively linked to MD, respectively.

Discussion: Schizophrenia and affective disorders overlap in several symptoms and cognitive deficits, however there appear to be distinct patterns in how longitudinal experience of depression is related to cognition in these disorders.

T81. Development of a platform agnostic software engine to facilitate widespread adoption of cognitive remediation therapy in schizophrenia

Brent Nelson1, Elias Boroda1, Suzanne Geier Jasberg1, Jazmin Camchong1, Kelvin Lim1

1University of Minnesota

Background: Studies have shown significant disruption in cognition in those with schizophrenia; with a strong relationship to poor long-term outcomes. Many studies have focused on developing tools to not only quantify the level of deficit but to also improve function. This is called cognitive remediation therapy (CRT). The systems powering CRT are generally a set of neuroscience tools operationalized into a specific technology framework with a variety of commercial and public domain offerings. While there are many choices there has been limited success in widespread adoption in schizophrenia specifically. There are many possible explanations for the limited adoption but we posit a major cause has been lack of an open solution that is technology agnostic and platform independent. With the dramatic change in technology over the last 10 years, researchers, clinicians, and patients have new expectations about how technology fits into their lives and specifically their health. Many CRT platforms do not take these expectations into account and instead rely on old technologies or passe trends. In order to gain widespread acceptance, a new methodology is required. Our solution, called Project Plasticity, is a new platform that hybridizes traditional neuroscience tasks with a popular video game engine and a cloud computing backend.
Methods: Our system is based on a series of well-defined cognitive tasks built on top of a custom, fully extensible framework. Tasks are written in either C# or JavaScript and utilize our framework in addition to the lower-level framework provided by the Unity game engine. The Unity engine is a leading video game development platform which provides game developers with robust 2D and 3D tools capable of being run on all modern platforms including desktop, mobile, WebGL, AR, and VR. Our framework sits between unity and the task implementations and provides core, common services (adaptive difficulty, response timing and verification, etc). Our framework also provides a pluggable cloud-based backend that is robust, resilient, and secure; capable of supporting any of the common core cloud providers. It scales elastically based on user demand and is able to allow focused management of data processing streams. Finally, the system encourages openness and transparency at every level so that patients, clinicians, and researchers can clearly document task operation and outcomes using consistent methods.

Results: The system is currently in the 6th round of iterative development. Multiple tasks have been developed alongside the core underlying services. Tasks have been tested under Android, Windows, and Mac but also have the capacity to run on iOS and a web browser under webgl. Tasks are configurable with respect to task parameters (number of trials and task complexity). During task administration, performance data are collected and stored in a cloud-hosted backend.

Discussion: Cognitive remediation is an important and relevant area with the potential to facilitate significant change in long-term outcomes. While neuroscience is moving forward rapidly, the technological implementations available to support widespread adoption are lacking. Due to the explosion of mobile devices, the cloud, and alternative platforms, new, exciting tools have become available to developers. It is now time to use these tools to build a next-generation platform that will enable improved access for patients, clinicians, and researchers. The goal being to evoke widespread change in an otherwise difficult to treat illness.

T82. The effect and mechanisms of implementation intention in improving prospective memory performance in schizophrenia spectrum disorders
Ya Wang1, Xing-jie Chen2, Li-Li Liu1, Simon S.Y. Lui3, Eric F.C. Cheung3, David Shum1, Raymond C.K. Chan6
1Institute of Psychology, Chinese Academy of Science, 2University of Massachusetts Amherst; 3Castle Peak Hospital, Hong Kong Special Administrative Region; 4Castle Peak Hospital; 5Griffith University; 6Neuropsychology and Applied Cognitive Neuroscience Laboratory, Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences

Background: Prospective memory (PM) refers to remembering to do something at a future time. Implementation intention is an encoding strategy in the form of “if I encounter X then I will do Y”. It can be used to improve people’s PM performance. Individuals with schizophrenia spectrum disorders are characterized by PM impairments. Three studies were conducted to examine the effect and mechanisms of implementation intention on PM in schizophrenia spectrum disorders. Methods: In the first study, we conducted a meta-analysis of the effect of implementation intention on PM in healthy participants. In the second study, we applied implementation intention to the schizophrenia spectrum including participants with schizotypal personality features (SPD) and schizophrenia patients to examine its improving effect on PM performance and the underlying mechanisms. In the third study, we explored the neural mechanisms of implementation intention on PM in healthy participants.

Results: In the first study, results showed that implementation intention can significantly improve PM performance in both young (d = 0.445) and older adults (d = 0.680). In the second study, results showed that implementation intention could help SPD participants and schizophrenia patients to improve their PM performance. However, they showed different mechanisms. SPD allocated significantly more cognitive resources to the PM task in the implementation intention condition. While for schizophrenia patients, implementation intention reduced their reliance on cognitive resources to perform the PM task and helped them to accomplish PM task more automatically.

T83. Pupil dilation response to imagined emotional future events: relations to high and low levels of apathy in a non-clinical sample
Marie-Jose Van Tol1, Jan Bernard Marisma, Nora Parigi1, Sander Martens1, Andre Aleman1
1University Medical Center Groningen

Background: Apathy is commonly defined as a quantitative reduction in goal-directed behavior (Levy & Dubois, 2006) and is a core negative symptom in schizophrenia. Apathy may partly result from a diminished capacity to foresee the rewarding value of a future pleasurable activity. Previously, it was shown that the pupil dilation response, a sympathetic nervous system marker, reflects levels of emotional arousal and interest (Bradly et al., 2008), indicating that pupil reactivity could serve as a psychophysiological marker of sensitivity to future reward. We therefore investigated whether pupil reactivity was related to valence of future positive, negative, and neutral events. We furthermore investigated whether apathy was specifically predictive of the pupil response during envisioning future pleasurable activities.

Methods: Forty-seven healthy participants (Mean age: 22.5, SD = 2; 33 female) were included in the present study. Apathy was assessed using the Dutch version of the apathy evaluation scale (AES) and ranged from 18 to 43 (M = 29.17, SD = 6.45). All participants generated emotionally loaded self-relevant possible future events (30 positive, 30 negative, and 30 neutral items), which were rated on relevance and vividness of imaginary. During pupil dilation measurements (using the Research EyeLink-1000 system), these events were presented in a pseudorandomized order with the instruction to envision the occurrence of these future events. Informed consent was obtained from all participants. Results: Participants with high levels of apathy (median-split based) demonstrated a lower maximum amplitude during affective forecasting of positive and negative events than low apathy individuals (F1, 45 = 4.62, P = .04), but no interaction of group and valence was observed (F1, 45 = .63, P = .43). No effects of valence, apathy, or interaction of valence and apathy was observed on the area under the curve estimation of total pupil responses.

Discussion: To our knowledge, this is the first study investigating the relation between apathy and the pupil dilation response during affective forecasting. Our findings suggest that pupil dilation response reflects levels of apathy to a certain extent and may be used as a complementary method to assess dimensions of apathy. Given the noradrenergic underpinnings of the pupil dilation response, and the relevance of noradrenaline and dopamine for motivated behavior, future studies using this approach could help unravel the neural basis of apathy.

T84. One year durability of the computer-assisted cognitive remediation therapy: neurocognition, self-esteem, quality of life and use of psychiatric emergency services
Gemma Garrido1, Maite Barrios2, Rafael Penadés2, Ana Costas-Carrera1, Josep Mª Vendrell1, Roser Guillamet1, Vicenç Valles1
1Consorci Sanitari de Terrassa; 2University of Barcelona; 3Barcelona Clinic Schizophrenia Unit; 4Hospital de la Santa Creu i Sant Pau de Barcelona

Background: The cognitive impairment may be related with difficulty in managing medications or pharmacotherapy adherence in
schizophrenia. Medication non-compliance has an important impact on emergency rooms visits or hospitalization and consequently on health care expenditure. The aim of the current study is to investigate the durability effectiveness of CACR on neurocognitive, quality of life and self-esteem outcomes and to examine their relationship with the use of psychiatric emergency services.

Methods: Sixty-seven participants were recruited from schizophrenia outpatients of the Department of Mental Health of Consorci Sanitari de Terrassa (NCT01598220). Thirty-eight were randomized to cognitive remediation therapy and twenty-nine to active control condition. For the follow-up study a total of 33 participants were enrolled in the study, 20 to the CACR condition group and 13 to the active control condition group. Sixteen subjects dropped out. All participants completed a comprehensive battery of neuropsychological tests and the Heinrichs-Carpenter Quality of Life Scale and the Rosenberg Self-esteem Scale. The use of emergency services and hospitalization were collected retrospectively at three assessment points: baseline (for the previous 12 month period; hereafter Time 0-T0), 12 month post-therapy (Time 1-T1), 24 month post-therapy (Time 2-T2) and 36 month post-therapy (Time 3-T3). The effect of CACR therapy on cognitive performance, quality of life and self-esteem measures was analyzed with two way mixed (time x group) analysis of variance (ANOVA) with treatment groups as the between-subjects factor (with two levels: therapy or active control group), and the three evaluations (baseline T1, post-treatment T2 and 12-month follow-up after intervention T3) as within-subject factors.

Chi-square test were used according to the nature of the variables as within-subject factors. T1, T2 and T3 in control group. Discussion: Results of the current study show that improvements on cognitive performance, quality of life and self-esteem measures are sustained after 12-months post-therapy. Moreover, CACR group results showed a higher use of emergency services and hospitalization on T1, T2 and T3. The neurocognitive variables and in QoL and self-esteem measures. The results of the current study show that improvements on neurocognition, quality of life, and self-esteem that occur after a CACR are sustained after 12-months post-therapy. Moreover, CACR group shows a lower use of the emergency services and hospitalizations after 12-months post-therapy.

T85. Neurocognition in help-seeking individuals at risk of psychosis and bipolar disorder: outcome after 24 months
Sibylle Metzler1, Diane Dvorsky1, Christine Wyss1, Susanne Walitza2, Karsten Heekeren1, Wulf Rössler1, Anastasia Theodouli1
1Psychiatric University Hospital Zurich; 2University Clinics for Child and Adolescent Psychiatry Zurich; 3University of Zurich, ZhiEP, Institute of Psychiatry, University of Sao Paulo

Background: An important aim in schizophrenia research is to optimize the prediction of psychosis and to ameliorate strategies for early intervention. The objectives of this study were to explore neurocognitive performance in individuals at risk of schizophrenic and affective psychosis and to optimize the predictions through a combination of neurocognitive and psychopathological variables.

Methods: Information on clinical outcomes after 24 months was available from 97 subjects who had completed an extensive assessment at baseline. Subjects at risk of psychosis converting to schizophrenia (CHR+), or who developed bipolar disorder (BIP). Logistic regression analyses and Receiver-Operating Characteristic curves were established to determine which baseline measure best predicts a transition to schizophrenia.

Results: The model that combined neurocognitive and psychopathological variables was the best for predicting clinical outcomes, presenting a specificity of 91.9%, sensitivity of 80.0%, and an overall positive predictive value of 88.5%. The area under the curve was 0.93 (SE 0.02, P < 0.000). The IQ and the neurocognitive domains of learning/memory and fluency significantly discriminated CHR+ and CHR-. However, BIP and CHR- individuals could not be discriminated based on their neurocognitive data.

Discussion: Our results confirm previous evidence suggesting moderate premorbid cognitive deficits in schizophrenia. Individuals converting to bipolar disorder exhibited premorbid performance within the lower mean. Overall, clinical symptoms appeared to be a more sensitive predictor than cognitive performance. Nevertheless, both might serve as complementary predictors when assessing one’s risk for psychosis.

T86. Smoking in pregnancy, adolescent mental health and cognitive performance in young adult offspring in a Finnish cohort sample
Hugh Ramsay1, Jennifer Barnett2, Graham Murray3, Pirjo Máki4, Tuula Hurtig5, Tanja Nordström6, Jouko Miettunen7, Vesu Kiveniemi7, Zdenka Pausova8, Tomas Paus9, Juha Veijola1
1Doctoral Student and Senior Registrar, Cambridge Cognition Ltd; 2University of Cambridge; 3University of Oulu; 4The Hospital for Sick Children, Toronto; 5University of Toronto

Background: The association between prenatal exposure to tobacco and adolescent cognition is debated, including if there are differences according to sex. The effect of mental health problems associated with cognition, namely attention and hyperactivity and psychosis risk, on the association between prenatal exposure to tobacco and adolescent offspring cognition also remains to be explored.

Methods: Participants were 471 individuals drawn from the Northern Finland 1986 Birth Cohort (NFBC 1986), matched by prenatal exposure to tobacco and socioeconomic factors and with rigorous exclusion criteria. Cognitive performance in adulthood was assessed with a range of tests and their association with exposure to smoking in pregnancy was measured by sex using linear regression controlling for potential confounders and followed by interaction analysis to examine associations with mental health where appropriate.

Results: There were no associations between prenatal exposure to tobacco and cognitive scores in females and associations with only vocabulary (-0.357 standard deviations, P = 0.020) and matrix reasoning (-0.293 standard deviations, P = 0.007) in males. There was evidence of mediation by attention and hyperactivity in the association between prenatal exposure to tobacco and matrix reasoning score in males. Prenatal exposure to tobacco was associated with poorer matrix reasoning scores in males not at risk for psychosis but not in males at risk for psychosis (P value for interaction = 0.017).

Discussion: While associations between prenatal exposure to tobacco and cognition were limited, observed findings with measures of general intelligence in males add support to efforts aimed to eliminate smoking in pregnancy.

T87. Cognitive profiles in first episode schizophrenia spectrum disorders
Mabel Rodriguez1, Zuzana Kratochvilova1, Iveta Fajnerova1, Veronika Vorackova1, Aneta Dorazilova1, Katerina Sedlakova1, Jitka Prajsova1, Martin Pustnak1, Juraj Jonas1, Filip Spaniel1
1National Institute of Mental Health

Background: Schizophrenia (SCH) is a disorder with variable phenotypic expression, variable patterns of course, complex etiology, and with the majority of affected population having a severe deteriorating course. The last decades have been marked by a significant interest in identifying clinical, neurocognitive, and other factors that can influence functional outcome in SCH. Abnormalities in cognitive
functions are a key component of SCH. Cognitive deficit in SCH appears heterogeneous with large intra-individual variability in test performance, that complicates the interpretation of cognitive test results. One of the causes of this heterogeneity is the assumption that cognitive domains in SCH are independent or only weakly correlated. The study of the interrelationships among domains is needed to better understand the patterns of intra- and inter- individual neuropsychological performance and clinical features. Taxonomic approaches may contribute to clarify cognitive heterogeneity. To our knowledge studies using taxonomic approaches in SCH are limited. The aim of this study is to identify in a first episode schizophrenia spectrum (FES) population if the decrease in the level of cognitive functions measured with the aid of a neuropsychological battery is random or dependent as possible to be explained by a common cause.

Methods: We recruited a study group (SZ) of 30 FES patients, who meet ICD-10 criteria, and a control group of 30 healthy volunteers (HC) matched for age, sex, and education. All participants completed a neuropsychological assessment which contained five basic domains: Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning and Memory, Visual Learning and Memory, and Executive Functions. For SZ psychotic symptoms were assessed based on the assessment of the PANSS scale. The dose of antipsychotic medication was converted to chlorpromazine equivalents to evaluate the effect of medication on cognitive functions. The raw scores for each test were converted to z-scores. To compose the cognitive domains, the average of the subtests’ z-scores was calculated. The SZ and HC global score of neuropsychological performance was compared using ANCOVA. Cluster analysis identified subgroups that were homogeneous and separated. Pearson correlations were calculated among the domain composites separately for SZ and HC. To compare the identified clusters with clinical and demographic variables one-way ANOVA and chi-squared test were used.

Results: In comparison to HC, the results of cognitive performance in SZ were significantly lower at most of the administered tests. Within the SZ, and within the HC group it was possible to distinguish several subgroups with different cognitive profiles based on the cognitive performance. However, SZ group presented higher correlations between domains compare to HC group. For SZ group, the performance measured in the majority of these tests was not directly affected by the antipsychotic medication dose when converted to chlorpromazine equivalents.

Discussion: There are two main preliminary findings in this study. The first finding is that a hierarchical model may characterize cognitive test performance. The second finding is, that correlations among cognitive variables in SZ group are relatively higher than in HC groups. This can suggest that the latent structure of cognitive performance in FES is more unitary than has often been assumed. In order to confirm, and generalize these findings, we are currently running a longitudinal study in a bigger sample, and comparing FES with chronic SH.

T90. Visual versus auditory cognitive training for people with schizophrenia

Linda Scorielis\(^1\), Lanissa Genaro\(^2\), André Polet\(^2\), Stella Keffer\(^2\), Paulo Santos\(^2\), Luana Gonçalves\(^2\), Walter Sena\(^2\), Melissa Fisher\(^3\), Sophia Vinogradov\(^4\), Rogério Panizzutti\(^5\)

\(^1\)Federal University of Rio de Janeiro; \(^2\)UFRJ; \(^3\)USCF/SFVAMC; \(^4\)San Francisco Veteran’s Affairs Medical Center

**Background:** Cognitive impairments are important determinants of functional outcome in schizophrenia, which are inadequately treated by antipsychotic medication. Neuroplasticity based computerized cognitive trainings have been emerging for the last two decades and are an attempt to help patients with their cognitive impairments and global functioning. The aim of this study was to perform a computerized cognitive training to improve attention, concentration, learning, clinical symptoms and quality of life in patients. We were interested in testing the differential efficacy between a specific visual versus auditory computerized cognitive training and explore the biological markers that may be involved in these neuroplasticity based training processes.

**Methods:** We conducted a 40 hours computerized, adaptable, perception specific, cognitive training program in patients with schizophrenia. Patients came for 1 hour, daily, and performed a visual or auditory training, for about 2 months. Visual and auditory exercises were chosen to be the equivalent of one another and targeted cognitive domains such as divided attention, working memory and social cognition. Clinical, cognitive, emotional and biomarker data were collected before the training, half way through, and after the training, to assess progress in several aspects of their functioning and biology.

**Results:** Forty-two patients were enrolled in the training. Visual and auditory trainings showed improvements in the specific cognitive and emotional areas trained. Improvements of 35% and 43% were observed in divided attention for the visual and the auditory training respectively; 54% and 55% in memory; and 56% and 63% in social cognition. Visual and auditory cognitive trainings showed a transfer of skills in other cognitive domains of attention \((P < 0.001)\), emotional decision making \((P < 0.05)\), and emotion recognition \((P < 0.01)\). The visual training was generally associated with higher improvement in these cognitive domains, and in the domains of working memory, spatial learning and reasoning and problem solving, whereas the auditory cognitive training was associated with milder improvements or sometimes a decrease in performance. Interestingly, both trainings showed improvements in the specific cognitive and emotional areas trained.

**Discussion:** Overall, the visual cognitive training appears to be highly efficacious in remediating cognitive impairments in schizophrenia. Further investigation is needed to understand why auditory training was not as efficacious. One hypothesis is that auditory hallucinations may generally prevent patients to focus on auditory stimuli as compared to visual ones. It was very encouraging to observe improvement in clinical symptoms with the training, which may help patients to reintegrate a more functional social and working life.

abnormal integration using simple stimuli, whereby overall task performance, response bias, and true perceptual differences can be disentangled.

**Methods:** We used the sound-induced flash illusion paradigm in a sample of individuals with SZ \((n = 40)\) and matched controls \((n = 22)\). A fusion illusion occurs when one visual flash, accompanied by two brief auditory beeps, is erroneously perceived as two flashes. Conversely, a fusion illusion occurs when two flashes, accompanied by a single beep, are misperceived as one. Signal detection theory (SDT) analyses were performed in order to characterise patients’ and controls’ sensitivity in distinguishing 1 and 2 flashes under varying auditory conditions.

**Results:** Patients and controls did not differ in their susceptibility to the fusion illusion. In contrast, patients experienced significantly fewer fusion illusions. SDT analyses confirmed that this was due to a difference in sensitivity rather than response bias. Susceptibility to the fusion illusion was furthermore negatively correlated with illness duration in patients. Finally, susceptibility to both illusions correlated positively in patients with SZ, but was unrelated in healthy controls.

**Discussion:** Patients with schizophrenia demonstrate a specific deficit in audio-visual integration that is associated with greater perceptual demand, suggesting a more limited capacity for integration relative to healthy control subjects. The dysfunction is likely exacerbated as the illness progresses and the integrative mechanisms of the brain deteriorate further, highlighting the importance of addressing multi-sensory deficits at an early stage of the illness. Our findings lend support for the notion that separate mechanisms underlie normal perception of the fusion and illusion illusions, whereas abnormal perception of both illusions in SZ is driven by a single dysfunction of MSI.

T91. Reduced susceptibility to the sound-induced flash fusion illusion in schizophrenia

Lucy Vaness\(^1\), Rebekah Wighton\(^1\), Thomas White\(^1\), Daniel Joyce\(^1\), Sukhi Shergill\(^2\)

\(^1\)King’s College London, Institute of Psychiatry; \(^2\)Cognition Schizophrenia and Imaging (CSI) Lab

**Background:** Schizophrenia (SZ) is characterised by the presence of abnormal complex sensory perceptual experiences. The illness has previously been conceptualised as a disorder of the normal connectivity and integration within the brain, suggesting that abnormal sensory experiences could arise as a consequence of dysfunctional multisensory integration (MSI). MSI has primarily been studied in SZ using complex perceptual stimuli, but it remains unclear whether a dysfunction of MSI exists at an elementary perceptual level. The sound-induced flash illusion offers a framework in which to study sensory de-deteriorate further, highlighting the importance of addressing multi-sensory deficits at an early stage of the illness. Our findings lend support for the notion that separate mechanisms underlie normal perception of the fusion and illusion illusions, whereas abnormal perception of both illusions in SZ is driven by a single dysfunction of MSI.

**Results:** Using the cut-off criteria, 26.5% \((41/162)\), 21.2% \((35/162)\), 35.8% \((59/162)\), 55.8% \((92/162)\), and 66.5% \((109/162)\) of the sample reported EA, PA, SA, EN, and PN, respectively. Patients from urban area in the sample had significantly higher language, and RBANS total scores compared to patients from rural area \((t = 2.800-2.864, P < 0.01)\). Patients with atypical antipsychotics in the sample had significantly higher delayed memory, and RBANS total scores compared to patients with typical antipsychotics \((t = 2.515-3.938, P < 0.01)\). Significant positive correlations existed between years of education years and RBANS total score \((r = 0.212-0.489, P < 0.05)\). Similarly, significant positive correlations were observed between family income and immediate associations \((r < 0.376, P < 0.05)\). However, duration of illness were negatively correlated with Language, delayed memory, and RBANS total score \((r = -0.203-0.252, P < 0.05)\). Times of recurrence, and admission were negatively correlated with delayed memory. Significant negative correlations existed between physical abuse, sexual

T92. The effect of childhood trauma on cognitive function in a sample of Chinese patients with schizophrenia

Chuan-Yue Wang\(^1\)

\(^1\)Beijing Anding Hospital

**Background:** Childhood trauma is a major public health problem which has existed in human society for a long period of time. Recent studies showed that exposure to childhood trauma has adverse effects on cognitive. A few limitations of the existing studies were existed in this area. We designed a study including 162 Chinese patients with schizophrenia, using two standardized, validated instruments to assess the history of childhood trauma and cognitive function, to evaluate the effect of all types of childhood trauma on a variety of cognitive functions in Chinese patients with schizophrenia.

**Methods:** All participants were inpatients or outpatients from two psychiatric hospitals, Beijing Anding Hospital and Beijing Daxing Psychiatric Hospital in Beijing, China. One hundred sixty-two patients were assessed with the Childhood Trauma Questionnaire-Short Form (CTQ-SF) and Repeatabale Battery for the Assessment of Neuropsychological Status (RBANS). Clinical data were also collected. Associations between specific types of trauma, demographic variables and cognitive function were examined. Statistical analyses were conducted using the Statistical Package of Social Sciences (SPSS, version 16.0). All statistical differences were considered significant when \(P < 0.05\) in both directions.

**Results:** Patients and controls did not differ in their susceptibility to the fusion illusion. In contrast, patients experienced significantly fewer fusion illusions. SDT analyses confirmed that this was due to a difference in sensitivity rather than response bias. Sensitivity to the fusion illusion was furthermore negatively correlated with illness duration in patients. Finally, susceptibility to both illusions correlated positively in patients with SZ, but was unrelated in healthy controls.

**Discussion:** Patients with schizophrenia demonstrate a specific deficit in audio-visual integration that is associated with greater perceptual demand, suggesting a more limited capacity for integration relative to healthy control subjects. The dysfunction is likely exacerbated as the illness progresses and the integrative mechanisms of the brain deteriorate further, highlighting the importance of addressing multi-sensory deficits at an early stage of the illness. Our findings lend support for the notion that separate mechanisms underlie normal perception of the fusion and illusion illusions, whereas abnormal perception of both illusions in SZ is driven by a single dysfunction of MSI.
abuse with language score ($r = -0.190$--$0.216$, $P < 0.05$). Similarly, physical neglect were negatively correlated with attention, delayed memory and RBANS total score ($r = -0.167$--$0.206$). Multiple linear regression analyses indicated that significant negative correlations existed between childhood physical neglect and story memory, attention, coding, list recognition, story recall ($P < 0.001$ for all). Similarly, multiple linear regression analyses indicated that sexual abuse was negatively correlated with language ($P < 0.001$), and physical abuse was negatively correlated with picture naming ($P < 0.001$).

**Discussion:** Using standard, quantitative instruments for both childhood trauma and cognitive function, we carefully assessed 162 Chinese patients with schizophrenia. We believe this is among the first to analyze all types of childhood trauma on a variety of cognitive functions using standardized instruments. Our findings indicate that specific forms of trauma contributed to different cognitive function in this sample. The results of this study lend weight to this proposition by finding neuropsychological differences between those patients with schizophrenia and who report childhood trauma and those who do not report such trauma.

**T93. Counterfactual reasoning deficits are related with acute negative symptoms in schizophrenia**

Auria Albacetet,1, Fernando Contreras,1, José Manuel Menchón1
1University Hospital of Bellvitge

**Background:** Counterfactual Thinking (CFT) is a mental process about spontaneous alternatives to past outcomes usually evoked as in a “if only” type of response. Used in response to real world experiences, counterfactual reasoning depends on mental models of alternative possibilities represented in the form of mental simulations. Previous research has found a global CFT impairment in schizophrenia, which might be the expression of a general cognitive impairment. In the present study we have further explored CFT performance of these patients and its relationship with socio-demographic characteristics, clinical symptoms and level of functioning.

**Methods:** The ability to generate counterfactual thoughts in front of a hypothetical scenario with a negative outcome was assessed in 40 patients diagnosed with schizophrenia (DSM-IV-TR criteria) and 40 healthy controls. Participants were matched by gender, age and educational level. We further explored whether any socio-demographic characteristic, clinical variables or level of functioning was related to performance in the experiment using the Positive and Negative Symptoms Scale (PANSS), the Clinical Global Impression-Schizophrenia Scale (CGI-SCH) and the Global Assessment of Functioning scale (GAF). Differences between groups was assessed using the Student’s-t parametrical test and the U-Mann Whitney non-parametrical test for continuous variables, and the t or p-Fisher tests for categorical variables. In multivariate analyses, binary, ordinal or linear regression models were used depending on whether the dependent variable was considered categorical, ordinal or continuous, respectively. Statistical analysis was performed using the statistical package SPSS Version 18.0.

**Results:** Replicating previous research, results revealed schizophrenia patients to generate fewer number counterfactual thoughts compared to healthy controls in front of a hypothetical social scenario. Furthermore, CFT statistically significantly correlated with civil status among schizophrenia patients, where single participants had more probabilities of generating less counterfactual thoughts. In addition, high scores in negative symptoms on the PANSS scale were found to be a predictor of a lessened capacity to generate CFT.

**Discussion:** Schizophrenia patients present difficulties activating alternatives that could help them face reality transforming a negative outcome into a positive through conditional reasoning. In addition, this impairment is related to accute negative symptomatology, which is not surprising if we take into account these sphere of symptoms include decreased context-dependent emotions and goal-directed activities. The relationship between negative symptoms and deficits in cognition has been well documented, and is known to persist irrespective of age and course of the disease. Taking in account the significant ecological impact of CFT deficits in functional outcome, we suggest that these deficiencies could be considered as potential targets for future treatments of schizophrenia.

**T94. Initial psychometric evaluation of social cognitive measures in Singapore**

Sara-Ann Lee1, Keane Lim1, Amy Pinkham2, Max Lam3, Junghhee Lee4, Jimmy Lee5
1Research Division, Institute of Mental Health, Singapore; 2Southern Methodist University; 3Institute of Mental Health; 4University of California, Los Angeles-Department of Psychiatry; 5Institute of Mental Health, Singapore

**Background:** Social cognition is an emerging area in schizophrenia research. Impaired social cognition in schizophrenia may be a primary mechanism through which patients exhibit poor functioning. Converging evidence indicate that social cognitive processes contribute to a variety of real world outcomes including social competence, quality of life and community functioning in schizophrenia. Social cognition shows promise as a treatment target and significant mediator that influences functional outcome in schizophrenia. While pharmacological agents have yet to demonstrate efficacy in improving social cognition, targeted interventions and remediation efforts improved social adjustment, social functioning and social skills. At present, there is a dearth of research that examines psychometric properties of social cognitive measures, thus limiting assessment and valid measurement of the construct and its related treatment response. The current study seeks to evaluate psychometric properties of 10 social cognitive measures based on results of a RAND panel (Pinkham et al., 2013) in Singapore.

**Methods:** 46 participants with schizophrenia completed 10 measures of social cognition across 5 domains: Ambiguous Intentions Hostility Questionnaire (AIHQ), Internal, Personal and Situational Attributions Questionnaire (IPSAQ), Bell-Lyserker Emotion Recognition Test (BLERT), Penn Emotion Recognition Test (ER-40), Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT), Profile of Nonverbal Sensitivity (Mini-PONS), Relationship Across Domains (RAD), The Awareness of Social Inference Task-Revised (TASIT-R), Hinting Task and the Empathic Accuracy Task. Participants completed two study visits, held between 4-6 weeks apart. These tasks were evaluated on i) internal consistency, ii) test-retest reliability and iii) utility as a repeated measure as indexed by evaluating practice effect or floor and/or ceiling effect. Data regarding task practicality (mean administration time in minutes) and tolerability (participants’ rating on their experience after completing the task) was also collected.

**Results:** Internal consistency as indexed by Cronbach’s α was adequate (0.56-0.92) except for one branch of the MSCEIT. Adequate test-retest reliability was demonstrated on most tests (Pearson’s r 0.54-0.84), except the AIHQ and one outcome score for the IPSAQ and two for the TASIT-R. There was little evidence of practice effects across tasks. With exception of the RAD, where 16% performed below chance level, there was little evidence that indicate floor or ceiling effects. Administration time ranged from 3.76 to 51.78 minutes. Tolerability ratings ranged from 4.78 to 5.45; with 1 representing extremely unpleasant and 7 representing extremely pleasant.

**Discussion:** Most tasks possess relevant psychometric properties. Nevertheless, continued research is necessary. Further assessment of psychometric properties in larger sample sizes, and test discriminability would be carried out. A brief battery that leverages on the psychometric assessment of each subtest would be formulated. A widely applicable and validated social cognition battery is likely to advance our understanding of social cognitive impairments in schizophrenia and facilitate ongoing remediation efforts and research.

**T95. Perceptual inferences in schizophrenia: a preliminary study in healthy participants**

Pantelis Leptourgos1, Charles - Edouard Notredame2, Renaud Jardri3, Sophie Denève1
1Group for Neural Theory, DEC, ENS; 2Université de Lille

**Background:** Bayesian inference is a powerful tool that can explain a variety of cognitive processes, including multisensory integration, visual illusions and motor control. Could it also explain pathological symptoms such as hallucinations and delusions? In a recent paper, Jardri and Denève proposed that positive symptoms in schizophrenia could be generated by an imbalance between excitation and
inhibition in brain networks, which leads to circular inference, an aberrant form of inference where bottom up messages are counted more than once (Jardri and Denève, 2013). Such an impairment would lead to a system that “expects what it senses” and thus, overweights even weak sensory evidence. Their hypothesis was then validated by a probabilistic reasoning task (in prep.). Here, we intend to validate, with a pilot study in a small sample, and in that case, by experimentally testing the respective impacts of sensory evidence, prior, and of their combination on perception in schizophrenia and ultimately validating the circular inference framework in the domain of visual perception.

Methods: Necker Cube is an ambiguous figure, known to induce oscillations between 2 mutually exclusive perceptions (perceptual bistability). Such figures were continuously presented to 50 healthy participants during 15 consecutive runs. We manipulated sensory evidence by adding shades to the stimuli (3 last runs) and prior expectations by giving different instructions to 3 different groups (15–15 – 20 participants), concerning the presence of an implicit prior. The cue systematically contradicted the instructions. Participants’ responses were discretely and pseudo-regularly collected (Mamassian and Goutcher, 2005). Moreover, their eye-movements were continuously recorded using an eyetracker and their psychotic tendencies were measured using the PDI and the LSHS scale.

Results: In the absence of any cue or instruction, the 2 interpretations of the cube were found not to be equiprobable, thus confirming the existence of an implicit prior (P < 0.001). Manipulation of this prior had significant opposite effect (P = 0.009), either by exacerbating or cancelling the intrinsic bias of the system. The effect of sensory evidence was even stronger (P < 0.001), and induced a significant bias corresponding to the direction of the cue, regardless of whether it was congruent or not with the implicit prior. This effect was so strong that it overcame the impact of the instructions and determined the perceptual pattern when sensory evidence adjunction and prior manipulation were combined. Moreover, we found no significant effect of the eye-movements on our results. Finally, we were not able to find significant correlations between bistability (relative predominance, mean phase duration) and the measured psychotic tendencies, mainly because of the small sample and the small range of the answers. Theoretically, we found that the behavior could be well fitted by Bayesian models (“simple” Bayes, model with Markovian statistics) with low statistical dependencies between successive time steps.

Discussion: The above findings will be used as a reference, in order to study patients with psychotic symptoms and test our initial claim that psychosis is the result of over-counted sensory evidence. Some preliminary results from patients will also be presented.

T96. Towards a core dysfunctional timing network in schizophrenia: a meta-analysis
Irene Alústiza1, Joaquim Radua2, Antón Albajes-Ejazigre2, Manuel Domínguez2, Felipe Ortuño1
1Clínica Universidad de Navarra; 2Institute of Psychiatry, King’s College, London

Background: A focus on temporal processing offers a window into understanding the schizophrenia cognitive profile. Timing and other cognitive domains are interrelated and share neuroanatomical basis. Increasing levels of cognitive control become them interlinked. Common brain regions engaged in timing and cognitive difficulty are abnormal in schizophrenia. We hypothesize that a dysfunctional temporal/cognitive change network underlies the mechanism underlying deficient cognition in schizophrenia. The main goal of this study was to identify any brain structure activated both by increases of difficulty while executing a cognitive task and during time perception tasks in schizophrenia patients.

Methods: A search at PubMed and Web of Science was carried out between January 2012 and December 2014 to identify fMRI studies reporting brain activation patterns associated with changes in cognitive control published. Keywords were (fMRI) AND (attention OR working memory OR executive functions OR controlled processes) AND (schizophrenia). Search criteria were studies 1) from which peak coordinates or statistical parametric maps could not be retrieved; 2) limiting their analyses to specific regions of interest; 3) using different thresholds in different regions of the brain; 4) using techniques other than fMRI; 5) that do not specify at least two levels of difficulty of the cognitive task or do not include some contrast between them; 6) considering a resting state or baseline as a lower level of difficulty; 7) using Independent Component Analysis; 8) case reports, qualitative studies, reviews and meta-analyses.

We conducted a Signed Differential Mapping (SDM) meta-analysis of functional neuroimaging studies in schizophrenia patients assessing the effects of increased difficulty. In addition, we performed the Signed Differential Mapping (SDM) meta-analysis of functional neuroimaging studies in schizophrenia patients assessing the effect of sensory evidence on perception in schizophrenia.

Abstracts

Discussion: Our findings support the hypothesis of activation of dysfunctional timing network by an increase in the difficulty of non-temporal cognitive tasks in schizophrenia.

T97. Does schizophrenia impair the ability to sustain attention? Investigation of the proactive and reactive modes of control by exploring the underpinning oscillatory activity.
Marc Hoonakker1, Nadège Doignon-Camus1, Anne Bonnefoi1
1INSERM U1114

Background: The inability to achieve and maintain the focus of cognitive activity on a given stimulation source or task, i.e. to sustain attention, is considered as a core cognitive deficit of schizophrenia, recognized as a probable causal explanation of multiple impairments observed in these patients (Green, 1996). Nevertheless, experimental results in this topic are not consistent highlighting either alteration or preservation, depending notably on the experimental approach (i.e. inhibiting ongoing behavior versus responding to infrequent targets) (for a review, see Hoonakker et al, in preparation). Furthermore, most studies cited in support of this view assessed overall performance rather than time on task effects related to sustaining attention per se (Demeter et al, 2013). The aim of our study is to address this controversial issue and to investigate, by exploring the underpinning oscillatory activity, the proactive and reactive modes of control underlying sustained attention ability. Indeed, the Dual Mechanisms of Cognitive Control Theory, proposes that cognitive control operates via two distinct modes: the proactive mode which relies on the anticipation of critical events and the reactive mode (stimulus-related and response-related) which is engaged after their occurrence (Braver, 2012). If this framework has yet proved to be very helpful to understand sustained attention ability in healthy subjects (Staub et al, 2014), it becomes even more relevant for schizophrenia in the sense that proactive control and associated fronto-parietal dysfunction may represent a robust marker of schizophrenia (Lesh et al, 2013).

Methods: Twenty-four patients (9 females; mean age: 40.9 years; years of education: 12.3) and 24 age-, gender- and education-matched healthy controls participated in this within-subject experiment. Two tasks (30-min each) differing only in response mode were used. One of the tasks was the sustained attention to response task (SART;
Robertson et al., 1997), a Go/No-Go task in which digits ranging from "1" to "9" were presented in a random order. Subjects were instructed to respond for each digit and inhibit response for the rare digit 3. In the second task, subjects were instructed to respond only to the rare digit 3. For performance and electrophysiological data analysis, the two tasks were divided into three 10-minute periods.

**Results:** Our first results which at this time only concern the Go/No-Go task, revealed that patients showed reduced performance overall (slower speed of responses and greater attentional fluctuations), but no greater time on task performance decline. Electrophysiological findings showed that the amplitude of the pre-stimulus slow-wave, a marker of proactive control, remained stable with time on task in both groups. However, schizophrenia-related specificities exist notably in the recruitment of stimulus-related reactive control over the course of the task: the amplitude of the P3 (component related to resource allocation) decreases over time and the difference in N2 amplitude of the task: the amplitude of the P3 (component related to resource allocation) decreases over time and the difference in N2 amplitude between Go and No-Go trials (related to conflict monitoring) is only evidenced during the first period of the task.

**Discussion:** These initial results suggest, in line with a recent study (Sanz et al., 2012), spared sustained attention ability in schizophrenia even in an extended version of a Go/No-Go sustained attention task. On the electrophysiological level, we demonstrate for the first time that patients utilized reactive control processes decreasingly with time on task. However, contrary to our expectations, they were also able to maintain proactive control over the course of the task.

**T98. Orthographic processing and lexical access in patients with schizophrenia: analysis of the N170 component**

Maxime Curzietti1, Anne Bonnefond1, Pierre Vidalhet1, Nadege Doignon-Camus1

1INSERM 1114

**Background:** Reading has been proposed among the cognitive functions affected in schizophrenia. Evidence comes from standardized tests of passage (GORT, WJTA) or single-word reading (WRAT), for which patients exhibit lower scores than comparison subjects (Martinez et al., 2013; Revheim et al., 2006, 2014). As skilful readers are characterized by the speed and effortlessness with which they recognize written words, the degree of automaticity of word recognition processes seems to be the best indicator of reading level. The present study aimed to investigate the automatization of word recognition processes in patients with schizophrenia. We focused on the first step of word processing, i.e., the orthographic processing by exploring the coding of sublexical representations and the access to lexical representations.

**Methods:** The orthographic sublexical coding was explored by manipulating mean bigram frequency in words (dependencies among letters in word-forms) while the lexical access was explored by manipulating lexical frequency. A group of patients with schizophrenia and a control group carried out a lexical decision task (i.e., is the presented stimulus a word or not?). Reaction times and the early N170 neuronal evoked response were registered to measure the degree of automatization of word recognition processes.

**Results:** Behavioral results indicated a significant interaction between bigram frequency and lexical frequency. An inhibitory effect of bigram frequency appeared with high frequency words whereas a facilitatory effect of bigram frequency appeared with low frequency words. No effect interacted with the group. Electrophysiological results indicated a significant effect of bigram frequency and a significant effect of lexical frequency on N170 amplitudes. Larger N170 amplitudes were observed for low frequency than for high frequency words; larger N170 amplitudes were observed for low bigram frequency than for high bigram frequency words. Most importantly, no effect interacted with the group.

**Discussion:** Behavioral and electrophysiological data showed that patients with schizophrenia, as comparison subjects, were sensitive to orthographic sublexical and lexical information in the course of lexical access. First, patients showed an unimpaired perceptual coding of orthographic properties within the first 200 ms of word perception, suggesting preserved abilities to encode letter position in letter strings and orthographic regularities throughout exposure to print. Second, the results indicated that the activation of lexical representations occurs at an early stage of word processing, suggesting preserved abilities to rapidly map the visual features of a word to its mental representation.

**T99. Effects of transcranial direct current stimulation (tDCS) on cognition, brain connectivity and symptoms in schizophrenia**

Robert C. Smith1, Stanley Colcombe2, Sylvia Boules2, Mary Yousef2, Karen Nolan3, Russel H. Tobe3, Mohammed Sharifi1, Revital Amiaz4, Sanela Mattiuz5, John M Davis1

1NYU Medical School, NK; 2NIH; 3Chaim Sheba Med CNTGR; 4Univ of Illinois, Chicago

**Background:** Schizophrenia (SZ) is characterized by persistent cognitive deficits. tDCS has been reported to be effective in reducing hallucinations and other symptoms in schizophrenia and proposed to have potential beneficial cognitive effects in healthy controls and schizophrenics (SZ). The current research was a double-blind sham-controlled study to investigate the effects of tDCS on cognition, cigarette smoking, and symptoms in SZ. Recent research using fMRI imaging has shown abnormalities in resting state brain connectivity networks (ICN) in schizophrenia compared to controls, in the fronto-parietal control network (FPN), default mode (DN) and other brain circuits, and some studies suggest that tDCS can alter these ICN in non-psychotic controls. We also present data from a preliminary open study of active tDCS which investigated tDCS effects on resting state brain connectivity circuits (ICN) in SZ.

**Methods:** 36 outpatients, with SZ or schizoaffective disorder (SA) participated in a double-blind study of 5 sessions of active or sham tDCS (active: tDCS for 20 min, 2 ma). 29 SZ provided valuable data on cognitive effects. Evaluations included MATRICS battery (baseline and 1 day after 5th sessions), VIGIL CPT (session 2), PANSS, and auditory hallucinations scale (Haddock). 4 SZ patients participated in a preliminary open study of active tDCS using the same design, where resting state fMRI (R-fMRI) with 3 Tesla scanner was utilized to investigate changes in ICN between baseline and 5 session of tDCS.

**Results:** One day after the 5th tDCS session active tDCS SZ showed significant improvements, compared to sham, in MATRICS battery COMPOSITE scores (P = .009), MATRICS DOMAIN scores on WORKING MEMORY (P = .002), and ATTENTION-VIGILANCE (P = .02), as well as T scores on CPT (P = .028) and Letter-Number Span (P = .009). Some of the other MATRICS Battery Domain scores also showed trends for improvement with tDCS. The other cognitive tests, which were evaluated directly after the tDCS session, did not show significant improvement of active vs sham tDCS, although there was a trend for reaction time to improve on VIGIL CPT with tDCS. There were no significant effects of tDCS on PANSS scores or auditory hallucinations. Preliminary R-fMRI data showed 5 sessions of tDCS showed changes in key areas of both executive and default mode networks suggesting an increase in FC strength/coherence for both networks.

**Discussion:** The positive effects of tDCS on cognitive scores on MATRICS battery suggest that tDCS may be an especially useful modality for improving cognition in SZ, but this findings needs to be confirmed and replicated in additional investigations. The beneficial effects of tDCS on improving cognition may be related to changes in connectivity in specific brain ICN networks since some of these ICN have been previously shown to be abnormal in SZ and bipolar patients compared to controls.

**T100. Age-specific abnormalities in working memory in early onset psychosis**

Maria Isabel Calvo-Rubiales1, Manuel Canal-Rivero1, Andrea Morina1, Miguel Ruiz Veguilla2

1Hospital Universitario Virgen del Rocio, 2University Hospital Virgen del Rocio (Seville)

**Background:** Working memory (WM) is often conceptualized as storage buffers that retain information briefly, rehearsal processes that refresh the buffers, and executive processes that manipulate the contents of the buffers. The prefrontal cortex (PFC) is a brain region featured with working memory function. The exact mechanism of how working memory...
operates within the PFC circuitry is unknown, but persistent neuronal firing recorded from prefrontal neurons during a working memory task is proposed to be the neural correlate of this mnemonic encoding. In our study we can see the difference between WM in patients who have suffered a First Episodic Psychotic (PEP) and controls taking in account the age onset psychosis. 

Methods: We included a group of 80 adolescents with a first episode of psychosis compared to a group of controls. Results: We found an interaction between age (< 16 years and ≥ 16 years) and group (psychosis vs controls) in working memory (P = 0.04). There were no difference in control group between those who are younger (< 16 years ) and older (≥16 years) (12.2 ± 2.3 vs 12.2 ± 2.3; P = 0.1) in WM. However, we found a significant difference performance in WM between those patients with age younger and older. Discussion: WM represents one’s ability to maintain and manipulate information simultaneously in a short period of time and correlates with other higher order cognitions, such as executive function and fluid intelligence. The patients who have suffered a PEP with 16 or more years have worse WM abilities this area is nuclear for patients with psychosis so it will be able to investigate this kind of therapy to improve cognitive abilities, restore daily functioning and reduce psychomatic symptoms.

T101. The relation of schizotypy and cognition with theory of mind in first-degree relatives of patients with diagnosis of schizophrenia
Onur Kucukcobotan1,2, Dafla Güneyi1, Aylin Yurdakul1, Özge Akgül1, Melih Dirioğ1, I. Tolga Binbay1, Koksal Alptekin1, Berna Binnur Akdede1
1Dokuz Eylül University

Background: Many of studies have reported that patients with schizophrenia have Theory of Mind (ToM) deficits. Also, investigations in first degree relatives of schizophrenia patients have reported that ToM deficits may be a candidate of endophenotype for schizophrenia. The aim of this study was to assess the ToM abilities and its relations with neurocognition and schizotypal traits in patients with schizophrenia and their first degree relatives.

Methods: 25 patients with schizophrenia, their unaffected 25 first degree relatives and 30 healthy controls included. To assess ToM, we have used Dokuz Eylül Theory of Mind Index (DEToMl) and to assess neurocognition, we have used Neuropsychological Test Battery for all participants. Patients were assessed with Positive and Negative Syndrome Scale (PANSS) to measure clinical situation. First degree relatives and controls were assessed with Structured Interview for Schizotypy-Revised (SIS-R) to evaluate schizotypal traits. All participants were assessed with Hamilton Depression Rating Scales to measure depressive symptoms.

Results: In first-degree relatives, “faux pas” task scores were found lower than controls but not in all neurocognitive tests. In relatives, we have found only one strong correlation about ToM task and neurocognitive tests relations. Schizotypal traits were higher than controls for some subscales. “Faux pas” and “suspiciousness” were correlated with middle power in relatives. In patients, all ToM task scores were lower than controls and many of neurocognitive tests scores were found lower than controls. Weak and middle correlations were found between ToM and neurocognitive measures.

Discussion: In our study, we have found ToM deficits in patient with schizophrenia and their first degree relatives. But, grade of ToM deficits of relatives were among the patients and controls. We found similar results for neurocognitive functions. There are relations between ToM and neurocognitive functions but we have found that degree of relations were substantially weak and middle. Also, in relatives, schizotypal traits were higher and one subscale of Tom and SIS-R were correlated with a middle power. Our results means, ToM has relations with neurocognitive function and schizotypal traits but the grade of this relations are little-middle. This study suggests that ToM may be a candidate of endophenotype for schizophrenia.

T102. Social cognition impairment profiles in treatment-resistant schizophrenia
Anzalee Khan1, Jean-Pierre Lindemayner2, Isidora Ljurić3, Abraham Goldberg1, Samantha Fregenti1, Veronica Ozog2, Luka Lucic4
1National S. Kline Institute for Psychiatric Research; 2New York University; 3Manhattan Psychiatric Center; 4Columbia University; 5ProPhase LLC

Background: The literature on social cognition profiles of patients with schizophrenia is sparse. Social cognition is linked to functional outcome and has become an important treatment objective. Social cognition remediation programs have generated considerable interest as these methods are far less costly than pharmacologic treatment and are likely to be safer. A growing consensus suggests that these interventions produce modest gains for patients with schizophrenia, however, very few of the studies completed to date have had sufficient statistical power to generate firm conclusions. The aims of the study were to assess the social cognition profiles of inpatients and outpatients with treatment-resistant and chronic schizophrenia, and to characterize the demographic and clinical illness features associated with social cognitive functioning.

Methods: Stable schizophrenia inpatients and outpatients (n = 63) who fulfilled the DSM-IV-TR criteria for schizophrenia or schizoaffective disorder were tested with the Penn Emotion Recognition Test (ER-40), Facial Emotion Identification Task, Facial Emotion Discrimination Task, Dynamic Social Cognition Battery (assessing verbal, non-verbal, facial recognition, Theory of Mind), and the MSCEIT from the MATRICS Consensus Cognitive Battery (MCCB). Cross-sectional characteristics for patients were compared using t-tests and analysis of variance for continuous, and chi-square test for categorical variables. Correlation and multiple linear regression analyses were performed between social cognition measures and demographic variables (gender, age, education), course of illness (duration of illness, number of hospitalizations, comorbid substance abuse, and comorbid anxiety), and current symptoms (PANSS). Due to the small number of patients relative to the large number of independent variables, analyses were conducted unadjusted and adjusted for age and education only. The level of statistical significance was set at P < 0.05.

Results: Social cognition impairments were marked in patients within all emotion recognition tasks and within the MCCB-MSCEIT domain. 75.12% patients had clinically significant impairment (> 1.5 SD below normal mean) in non-verbal emotion recognition, facial emotion identification and social cognition as measured by the MCCB-MSCEIT (P = 0.042). The global neurocognitive score as measured by the MCCB composite score correlated positively with social cognitive impairment (r = 0.536, P = 0.023). Higher age was associated with greater social cognition deficits compared to age-adjusted norms.

Discussion: A large proportion of patients with schizophrenia exhibited significant social cognitive impairments in emotion identification and recognition, and theory of mind, associated with clinically significant severity. These pervasive deficits support a strong emphasis on the need for effective treatment interventions for patients with social cognition impairments.

T103. Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ cohort
Ophelia Godin1,2, Pierre-Michel Llorca2, Nicolas Gired3, Marion Leboyer4, Guillaume Fongé4
1Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d’Épidémiologie et de Santé Publique, F-75013, Paris, France; INSERM, UMR_S 1136, Institut Pierre Louis d’Épidémiologie et de Santé Publique, F-75013, Fondation FondaMental, Paris, France; 2CMF, B, CHU, EA 7280 Faculté de Médecine, Université d’Auvergne, BP 69 63003 Clermont-Ferrand Cedex 1, France; 3Inserm, centre d’investigations cliniques 9501 & U1116, université de Lorraine, Institut Lorrain du cerveau et des vaisseaux Louis-Mathieu, CHU de Nancy; 4Translational Psychiatry Depart- ment, H Monzor Hospital, DHU Pépsy, Inserm U955 eq15, Paris-Est University, Fondation FondaMental

Background: Abdominal obesity was suggested to be a better predictor than Metabolic Syndrome (MetS) for cardiovascular
mortality, however is has not been extensively studied in schizophrenia. Hyperuricemia (HU) was also suggested to be both an independent risk factor for greater somatic comorbidity and a global metabolic stress marker in patients with schizophrenia. The aim of this study was to estimate the prevalence of MetS, abdominal obesity and HU, to examine the association between metabolic parameters with HU in a cohort of French patients with schizophrenia or schizoaffective disorder (SZ), and to estimate the prevalence rates of treatment of cardio-vascular risk factors.

Methods: 240 SZ patients (age = 31.4 years, male gender 74.3%) were systematically included. Metabolic syndrome was defined according to the International Diabetes Federation and HU if serum uric acid level was above 360 μmol/L.

Results: MetS, abdominal obesity and HU were found respectively in 24.2%, 21.3% and 19.6% of patients. In terms of risk factors, multiple logistic regression showed that after taking into account the potential confounders, the risk for HU was higher in males (OR = 3.1, IC95 [1.1-8.3]) or hypertriglyceridemia (OR = 4.9, IC95 [1.9-13]). No association with hypertension, low HDL cholesterol or high fasting glucose was observed. Only 10% of patients with hypertension received a specific treatment, 18% for high fasting glucose and 8% for dyslipidemia.

Discussion: The prevalence of MetS, abdominal obesity and hyperuricemia is elevated in French patients with schizophrenia, all of which are considerably under-diagnosed and undertreated. HU is strongly associated with abdominal obesity but not with psychiatric symptomatology.

T104. Somatic diseases increase the risk of early re-hospitalization among 6,987 incident patients with schizophrenia

Ole Köhler1, Holger Jelling Sørensen2, Michael Eriksen Benros2, Christiane Gasse3

1Psychos Research Unit, Aarhus University Hospital; 2Mental Health Centre Copenhagen, University of Copenhagen; 3National Centre for Register-Based Research, Aarhus University

Background: Prior somatic diseases are associated with an increased incidence of schizophrenia, but the extent to which somatic diseases are related to subsequent re-hospitalization after a first-time diagnosis with schizophrenia is unknown. To increase awareness about the importance of somatic diseases among patients with schizophrenia, the current study investigated whether prior somatic diseases predicted subsequent psychiatric re-hospitalization among people with incident schizophrenia.

Methods: Using Danish nationwide register data, we conducted a cohort-study among all individuals born in Denmark after 1977, with a first-time schizophrenia diagnosis between January 1, 1996 and December 31, 2012, and followed until December 31, 2013. All prior somatic diseases diagnosed within the secondary healthcare system were identified, and we adjusted for important covariates (age, gender, year of diagnosis, in- or outpatient at first-time schizophrenia diagnosis, education, use of antipsychotics within the year prior to first-time diagnosis, parental psychiatric contacts and highest educational level, and psychiatric diagnoses prior to first-time schizophrenia diagnosis). We performed multivariable Cox proportional hazards regression analysis and reported hazard rate ratios (HRR) of the association between prior somatic disease(s) and risk of (re)-hospitalization after one, two and five years.

Results: Of 6,987 individuals with incident schizophrenia, a total of 6,563 (94.9%) have had a hospital contact with a somatic disease prior to the schizophrenia diagnosis. Any somatic disease predicted a 1.32 (95%-CI: 1.06-1.65) fold higher re-hospitalization risk during the first five years of follow-up. We found a significant dose-response relationship between the number of prior somatic diseases and re-hospitalization risk ($P < 0.05$). In particular, infectious diseases (HRR = 1.15; 95%-CI = 1.04; 1.28), cardiovascular diseases (HRR = 1.13; 95%-CI = 1.09; 1.62), musculoskeletal diseases (HRR = 1.13; 95%-CI = 1.01; 1.25), epilepsy (HRR = 1.23; 95%-CI = 1.05; 1.44), and brain injury (HRR = 1.11; 95%-CI = 1.01; 1.21) significantly increased re-hospitalization risks.

Discussion: The current study identifies specific pre-existing somatic diseases as candidate predictors for the early illness course following first diagnosis of schizophrenia. In particular, cardiovascular diseases increased the risk of hospitalizations. Notably, well established risk factors for schizophrenia did not materially attenuate predictive effects of prior somatic diseases. Future studies should investigate if better treatment of somatic diseases may have an impact on the early treatment course of schizophrenia.

T105. Body weight and clinical outcomes in first episode psychosis patients: a 1-year follow-up study

Priyanthi Borgen Gjerde1, Carmen Simonsen2, Tatiana Polushina3, Ingrid Dieset4, Ole Andreas Andressen4, Vidar Martin Steen3, Ingrid Melle1

1University of Bergen; 2University of Oslo; 3Oslo University Hospital

Background: Patients with schizophrenia have increased risk of obesity, high morbidity for cardiovascular disorders and reduced life expectancy as compared to the general population (Saha et al. 2007; De Hert et al. 2011), which at least in part has been attributed to weight gain and dyslipidemic effects of antipsychotic drugs (Allison et al. 1999). There is, however, some evidence of a positive correlation between weight gain and clinical response to antipsychotic drug treatment (Meltzer et al. 2003; Hermes et al. 2011), possibly due to increased cholesterol favoring myelin development and neuron protection (Ferno et al. 2005 and 2006). In order to minimize the influence of environmental factors and poor treatment response that typically increases along the disease course, the current study focused on patients with first episode psychosis (FEP). We, thus, examined whether weight at inclusion and weight gain during antipsychotic drug treatment is associated with symptomatic remission and global functioning at 12-month follow-up in FEP. We hypothesized that there might be a positive correlation between weight gain and clinical outcome in FEP patients.

Methods: A total of 122 FEP patients were included from the ongoing naturalistic longitudinal TOP-study (Oslo, Norway). Inclusion criteria were (1) age 18 to 65 years and (2) a first episode of non-affective psychosis according to DSM-IV. The mean age of the patients was 28.52 (SD: 7.60), and 43 (35%) were women. Median duration of untreated psychosis (DUP) was 40 weeks (range: 1–572). Ninety-nine patients (81%) were using antipsychotics at baseline. Weight was assessed with baseline BMI (i.e. body weight (kg) divided by the square of height (m)). Weight gain (kg) was measured as the difference between baseline weight and weight at 12 months. Antipsychotic use was dichotomized into yes/no variables. Symptomatic remission was measured with the PANSS (Kay et al. 1987) using the criteria outlined by Andreasen et al. 2005, and overall functioning with GAF split version (Guy et al. 1976). Regression models were used to assess how BMI at baseline and weight gain during the first 12 months correlates with clinical remission and global functioning (GAF-F). Based on previous literature, relevant covariates such as age, gender, ethnicity and DUP were included in the analyses.

Results: Among the 122 FEP patients eligible for analysis, preliminary analyses of GAF-F using linear regression models did not show a significant association with baseline BMI (P = 0.65) or weight gain (P = 0.47), neither did logistic regression models for remission and baseline BMI (P = 0.39) or weight gain (P = 0.83). Multiple covariates including DUP, age, gender and ethnicity were used in all analyses.

Discussion: Previous literature has suggested a possible link between weight gain and favorable clinical response to antipsychotic treatment. Our preliminary analyses, however, does not support an association between BMI at baseline or weight gain during 12 months of follow-up and global functioning or symptomatic remission. This is in agreement with some studies on weight gain and clinical response (Hummer et al. 1995), but incongruent with others (Meltzer et al. 2003). Possible reasons for this might be differences in the subjects’ age, prior antipsychotic exposure, study duration and outcome measures. Advanced models adjusted for multiple confounders will be performed to examine the associations in greater details.

T106. Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: a meta-analysis

Leticia Gonzalez-Blanco1, Anne Marie Greenhalgh2, Clemente Garcia-Rizo3, Emilio Fernandez-Egea4, Brian Miller5, Brian Kirkpatrick2
1Service de Salud del Principado de Asturias, Universidad de Oviedo; 2University of Nevada School of Medicine; 3Neuroscience Institute, Hospital Clinic, University of Barcelona. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM); Institute of Biomedical Research Agustí Pi i Sunyer (IDIBAPS); 4University of Cambridge; Cambridgeshire and Peterborough NHS Foundation Trust; 5Medical College of Georgia, Georgia Regents University

Background: The use of dopaminergic antipsychotics is associated with hyperprolactinaemia. However, some studies have found increased prolactin concentrations in patients with nonaffective psychosis (NAP) when they are antipsychotic-naïve (Song et al, 2014; Albayrak et al, 2014; Garcia-Rizo et al, 2012), while other studies have failed to replicate an increase.

Methods: We conducted a systematic review and meta-analysis of studies of prolactin in antipsychotic-naïve, newly diagnosed patients with NAP. Males and females were considered separately. We identified articles by searching Pubmed, Psychno, Web of Science, and reviewing reference lists of identified studies. We also conducted meta-regression of potential moderating variables.

Results: Seven studies of males (N = 141 patients, N = 191 controls) and five studies of females (N = 67 patients and N = 116 controls) met criteria for inclusion. The mean effect size for males was 1.02 (95% CI, 0.77, 1.26; P < 0.001) and 0.43 for females (95% CI 0.11, 0.76; P < 0.02).

Meta-regression analyses for age, smoking, body mass index and cortisone were not significant. Funnel plots did not suggest the presence of a publication bias.

Discussion: Our meta-analyses found significantly increased prolactin levels in both male and female antipsychotic-naïve patients with NAP. The effect size was much larger for males than females. The small number of studies and limited matching for potentially confounding variables were limitations of the individual studies. These results have clinical implications, as prolonged hyperprolactinaemia may lead to sexual dysfunction and osteoporosis, and first-generation and some second-generation antipsychotics can cause hyperprolactinaemia.

T107. Lipid profile in schizophrenia: Tunisian study about 78 patients with schizophrenia and 68 controls

Ahmed Mhalla1, Rim Mensi1, Armel Messaoud1, Walid Bel Hadj Salah1, Wahiba Douki1, Loth Gaha1
1University of Monastir Monastir Tunisia

Background: Cardiovascular diseases are common co morbidities of schizophrenia and constitute the main factors of high mortality in this pathology. Cardiovascular damages are favored by some risk factors, of which one of the most important is dyslipidemia. In this context, a study of lipid profile in schizophrenia is interesting.

The aims of this study were to estimate the prevalence of dyslipidemia among patients with schizophrenia, compare it with healthy controls and study its correlations with sociodemographic, clinical, and therapeutic characteristics.

Methods: It was a cross-sectional, comparative and analytical study conducted between April 2013 and March 2014 on 78 patients with schizophrenia and 68 healthy subjects who benefited from the dosage of four serum lipid parameters: total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-c), Low Density Lipoprotein Cholesterol (LDL-c) and triglycerides (TG). For associations with the sociodemographic and clinical settings, we used an information sheet and the following psychometric scales: PANS (Positive And Negative Syndrome Scale), CGI (Clinical Global Impression), GAF (Global Assessment of Functioning) and Calgary scale for depression.

Results: Patients showed significantly higher levels of TC and LDL-c than controls with respectively (t = 2.83, P = 0.008) and (t = 9.35, P < 0.001). They also had a significantly higher cardiovascular index (CRI = TC / HDL-c; (t = 2.23, P = 0.033).

Further, the prevalence of hypercholesterolemia (TG ≥ 5mmol/L) was significantly higher than that of healthy controls (Relative Risk = 2.96; P = 0.002); likewise, the rate of patients with a hyper LDL-c (LDL-c ≥ 3 mmol / L) was significantly higher than that of healthy controls (Relative Risk = 18.79; P < 0.001). For the patients, LDL-c levels were significantly higher for patients aged 35 or over, the CRI was on average higher than 4 for men indicating a high cardiovascular risk and lower than 4 for women.

Patients with alcohol use showed significantly higher TC levels (t = 1.6; P = 0.038) and higher CRI (t = 1.94; P = 0.015), they had significantly lower LDL-c levels (t = -2.91; P = 0.002) and HDL-c levels (t = -2.45; P = 0.044). Patients with cannabis use showed lower TG levels (t = -2.02; P = 0.049).

Concerning clinical associations, The comparison of different patient groups according to the type of schizophrenia found that the paranoid type was associated with values of the CRI significantly lower compared to other patients (t = 1.98; P = 0.05). There was a positive correlation between the scores of Calgary scale of depression and of TG plasma concentrations (r = 0.39; p < 0.001).

Concerning therapeutic associations, there was a negative correlation between TG plasma concentrations and antipsychotic doses in chlorpromazine equivalent (r = -0.3; P = 0.008).

Discussion: The relatively small number of both populations, the small number of patients treated by atypical antipsychotics and the lack of evaluation of nutritional statute should be noted. The vast majority of the literature confirms that lipid disturbances were more frequent in patients with schizophrenia and that these disturbances concern all lipid parameters. Reviewing the studies focusing on lipid profile in schizophrenia, lipid disturbances appear to be more common for older patients and for men, as it is the case in our study. Smoking and alcohol consumption appear to disrupt all lipid parameters.

Concerning clinical associations, most studies are consistent with our work. In fact, paranoid type of schizophrenia and the positive symptoms appear to be associated with less dyslipidemia while depressive symptoms worsen lipid parameters.

T108. Blood metabolite signature of the development of metabolic syndrome in first-episode psychosis

Tommi Suivitai1∗, Jaana Suvisaari2, Oiti Mantere2, Tuula Kieseppä2, Tuulia Hyötyläinen1, Matej Oresic1
1Steno Diabetes Center A/S; 2National Institute for Health and Welfare, Helsinki

Background: Psychosis patients are a high-risk group for type 2 diabetes (T2D). The co-morbidity is hypothesized to be related to both treatment side-effects and to metabolic changes occurring during the psychosis. However, the molecular mechanisms of this co-morbidity are not known currently. Metabolomic profiling could potentially enable the early personalized assessment of the T2D-risk and the selection of the lowest-risk antipsychotic treatment. In this study, we investigated aberrations in blood metabolite levels in first-episode psychosis patients at early stages of the antipsychotic treatment, and followed-up the development of the patients to associate the observed aberrations with clinical outcomes.

Methods: First-time psychosis patients (N = 36; among whom 18 with schizophrenia) were followed up for one year with data collected at baseline, two months and one year. Blood metabolites were analysed with two mass spectrometry-based platforms with broad analytical coverage of polar metabolites and molecular lipids (two-dimensional gas chromatography and time-of-flight mass spectrometry, GC×GC-TOFMS, 363 metabolites; and ultra-high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry, UHPLC-QTOFMS, 318 lipids; respectively). The observed metabolomic variables were clustered with a Bayesian nonparametric model to identify coherent compound groups. The molecular cluster profiles were analysed for differences between the case and control groups, for temporal changes during the follow-up, and for effects of antipsychotic medication (olanzapine, N = 11; risperidone, N = 9).

Further, the profiles of metabolically healthy subjects at baseline (N = 10) were analysed for associations to follow-up changes in clinical markers of metabolic syndrome. Uncertainty arising from measurement noise, subject heterogeneity and low sample size were accounted for by using non-parametric statistical methods and resampling techniques.

Results: Case subjects had lower levels of fatty acids and higher levels of polyunsaturated triacylglycerols at baseline. Saturated and...
to follow up, a direct comparison of the current CHD prevalence with the previously estimated 10-year risk could not be made. **Discussion:** Metabolic Syndrome prevalence was found to be increased among schizophrenia patients through time. Our study implies no association between the increase in MetS prevalence and socio-demographic/clinical characteristics, severity of psychopathology, and antipsychotic treatment. It seems that causal factors such as nutritional status, unrelated to clinical features and psychiatric treatment, play a role in this increased prevalence of MetS. The majority of deaths in schizophrenia patients was found to be due to CHDs.

T110. Clinical features of schizophrenia patients with violent behaviours: the need to consider distinct subtypes

Matthide Horn1, Laura Gangloff2, Axelle Gharib2, Pierre Thomas3, Delphine Pins3

1Univ. Lille, CNRS UMR 9193, Laboratoire de Sciences Cognitives et Sciences Affectives (SCALab), Lille / CHU Lille, Clinique de Psychiatrie, CURE, Lille; 2CHU Lille, Clinique de Psychiatrie, CURE, Lille; 3Univ. Lille, CNRS UMR 9193, Laboratoire de Sciences Cognitives et Sciences Affectives (SCALab), Lille

**Background:** Violent behaviour has important social relevance for the political, criminal justice, and health care systems. Evidence has accumulated that people with schizophrenia are associated with a greater risk of violence compared with the general population. Nevertheless, patients with schizophrenia do not constitute a homogeneous population and distinct phenotypes of schizophrenia patients (SP) with violent behaviour have been identified. However, little is known about the clinical features that are associated with these forms of behaviour. Different authors have suggested that at least two distinct pathways could lead to violent behaviour in schizophrenia: one associated with premorbid conditions, including antisocial conduct and another associated with the acute psychopathology of schizophrenia. Besides, some authors have indicated that patients suffering from delusional misidentification syndromes (DMS) present an increased risk for violent behaviours with medical and legal consequences. DMS are group of phenomena whereby patients misidentify familiar persons, objects, or themselves and believe that they have been replaced or transformed. The problem is that DMS are descriptive and do not denote well-defined mental disorders, and so there are no formal guidelines for delineating the standards of assessment of these syndromes. Accordingly, we proposed to systematically test familiarity disorders in SP with violent behaviour. In this study, we aimed at identifying the clinical features that are associated with violent behaviour in SP, and more especially determining if some of these clinical features are more specifically associated with a particular form of violent behaviour; second, we focused on the prevalence of familiarity disorders and compared the profiles of patients with and without history of familial disorders. 24 incarcerated individuals who meet the diagnostic criteria of schizophrenia have been recruited. Psychotic symptoms, substance-use disorders and antisocial personality disorder have been assessed using the Positive and Negative Symptom Scale (PANSS) and the Mini International Neuropsychiatric Interview (MINI). The MacArthur Community Violence Interview and the Baratt Impulsivity Scale have been used to assess and characterize aggressive behaviour and impulsivity. Delusional misidentification syndromes have been explored on the basis of the psychiatrist interview.

**Results:** In our sample, 67% of patients presented substance use disorders, 71% presented or had presented a familiarity disorder and 74% have committed a severe physic assault (homicide or homicide tentative). In the group of patients who have committed a severe physic assault, we found a lower prevalence of antisocial personality disorder (33% versus 50% in the group without history of severe physic assault), but a higher prevalence of familiarity disorder (82% versus 50%). The comparison of patients with and without history of familiarity disorders revealed that more patients with history of familiarity disorders have committed severe physic assault. Moreover, these patients showed a higher PANSS score. **Discussion:** These preliminary results confirm the heterogeneity of aggressive behaviour in SP, with in particular a profile of patients that present more psychotic symptoms, a familiarity disorder and who are at risk for severe violent behaviour such as homicides. The recruitment
T111. Reliability and validity of low scores on the positive and negative syndrome scale (PANSS) and the influence of prior information

Steven De Jong*, Selwyn Renard1, Wilko Bodde1, Pieter-Jan Mulder2, Paul Lysaker1
1Rijksuniversiteit Groningen; 2Universiteit Medisch Centrum Groningen; 3Roudebush VA

Background: Advances in the treatment of schizophrenia spectrum disorders have led to improved prognoses, but have also given rise to the question what exactly should be considered remission in the context of these disorders. The Remission in Schizophrenia Working Group recommended that for symptomatic remission, a patient has to maintain scores of mild (a score of 3 on the PANSS) or less on all of the following items: Delusions (P11), Unusual Thought Content (G9), Hallucinatory Behavior (P3), Conceptual Disorganization (P2), Mannerisms / posturing (G5), Blunted Affect (N1), Social Withdrawal (N4) and Lack of Spontanity (N6). It was tested whether the PANSS could adequately detect patients in remission who may be so symptom-free that they can be considered to function at the same level as ‘healthy controls’ and whether prior information regarding the patient’s diagnosis may influence scoring of the PANSS.

Methods: This study included three groups of participants: four interviewees, two PANSS interviewers and 25 additional PANSS raters. The CAPE was administered to ensure none of the interviewees would be considered ‘ultra high risk’. Interviewers and raters were either told that he / she would conduct and score a PANSS interview with someone considered at ultra high risk for developing a psychotic disorder (condition A), and once after being told via email that he/she would conduct and score a PANSS interview with someone considered at ultra high risk for developing a psychotic disorder (condition B). Data were analyzed on the item level, secondly the data were analyzed on an item level and finally for exploratory purposes the individual ratings were examined. To test whether prior information influenced the PANSS ratings paired samples t-tests were performed.

Results: Our sample of healthy controls received a significantly lower score on all scales when compared to the results from the validation study conducted by Kay et al. (1987). We examined the individual ratings and compared them with the remission criteria. The results showed that one healthy interviewee did not meet these criteria as rated by four PANSS raters. However ten other raters did rate this participant as being in remission. Furthermore all other individual ratings met the remission criteria. As for the two experimental conditions, no significant differences were found between the condition in which the raters had prior information and the condition in which they did not have this information.

Discussion: Informing interviewers and/or raters that persons are at risk of psychosis does not significantly influence their scoring. On average, raters did not rate participants as suffering from a psychotic disorder. In addition, the healthy subjects differed significantly on the PANSS total and subscale scores from reference scores of schizophrenia patients. These results should allay most concerns regarding the use of the PANSS to detect a state of remission defined by the Schizophrenia Working Group. The single rating where one interviewee did not meet the criteria for remission should likely be considered measurement error.

T112. Demographic, clinical, functional and cognitive profiles of individuals presenting with at-risk mental state (ARMS) for psychosis to arms screening program in Hong Kong

HC Lee¹, Wing Chung Changa¹, S.I. Chan¹, S.Y. Chiu¹, L.M. Hui¹, K.W. Chan¹, H.M. Lee¹, E.Y.H. Chen¹
¹The University of Hong Kong

Background: An increasing number of specialized early intervention programs using standardized clinical criteria in identifying individuals with at-risk mental state (ARMS) for psychosis have been established worldwide in the two decades. Literature has indicated that approximately one-third of ARMS subjects will develop full-threshold psychotic disorder over 3 years. Thus far, the majority of clinical services and research on ARMS were conducted in western countries. Data on baseline profiles and clinical trajectories of ARMS subjects in Chinese population are lacking.

Methods: Ninety-eight individuals aged 15-40 years who fulfilled the clinical criteria for ARMS by Comprehensive Assessment of At Risk Mental State (CAARMS) were recruited from a pilot screening program in Hong Kong between 2014-2015. Subjects will be followed up for 2 years. This report focuses on the findings of baseline assessments encompassing socio-demographic, clinical, functional and cognitive profiles.

Results: The sample had a mean age of 20.9 years. The majority were single (91.8%) and full-time students (61.2%), and 43% were male. Of the 98 subjects, 81, 5, 3 and 9 were categorized as attenuated psychotic symptom, brief-limited intermittent psychosis, vulnerability, and mixed groups (attenuated psychosis and vulnerability), respectively. Approximately 45% had psychiatric co-morbidity with depressive disorder (26.5%) being the most common diagnosis, and 12 subjects (12.2%) had history of attempted suicide. Most subjects exhibited poor role (GF: Role Scale score < 7; 71.4%) and social functioning (GF: Social Scale score < 7; 65.3%). The sample displayed significantly poorer cognitive functions than matched healthy controls (n = 32) in terms of working memory (P < 0.001), processing speed (P < 0.001), sustained attention (P < 0.01), verbal fluency (P < 0.001), and visual memory (P < 0.05) domains.

Discussion: Our findings concur with the literature that ARMS subjects display a high rate of psychiatric co-morbidity, poor social and role functioning, and significant cognitive impairment. Data on 2-year follow-up assessments, which are currently underway, will help clarify the longitudinal outcome of ARMS and prediction of psychosis transition.

T113. Early psychosis patients’ and relatives’ attachment style: association with clinical and functional presentation

Lidia Hinojosa-Marqués*, Tamara Shenbaum¹, Paula Cristóbal-Narváez¹, Manel Monsonet¹, Thomas R. Kwapi², Tecelli Dominguez-Martínez², Neus Barrantes-Vidal³
¹Universitat Autònoma; ²University of North Carolina at Greensboro; ³Instituto Nacional de Psiquiatría Ramón de la Fuente Muñoz

Background: Research in both clinical and early psychosis samples is increasingly indicating that the patients’ attachment style impacts on psychosis symptom expression and functional adaptation. However, to our knowledge, the role of the relatives’ attachment style has not been sufficiently examined. This study examined whether the patients’ and relatives’ attachment style impacts on the family environment on the patients’ level of severity and long-term outcome. This study examined whether attachment styles of both early psychosis patients and their unaffected relatives were associated with patients’ clinical and functional presentation.

Methods: A total of 31 (20 At-Risk Mental State and 11 First Episode Psychosis) patients in the early stages of psychosis and their respective relatives participated in the study. Relatives were those who had most contact and/or the most significant relationship with the patient. Both patients and relatives completed the Attachment Measure. In addition, patients were administered the Positive and Negative Syndromes Scale and two complementary measures of social functioning, one based on the clinician’s perspective (the Global Functioning—Social Scale) and another based on the patient’s perspective (the short version of the critical Social Functioning Scale). The analyses examined the association of patients and relative attachment dimensions (anxiety and avoidance) with patient symptom dimensions (positive, negative and general psychopathology) and social functioning.

Results: Correlational analyses indicated that patients’ attachment anxiety was positively associated with general psychopathology, whereas no associations were found between attachment avoidance and symptom dimensions. Self-reported social functioning was positively associated with patients’ attachment anxiety and negatively associated with patients’ attachment avoidance. Relatives’ attachment...
anxiety was inversely related to patients’ negative symptoms. No significant associations were found with relatives’ attachment avoidance. Notably, all significant associations were of medium effect size.

**Discussion:** The preliminary results suggest the relevance of considering the role of the relatives’ attachment style, given that attachment style of both patients and relatives may affect the expression of symptoms/functioning in the early stages of psychosis. Future studies may consider investigating how patients’ and relatives’ attachment styles interact with other components of the family environment (such as relatives’ expressed emotion and illness attributions) in affecting the course of early psychosis. It may be useful to examine patients’ and relatives’ attachment style in the context of psychological formulation and treatment planning of early psychosis patients.

### T114. Affective symptoms in first episode psychosis: a dimensional approach

Diego Quattrone¹, Olesya Ajnakinà, Marco Colizzi, Elena Carra, Sara Fraietta, Fiona Gaughran, Marta Di Forti, Robin Murray

**Background:** The affective dimension in first episode psychosis (FEP) has received relatively little attention compared to the focus on psychotic features. This may be in part because the current classification of endogenous psychoses is based on the Kraepelinian neat schizophrenia/affective dichotomy, despite the fact that this model does not fit to Schneider’s “cases-in-between” - who present both prominent mood and psychotic symptoms, thus raising the likelihood of a continuum between schizophrenia and bipolar affective disorder.

Our aims were to investigate the prevalence and significance of affective symptoms in FEP and their relationship with current categorical diagnostic classification.

**Methods:** An affective assessment including Calgary Depression Scale for Schizophrenia (CDSS) and Young Mania Rating Scale (YMRS) on 144 FEP patients at their first contact with psychiatric services in South London, UK, was performed as part of the Genetics and Psychosis (GAP) study.

A principal component analysis of CDSS and YMRS was carried out and composite scores of each dimension were obtained using Anderson-Rubin method. Patients were grouped in affective psychosis (AP) and non affective psychosis (NAP) on the basis of their Operational Criteria Checklist for Psychotic Illness (OPCRIT) diagnosis, and the ability of affective dimensions to discriminate this diagnostic dichotomy was tested after analysis of variance.

**Results:** The occurrence of depressive symptoms was found to be common in both affective (CDSS scores: M = 5.5, SD = 5.6) and non affective (CDSS scores: M = 4.7, SD = 5) psychosis; t(141) = 0.8, P = 0.4. Manic symptoms were found to be present in both affective (YMRS scores: M = 5.8, SD = 5.1) and non affective (YMRS scores: M = 5.7, SD = 5.7) psychosis; t(141) = 0.1, P = 0.36. A three component-model was the best solution found to describe the spectrum of affectivity in FEP, which shared three core of symptoms, namely depression, activation, and mania. The group of non affective psychosis showed higher scores on the ‘activation’ dimension (F(1,138) = 4.19, P = 0.043; Bonferroni corrected) than the group of affective psychosis. The other affective dimensions didn’t show any significant difference between the groups.

**Discussion:** Our findings challenge the clear-cut dichotomy concept of schizophrenia versus mood disorders. We showed that affective symptoms overlap in the two groups which, theoretically, have to be mutually excluded – i.e. paradoxically, we found higher level of activation in the so-called non-affective psychosis. Thus, dimensionality is a good basis to depict the affective spectrum of psychosis, cutting across multiple traditional diagnostic categories. In the long run, dimensional approaches to psychosis, reflecting the continuous symptom distribution, may be perhaps useful to investigate more biologically defined phenotypes.

### T115. A multidimensional examination of delusionality and insight in body dysmorphic disorder versus psychotic disorders

Wei Lin Toh¹,², David Castle³, Rachael Mountjoy³, Ben Buchanan⁴, Susan Rossell⁵

¹Monash Alfred Psychiatry Research Centre; ²University of Melbourne St Vincent’s Hospital; ³La Trobe University; ⁴Monash University; ⁵Swinburne University

**Background:** Body dysmorphic disorder (BDD) is characterised by (i) an excessive preoccupation with an imagined defect in appearance, as well as (ii) repetitive behaviours and/or mental acts that occur in response to the preoccupation. Yet little is known about the nature of these overvalued ideas, as well as whether and how they differ from delusional beliefs typically encountered in psychosis. This study therefore aimed to perform a multidimensional examination of delusionality and insight in BDD relative to schizophrenia (SCZ) and schizoaffective disorder (SZA).

**Methods:** Participants were 27 BDD participants, 20 SCZ/SZA participants and 42 non-clinical controls (NC). Standard clinical and demographic information was collected. These participants also completed the Brown Assessment of Beliefs Scale (BABS) in relation to a principal preoccupation regarding body shape/weight in BDD (or general body dissatisfaction in NC) or a predominant delusion in SCZ/SZA. The Peters Delusions Inventory (PDI) was employed to assess a range of unusual beliefs and mental experiences.

**Results:** For total BABS, BDD (M = 16.4, SD = 6.4) and SCZ/SZA (M = 15.0, SD = 5.0) participants scored significantly higher than NC participants (M = 9.3, SD = 5.1). This pattern of significance was replicated for individual BABS items, except for Perception of Others’ Views (BDD = SCZ/SZA = NC) and Reference (BDD > SCZ/SZA = NC). On the PDI, there were significant group differences on the number of questions endorsed (SCZ/SZA > BDD > NC), with the BDD and SCZ/SZA groups also differing significantly from the NC group on dimensions of Distress and Preoccupation, but not Conviction.

**Discussion:** These findings suggest that appearance-related concerns in BDD may not merely represent overvalued ideas, but in fact, bear a strong semblance to delusions often seen in psychosis. Such an inference conveys key nosological and therapeutic implications.

### T116. Auditory verbal hallucinations in bipolar disorder (BD) and major depressive disorder (MDD): a systematic review

Wei Lin Toh¹,², Neil Thomas², Susan Rossell³

¹Monash Alfred Psychiatry Research Centre; ²University of Melbourne St Vincent’s Hospital

**Background:** Auditory verbal hallucinations (AVHs) are not uncommon in bipolar disorder (BD) and major depressive disorder (MDD), but there has been scant research in the area. The current paper aims to draw together and provide a critical overview of existing studies of AVHs in BD and MDD.

**Methods:** A systematic review was undertaken using the search terms ‘hallucinations’ or ‘hearing voices’ in conjunction with ‘bipolar disorder’, ‘mania’ or ‘manic-depressive’ or ‘major depressive disorder’ or ‘depression’ or ‘affective disorders’ or ‘mood disorder’. After applying a pre-defined set of inclusion criteria, 14 eligible peer-reviewed publications were accepted for further analysis.

**Results:** Prevalence rates of AVHs in BD (11.3-62.8%) and MDD (5.4-40.6%) varied. When psychotic features were examined, persecutory and grandiose delusions were especially common in BD (though the latter did not necessarily occur in conjunction with AVHs). A single known neuroimaging study has suggested increased frontal-temporal connectivity relating to AVHs in BD.

**Discussion:** AVHs remains a central but largely understudied symptom in BD and MDD. Methodological challenges relating to fluctuations in mood states and limited use of validated instruments, coupled with post-epistle recall bias, pose as specific barriers to the collection of meaningful phenomenological information. Future research examining its phenomenology and clinical/neural correlates could bring about positive clinical implications as well as adapted therapeutic applications.
T117. Domains of psychosis in schizophrenia spectrum disorders
Kristan Armstrong*,1, Stephan Heckers1
1Vanderbilt University

Abstracts

Background: Psychotic disorders are defined by five domains of psychopathology: delusion, hallucination, disorganized speech, abnormal psychomotor behavior, and negative symptoms. Abnormalities in two of the five domains of psychosis are sufficient for the diagnosis of schizophrenia spectrum disorders. We hypothesized that schizophrenia spectrum disorder patients with abnormalities in no more than two domains differ in illness severity and functional impairment from patients with abnormalities in three or more domains of psychosis.

Methods: Chronic patients with schizophrenia spectrum disorders (104 schizophrenia and 59 schizoaffective disorder patients) were assessed with SCID-IV-TR, HAMD, YMRS, and PANSS. 63 patients were diagnosed with abnormalities in only two domains, the remaining 100 patients were diagnosed with abnormalities in three or more domains. The two groups were matched for age, gender, and race.

Results: Patients with abnormalities in three or more domains of psychosis had a greater number of psychiatric hospitalizations (P < 0.05), higher PANSS positive and total scores (P < 0.01 and P < 0.05), and lower general functioning as measured by the GAF scale (P = 0.06). Patients with abnormalities in no more than 2 domains of psychosis were more often diagnosed with anxiety disorders (P < 0.05) and less often with substance use disorders (P < 0.05).

Discussion: The polythetic definition of schizophrenia spectrum disorders leads to varying degrees of illness severity. We found that patients with less severe psychosis had higher rates of anxiety disorders and were less likely to be diagnosed with substance use disorders. This provides evidence that the number of psychotic symptoms can explain some of the heterogeneity of schizophrenia spectrum disorders.

T118. Low vitamin D associated with negative and depressive symptoms in psychotic disorders, but not with pro-inflammatory immune markers
Mari Nerhus*1, Akiah Berg2, Ingrid Melle1
1NORMENT, KG Jebsen Center for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Norway; NORMENT, Oslo University Hospital; 2NORMENT KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo University Hospital

Methods: Chronic patients with schizophrenia spectrum disorders were recruited consecutively from in- and outpatient psychiatric units from a catchment area based health care system. A five factor model from the PANSS was used to evaluate positive and negative symptoms. We performed multivariate regression models for each of the outcome variables to evaluate the effect of S-25OHD on the outcomes i.e. positive symptom factor, depressive symptoms, and suicidal ideations (dichotomized from item 8 on CDSS). Variables with significant bivariate correlations with both the outcome variable and S-25OHD were entered hierarchically in blocks as possible confounders in the models. For the second research aim we investigated the correlations between S-25OHD and the pro-inflammatory markers sTNF-R1, IL-1ra and OPG in a subsample with available immune analyses (N = 232).

Results: Low S-25OHD was significantly associated with negative symptoms (adjusted R2 = 0.113, F(6,357) = 8.58, P < 0.001). This was not influenced by gender, years of education, diagnosis or ethnic background. Low S-25OHD was also significantly correlated with depression (adjusted R2 = 0.045, F(4,357) = 5.233, P < 0.001), and this was not influenced by gender, season of the year or thyroxine levels. Low S-25OHD was bivariate correlated with suicidal ideations and this association was mediated by depression. The association between S-25OHD and positive symptoms was not significant after controlling for confounding variables. The bivariate correlations between S-25OHD and sTNF-R1, IL-1ra and OPG were not significant (Spearman’s rho; r = 0.095, P = 0.15, r = -0.029, P = 0.66 and r = 0.086, P = 0.19 respectively), and we therefore did not continue further multivariate analyses.

Discussion: The significant association between low S-25OHD and higher negative symptom score is of great clinical relevance since negative symptoms are considered to have high impact on the patients’ impaired quality of life and possible treatment strategies are in demand. Many patients with a primary psychotic disorder also suffer from co-morbid depressions that influence on life quality and have potential to increase self-harming actions; and we found a significant association between low S-25OHD and higher scores on the depression scale, including severe depression with suicidal ideations. The associations between low S-25OHD and both negative and depressive symptoms could go both ways, possible with self-amplifying effects, and randomized controlled trials should be performed to sort out the causality. Other biological mechanisms, like vitamin D’s neuroprotective properties against oxidative stress or neurotrophic properties in the developing brain emerge as more important pathways than inflammatory pathways in the associations between vitamin D and symptomatology.

T119. Effect of stressful life events on schizotypal symptoms in siblings of patients with first-episode psychosis and healthy controls.
Anna Butjosa*1, Ulrich Reininghaus2, Juana Gómez-Benito3, Susana Ochoa4, GROUP investigators5
1Parc Sanitari Sant Joan de Déu, Teaching, Research & Innovation Unit; University of Barcelona; 2Maastricht University; 3University of Barcelona; Institute of Brain, Cognition, and Behavior (IRIC); 4Parc Sanitari Sant Joan de Déu, Teaching, Research & Innovation Unit; 5Maastricht University Medical Center, School for Mental Health & Neuroscience

Methods: Participants were siblings of patients with first-episode psychotic and healthy controls (n = 1057) and healthy controls (n = 590). This research was part of a longitudinal observational study called the ‘Genetic Risk and Outcome of Psychosis Project’ (GROUP) in the Netherlands. Recent life events were assessed with the Interview for Recent Life Events (Paykel, 1997). Participants reported the frequency, valence (positive or negative) and type (dependent and independent) of LE. Positive Schizotypy was assessed with the Structured Interview for Schizotypy-Revised (SIS-R; Kendler et al. 1989; Völlema & Ormel, 2000; Völlema & Postma, 2002).

Results: The frequency of LEs was associated with positive schizotypy in siblings with first-episode psychosis (n = 1057) and healthy controls (n = 590). This research was based on a few studies only, some of them of poor quality. Furthermore, very few studies have examined the quality and context of the LE, such as being dependent versus independent from the illness, the valence of the LEs or the emotional impact (i.e., positive (desirable) and negative (undesirable) events). The proposed analyses will investigate the association between frequency, valence and type of LEs and positive schizotypy in siblings of patients with first-episode psychosis and healthy controls.

Discussion: A recent review suggested a role of stressful life events (LEs) in the etiology of psychosis (Beards et al., 2013). However, this conclusion was based on a few studies only, some of them of poor quality. Furthermore, very few studies have examined the quality and context of the LE, such as being dependent versus independent from the illness, the valence of the LEs or the emotional impact (i.e., positive (desirable) and negative (undesirable) events). The proposed analyses will investigate the association between frequency, valence and type of LEs and positive schizotypy in siblings of patients with first-episode psychosis and healthy controls.
marginaly stronger association between independent LEs and positive schizotypy in the siblings (B 0.05, 95% CI 0.02-0.07, \( P < 0.001 \)), compared to the control subjects (B 0.03, 95% CI 0.01-0.06, \( P < 0.05 \)).

Discussion: This paper in a large sample of subjects confirmed a clear association between exposure to LEs and positive schizotypy. This was particularly true for positive LEs. When we specifically focus on independent LEs, the association was stronger in siblings compared to healthy controls, tentatively suggesting an interplay between genetic vulnerability and sensitivity to stressful environments in the etiology of positive schizotypy.

References:

T120. Positive and negative schizotypy prediction of prodromal symptoms and schizophrenia-spectrum personality disorder traits: a 3-year prospective study
Anna Racioppi*,1, Tamara Sheinbaum1, Sergi Ballespi1, Mercè Mitjavila1, Georgina M. Gross2, Thomas R. Kwapii2, Neus Barrantes-Vidal1
1Universitat Autònoma de Barcelona; 2University of North Carolina at Greensboro

Background: Schizotypy, a multidimensional personality organization, is a helpful construct for investigating the development of schizophrenia-spectrum psychopathology. There is ample evidence supporting the validity of the positive and negative schizotypy dimensions, but high-criteria investigations are needed. This study examined the prospective associations of positive and negative schizotypy with interview measures of prodromal symptoms and schizophrenia-spectrum personality disorder (PD) traits.

Methods: Data were derived from an ongoing longitudinal project examining risk for psychosis. At the first assessment, 547 nonclinical Spanish young adults completed the Wisconsin Schizotypy Scales. At the third assessment, approximately 3 years later, a selected subset of these participants (n = 103), oversampled for high schizotypy, were interviewed for prodromal symptoms (Comprehensive Assessment of At-Risk Mental States) and schizophrenia-spectrum PDs (Structured Clinical Interview for DSM-IV Axis II Disorders).

Results: Positive schizotypy predicted positive, behavioral, and general psychopathology symptoms. Negative schizotypy predicted emotional disturbance and schizoid PD traits. In addition, both dimensions predicted motor/physical symptoms as well as paranoid and schizotypal PD traits.

Discussion: Positive and negative schizotypy showed meaningful distinctive and overlapping prospective associations with prodromal symptoms and schizophrenia-spectrum PD traits, providing evidence of the predictive validity of these dimensions. The findings underscore the notion that schizotypy provides a valid framework for identifying risk for psychosis and the study of etiological mechanisms and trajectories of risk and resilience that should inform prophylactic interventions.

T121. Age at first-contact and 9-month outcome in patients with first-episode schizophrenia spectrum disorders
Giovanni de Girolamo for the GET-UP Group*1
1IRCCS St. John of God Clinical Research Centre

Background: Over the last years, the interest about the study of early and late onset of patients with schizophrenia has substantially increased, till to consider Age Of Onset (AOO) a surrogate measure of illness severity. Nevertheless, research findings on the role of AOO on clinical and functional outcomes in patients with schizophrenia and related psychosis are far to be consistent and more insight in this issue, through large sample follow-up studies of patients experiencing their first schizophrenic episode, is needed.

The aims of this study are to examine the influence of age of first contact (used as a proxy of AOO) with mental health services on the 9-month outcome (e.g. course of illness, number of hospitalization days and level of psychopathology, etc), in a large cohort of patients with first-episode schizophrenia spectrum disorders.

Methods: This study was conducted in 110 Community Mental Health Centres (CMHCs) in Northern Italy, delivering care to approximately 10 million inhabitants. The sample (\( N = 346 \) patients with first-episode psychosis, males 59.8%) was stratified into 3 groups according to the age at first service contact: Group 1 (15-24 years), Group 2 (25-34 years), Group 3 (35-54 years). A set of standardized measures (PANSS, PSYRATS, GAF, HAM-D) was administered at both baseline (i.e., after clinical stabilization and before treatment initiation) and 9-month follow-up.

Results: At 9-month follow-up, younger patients were more likely to be hospitalized and, among those hospitalized, older patient had longer hospital stays. Age of first contact did not predict a specific type of course (continuous, episodic and mixed) at the 9-month follow-up. However, a higher proportion experiencing large improvements in negative and general symptoms was observed in younger patients. More than one third of the youngest patients exhibited a significant reduction in general and negative symptomatology at 9 months as compared to the oldest group.

Discussion: Age of onset was the main factor that predicted improvements in negative and positive symptoms. Further research in this area is needed.

T122. Temperament in individuals with psychotic disorders before and after the onset of illness
Jouko Miettunen*,1, Nina Rautio1, Matti Penttilä2, Eka Roivainen3, Juha Veijola4, Matti Isohanni2, Erika Jääskeläinen1
1Center for Life Course Health Research, University of Oulu; 2Research Unit of Clinical Neuroscience, University of Oulu; 3Cognitive Neuropsychology Laboratory, Verve Research; 4Research Unit of Clinical Neuroscience, University of Oulu and Oulu University Hospital

Background: The Temperament and Character Inventory (TCI) is used to measure novelty seeking (NS), harm avoidance (HA), reward dependence (RD), and persistence (P). There are not many longitudinal studies of temperament in psychoses. We were able to study the stability of temperament in individuals with psychotic disorders (with onset of illness before and after first follow-up) and in non-psychotic controls.

Methods: As part of the 31-year follow-up survey of the prospective population based Northern Finland 1966 Birth Cohort, the TCI was filled by a large sample of individuals. A subsample of psychotic individuals, with the onset of illness before (n = 16) or after (n = 15) the 31-year follow-up, and non-psychotic controls (n = 117) filled in these scales again at the age of 43. We also studied the association between temperaments traits and psychotic symptoms (measured with Positive and Negative Syndrome Scale, PANSS) and attitudes to medication (Drug Attitude Inventory, DAI).

Results: The 31-year and 43-year temperament scores correlated strongly among controls (Pearson’s r: NS 0.68, HA 0.60, RD 0.56, P 0.54), whereas correlations among psychotic individuals with the onset of psychosis before first follow-up were weaker (NS 0.38, HA 0.50, RD 0.17, P 0.53). Individuals who had their onset of psychosis after the first follow-up had a significant \( P = 0.02 \) increase in HA from age 31 to 43-years when compared to controls. High HA before the onset of illness (at age of 31 years) associated significantly with a lower likelihood of remission and with more negative, disorganization and cognitive symptoms in the PANSS. High NS before illness onset was associated with a higher likelihood of remission according to the PANSS. At the age of 43 years, high HA score correlated positively with the total PANSS score, especially among those with earlier onset of psychosis (r = 0.86), but also among those with onset before the age of 31 years (r = 0.44). Other temperament dimensions were quite independent from the psychotic symptoms in cross-sectional analyses at age 43-year, high RD associated with better attitude to medication \( P = 0.012 \).

Discussion: Temperament was stable among controls, and more unstable in psychoses. In psychoses, increase in harm avoidance associated with getting ill, and it had a very strong positive association

with the amount and severity of symptoms. Premorbid harm avoidance and novelty seeking may also predict the clinical outcome in schizophrenia. Interestingly, also drug attitudes related to temperament. When studying the temperament in psychoses, the duration of illness and symptom severity should be taken into account.

T123. Neighbourhood characteristics and the rate of identification of young people at ultra-high risk for psychosis and risk of transition

Brian O’Donoghue1*, Alison Yung2, Stephen Wood3, Abbie Lane4, Andrew Thompson4, Ashleigh Lin5, Patrick D McGorry1, Barnaby Nelson1
1Oygen; 2University of Manchester, 3University of Birmingham; 4University College Dublin; 5University of Warwick; 6Telethon Kids Institute

Background: There is a higher incidence of psychotic disorders in more socially deprived neighbourhoods and a higher risk in migrants living in neighbourhoods of low ethnic density. Yet it is unclear at what stage these neighbourhood environmental factors may exert an influence on the risk for psychosis. This study aimed first to determine if the rate of identification of individuals who were at ultra-high risk for psychosis (UHR) was associated with the level of social deprivation in the neighbourhood of residence. Second, it was aimed to determine if the rate of identification of UHR individuals who were migrants was associated with the proportion of migrants in the neighbourhood of residence (i.e. ethnic density). Finally, it was aimed to determine if the level of social deprivation or migrant status was associated with an increased risk of transition to psychosis.

Methods: UHR individuals at the Personal Assessment and Crisis Evaluation (PACE) service in Melbourne were included. Social deprivation as assessed according to postal code area of residence was obtained from census data and Cox regression analysis was used to calculate hazard ratios. Rate ratios were calculated to determine if there was a higher rate of identification of UHR individuals according to neighbourhood characteristics.

Results: A total of 219 UHR individuals were included and 9% of UHR individuals were first generation migrants and 41.9% were second generation migrants. There was a trend for UHR individuals to reside in relatively more deprived areas and there was no association between the rate of identification of UHR migrants and neighbourhood density. Over a median follow-up time of 4.8 years, 32 individuals (14.6%) were known to have transitioned to a psychotic disorder. The level of social deprivation was not associated with the risk of transition ($P=0.83$). Similarly, first or second generation migrants did not have an increased risk of transition to psychosis ($P=0.84$).

Discussion: There was a trend for individuals identified as being ultra-high risk for psychosis to live in more deprived neighbourhoods and this has implications for where services for these individuals should be located. Despite being established risk factors for psychotic disorders, social deprivation and migrant status did not increase the risk of transition to psychosis.

T124. A population-based longitudinal study of maternal prenatal depression and risks of psychosis and depression in adult offspring: role of childhood serum interleukin 6

Golam Khandaker1*, Sarah Rabha1, Jan Stochl1, Rebecca Pearson2, Jonathan Evans2, Stan Zammit3, Glyn Lewis3, Peter Jones1
1University of Cambridge; 2University of Bristol; 3University College London

Background: Maternal prenatal depression is associated with an increased risk of psychiatric disorders in offspring but precise mechanism for this association is unclear. We examined whether maternal depression during pre and postnatal period are associated with risks of psychosis and depression in adult offspring. We also examined whether these associations are influenced by serum interleukin 6 (IL-6) levels, an inflammatory cytokine, in childhood.

Methods: Main analysis of the association between maternal prenatal depression and psychiatric risk in offspring was based on 4198 participants from the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort. Depression was measured in mothers at 32 weeks pregnancy and 8 weeks postpartum and in fathers at 32 weeks pregnancy using the Edinburgh Postnatal Depression Scale (EPDS). In offspring, serum IL-6 levels were measured at 9 years using enzyme-linked immunosorbent assay. Psychotic experiences (PE) and psychotic disorder were assessed using the face-to-face, semi-structured Psychosis-Like Symptom Interview (PLIKSI) at age 18 years. Diagnosis of depression according to International Classification of Diseases, 10th Revision, (ICD-10) criteria was obtained by the computerized version of the Clinical Interview Schedule-Revised (CIS-R) at age 12 years. Logistic regression analysis was used to calculate the odds ratios (ORs) for PE, psychotic disorder and depression at 18 years for each SD (five points) increase in EPDS score at 32 weeks pregnancy (mothers and fathers separately) and 8 weeks postpartum (mothers). Linear regression examined the association between parental depression around pregnancy and serum IL-6 levels in childhood. Moderating effect of IL-6 on the association between maternal prenatal depression and risks of psychosis and depression in offspring was examined.

Results: At age 18 years out of 4198 participants 203 were assessed to have definite PE (4.8%), 68 met criteria for psychotic disorder (1.6%), and 317 met criteria for depression (7.8%). Maternal prenatal depression was associated with risks of psychotic disorder (adjusted OR, 1.46; 95% CI, 1.02-2.09) and depression (adjusted OR, 1.20; 95% CI, 1.01,1.40) in offspring. IL-6 levels in offsprings were used to calculate the potential confounders including postnatal depression. Maternal prenatal depression was associated with IL-6 levels in childhood at age 9 years (adjusted regression coefficient, 0.09; SE, 0.04; $P=0.03$). Childhood IL-6 levels moderated the association between maternal prenatal depression and offspring psychosis and depression. There was significant association between maternal prenatal depression and risks of PE, psychotic disorder and depression in offspring at 18 years in the group with high (but not low) IL-6 levels at 9 years (OR = 1.37, 95% CI, 1.06-1.77; OR = 1.88, 95% CI, 1.23-2.87; and OR = 1.35, 95% CI, 1.09-1.68, respectively). Maternal postnatal depression or father’s depression during pregnancy were not associated with IL-6 or psychiatric risk in offspring.

Discussion: Maternal depression in pregnancy contributes to risks of psychosis and depression in adult offspring. Maternal depression in pregnancy is associated with levels of the inflammatory cytokine IL-6 in childhood. Childhood IL-6 levels moderated the association between maternal prenatal depression and psychosis in adult offspring. Maternal depression in pregnancy and risks of psychosis and depression in adult offspring.

T125. Childhood traumas in young adults with clinical and familial risk for psychosis - the Northern Finland 1986 birth cohort

Pirjo Mäki1*, Tuija Mähönen1, Tanja Nordström2, Juha Veijola3
1University of Oulu and Oulu University Hospital; 2University of Oulu

Background: Childhood trauma increases the risk for psychotic disorder and prodromal symptoms according to previous studies. However, childhood trauma in subjects with familial risk for psychosis is less studied. We aimed to replicate the previous findings of the connection between childhood trauma and prodromal symptoms for psychosis in a birth cohort sample. In addition, we studied the childhood trauma in young adult offspring of parent with history of psychosis.

Methods: A field study for a subsample of the general population-based Northern Finland 1986 Birth Cohort (NFBC 1986) was conducted in 2007-2010 when the participants were 21-24 years old. The subsample is called the Oulu Brain and Mind Study. According to the Structured Interview for Prodromal Syndromes (SIPS) and Finnish Hospital Discharge Register (FHDR) and other register data for four groups were created: psychosis ($N=30$), Clinical Risk CR ($N=47$) and Familial Risk FR ($N=61$) of psychosis and controls ($N=74$). CR presented prodromal syndromes for psychosis. FR group consisted of the offspring (cohort members) of parents with history of hospital-treated psychosis or A-type personality disorder. Subjects who had
psychosis or prodromal symptoms according to SIPS were excluded from FR group and included in the psychosis and CR groups. The Trauma and Distress Scale (TADS) – self report questionnaire (Patterson et al., 2002) was used to measure five types of traumatic childhood and adolescence experiences: emotional abuse, physical abuse, sexual abuse, emotional neglect and physical neglect. The TADS questionnaire was originally used in the European Prediction of Psychosis Study (EPOS).

Results: Young participants with psychosis had statistically significantly increased risk having had experienced emotional abuse (P < 0.05), physical abuse (P < 0.05) and sexual abuse (P < 0.01) in childhood compared to controls when adjusted with gender, family SES and family type. Subjects with CR had increased risk for emotional abuse (P < 0.01), physical abuse (P < 0.05) and emotional neglect (P < 0.01) compared to controls. Subjects with FR did not have increased risk for any of the five trauma types compared to controls.

Discussion: Childhood traumas were connected to psychoses and prodromal syndromes for psychosis. These findings are in general in line with previous studies. Interestingly, parental psychosis did not increase the risk for childhood trauma in this study. This was a new finding.

References:

T126. Tobacco smoking and risk of first episode psychosis: a case-control study in Sao Paulo, Brazil
Paulo Menezes*,1, Geraldo Busatto1, Philip McGuire2, Robin Murray3, Marcia Scazufca1
1Universidade De São Paulo; 2Institute of Psychiatry, Psychology & Neuroscience, King’s College London

Background: There is growing evidence suggesting that there may be a causal link between tobacco smoking and risk of first episode psychosis (FEP). A recent systematic review estimated a mean Odds Ratio of 3.2 for risk of FEP among smokers, compared to non-smokers. However, confounding by cannabis use and publication bias may explain, at least partially, that association. We examined whether the association between tobacco smoking and risk of FEP might be confounded by other exposures.

Methods: A population-based case-control study was carried out in Sao Paulo, Brazil. First episode psychosis cases from a specified catchment area of about 1.2 million inhabitants, aged between 18 and 64 years were individually matched by sex, age group, and neighbourhood to healthy controls (ratio 1:2). Information on history of tobacco smoking was obtained through direct interviews. For cases, number of years of healthy controls (ratio 1:2). Information on history of tobacco smoking were individually matched by sex, age range, and neighbourhood to area of about 1.2 million inhabitants, aged between 18 and 64 years

Results: Young participants with psychosis had statistically significantly increased risk having had experienced emotional abuse (P < 0.05), physical abuse (P < 0.05) and sexual abuse (P < 0.01) in childhood compared to controls when adjusted with gender, family SES and family type. Subjects with CR had increased risk for emotional abuse (P < 0.01), physical abuse (P < 0.05) and emotional neglect (P < 0.01) compared to controls. Subjects with FR did not have increased risk for any of the five trauma types compared to controls.

Discussion: Childhood traumas were connected to psychoses and prodromal syndromes for psychosis. These findings are in general in line with previous studies. Interestingly, parental psychosis did not increase the risk for childhood trauma in this study. This was a new finding.

References:

T127. The influence of polygenic risk scores on the association between infections and schizophrenia
Michael Benros*,1, Betina Trabjerg2, Sandra Melanie Meier3, Manuel Mattheisen3, Preben Mortensen3, Ole Mors5, Anders Bergljum6, David Hougaard7, Bent Nørgaard-Pedersen7, Merete Nordenfelt8, Esben Agerbo9
1Mental Health Centre Copenhagen; 2Aarhus University - NCCR; 3National Centre of Register-Based Research, Aarhus University; 4Aarhus University; 5National Centre for Register-Based Research, Aarhus University; 6Aarhus University Hospital; 7SSI Denmark; 8Mental Health Center Copenhagen, University of Copenhagen; 9National Centre for Register-Based Research

Background: Several studies have suggested an important role of infections in the etiology of schizophrenia; however, shared genetic liability towards infections and schizophrenia could influence the association. We therefore investigated the possible effect of polygenic risk scores (PRS) for schizophrenia on the association between infections and the risk of schizophrenia.

Methods: We conducted a nested case-control study on a Danish population-based sample born after 1981 comprising of 1,692 cases diagnosed with schizophrenia between 1994-2008 and 1,724 matched controls. All individuals were linked utilizing nationwide population-based registers with virtually complete registration of all hospital contacts for infections. PRS were calculated using discovery effect size estimates weights from a separate meta-analysis (34,600 cases and 45,968 control individuals).

Results: A prior hospital contact with infection had occurred in 41% of the individuals with schizophrenia and increased the incidence rate ratio (IRR) of schizophrenia by 1.43 (95%CI = 1.22-1.67). Adding PRS, which was robustly associated with schizophrenia (by an IRR of 1.46 (95%CI = 1.34-1.60) per standard deviation of the score), did not alter the association with infections and the increased risk of schizophrenia remained (IRR = 1.41; 95%CI = 1.20-1.66). Furthermore, there were no interaction between PRS and infections on the risk of developing schizophrenia (P = 0.554). Neither did PRS affect the risk of acquiring infections among patients with schizophrenia (OR = 1.00; 95%CI = 0.89-1.12) nor among controls (OR: 1.09; 95%CI: 0.96-1.24).

Discussion: PRS and a history of infections have independent effects on the schizophrenia risk and the common genetic risk measured by PRS did not account for the association with infection in this sample.

T128. Inadequate cancer diagnostics among persons with severe mental illness: a population-based cohort study
Anita Tender Nielsen*,1, Trine Munk-Olsen2, Mogens Vestergaard2, Janne Tidelskab Larsen3, Nis Palm Suppli4, Susanne Oksbjerg Dalton5, Peter Vedsted6, Merete Nordenfelt7, Thomas Munk Laursen1
1The National Centre for Register-Based Research, Aarhus University; The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH); Centre for Integrated Register-Based Research (CIRRAU), Aarhus University, Mental Health in Primary Care (MEPRICA), Institute of General Medical Practice, Aarhus University; 2National Centre for Register-Based Research, Aarhus University; The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH); Mental Health in Primary Care (MEPRICA); Institute of General Medical Practice, Aarhus University; 3Department of Public Health, Institute of General Medical Practice, Aarhus University; 4Mental Health Centre Copenhagen; The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH); Mental Health in Primary Care (MEPRICA); Department of Public Health, Institute of General Medical Practice, Aarhus University, Denmark; 5Aarhus University, iPsych Research Forum; 6Survivorship, Danish Cancer Society Research Center, 7Institute of General Medical Practice, Aarhus University; 8Mental Health Centre Copenhagen; The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH); 9Aarhus University, The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH); Mental Health in Primary Care (MEPRICA); Institute of General Medical Practice, Aarhus University

Background: Persons with severe mental illness (SMI) including schizophrenia, schizoaffective- and bipolar disorder, have a 15- to 20-year reduction in life expectancy compared to the general population; partly caused by a diagnostic delay of physical diseases. For cancer, a late diagnosis may lead to a more extended level of disease and hence more severe disease, which may explain the increased cancer
mortality seen in persons with SMI. Delayed or missing diagnosis of a cancer illness may explain why persons with SMI have a similar cancer incidence as the general population concurrently with the increased cancer mortality. However, conflicting results exist and there is a lack of knowledge to which extent more extended level of cancer contributes to the reduced life expectancy in persons with SMI. We aimed to compare cancer incidence rates for all cancer sites stratified on level of extent of disease and subsequent mortality rates among persons with SMI with the general population.

Methods: We used nationwide, population-based registers as data sources. A cohort including all persons born between year 1900-2001 and living in Denmark during follow up was followed for incident cancer between 1978 and 2011 and for mortality between 1978 and 2012. SMI was considered as a time varying exposure and persons with and without SMI with no prior cancer diagnosis was followed in two subcohorts. Incidence rate ratios (IRR) and mortality rate ratios (MRR) were calculated with survival analysis (Poisson regression). All cancer sites were included except Non Melanoma Skin Cancer. The severity of cancer was given by subdivision of cancer into extent of disease, which indicates degree of spread; localised, regional, metastasized or unknown. All estimates for IRR and MRR are adjusted for age, calendar time and gender.

Results: Incidence

Our preliminary results show that 5,464 persons with SMI and 703,813 persons without SMI developed incident cancer during follow up. Incidence of cancer diagnosis (IRR) in persons with SMI compared to those without, by extent of disease;

- Localized cancer: 0.91 (95% CI: 0.87-0.95)
- With regional spread: 1.03 (95% CI: 0.98-1.09)
- Metastasized cancer: 1.13 (95% CI: 1.06-1.20)
- Unknown extent of disease: 1.14 (95% CI: 1.08-1.21)

Mortality

Our preliminary results show that 4,262 persons with SMI and 524,962 persons without SMI died after being diagnosed with cancer.

Mortality rates (MRR) in persons with SMI compared to those without, stratified by extent of disease;

- Localized cancer: 1.87 (95% CI: 1.77-1.98)
- With regional spread: 1.40 (95% CI: 1.32-1.50)
- Metastasized cancer: 1.82 (95% CI: 1.71-1.93)

Discussion: Persons with SMI have lower mortality compared to persons without SMI with no prior cancer diagnosis. Persons with SMI have higher mortality following a cancer diagnosis on all levels of extent of disease compared to persons without SMI. This higher mortality may indicate that persons with SMI do not have the same access to or receive a lower level of cancer treatment due to lower level of compliance or response to the given treatment compared to persons without SMI.

The results indicate a diagnostic delay in the cancer diagnosis among persons with SMI. This delay, together with unequal access to cancer treatment and a high level of multi morbidity, contributes to the increased mortality after a cancer diagnosis and hence the considerable reduced life expectancy.

T129. Pathway from perinatal circumstances to mortality at midlife in psychoses: a 45-year follow-up study of the Northern Finland birth cohort 1966

Nina Rautio1*, Erika Jääskeläinen2, Tanja Nordström2, Jouko Miettunen1, Matti Isohanni3, Jussi Seppälä4

1Center for Life Course Health Research, University of Oulu; 2University of Oulu

Background: Excess mortality in schizophrenia has been reported widely, but less is known about other psychoses and perinatal circumstances as predictors of mortality. The aim of the study is to examine mortality and causes of death in schizophrenia and other psychosis compared to individuals without psychosis and whether perinatal circumstances predict mortality.

Methods: Among the individuals of the Northern Finland Birth Cohort 1966 (n = 10,933), mortality and causes of death were followed until 31.12.2011 by national registers. Overall, 203 individuals had schizophrenia and 178 other psychoses until 31.12.2011.

Mother’s antenatal depression, wantedness of pregnancy, mother’s age at birth, smoking during pregnancy, parity, paternal socio-economic status and family type at birth were considered as predictors of mortality.

Results: Overall, 11.8% of individuals with schizophrenia, 12.9% with other psychosis and 3.2% without psychosis had died. Individuals with schizophrenia (HR 3.60; 95% CI 2.38-5.45) and other psychoses (HR 4.05; 2.65-6.17) had elevated risk for mortality compared to individuals without psychosis after adjustment for gender. Overall, 43.5% of individuals with other psychoses had died of natural causes compared to 36.8% without psychosis (P = 0.018) and 20.8% with schizophrenia (P = 0.015). The causes of death did not differ between individuals with schizophrenia and without psychoses (P = 0.154). In individuals with psychoses, those whose father belonged to socio-economic class of farmers (V), had lower risk for mortality (HR 0.19; 0.05-0.82) than individuals, whose father belonged to high socio-economic class (I-II) after adjustment for gender and parental psychoses. In individuals without psychoses, mother’s antenatal depression (HR 1.33; 1.00-1.77), smoking during pregnancy (HR 1.34; 1.02-1.77) and father’s low socio-economic status (III-IV, HR 2.25; 1.26-4.00, V, 1.87; 1.00-3.48) predicted higher mortality after adjustments for gender and parental psychoses (and paternal socio-economic status).

Discussion: Individuals with psychosis, especially other psychoses, had excess mortality compared to individuals without psychosis. Individuals with other psychoses had relatively more natural causes of death than individuals with schizophrenia and without psychosis. Perinatal circumstances seem to be more important predictors of mortality in individuals without psychoses than with psychoses. It is important to pay attention to somatic morbidity in individuals with other psychoses in order to prevent their higher mortality.

T130. Joint effects of prenatal exposure to infection and peripubertal adversity in schizophrenia

Jean-Christophe Debost1*, Janne Tisdalb Larsen2, Liselotte Petersen1, Trine Munk-Olsen1, Preben Bo Mortensen1

1National Centre for Register-Based Research, Aarhus University; 2Aarhus University, IPsyCh Research Forum

Background: Prenatal exposure to infection and early life adversity has both been linked with schizophrenia with rather modest effect sizes, and none of these factors seem sufficient to cause the disorder. However, evidence is accumulating to consider these factors as pieces in a multi-factorial causal path network.

Methods: We conducted a prospective cohort study on Danish register data, following 979,701 persons from their 15th birthday until onset of schizophrenia, emigration from Denmark, death or December 31, 2013, whichever came first. 9.656 individuals developed schizophrenia within the 8.84 million person years of follow-up. We estimated the independent and joint effects of prenatal exposure to infection and peripubertal adversity.

Results: We found a significantly increased risk of schizophrenia among females exposed to infection in utero, significantly higher compared to males. Males on the contrary had a higher risk of schizophrenia after exposure to both insults, with interaction between infection and peripubertal adversity increasing the risk. Correlations between adversities throughout early life however, made it difficult to disentangle exposure into different periods.

Discussion: This study showed a significantly higher risk of schizophrenia among females after prenatal exposure to infection compared to males. It also showed that infection and adversity might combine synergistically to increase the risk of schizophrenia in males. Strong correlation between exposures however, made these difficult to disentangle.
T131. Cannabis use and adherence to antipsychotics: a systematic review and meta-analysis

Enrico Foglia¹, Tabea Schoeler², Ewa Klamerus¹, Kevin Morgan², Sagnik Bhattacharrya³

¹Institute of Psychiatry, Psychology & Neuroscience, King’s College London; ²University of Westminster

Background: Antipsychotic medications play an essential role in the treatment of psychosis, but their effectiveness is often hindered by poor adherence. Previous reviews suggested that substance abuse may increase the risk of non-adherence to antipsychotics, resulting in negative outcomes in patients with psychosis. Cannabis is the most prevalent illicit drug in patients with psychosis, but the magnitude of its effect on non-adherence to antipsychotics has not been estimated as yet.

Methods: A meta-analytic method was adopted. Studies were identified through a systematic database search following the MOOSE guidelines. Studies were identified through a systematic database search. Adopting random-effects models, pooled odds ratios (OR) for risk of non-adherence to antipsychotics were calculated comparing: cannabis-users at baseline (CU) vs non-users at baseline (NU); NU vs continued cannabis users at follow-up (CCU); NU vs former users at follow-up (FU); FU vs CCU. Additionally, sub-group analysis, meta-regression and sensitivity analyses were performed.

Results: Fifteen observational studies (n = 3678) were included. Of these, 11 provided enough data for the estimation of a pooled effect-size. At baseline, increased risk of non-adherence was observed for CU as compared to NU (OR = 2.46, n = 3055). At follow up, increased risk was observed for continued users (CCU) as compared to NU (OR = 5.79, n = 175) and FU (OR = 5.5, n = 192), while there was no difference between FU and NU (OR = 1.12, n = 187). Sub-group analysis, meta-regression and sensitivity analyses did not detect significant effects of possible confounding variables.

Discussion: Cannabis use increases the risk of non-adherence and may represent a potential target for intervention to improve medication adherence in those with psychosis, for instance by an early switch to depot medication for cannabis users.

T133. Using home-recruitment to increase participation and representativeness of research among individuals with psychosis

Marianne Haaapea¹,1, Matti Isohanni2, Erika Jääskeläinen¹, Juha Veijola3, Jouko Miettunen¹

¹Center for Life Course Health Research, University of Oulu; ²Unit of Clinical Neuroscience, University of Oulu; ³Research Unit of Clinical Neuroscience, University of Oulu and Oulu University Hospital

Background: The participation rates in epidemiologic cohort studies have declined in recent decades. Missing data is a serious problem especially in population based research reducing sample size and statistical power. We aimed to evaluate the effect of intensive home-recruitment on participation rate and non-response bias in a follow-up study on psychosis.

Methods: In the Northern Finland Birth Cohort 1966, baseline (1999-2001) and follow-up (2008-2010) studies were conducted for individuals with psychosis. The studies consisted of magnetic resonance imaging (MRI) of brain, cognitive testing, and psychiatric assessments. Altogether 81 out of 91 baseline participants were eligible and invited to participate in the follow-up study. In order to increase participation in the follow-up, those who were about to drop out were offered to be interviewed at home and chauffeured to the Oulu University Hospital for the MRI scan and cognitive testing. Positive and Negative Syndrome Scale (PANSS), Social and Occupational Functioning Assessment Scale (SOFAS), cognitive performance (selected measures from the California Verbal Learning Test (CVLT) and Hopkins Verbal Learning Test (HVLT) as well as years of antipsychotic medication by the time of the follow-up study were compared between the home-recruited and standard protocol participants and the nonparticipants. Effect sizes (g) were calculated to compare the means.

Results: Altogether 18 (33%) of the follow-up participants (n = 54) were interviewed at home. Of the participants with schizophrenia 14 (35%), and with other psychoses 4 (29%), were interviewed at home. Compared to the standard protocol participants, the home-recruited participants had more total, negative, disorganization and excitement symptoms (total 63.1 vs. 43.4, g 0.95, P = 0.003; negative 18.5 vs. 11.7, g

© 2016 Schizophrenia International Research Society/Nature Publishing Group

npj Schizophrenia (2016) 16007
T134. Exploring risk factors in early and late onset schizophrenia

Ajit Selvendra1, Laura Chen2, Anne Stewart2, David Castle3

1University of Melbourne; 2St. Vincent’s Hospital; 3University of Melbourne; 4St. Vincent’s Hospital

Background: This study reviews key risk factors in patients diagnosed with schizophrenia in order to identify trends according to age of onset by comparing presentations prior to 26 years (youth onset), between 26 and 40 years (middle adult age group), and after 40 years of age (Late onset schizophrenia or LOS).

Methods: The early psychosis program at St Vincent’s Hospital Melbourne treats patients presenting in the early stages of psychosis between 16 and 65 years of age. A database was developed to capture key risk factors in all patients with an eventual diagnosis of schizophrenia (n = 225) and a file review of these cases was undertaken. These results were compared with results obtained from direct interview of current patients. Risk factor profiles were compared for patients with an onset prior to 26 years (n = 104), between 26 and 40 years (n = 81), and after 40 years of age (n = 40).

Results: The peak age of onset in the study sample was in the youth group especially between 17 and 22 years, with median age of 27. The proportion of males is greatest in the youth cohort (72.1%) and steadily decreases with age. The male and female prevalence rates approximately each other in later life. Older age of onset was found to be associated with several graded trends in risk factors. This includes a reduction in the rates of a positive family history for schizophrenia as well as other mental illnesses. With age there was also a reduction in the rates of both recent and lifetime substance use. With an increased age of onset we noted trends towards greater levels of educational completion and better early psychosocial functioning. A higher proportion of first generation migrants and increased frequency of comorbid physical health problems was also reported with increased age of onset.

Of these trends, the older age groups had a statistically significant difference in family history of schizophrenia specifically, educational completion and some substance use on Chi-square testing (P < 0.01) compared to the youth age group. Weak trends were also suggested between older age of onset and risk factors occurring proximal to the onset of psychosis; including social isolation around time of onset, unemployment and unstable accommodation in the two years prior to onset.

Discussion: Distinct trends are noticeable with age. LOS patients have characteristic differences in their background risk factors compared to youth and middle adult groups, including less hereditary influence and greater female preponderance. Risk factors closer to the onset of psychosis appear to play a larger role in LOS, possibly as precipitants or markers in the development of disease. Substance use is a much greater issue among youth and middle adult groups, while physical health problems are considerably more prevalent among older patients.

Identifying the roles and mechanisms of specific risk factors in these distinct age-onset groups can enhance our understanding of possible aetiological mechanisms and facilitate tailoring of clinical management and service development to the needs of each specific age group.

T135. Estimation of incidence rate of first episode psychosis in a Brazilian large catchment area

Rosana Shuhama1, Camila Loureiro1, Taciana Ragazzi1, Craig Morgan2, Jim van Os3, Antonio Santos1, Paulo Louzada-Junior2, Cristina Del-Ben1

1Faculty of Medicine Ribeirão Preto USP; 2King’s College London; 3Maastricht University

Background: The psychotic disorders, as schizophrenia, figure as a public health problem with important social and psychological impact to both patients and their relatives. This is an effort to estimate the incidence of first episode psychosis (FEP), during a period of three years, in a large catchment area in Brazil, a low/middle-income country. It results from our membership in the international consortium ‘European Network of National Networks Studying Schizophrenia Gene-Environment Interactions’ (EU-GEI: http://www.eu-gei.eu/). Here, we describe an update of the incidence study currently in course in the region of Ribeirão Preto city, São Paulo State, Brazil, with a population at risk of 2,824,377 in three years.

Methods: FEP patients aged between 16 and 64 years old, seeking a mental health treatment for the first time in the defined catchment area from 1st April 2012 to 31st March 2015, were included in the study. The leakage study, as the final phase for the incidence estimation, covered, so far, 85% of the population at risk and is expected to finish in two months. The diagnostic diagnosis was made by trained research professionals according to the DSM-IV criteria and based on face-to-face interviews, medical records and information obtained with mental health professionals. Ethical consent was obtained from participants and from the coordinators of the department of health of the catchment area.

Results: Four hundred and thirty six FEP patients (56% males) were identified until now. Male FEP patients (mean = 30.47, SD = 11.90 years old) were significantly younger (t = 3.39, df = 432, P = 0.001) than female ones (mean = 34.20, SD = 11.84). The diagnoses of non-affective and affective psychosis correspond respectively to 51% and 49% (χ² = 0.083, df = 1, P = 0.774). The period between the beginning of the psychotic symptoms and the first contact with a mental health service ranged from 0 to 1292 weeks (median = 13.4 weeks). The incidence estimate of FEP with data collected at this moment is 15.5/100,000 inhabitants.

Discussion: Based on current data available, the incidence of first episode psychosis in Ribeirão Preto catchment area is similar to the observed in São Paulo city, which is characterized as one of the largest economic centers in the country. Further examination of incidence rates by population size of each municipality may contribute to better understand the relationship between urbanicity and incidence of FEP in this setting.

T136. Resilience in schizophrenia: a comparative study between a remote island and an urban area in Japan

Kazunari Yoshida1, Takefumi Suzuki2, Yasushi Imasaka3, Ken-ichiro Kubo4, Yuya Mizuno1, Juri Saruta5, Keiichi Tsukinoki6, Masaru Mimura1, Hiroyuki Uchiyad1

1Keio University School of Medicine; 2Keio University School of Medicine; Inokashira Hospital; 3Ohzumi Hospital; 4Ohzumi Hospital; Ohshima Medical Center; Keio University School of Medicine; 5Kanagawa Dental University Graduate School of Dentistry/Research Institute of Salivary Gland and Health Medicine; 6Kanagawa Dental University Graduate School of Dentistry; Keio University School of Medicine; Centre for Addiction and Mental Health

Background: Resilience, the “relative resistance to psychosocially adverse experiences”, is influenced by various factors, but has rarely been investigated in patients with schizophrenia. Moreover, possible differences between residential areas have never been explored to our knowledge. Therefore, the aim of this study was to compare the resilience levels between patients with schizophrenia who were living on a rural island and an urban area in Tokyo, Japan, and to identify the factors associated with resilience in those patients.

Methods: This cross-sectional study was conducted for outpatients with schizophrenia or schizoaffective disorder (ICD-10) who live in...
T137. Socio demographic and clinical characteristics in first episode psychosis
Ahmet Ayer1, Esra Aydinli2, Koksal Alptekin3
1Manisa Mental Health Hospital; 2Dokuz Eylul University; 3Dokuz Eylul Universitesi Tip Fakultesi Department of Psychiatry

Background: In this study the relation between socio-demographic variables, alcohol and substance use, the environmental factors such as traumatic life events and psychotic symptoms in the first episode psychosis patients were examined.

Methods: The study sample consisted of 60 First Episode Psychosis patients and 60 healthy control subjects. Psychosocial risk factors were assessed using Social Environment Measurement Tool, Life Events Scale, Tobacco Alcohol Use Scale and Substance/Marijuana Use Scale. In addition to the clinical evaluation of the patient group PANSS, the Young Mania Symptoms Scale and Insight Scale were used for assessing social skills and biomarkers (i.e. SSA and plasma BDNF levels). A P-value of < 0.05 was considered statistically significant (two-tailed).

Results: Eighty subjects were included (40 each in two areas). No significant difference was found in the RS scores between the two groups (mean ± S.D., 103.9 ± 26.1 in Ohshima Island versus 109.4 ± 22.3 in the urban area, P = 0.32). There were significant differences in some of the characteristics between the two groups: higher BMI score, more siblings, less frequency of low birth weight, fewer previous hospitalizations, more frequent use of anticholinergic drugs, less use of social resources, history of low birth weight (< 2500 g), GAF score, PANSS total score and biomarkers (i.e. SSA and plasma BDNF levels). A P-value of < 0.05 was considered statistically significant (two-tailed).

Discussion: Patients with schizophrenia living on a remote island and in urban area showed comparable degrees of resilience despite the difference in geographical location. Although resilience levels are known to be influenced by various environmental factors, those factors in the two groups, both of which are parts of Tokyo Metropolitan City, may have no essential differences. Moreover, even if the surrounding environment and cultural background are different, a similarity in illness severity and social functioning in the two groups may be typical for similar resilience levels. On the other hand, a significant correlation was found between a longer duration of illness and greater resilience levels, which is a novel finding to the best of our knowledge. Illness duration and subjective quality of life may be more pertinent than urbanicity of residential area in determining resilience levels. Namely, greater resilience among people with a longer duration of illness may represent their successful psychological coping and adaptation.

References

© 2016 Schizophrenia International Research Society/Nature Publishing Group
npj Schizophrenia (2016) 16007

Ahmet Ayer*, Esra Aydinli, Koksal Alptekin

1Manisa Mental Health Hospital; 2Dokuz Eylul University; 3Dokuz Eylul Universitesi Tip Fakultesi Department of Psychiatry

T138. Schizophrenia-spectrum disorders and violent reoffending: a national cohort study of convicted prisoners
Seena Fazel1, Zheng Chang2, Henrik Larsson3, Paul Lichtenstein3
1University of Oxford; 2Karolinska Institute

Background: There are more than 10 million currently imprisoned, of which around 4% have schizophrenia-spectrum disorders according to systematic reviews. In the US and UK, over one-third of released prisoners are reconvicted for a new crime within 2 years. Evidence on whether schizophrenia-spectrum disorders increase the risk of reoffending is inconsistent. With large numbers of individuals with psychotic disorders in jails and prisons, clarification of this association is important to inform mental health services in criminal justice and on release from custody.

Methods: We undertook a longitudinal cohort study of 47,326 prisoners who have been imprisoned since January 1, 2000 and released before December 31, 2009 in Sweden. Data on diagnosed psychiatric disorders were obtained from both inpatient and out-patient registers. Socio-demographic and criminalological factors were obtained from other population-based registers. Hazard ratios (HRs) for violent reoffending were calculated by Cox regression.

Results: 1237 (3%) of the men 130 (4%) of women had schizophrenia-spectrum disorders. A significantly increased hazard was also found for male prisoners with schizophrenia-spectrum disorders after adjustment for socio-demographic and criminalological factors (adjusted HR = 1.20 (1.09-1.33), but not in the women (HR = 0.74 [0.45-1.20]). Comorbid substance use disorders increased these hazards (Adjusted HR in the men = 2.68 [2.41-2.98]).

Discussion: Contrary to expert opinion and previous research, we found that schizophrenia-spectrum disorders are independent risk factors for violent reoffending in male prisoners. National violence prevention strategies should consider the role of prison psychiatry.

© 2016 Schizophrenia International Research Society/Nature Publishing Group
npj Schizophrenia (2016) 16007
T140. A comparative study on the prevalence rate and treatment of agitation among Chinese newly hospitalized schizophrenics between psychiatric hospitals and general hospitals

Hongyan Zhang1, Suzhen Zhang1, Wifeng MI1, Qi Liu1, Lingzhi Li1
1Peking University Sixth Hospital, Peking University Institute of Mental Health

Background: Agitation is frequently reported with newly hospitalized patients suffering from schizophrenia, and may result in substantial adverse outcomes for themselves, others, and property. This study was designed to investigate the prevalence rate and treatment of agitation among newly hospitalized schizophrenics between psychiatric hospitals and general hospitals.

Methods: We conducted a non-interventional, multicenter, observational study in 10 psychiatric hospitals and 4 general hospitals. Information about agitation and treatment of all enrolled patients were investigated including general demographic data, disease characteristics, Clinical Global Impression-Severity (CGI-S), Positive and Negative Syndrome Scale–Excited Component (PANSS-EC), Modified Overt Aggression Scale (MOAS) and prescription.

Results: 1.0% of 1512 patients enrolled in the study, 1400(92.6%) were eligible; the prevalence of agitation among psychiatric hospitals was significantly higher than that of general hospitals (52.8%, P<0.01%). 2. The general hospitals had higher proportion of oral medication (P<0.05%), whereas the psychiatric hospitals had higher proportion of intramuscular medication (P=0.01%) and a combination of oral medication with intramuscular medication (P=0.01%). 3. Oral medication most frequently prescribed was olanzapine (32.24%), subsequently were risperidone (30.25%), subsequently were clozapine (12.90%), intramuscular medication most frequently prescribed was haloperidol (35.40%), subsequently were ziprasidone (36.11%), subsequently were benzodiazepines (4.69%). The general hospitals had more than double use frequency of clozapine than the psychiatric hospitals (P<0.01%). With respect to ziprasidone intramuscular, 12.5% of patients from psychiatric hospital had ziprasidone intramuscular, while none of the patients from psychiatric hospital did. No statistically difference were found in the risk of clozapine and haloperidol intramuscular (P=0.05%) between the psychiatric hospitals and general hospitals.

Discussion: Our study indicated that, in China, the prevalence of agitation among psychiatric hospitals was significantly higher than that of general hospitals (64.30% vs. 52.8%, P<0.01%). In addition, patients in the psychiatric hospitals experienced a significantly older age, longer illness duration, more numbers of hospitalizations and higher CGI score, higher proportion of history of aggressive behaviors and involuntary admission than the general hospitals. These findings suggest that the psychiatric hospital group were more likely to be in more complex situations, higher risk of uncooperativeness and refractory schizophrenia, which may contributing to the different treatment. For the agitation sample, the psychiatric hospitals were more inclined to use intramuscular medication in managing this condition with schizophrenia, mainly haloperidol and ziprasidone. While no one used ziprasidone intramuscular in general hospital, considering the high prevalence and deficient clinical practice play a role. As to clozapine, the use frequency in psychiatric hospitals and general hospitals was 9.8% and 23.4% respectively. Over the last decade, there was a falling trend in using frequency of clozapine in China. Since its unique advantages in psychiatric illness, it is significant to avoid the low utilization of clozapine and improve the rational use in the indication.
participants together with background data and information regarding neuropsychological, physical, and social functioning.

Discussion: Our preliminary data will be discussed. We hope that the collection of a broad range of data will provide clinicians with significant information that will improve diagnostics and thereby benefit the patients. We are still in the process of fine tuning the clinical protocol and would highly value input that might help us to improve the protocol.

T142. Exploring the effect of COMT and BDNF polymorphisms on association between psychotic experiences and depression-suicidal ideation in a six-year follow-up of general population based sample

Tolga Binbay1, Umut Kfir2, Hayriye Elbi3, Bülent Kayahan3, Hüseyin Onay3, Ferda Özkınay4, Jim van Os5, Koksal Alptekín5
1Dokuz Eylül University; 2Ege University; 3Maastricht University Medical Centre

Background: Individuals reporting psychotic experiences (PEs) are at increased risk of developing not only psychotic disorder but also depression and anxiety. PE has been also highlighted as a valuable clinical marker of risk for suicidal behaviour. There have been few studies to date, however, to assess psychotic experiences as a predictor of depression and suicidality over time. Furthermore, association between PEs and depression and suicide may be moderated by genotype including single-nucleotide polymorphisms of COMT and BDNF.

Methods: The TürkSch study (İzmir Mental Health Survey for Gene-Environment Interaction in Psychoses) is a prospective-longitudinal study consisting of several data collection stages to screen and follow up mental health outcomes in a general population sample. At baseline (T1, 2008), 4011 individuals aged 15–64 years were assessed on depression, suicidal ideation and extended psychosis phenotype using CIDI 2.1 and SCID-I. At follow-up (T2 on average 60 months later, 2014) participants (n: 2185) were interviewed for presence of any major depressive episode and suicidal ideation/attempt. Alleles rs4680 (COMTv1158met) and rs6265 (BDNFval66met) were genotyped in a sub-sample (n: 262). Analyses excluded respondents with any psychotic disorder at T1 and T2 and based on outcomes of individuals with subsclinical expression of PEs.

Results: Individuals with psychotic experiences at T1 were more than 2 and 2.5 times (adjusted OR: 2.3; 95% CI: 1.7-3.1 and OR: 2.7; 95% CI: 1.9-3.7 respectively) likely to experience at least one depressive episode or any suicidal ideation in the six-year follow-up (T2). While the rate of any depressive episode at T2 6.7% (n: 109) in the non-PE group (n: 1616), the same rate at T2 was 14.8% (n: 77) in the any PE group of T1 (n: 521). Suicidal ideation at T2 was reported by 6.1% (n: 99) of non-PE individuals at T1 while 16.3% (n: 85) of the respondents with any PE at T1 reported suicidal ideation at T2. Associations between PEs at T1 and depression and suicidal ideation at T2 were neither moderated by COMT nor BDNF polymorphisms.

Discussion: This is the first prospective general population study to examine moderator effects of COMT and BDNF on associations between PEs and depression and suicidal ideation. There was no evidence of an effect of COMT or BDNF polymorphisms. PEs are important but under-recognized marker of risk for depression and suicidal ideation.

T143. Evidence for neighbourhood effects on sub-clinical psychotic experiences: preliminary results from the south east London community health study

Visalh Bhavsar1, Philip McGuire1, Matthew Hotopf1, Victoria Harris1, Stephani Hatch1, Jane Boydell1
1King’s College London

Background: Psychotic-like experiences (PLEs) are discernible phenomena in community populations, that display evidence of aetiological and temporal continuity with psychosis per se. Risk factors for PLEs based on current evidence include male gender, age, non-White ethnicity, unemployment and lower socioeconomic status, and urbanicity, defined as exposure to urban residential environments over life. Associations with city living might exist because urban environments tend to be more deprived than rural areas. This is consistent with the psychosis literature- patterning of psychosis by area may in part be explained by local differences in deprivation, cohesion, and ethnic composition. No studies thus far have assessed these effects for PLEs in general population samples. One study by Oner and others, evaluated the spatial distribution of psychotic symptoms in people with established psychotic disorder. However, the relevance of neighbourhood characteristics in influencing risk of psychotic symptoms in those without psychosis is unknown. This study uses a representative household survey located in South East London to assess the association between neighbourhood deprivation and psychotic-like experiences in the general population.

Methods: The South East London Community Health Survey (2008-2010) is a representative health survey of the residential population of two large inner-city boroughs in South East London, Lambeth and Southwark. The sample consisted of 1698 individuals, residing in 1075 households, collected through random sampling of a postcode address file for South London, who were then interviewed by trained researchers. For this analysis, the Psychosis Screening Questionnaire was used to assess the presence of different non-affective psychotic experiences (strange experiences, paranoia, hallucinations, and thought disorder). Information on neighbourhood deprivation was derived from the Index of Multiple Deprivations (IMD, 2011) dataset, which contains scores for deprivation for each small area of England and Wales based on census information. Latent variable analysis was done in STATA 14 using the item response theory command, accounting for the survey design. Univariate associations between the latent psychotic experience variable and neighbourhood deprivation indices were estimated using the mixed command.

Results: A ten-point increase in neighbourhood deprivation was associated with a small increase on the psychotic experiences latent variable (effect size=0.0048, 95%CI:0.0005,0.009), which remained after adjusting for age and gender(effect size 0.0047, 95%CI:0.0005,0.009), but was rendered only marginally significant on adjustment for unemployment(0.0042,95%CI:0.0003,0.008).

Discussion: Psychotic experiences was associated with neighbourhood deprivation in this analysis of survey data, after accounting for age and gender. Remaining variability was explained in large part by individual unemployment, but there remained some weak statistical evidence for contextual effects. Further work should address this question in larger samples.

T144. Determinants of outcome in first-episode psychosis: readmissions to psychiatric inpatient care

Simone Ullrich1
1Queen Mary University of London

Background: The content and organisation of mental health services have been changing seeking an optimal balance of services between community- and hospital-based psychiatric inpatient care. Attention has also increasingly been directed towards patients with chronically disabling conditions and the importance of long-term outcomes and functional abilities. A large body of research has been dedicated to uncovering the correlates of readmission and identification of risk factors for treatment planning, preparation of discharge and mental health policy planning.

Methods: We carried out a retrospective cohort follow-up study of 490 patients who presented with a first episode of affective and non-affective psychosis in east London between 1996 and 2000. Data were collected using standardized instruments from medical records in 53 primary and secondary care Trusts in England. Symptoms of mental illness were coded using the OPCRIT system. A full 10 year follow-up was achieved for 82% (n = 350) of the sample still alive and living in England. The follow-up period was divided into 6 month time windows resulting in a maximum of 7,000 observations for statistical analysis.

Results: Approximately one third of the sample (n = 102, 29.1%) were not re-admitted to psychiatric inpatient care after first presentation. A further 124 (35.4%) were re-hospitalized 1 to 3 times during follow-up and the remainder of the sample was more frequently re-admitted. A
small proportion of patients (41, 11.7%) were classified as revolving door patients with 11+ re-admissions during the follow-up. Factors characteristic for this group were: young age at first presentation, being male, black ethnicity, living in the borough of Hackney, UK born, single marital status, not owning the property where they lived in, parental discord before the age of 15, and a family history of criminal behavior. Surprisingly none of the clinical characteristics at baseline discriminated the groups. The eight risk factors were added up and the distribution of scores was significantly different in the revolving-door patients. With regard to psychopathology during the follow-up, the most discriminating factor in this group was continuous abuse of drugs (pre-and post-onset of illness).

Discussion: Our findings suggest a dose relationship between vulnerabilities and severity of symptomatology with subsequent rehospitalization. They further highlight the relevance of area effects on the occurrence of stressors which, in combination with continuous use of drugs, may lead to an early onset of psychotic illness. Further drug use and non-compliance may lead to re-emergence of psychotic symptoms with subsequent re-admissions.

T145. Does a syndemic or ethnicity explain disparities in psychosis in the UK?
Jeremy Coid*
Queen Mary University of London

Background: Incidence studies in Europe have shown that certain ethnic groups have greater risk of all psychoses. In the UK the risk appears highest among African-Caribbeans. However, many migrant groups live in socio-economically deprived areas, some with unusual racial disparities, this questions whether there is a true association out in these same areas for the purpose of demonstrating ethnic and racial disparities. In the UK the risk appears highest among African-Caribbeans. However, many migrant ethnic groups have greater risk of all psychoses. In the UK the risk appears highest among African-Caribbeans. They also suggest that ethnic area effects.

Methods: The sample consists of a subset of children from a large population-based cohort in Western Australia: 3,169 children of mothers with serious mental illness, including schizophrenia, bipolar disorder, unipolar major depression, delusional disorder or other psychoses (ICD-9 codes 295-298), and 88,353 children of comparison mothers without psychiatric morbidity. The sample was stratified by maternal ethnicity, and psychiatric morbidity using standardized instruments. Psychotic-like-experiences were measured using the Psychosis Screening Questionnaire (PSQ). Confirmatory factor analysis was performed to assess evidence for a syndemic explanation of observed ethnic disparities.

Results: Overall, a higher proportion of children of mothers with serious mental illness performed below-benchmark (43.1%) than the reference group (30.3%; children of mothers with no known psychiatric disorder). Children of mothers with schizophrenia performed most poorly. After adjusting for covariates, children of mothers with serious mental illness were more likely than the reference group to perform below-benchmark across all academic domains except reading. Children of mothers with schizophrenia were more likely than the reference group to perform below-benchmark in any of the academic domains (OR = 1.38; 95%CI for OR = 1.07-1.79).

Discussion: If psychotic-like-experiences at the population level reflect the risk for incidence cases of psychosis, these findings cast doubt on the notion of increased risk of psychosis in ethnic minority groups, specifically African-Caribbeans. They also suggest that socio-demographic factors are not sufficient to explain previous observations of disparity. The study found a syndemic consisting of psychiatric morbidity (specifically psychotic-like-experiences and symptoms of anxiety), poor sexual health, substance dependence and violence/ criminality with a positive biological interaction that exacerbates the negative health effects of each condition operating on black and Asian men in Hackney. Syndemic effects in the same areas in which incidence studies have demonstrated ethnic and racial disparities in psychosis may be the true underlying explanation of these disparities.

T146. Academic performance in children of mothers with schizophrenia and other severe mental illness, and risk for the development of psychosis: a population-based study
Ashleigh Lin1, Patricia DiPrinzio2, Deidra Young3, Peter Jacoby1, Andrew Whitehouse1, Flavie Waters4, Assen Jablensky4, Vera Morgan5
1Telethon Kids Institute; 2Neuropsychiatric Epidemiology Research Unit, University of Western Australia; School of Psychiatry & Clinical Neurosciences, 3School of Psychiatry and Clinical Neurosciences, The University of Western Australia; Clinical Research Centre, North Metropolitan Health Service Mental Health; 4School of Psychiatry & Clinical Neurosciences, The University of Western Australia

Background: Neurocognitive impairments are present in a significant proportion of individuals with schizophrenia and often precede the onset of overt psychotic symptoms. Such impairments are also detectable in the first-degree relatives of individuals with schizophrenia. Academic performance is generally considered evidence for neurocognitive ability. However, the associations between academic performance, subsequent schizophrenia and familial risk for psychosis are unclear. Using data from a large population-based cohort, we examined academic performance in Year 7 of children of mothers diagnosed with schizophrenia or other serious mental illness.

Methods: The sample consists of a subset of children from a large population-based cohort in Western Australia: 3,169 children of mothers with serious mental illness, including schizophrenia, bipolar disorder, unipolar major depression, delusional disorder or other psychoses (ICD-9 codes 295-298), and 88,353 children of comparison mothers without psychiatric morbidity. Academic performance was indexed on the Western Australian Numeracy and Literacy Assessment, a mandatory state-wide test, administered in Year 7 (approximately at age 12, representing readiness for secondary school). We examined below-benchmark performance (i.e. lower than the minimal acceptable standard) in the domains of spelling, numeracy, reading, writing, or in any of these domains. Demographics, maternal obstetric data and other parental information were obtained from linked databases and used as adjustments analyses.

Results: Our data confirm that children of mothers with serious mental illness are at increased risk to perform below-benchmark across all academic domains except reading. Children of mothers with schizophrenia were more likely than the reference group to perform below-benchmark in any of the academic domains (OR = 1.38; 95%CI for OR = 1.07-1.79).

Discussion: If psychotic-like-experiences at the population level reflect the risk for incidence cases of psychosis, these findings cast doubt on the notion of increased risk of psychosis in ethnic minority groups, specifically African-Caribbeans. They also suggest that socio-demographic factors are not sufficient to explain previous observations of disparity. The study found a syndemic consisting of psychiatric morbidity (specifically psychotic-like-experiences and symptoms of anxiety), poor sexual health, substance dependence and violence/ criminality with a positive biological interaction that exacerbates the negative health effects of each condition operating on black and Asian men in Hackney. Syndemic effects in the same areas in which incidence studies have demonstrated ethnic and racial disparities in psychosis may be the true underlying explanation of these disparities.
T147. Higher complexity of EEG signal as a state marker in first episode psychosis compared to individuals with at risk mental state for psychosis and healthy controls.

Vincent Laprevote1, Avinash Ramyead2, Julien Krieg3, Erich Studerus2, Christina Andreou2, Raymund Schwan4, Anita Riecher-Rössler2

Studies have shown increased complexity estimators in estimators vary across stages of the disease. Importantly, several studies have shown increased complexity estimators in first episode psychosis compared to healthy controls, thus indicating a higher level of chaotic activity in early psychosis (Fernandez et al. 2013). However, it is still unknown if increased complexity is a state marker of FE psychosis or a trait marker of the risk of psychosis. In order to address this issue, we studied the complexity of EEG signal in patients with FEP, compared to individuals with at risk mental state for psychosis (ARMS) and healthy controls (HC).

Methods: Patients and HC were recruited within the Basel FePsy Study for the early detection of psychosis (Riecher-Rössler et al. 2009). We included 47 patients with FEP, 67 with ARMS and 29 HC using the FEPSY study criteria, based on the Basel Screening Instrument for Psychosis (BSIP) (Riecher-Rössler et al. 2008). Symptoms of psychosis were assessed by BPRS and SANS. All the participants underwent a 19 channels resting state EEG recording at their inclusion in the study. After EEG pre-processing, the complexity of EEG signal was estimated with the Lempel Ziv Complexity (LZC). The LZC is a non-parametric measure in a one-dimensional signal, which counts the number of distinct substrings and the rate of their recurrence before computing it in a Z-score. The LZC was compared with an ANOVA with the group as between factor and the electrode location as within factor.

Results: The analysis showed a main effect of group, indicating that LZC was similar in ARMS and HC but was higher in FEP. The analysis also showed a main effect of electrode location on LZC but no interaction between electrode and group on LZC. Correlation analysis revealed a significant correlation between LZC and age.

Discussion: To our knowledge, this is the first study measuring EEG complexity in people with ARMS in comparison with FEP and HC. We showed a similar EEG complexity in people with ARMS and HC, but an increased EEG complexity in FEP patients. This result can possibly be interpreted as a higher level of neural chaotic activity in FEP patients. There was no gradation of LZC across HC, ARMS and FEP, which could eliminate this measure as a risk marker for psychosis. Since only FEP patients elicit an increased LZC, such a pattern could rather be considered as a state marker, specific for psychosis in comparison with ARMS and HC.

T148. Mismatch negativity (MMN) in psychosis following traumatic brain injury (PFTBI)

Rachel Batty1, Philip Makarios1, Susan Rossell1

Swinburne University of Technology

Background: Patients who develop psychotic symptoms following a traumatic brain injury (PFTBI) are relatively rare (i.e., ~10%). Circuitry implicated in the neurogenesis of psychotic symptoms overlaps with circuitry typically affected by traumatic brain injury (TBI), however the neurobiological precursors and/or processes in the development of PFTBI remain unknown. Auditory mismatch negativity (MMN) is an event-related potential that indexes the preattentive detection of changes in the acoustic environment. Although impoverished MMN has been shown across a range of disorders, MMN deficiency has recently been described as a “break-through biomarker” in the prediction of disease risk/symptom onset. We sought to determine whether PFTBI patients demonstrate impoverished MMN akin to patients with schizophrenia as further evidence for the MMN biomarker for psychosis. We expected that MMN amplitude would be significantly reduced in both psychotic cohorts relative to TBI patients without psychosis and non-clinical controls.

Methods: Duration (100ms vs 50ms standard) and frequency (1050 Hz vs 950 Hz standard) MMN was measured at frontal sites where the difference waveform was maximal (F3, FZ, F4): in nine PFTBI patients, nine TBI patients without psychosis, 17 schizophrenia patients without TBI, and 17 nonclinical controls.

Results: PFTBI and schizophrenia patients demonstrated significantly reduced amplitudes to both duration and frequency MMN at all three electrode sites relative to nonclinical controls as expected. However, TBI patients demonstrated statistically comparable amplitudes to both the psychotic cohorts and to the nonclinical controls (with the exception of frequency amplitude at F3 where TBI amplitudes were significantly larger than in schizophrenia).

Discussion: This is the first empirical event-related potential study in dually-diagnosed PFTBI. In support of a biomarker for psychosis, impoverished MMN to both duration and frequency deviants is apparent in PFTBI, akin to schizophrenia. Although MMN amplitude in TBI patients without psychosis was not significantly different from psychotic patients on the majority of contrasts, we note that peak amplitude was largely variable in TBI, with the mean looking more like nonclinical controls. Future work should determine the variability of MMN amplitude in TBI according to injury profile/lesion location, and follow TBI patients with reduced MMN amplitude to determine risk for transition to psychosis.

T149. C9ORF72 Repeat expansions that cause frontotemporal dementia are detectable among patients with psychosis.

Annie Watson1, Moctar Pribadi2, Kodavali Chowdari1, Sue Clifton1, Joel Wood1, Bruce L Miller3, Giovanni Coppola1, Vishwajit Nimgaonkar*4

1Univ of Pittsburgh, School of Medicine; 2Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, Univ of California Los Angeles; 3Memory and Aging Center/Sandler Neurosciences Center, Univ of California San Francisco; 4University of Pittsburgh

Background: A pathologic hexanucleotide repeat expansion in the regulatory region of C9orf72 causes frontotemporal dementia (FTD) or amyotrophic lateral sclerosis (ALS). In addition to features of dementia, behavioral abnormalities can be present among mutation carriers. It is uncertain whether a proportion of individuals clinically diagnosed with psychoses bear pathologic C9orf72 expansions in the absence of dementia.

Methods: We screened for C9orf72 repeat expansions among individuals diagnosed with functional psychoses such as schizophrenia (SZ)/schizoaffective disorder (SZA), and described the clinical features of individuals with the mutation.

Results: Pathogenic C9orf72 repeat expansions were detected in two pairs of related individuals following a survey of 740 participants in a psychiatric genetic research study. The mutation carriers included two siblings with schizophrenia, another unrelated individual with schizoaffective disorder and her non-psychotic mother. All the mutation-bearing patients with SZ/SZA had severe, florid illness, but did not provide a history suggestive of dementia or ALS.

Discussion: In conclusion, a small proportion of patients with SZ/SZA could bear C9orf72 repeat expansions. The patients showed atypical psychotic features without the typical cognitive features of dementia.
T150. Neurotrophin signaling in first episode psychosis: relation to response to antipsychotics after 1 year of follow-up

Monica Martinez-Cengotitabengoa¹, Karina MacDowell², Susana Alberich¹, Mara Parellada³, Pilar Saiz², Roberto Rodriguez², Esther Berrocuso³, Miguel Bernardo⁴, Ana Gonzalez-Pinto⁵, Juan Carlos Leza³

¹CIBERSAM-University Hospital of Alava, Psychiatry Department; ²CIBERSAM, Pharmacology Department, Medicine School, Universidad Complutense de Madrid; ³CIBERSAM, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid; ⁴CIBERSAM, Departamento de Psiquiatria, University of Seville; ⁵CIBERSAM, Instituto de Investigación; ⁶CIBERSAM, Universidad de Cádiz; ⁷CIBERSAM, Hospital Clinic y Universidad de Barcelona; ⁸CIBERSAM, Hospital Universitario Araba, Universidad del País Vasco

Background: Previous studies have shown a pro/anti-inflammatory imbalance in patients with a first episode of psychosis (PEP), which continues 12 months after diagnosis. Research in this area is increasingly focused on finding biomarkers that help us understand the pathophysiological mechanisms underlying the disease. The aim of this study is to evaluate changes in the expression of neurotrophins BDNF and NGF and their receptors in peripheral blood to identify any potential correlation with levels of inflammation, clinical symptoms over time and response to antipsychotic treatment.

Methods: The study included 94 patients with a PEP and 80 healthy subjects. Blood samples and clinical data were taken both at baseline and 12 months later. The expression of BDNF, NGF and their receptors TrkB (functional and truncated) and TrkA was measured in peripheral mononuclear cells. The pro/anti-inflammatory parameters evaluated were NKfβ, COX-2, iNOS, PPARgamma and 15sd-PG12. Patients’ functionality was measured by the GAF scale.

Results: Expression of the functional isoform (FL) of the BDNF receptor increases 1 year after diagnosis, whereas the truncated form (T) (inactive) descends. The ratio of both forms FL/T increases during follow-up both in patients with a higher ratio. Besides, the FL/T ratio could have a predictive role of the functionality of patient after 1 year, depending on whether the patient is treated with antipsychotic treatment or not.

Discussion: Inflammatory processes, neurotrophins pathways and functional status of the patient appear to be related which has important translational relevance. In particular, the level of expression of TrkB receptor isoforms (FL and T) should be considered before starting antipsychotic treatment in patients with a PEP.

T151. Minor neurological signs and clinical course in first-episode psychosis: a ten-year follow-up study

Naika Ferruccio¹, Julia Lappin¹, Margaret Heslin¹, Kevin Morgan¹, Adanna Onyejiaka¹, Tim Croudace², Peter B. Jones³, Robin Murray³, Paul Fearon⁴, Gillian Doody⁵, Craig Morgan¹, Paola Dazzan¹

¹Institute of Psychiatry, Psychology & Neuroscience, King’s College London; ²University of Dundee; ³University of Cambridge; ⁴St. Patrick’s University Hospital and Trinity College Dublin; ⁵University of Nottingham

Background: Minor neurological signs are already present not only at the time of first episode but even during prodromal phase in high-risk individuals and in healthy relatives of patients. They have therefore been proposed as a potential vulnerability biomarker for psychotic disorders. Here, we have investigated whether neurological signs at onset predict clinical course over the first ten years of illness.

Methods: Subjects were recruited as part of a large epidemiological study (AESP); Aetiology and Ethnicity in Schizophrenia and other Psychoses, carried out in South London (UK). The presence and the severity of neurological signs was assessed in patients with first episode psychosis (n = 234) and in healthy controls (n = 172) with the Neurological Evaluation Scale (NES). After 10 years, we evaluated illness course using an amended version of the WHO Life Chart. Illness course was defined as episodic (one or more period of remission of at least 6 months, and no episode of psychosis lasting 6 months or more) or continuous (no period of remission lasting 6 months or longer). Premorbid IQ was assessed using the National Adult Reading Test (NART). In a subgroup of 55 patients neurological signs were also re-evaluated.

Results: At baseline, individuals with psychosis showed significant higher mean scores than healthy controls in primary (P < 0.001), motor coordination (P < 0.001), motor sequencing (P = 0.005) and total signs (P < 0.001) compared with controls (t-test). The ANCOVA analysis showed that continuous patients had significantly higher scores than episodic patients for primary signs, motor coordination and motor signs at the follow-up (P < 0.001) respectively. In contrast, controls had significantly lower scores than both continuous and episodic patients for motor coordination (P < 0.001) and total signs (P = 0.025 and P < 0.001). Even when covarying for age and NART IQ, the differences remained significant. Repeated measure analysis carried out on subjects with two neurological evaluations did not show any significant change in neurological scores over time.

Discussion: To our knowledge few studies have investigated the long-term predictive clinical significance of neurological signs at illness onset. This study provides further supports to the hypothesis that primary and motor dysfunction may characterize a subgroup of individuals more likely to have a non-remitting illness course. This is also consistent with previous evidence suggesting that an impairment of fine motor coordination and motor development can predict schizophrenia-spectrum disorders.

T152. Psychosis-risk is associated with increased cerebral blood flow in the striatum: results of an arterial spin labeling MR-study

Jochen Kindler¹, Frauke Schultz-Lutter¹, Martinus Hauf¹, Chantal Michel¹, Thomas Diersk¹, Benno G. Schimmelmann¹, Daniela Hubi²

¹University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern; ²Support Center for Advanced Neuroimaging (SCAN), Institute for Diagnostic and Interventional Neuroradiology, University of Bern; ³University Hospital of Psychiatry, University of Bern

Background: Research on clinical high risk (CHR) states for psychosis indicates increased presynaptic striatal dopamine synthesis in CHR individuals as compared to controls. An increase in metabolic rate might also affect cerebral blood flow (CBF) in the respective regions. Here, we examined (1) if CBF in striatum differ between patients with and without CHR, and (2) if similar CBF changes are found in full-blown psychosis when compared with controls.

Methods: Samples: For the first aim, a total of 35 patients of the Bern Early Recognition and Intervention Centre were included. A CHR state was alternatively defined by ultra-high risk (UHR) or basic symptom (BS) criteria and met by 23 patients (CHR). UHR criteria were assessed by the Structured Interview for Psychosis-Risk Syndromes, BS criteria by the Schizophrenia Proneness Instrument. The clinical controls (CC, n = 12) did not fulfill CHR criteria or suffered from psychosis. Global level of psychosocial functioning was estimated using the Social and Occupational Functioning Assessment Scale (SOFAS). CHR and CC did not differ in age, sex or social functioning.

For the second aim, patients with an ICD-10 diagnosis of schizophrenia or schizoaffective disorder (SZ, n = 32) and healthy controls (HC, n = 31), matched for sex and age, were included. All patients reported medication-resistant positive symptoms at the time of scanning. Symptom severity in SZ was assessed with the Positive and Negative Syndrome Scale (mean total score = 76.6 ± 17.4).

Data Analysis: MRI was conducted on a 3 T MRI system. Participants were told to rest in the scanner with eyes closed. A pseudo-continuous arterial spin labeling (ASL) technique was used to measure CBF. ASL data analyses were performed with the aslm toolbox with MATLAB R2012a and SPM8. Data were t-transformed (z = [voxel CBF—global GM CBF] / SD) and corrected for gray matter (GM) volume. Because of inter-scanner variability, no direct comparison between the first (CHR, CC) and second (SZ, HC) samples was calculated. First, CHR were compared to CC with 2-sample t-tests, in a whole-brain, voxel-wise analysis. For the region of interest (ROI) analysis (ROI striatum = caudate & putamen, wfu-pickatlas), CBF values were extracted for left and right striatum, separately. Finally, SZ were...
compared to HC in 2-sample t-tests with small volume correction for the ROI, i.e., the striatum.

**Results:** In the whole-brain voxel-wise analysis, CBF was significantly increased in CHR in the left putamen, the left insula and the lentiform nucleus, and significantly decreased in the right inferior frontal gyrus and the right middle temporal gyrus as compared to CC (P < 0.001, uncorrected). The ROI analysis revealed significantly increased CBF in CHR in the left striatum. In comparison to HC, SZ demonstrated a significantly increased striatal CBF, predominantly in the caudate head and body (family-wise error corrected).

**Discussion:** This is the first study to demonstrate increased metabolic and neuronal activity within the striatum in a CHR sample. In both CHR and SZ, CBF in putamen and/or caudate was significantly increased as compared to the respective controls. Our results indicate that alterations of CBF in striatum might be a useful biomarker reflecting dopaminergic abnormalities that precede the onset of frank psychosis and positive symptoms, respectively. However, follow-ups of CHR patients and larger samples are required to examine prognostic accuracy of these alterations and potential associations with CHR symptoms, in particular with cognitive-perceptual BS and attenuated psychotic symptoms.

**T153. Visual habituation is impaired in unaffected siblings of subjects affected by schizophrenia: a pattern-reversal VEP study**

Giorgio Di Lorenzo*1, Fabio Ciabattini1, Emanuela Bianciardi1, Fabiola Ferentino1, Cherubino Di Lorenzo1, Gianluca Coppolla1, Michele Ribolbi1, Cinzia Niolu4, Francesco Pirelli1, Alberto Siracusano1, Stefano Seri1

1University of Rome Tor Vergata; 2Don Carlo Gnocchi Omlus Foundation; 3G.B. Bietti Eye Foundation; 4Fondazione Policlinico Tor Vergata; 5IRCCS; 6Aston University

**Background:** Sensory perception, including early phases of visual processing, are impaired in Schizophrenia. Relatives of subjects affected by Schizophrenia (SCZ), despite the absence of the characteristic clinical picture of illness, show similar perceptual deficits, including those of visual modalities. Also measures of sensory gating (or sensory habituation), considered as a protective mechanism against over-stimulation, results altered in relatives of SCZ. Impairment of habituation phenomena from visual paradigms, however, has not been yet demonstrated in relatives of SCZ. Recently, our group proposed that visual habituation, a reduction of the visual evoked response to sequential presentation of spatially structured stimuli measured with a Pattern-Reversal Visual Evoked Potential (PR-VEP) paradigm, is impaired in Schizophrenia. The aim of the present study was to measure the evoked responses of visual habituation PR-VEP paradigm in SCZ, their unaffected siblings (US) and healthy volunteers (HV), in order to investigate the hypothesis that US show abnormalities in visual habituation with an intermediate behaviour respect to SCZ and HV. Methods: Twenty-four SCZ, with a clinical and pharmacological stable condition, were selected from an outpatient program, along with their twenty-eight US. Twenty HV were recruited as control group, in order to investigate the hypothesis that US show abnormalities in visual habituation. Each subject group was analyzed separately. The baseline predosing EEG signal was continuously recorded from a midline occipital electrode. EEG recording was divided in eight blocks of 100 consecutive trials. The peak latencies of N75, P100 and N145 components as well as the N75-P100 and P100-N145 amplitudes of the eight-block PR-VEP grand-average were different between the three groups; SCZ had significantly lower values than HV whereas US showed intermediate values between SCZ and HV. Repeated measure ANOVA models showed that the N75-P100 and P100-N145 amplitudes for the whole sample decreased between first and eighth block. Moreover, the “block x group” interaction effects resulted also significant: over the eight blocks, US amplitudes had middle values between those of HV, that showed a physiological reduction during the visual paradigm presentation, and those of SCZ, that did not present a reduction in PR-VEP amplitudes. The slope measures confirmed the halfway position of US between the normal values of HV and those of SCZ that revealed a lack of visual habituation. We didn’t find significant differences between the three groups in the N75, P100 and N145 latencies in the average response to the 800 stimulation blocks between the BB blocks. Discussion: According to our hypothesis, visual habituation was abnormal in US showing intermediate neurophysiological indices between SCZ and HV. Our data contribute to extend the evidence of deficit in early sensory processing in Schizophrenia spectrum, proposing visual habituation as a potential novel endophenotype of Schizophrenia. Moreover, current findings suggests that visual habituation in Schizophrenia should be investigated more systematically in order to reveal new mechanisms that may have a role in the pathophysiology of Schizophrenia.

**T154. The effects of TAK-063 on cognition in a multiple dose, phase 1 study in healthy Japanese subjects and subjects with schizophrenia are consistent with its somnolent effects**

Tom Maciek*,1, Maggie McCue1, Jinhui Xie1, Keith Wesnes2

1Takeda Development Center Americas, Inc.; 2Wesnes Cognition Ltd

**Background:** TAK-063 selectively inhibits phosphodiesterase 10 A (PDE10A), which hydrolyzes both cyclic adenosine monophosphate and cyclic guanosine monophosphate. PDE10A is predominantly expressed in medium spiny neurons (MSNs) in the striatum, and PDE10A inhibition may modulate, indirectly or directly, the effects of glutamatergic and dopaminergic signaling. TAK-063 has demonstrated potential pro-cognitive effects in a variety of rodent models of attention, working memory, visual memory, and executive function. We have previously reported the pharmacokinetics and safety/tolerability of TAK-063 in a multiple rise-dose study in healthy Japanese subjects (HJS) and subjects with schizophrenia (SS) in which subjects received either TAK-063 or placebo once daily for 7 days (TAK-063_104). In this study, TAK-063 was safe and well tolerated, and somnolence was the most common adverse event. Here, we report the effects of TAK-063 on cognition and postural sway as measured by the Cognitive Drug Research (CDR) computerized cognitive battery.

**Methods:** Healthy Japanese subjects (n = 30) and stable schizophrenia subjects who were washed out of their antipsychotic medications (n = 47) were enrolled in cohorts of 10 subjects each and randomized to either TAK-063 or placebo (8:2). The doses in HJS were 3, 10, and 20 mg; the dose levels in SS were 3, 10, 20, 30, and 100 mg. Safety and PK assessments were recorded throughout. Each subject completed 2 training sessions of the CDR test battery on Day-1, with additional assessments on Days 1, 2, 4, 6, and 7 prior to dosing and 2 and 6 hours after dosing. Data were analyzed as change from baseline (Day 1, predose). Mixed-mode for repeated measurements analyses of covariance were utilized for analysis with baseline as covariate and dose and visit as fixed factors. Subjects nested within dose were fitted as a random factor. Visit was fitted as a repeated factor. The root mean square error was used to compute effect sizes (Cohen’s d) for change from baseline difference to placebo scores. Each subject group was analyzed separately. The baseline predosing scores of the volunteers and patients were also contrasted using t-tests.

**Results:** With the exception of cognitive reaction time, deficits in various cognitive domains were observed in SS compared to HJS at Baseline. These deficits were mostly of medium to large effect sizes (0.5 to 0.8). In general, in both groups, TAK-063 caused impairments in measures of attention, working memory, and verbal and nonverbal episodic memory that were generally dose dependent and with medium to large effect sizes. In both groups, TAK-063 did not have an effect on speed of processing (cognitive reaction time). A large effect was noted in power of attention in HJS at 10 mg, with little impairment at 3 and 30 mg. Slight improvements in working memory in SS were observed at 3 and 10 mg, with dose-dependent impairments at higher doses. In HJS, but not SS, improvements in speed of memory were observed at all dose levels. Postural sway was increased with 10, 30, and 100 mg in SS with small to medium effect sizes, and by 10 mg in HS with a medium to large effect size.
Abstracts

Discussion: Preclinical studies in rodent models suggest that TAK-063 has potential pro-cognitive effects. In clinical studies of TAK-063, the most common adverse event has been dose dependent somnolence. The observed changes in cognitive measures in this study in both HJS and SS are generally consistent with somnolent-like adverse effects of TAK-063. The objective of dosing, though the results of the study are limited by the study design and small sample size. It is unknown whether any accommodation to the somnolent effects of TAK-063 would occur with longer dosing or would result in improvements in cognition.

T155. TAK-063 increases gamma synchrony in subjects with schizophrenia

Tom Macek1, Maggie McCue2, Jinhui Xie3, Jack Johnstone2, Peter Boeijinga1
1Takeda Development Center Americas, Inc.; 2Q-Metrix, Inc.; 3Neuroelectric Marker Expertise Admissions Group

Background: TAK-063 selectively inhibits phosphodiesterase 10 A (PDE10A) and is in clinical development for the treatment of schizophrenia. Differences in electroencephalographic [EEG]; auditory mismatch negativity [MMN]; and eye-blink prepulse inhibition [PPI] deficits have been reported in schizophrenia patients indicative of impairments in gating, pre-attentional information processing, and neural synchrony, the latter evidenced by reductions in gamma power. In preclinical studies, TAK-063 has been shown to reverse the effects of ketamine on gamma EEG in rats and monkeys. This objective of this study was to explore the effects on neurophysiological biomarkers in subjects with schizophrenia and are reported here.

Methods: Schizophrenia patients (n = 47) who were off-medication were dosed once daily with 3, 10, 20, 30, and 100 mg TAK-063 or placebo for 7 days. For these analyses, 43 completers were included: 9 randomized to placebo and 34 randomized to TAK-063. A battery of neurophysiological measures was conducted at predose and at 4 h postdose on Day 1 and 4 h postdose on Day 7 using standard methods. The battery consisted of resting EEG, EEG with high-frequency auditory stimuli (30, 40, and 50 Hz) and auditory MMN with duration deviants and PPI (60 msec prepulse). MMN-processing consisted in the negative peak between 100–240 ms for deviant-standard responses and PPI-ratios were taken from peak-values in rectified blink-EMGs. Multi-electrode EEG recordings were reviewed to reject extracerebral artifacts. Digital filtering techniques were utilized and denoised data were transformed using the Fast Fourier method to obtain the following bands: delta (0–3.5 Hz), theta (4–7.5 Hz), alpha (8–12 Hz), beta (13–25 Hz), global gamma (30–50 Hz), and high gamma (40–50 Hz) and quantified in 5 regions as frontal, central, parietal, occipital, and temporal. Baseline-adjusted data were averaged in groups in order to compare each dose with placebo, and either a mixed model for repeated measurements or ANCOVA models was used which included baseline as a covariate and treatment group as fixed factor. For the EEG parameters, brain region and treatment group by region were added to the model.

Results: At baseline, presumed deficits in gamma power during the 40 Hz stimulus were present. Four hours after dosing on Day 1, significant restoration of synchronized 40 Hz EEG was observed for the 20 mg and 100 mg doses in all 5 regions (P < 0.05); no improvement was observed on Day 7. On Days 1 and 7, increases in (eyes-closed) resting alpha were observed, especially at the 20 mg dose (globally) and more modestly at 10 and 100 mg (posteriorly) with coincident decreases in slow waves. Trends of improvement of moderate MMN deficits were observed in the peak analyses in the 10 and 20 mg dose groups. No improvement in PPI in any dose group was observed.

Discussion: The effects of TAK-063 on neurophysiological measures are indicative of pharmacological effects in the brain. Improvements in gamma power and increases in alpha and coincident reductions in slow waves may be indicative of improved sensory awareness and cognitive function. These results, however, are limited by the small sample size and limitations of the study design.

T156. The PDE-10 a inhibitor TAK-063 reverses ketamine-induced changes in FMRI bold signal

Deborah Yurgelun-Todd1, Perry Renshaw1, Paul Goldsmith2, Jinhui Xie3, Tolga Uz3, Tom Macek3
1The Brain Institute, University of Utah; 2Takeda Development Center Europe, Inc.; 3Takeda Development Center Americas, Inc.

Background: Ketamine is an NMDA antagonist that has been used in preclinical and clinical models of psychosis. At sub-anesthetic doses in humans, ketamine produces effects that are similar to the positive, negative, and cognitive symptoms of schizophrenia. Ketamine has also been shown to induce changes in Blood Oxygen Level Dependent (BOLD) magnetic resonance signal in areas of the brain that are involved in the pathogenesis of schizophrenia. Lamotrigine and risperidone have been shown to attenuate the effects of ketamine on BOLD signal. Here we report the effects of a novel phosphodiesterase 10 A (PDE10A) inhibitor, TAK-063, on ketamine induced BOLD signal changes in humans.

Methods: This was a randomized, investigator- and subject-blinded, placebo-controlled, 3-period, incomplete crossover, phase 1 study designed to evaluate the effect of TAK-063 on fmri BOLD signal during resting state and during a working memory activation task. The study population included 27 eligible healthy male subjects aged 18–45 years. Subjects were randomized in equal ratios to 1 of 9 treatment sequences. Each subject received placebo or 2 of the 3 doses of TAK-063 (3, 10, 30 mg) five hours prior to initiating scanning. Midway through the scanning protocol, subjects were administered IV ketamine designed to achieve a steady plasma concentration based on weight. BOLD echo planar images were obtained during a 20-minute resting-state sequence using a 3 T Siemens Verio scanner (TR = 2 s, TE = 28 ms, 40 slices, 3 mm slice thickness). FMRI images were analyzed using SPM8 and Matlab. Percent signal change for resting state data was calculated between pre-ketamine and post-ketamine infusion based on a priori regions of interest using SPM’s Anatomy Toolbox. Percent signal change for the working memory task was calculated for the task versus baseline in the post-ketamine condition using the same region of interest used for resting state. An ANOVA model was used to perform the analyses for BOLD signal changes.

Results: Consistent with previous reports, ketamine administration increased BOLD signal in most regions of interest. Compared to placebo, TAK-063 at doses of 3 and 30 mg decreased the ketamine-induced BOLD signal changes in left and right anterior and posterior cingulate cortex, striatum, and ventrolateral and dorsolateral prefrontal cortex; effect sizes were generally dose-dependent. In substantia nigra, there was a decrease in BOLD signal at all dose levels. In general, TAK-063 reversed the ketamine-induced increases in resting BOLD signal. However, the observed effects at 10 mg were reduced relative to the effects of other dose groups. Signal changes observed during the working memory task showed TAK-063 decreases in task-related activation in anterior and posterior cingulate cortex, striatum, substantia nigra, as well as other regions. Similar to the resting state, the effect sizes were generally less in the 10 mg than in the other dose groups.

Discussion: Overall, these study results are consistent with observed reversal of ketamine-induced changes in BOLD signal by risperidone. To date, PDE10A inhibitors have not demonstrated clinical efficacy in the treatment of schizophrenia and it is unknown if these data are predictive of potential antipsychotic activity. The reason for the non-linear dose response of TAK-063 is unknown, but if these data are predictive of potential antipsychotic activity. The reason for the non-linear dose response of TAK-063 is unknown, but if these data are predictive of potential antipsychotic activity.

T157. Altered right anterior insula activity during anticipation of food and social rewards in schizophrenia: an fMRI study
Chao Yan1, Zheng-hui Yi1, Qin-yu Lv1, Xu Li1, Raymond C K Chan2
1School of Psychology and Cognitive Science, East China Normal University; 2Shanghai Mental Health Center; 3Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences; 4Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China

Background: Previous studies have suggested that schizophrenia demonstrated diminished ventral striatal (VS) and anterior insula (AI) activities in anticipation to potential monetary reward. However, it is still not quite clear about whether the VS and AI dysfunction would be affected by different types of reinforcements (i.e. food and social interaction). In the present study, we employed both Food incentive delay (FID) task and social incentive delay (SID) task to detect neural substrates of reward anticipation with regarding of both physical and social domain in schizophrenia.

Methods: Twenty-eight patients with schizophrenia (Sz) diagnosed by DSM-IV and 29 healthy controls (HC) with aged, gender, educational level matched were recruited and administered to the FID and SID task in the scanner. In order to explore the group differences in activities across brain regions, we firstly performed two-sample T tests between Sz and HCs for the contrast of anticipation of positive/negative valenced food/social images versus neutral images, respectively. Multiple corrections were performed using family-wise error rate at p < .05. In order to further examine the group difference in neural activity within the prior regions of interest (ROI), two-way repeated measure ANOVAs were performed on the % BOLD signal change of the bilateral VS and the AI during anticipation phase with valence (positive, neutral, negative) as within-subject variable and group (HC vs. Sz) as between-subject variable for FID and SID, respectively. Pearson correlations were performed between regional BOLD signal change percentage during reward anticipation, Chapman physical and social anhedonia scales, and clinical symptom scales in respectively. Pearson correlations were performed between regional BOLD signal change percentage during reward anticipation, Chapman physical and social anhedonia scales, and clinical symptom scales in schizophrenia.

Results: In the whole brain findings, we did not observed diminished VS and AI activities during food and social reward/punishment anticipation, although patients with Sz exhibited diminished brain activity in the right superior temporal gyrus (63 -42 18, BA 22) during anticipation of avoiding disgusting food images compared to healthy controls. In viewing of absence of the VS and right AI dysfunctions in Sz, we further performed the ROI analysis within these two prior ROIs. It was found patients with schizophrenia demonstrated no significant difference in the right AI activity among the positive, negative and neutral condition during anticipation phase (F (2,110) = 1.42, p = .246) while HC exhibited stronger right AI activations in anticipation of positive and negative food images compared to neutral images (positive > neutral: p = .001; negative > neutral: p < .001), reflected by a significant group x valence interaction (F (2,110) = 6.515, p = .002). As for social interaction images, similar findings were observed, reflected by a significant group x valence interaction (F (2,110) = 8.402, p < .001). However, there was no significant group difference in brain activation in the bilateral VS during anticipation of food and social reward/punishment. Moreover, the right AI activities during anticipation of positive and negative food images were inversely associated with physical anhedonia score in Sz (positive food: r = .415, p = .028; negative food: r = .502, p = .004). General symptom in schizophrenia, however, was observed positively correlated with the left VS activity during anticipation of negative social images.

Discussion: Our findings suggest that 1) the flat right AI response pattern might play an important role in understanding the nature of reward and punishment anticipation dysfunction in schizophrenia; 2) this altered response pattern of the right AI in Sz may be independent of the reinforcement types.

T158. PET imaging evidence of altered dopaminergic modulation of reward responses in ventral striatum in familial risk to psychosis
Zuzana Kasanova1, Jenny Ceccarini2, Therese van Amelsvoort3, Michael Frank4, Jan Boog5, Alexander Heinz6, Ye Rong7, Oliver Winz8, Felix Mottaghy6, Inez Myin-Germeys1
1KU Leuven- Leuven University; 2University Hospitals Leuven; 3Maastricht University; 4Brown University; 5Academic Medical Center, University of Amsterdam; 6University Hospital RWTH Aachen University

Background: Abnormalities in reward processing are a consistent finding in psychotic disorder and have been proposed to be linked to dysregulated mesolimbic dopaminergic (DA) neurotransmission. Chaotic firing of DA neurons in the striatum of the patients is thought to attribute salience to irrelevant stimuli instead of signaling potential rewards. Despite the circumstantial evidence in support of this notion, it has never been decisively corroborated using neuromolecular imaging. We applied this method in a sample of first-degree relatives of individuals with psychosis to investigate the putative DAergic basis of the reward dysfunction as a mechanism of familial risk for psychosis.

Methods: Using a single DA D2/3 receptor [18 F]fallypride positron emission tomography (PET) scan we explored the DAergic activity in the mesolimbic regions of 16 unaffected siblings of individuals with psychosis and 16 gender-, age- and IQ-matched controls under reward condition. In six 10-minute independent learning blocks monetary reinforcement was probabilistically delivered upon the selection of the correct stimulus, and withdrawn upon the choice of the incorrect one. The main outcome measure was the reward-related DA activity (defined as the magnitude of reward-induced [18 F]fallypride displacement) in reward versus control condition in the right and left hippocampus, amygdala, putamen, caudate nucleus (CN) and ventral striatum (VST). Secondary outcome was the behavioral performance defined as the amount of money earned in the reward task.

Results: The relatives did not differ from controls in performance on the task (P = .091, t(31) = .11, β = .11), nor was there an effect of group on magnitude of reward-related tracer displacement in all ROIs (all P > .05). The relatives showed significant reward-related DA release in all regions except for right putamen and left CN. Importantly, in right VST there was a significant group x tracer displacement interaction on performance (P = .047, t(31) = -2.9, β = -118.26), with controls demonstrating a significant association between reward-related tracer displacement and performance on the reward task (P = .003, t(15) = 2.5, β = 114.72), that was not present in the relatives (P = .26, t(15) = -1.2, β = 44.26).

Discussion: Unaffected first-degree siblings of patients with psychosis demonstrated reward-induced mesolimbic DA activation comparable to healthy controls. However, unlike in controls, higher task-induced DA release in the right VST of the relatives was not associated with better performance on the task, possibly indicating altered mechanistic of DAergic modulation of reward processing in this group. This result converges with prior reports implicating aberrant neural VST activity in reward dysfunction in patients with psychosis, and provides initial evidence for a qualitative DAergic abnormality related to familial risk to psychosis.

T159. Neural correlates of the negative prior expectancy bias in schizophrenia: an FMRI multiariate analysis
Ilvana Dzačić1, Andrew Martin*2, Hana Burianová3, Bryan Mowry2
1Queensland Brain Institute; 2The University of Queensland

Background: Impaired emotion perception is a well-established and stable deficit in schizophrenia, having a significant impact on functional outcome. Recent work has examined the basic processes underlying emotion perception impairment, finding that difficulties arise from over-derpendence on ‘prior expectations’. Prior expectations direct attention to emotions that are congruent with what is expected; in schizophrenia, dependence on negative prior expectations is heightened, and results in attribution of threatening emotions to non-threatening or neutral expressions. However, the brain processes underlying this negative prior expectancy bias in schizophrenia have

not been examined. The present study aimed to investigate the effect of negative prior expectations (induced by cues) on dynamic, multisensory emotion perception in patients with schizophrenia and the brain networks associated with impaired perception of neutral expression.

**Methods:** Twenty patients with schizophrenia and 20 healthy controls completed the study. We used a functional Magnetic Resonance Imaging (fMRI) paradigm with emotional videos and manipulated prior expectations with congruent or incongruent preceding emotional cues.

**Results:** We found that when viewing neutral videos preceded by angry cues patients with schizophrenia had significantly lower accuracy compared to healthy controls, and recruited a brain network involving the temporoparietal junction and hippocampus.

**Discussion:** There is converging evidence that hyper-connectivity between the temporoparietal junction and hippocampus produces symptoms such as delusions and hallucinations. In schizophrenia the negative prior expectancy bias may be a result of aberrant related brain activation contributing to poor functional outcome. Particularly nonverbal communication is disturbed. Neural correlates of impaired gesture performance are currently unclear. We thus tested functional correlates of gesturing in schizophrenia patients and healthy controls.

**Methods:** In total, 22 patients and 25 controls matched for age, gender and education level participated. We used an event-related (induced delay) paradigm to dissociate brain activation during planning and execution of familiar (e.g. use scissors) and novel (e.g. spread little finger outwards) gestures. Performance was assessed by video monitoring and analyzed by blinded raters according to diagnosis and clinical status.

**Results:** During planning and execution of both gesture subtypes both groups activated brain areas of the praxis network. However, patients had reduced dorsolateral prefrontal cortex (DLPFC) activity and increased inferior parietal lobe (IPL) activity. Performance accuracy was associated with DLPFC activity in controls and with IPL activity in patients. During planning only patients showed additional activity in temporal poles, amygdala and hippocampus associated with delusion severity. Furthermore patients demonstrated increased dorsomedial prefrontal cortex activity during planning of novel gestures.

**Discussion:** We demonstrated an aberrant pattern of brain activation during gesturing in schizophrenia. In fact, a differential neural association with performance accuracy (DLPFC vs. IPL activity) was discovered. Moreover, only in patients we detected limbic activity, linked to delusion severity. These findings may reflect impaired action planning and a limbic interference planning gestures in schizophrenia. Together these alterations may contribute to poor gesture performance in schizophrenia.

**T161. The effect of aripiprazole versus risperidone on planning-related brain activation**

Edith Liemburg1, Frank Van Es1, Henderikus Knegethering2, Andre Aleman1

1University Medical Center Groningen; 2Lentis and RGOC/NIC UMC Groningen

**Background:** Impaired function of a fronto-striatal-parietal brain network may be the source of both negative symptoms and neurocognitive problems in psychotic disorders. Whereas most antipsychotics have a poor effect on negative symptoms and may decrease prefrontal activation, the partial dopamine D2-receptor agonist aripiprazole is hypothesized to improve negative symptoms. This study investigated whether patients with a psychotic disorder would show larger increases in prefrontal activation and concurrent negative symptom improvement after treatment with aripiprazole compared to risperidone.

**Methods:** In this pharmacological neuroimaging study, 24 patients were randomly assigned to either aripiprazole or risperidone. At baseline and after nine weeks treatment they underwent an interview and MRI session. Here we reports on arterial spin labeling findings during performance of a planning task, the Tower of London that activates the prefrontal cortex.

**Results:** Aripiprazole treatment resulted in decreased activation of the middle and superior frontal gyrus and occipital gyrus, while activation increased in these regions after risperidone treatment. Activation increased in the ventral ACC and posterior insula after aripiprazole treatment, while it decreased after risperidone. Both treatment groups had an increase in ventral insula activation, and a decrease in occipital cortex, precursoes and caudate head activation. Positive symptoms, general pathology and depressive symptoms improved in both groups, but negative symptoms did not.

**Discussion:** In conclusion, risperidone and aripiprazole had differential, albeit partly overlapping, effects on planning-related brain activation that may be explained by their specific effects on the dopamine and serotonin system. Prefrontal capacity of aripiprazole treated patients appeared to improve, while posterior brain regions show a similar response to both antipsychotics.

**T162. Are emotion processing deficits in schizophrenia and major depression mood-related symptoms?**

Jennifer Engelen1, Felicitas Meier1, Bröhl Henrik1, Heinen Jessica1, Dietsche Bruno1, Krug Axel1, Kircher Tilo1, Dannlowski Udo2

1Marburg University; 2Münster University

**Background:** Social interaction determines our daily life. Automatic neuronal circuits like emotion processing are involved in these interpersonal contacts. Both schizophrenia (SZ) and major depression (MD) often come along with patient’s impairment of social interaction. This symptom as well as impaired emotion processing is well described for both diagnoses. Just like further studies showing amygdala hyperactivity in MD bias the automatic judgment of facial expressions, in SZ facial emotion processing deficits are associated with temporal lobe abnormalities. Nevertheless only few studies compare those different groups of patients directly.

**Methods:** To date approximately 60 patients with SCID-I confirmed diagnoses of SZ or schizo-affective disorder (SA) as well as an equal number of both matched patients with mood disorders and matched healthy controls (HC) were included in this study. They were phenotyped by self-assessment questionnaires (e.g. BDI, NEO-FFI, childhood trauma questionnaire (CTQ)) just as assessment by trained psychologists (e.g. HAMD, SAPS/SANS). They also underwent functional magnetic resonance imaging using a 3-Tesla Siemens scanner. Via the affective priming paradigm sad, happy and neutral faces as well as a no-face stimulus were subliminally presented and masked by neutral faces (Dannlowsk et al., 2013). The participants were asked to evaluate the facial expression fast and intuitively by button-press.

**Results:** In our study we will have a closer look at the influence of clinical outcome, especially affective and negative symptoms as well as personal traits on specific activation patterns like amygdala hyperactivation or temporal lobe abnormalities. We hypothesize to find influencing factors independently of diagnosis themselves.

**Discussion:** The aim of this study is to show possible differences or similarities not just between SZ/SA and HC but also between SZ/SA and MD. Focusing on different clinical outcomes and personal traits between SZ/SA and mood disorder patients as well as HC will lead to a better understanding of shared neurobiological fundamentals and maybe risk-factors of impaired emotion processing.
T163. Neurobiology of insight in schizophrenia: findings from a systematic review
Rose Mary Xavier1, Allison Vorderstrasse1
© 2016 Schizophrenia International Research Society/Nature Publishing Group

Background: Insight in schizophrenia, clinically, defined as awareness into illness, symptoms and need for treatment has long been associated with cognition, adverse clinical and functional outcomes and other psychopathological symptoms. Impaired insight has been associated with medication non-adherence, increase in relapse, frequent hospitalizations and increased involuntary commitments. Clinically, insight is associated with severity of positive and negative symptoms, longer duration of untreated psychosis, violence towards self and others and mood symptoms. Functionally insight has been associated with psychosocial functioning, vocational functioning and quality of life. Insight is also closely tied to patient-reported outcomes in schizophrenia. Emerging literature in insight in schizophrenia points to a neurobiological basis with a multifactorial etiology linking problems with facets of cognition such as neurocognition, social cognition and metacognition. However, the biological basis of insight is still poorly understood. The aim of this systematic review was to (1) critically evaluate and summarize advances in the study of the biologic basis of insight in schizophrenia and (2) to identify gaps in this knowledge.

Methods: PubMed, CINAHL, PsycINFO and EMBASE databases were searched. Identify articles relevant to the neurobiology of insight in schizophrenia that was published in the last 6 years. Articles were chosen if the focus of examination was neurobiological. Articles on insight in conditions other than schizophrenia or psychoses and which did not investigate the neurobiological underpinnings of insight were excluded from the review.

Results: Twenty-six articles that met the inclusion criteria were systematically reviewed. Of the twenty-six articles, twenty-three used neuroimaging technology and three focused on cellular abnormalities. These studies identify the prefrontal cortex, cingulate cortex and regions of the temporal and parietal lobe (precuneus, inferior parietal lobule) and hippocampus as the broad neural correlates of insight. Discussion: There is a growing body of literature that attests to the neurobiological basis of insight in schizophrenia. Current evidence supports a neurobiological basis of insight in schizophrenia and identifies specific neural correlates for insight types and its dimensions. Further studies that examine the precise biological mechanisms of insight are needed in order to apply this knowledge to effective clinical intervention development.

T164. Stress and emotion processing in siblings of schizophrenia patients: preliminary results
Judit M.C. van Leeuwen1, Matthijs Vink2, Sebastiaan F. W. Neggers1, Marian Joëls1, René S. Kahn1, Christiaan H. Vinkers1
1University Medical Center Utrecht; 2University Medical Center Utrecht; Utrecht University

Background: Stress is an important risk factor for schizophrenia (Corcoran et al., 2003). However, the underlying neurobiological mechanisms are currently unknown. Key brain areas involved in stress regulation are the hippocampus and amygdala. Altered function and structure of these limbic structures have consistently been reported in schizophrenia patients, as well as healthy siblings of schizophrenia patients, implying that problems in stress regulation and emotion perception and expression are related to the genetic vulnerability for schizophrenia (van Buuren et al., 2011). To further substantiate this notion, we aimed to identify the role of the limbic system in stress integration in healthy male siblings of schizophrenia patients, who are at genetic risk but are not ill and do not take antipsychotic medication. To this end, the effects of acute psychosocial stress on emotion processing were examined in unaffected schizophrenia siblings and matched healthy controls (in both groups psychiatric disorders were excluded) after exposure to the stress or control condition of the validated Trier Social Stress Test (TSTT). The four groups (sibling-stress, sibling-no-stress, control-stress, control-no-stress) did not differ in age, education, ethnicity or body mass index. Saliva samples and subjective stress measurements were obtained throughout the experimental protocol. Regions of interest (ROIs) consisted of amygdala and hippocampus and were created using the AAL-atlas (Tzourio-Mazoyer et al., 2002). Preprocessing and statistical analyses of the images were performed with SPM8. GLMs were performed to test for the effects of stress (stress, no-stress), group (siblings, control) and their interaction on brain activation. Results: Successful stress induction was confirmed by increased subjective stress level (visual analogue scale; main effect of stress, P = 0.006) and cortisol levels (main effect of stress, P = 0.029) in both healthy controls and schizophrenia siblings. We found a significant stress and disease interaction effect bilaterally in hippocampus activity during positive picture presentation (left, P = 0.034; right, P = 0.026). No significant interaction was found in the amygdala. Discussion: These preliminary results suggest that schizophrenia siblings display different stress-induced activation patterns in the hippocampus in response to affective stimuli compared to healthy controls. Despite the absence of any psychiatric symptoms, the genetic vulnerability to develop schizophrenia may therefore be associated with abnormalities in the neural circuitry of emotion processing and an altered central stress sensitivity.

References:

T165. Emotion regulation and insight in schizophrenia: an FMRI task study
Daouia Larabi1, Lisette van der Meer2, Branslava Curtič-Blake1, André Aleman1
1University of Groningen; 2Lentis Psychiatric Institute

Background: Insight is impaired in the majority of individuals with schizophrenia. Impaired insight is one of the most common reasons for poor treatment adherence and has been associated with poorer outcome. The etiology of poor insight remains unknown. In addition, numerous studies have shown emotional dysregulation in schizophrenia. In this study, we investigated the association between insight and brain activation during the most investigated emotion regulation strategy, namely reappraisal. We hypothesized a positive association between insight and activation of prefrontal areas and the insula during reappraisal.

Methods: 30 schizophrenia patients and 15 healthy controls were included. Clinical insight was measured with the Schedule of Assessment of Insight – Expanded (SAI-E; Kemp & David, 1997) which consists of three subscales: (1) awareness of illness, (2) relabeling of symptoms and (3) need for treatment. Cognitive insight was measured with the Beck Cognitive Insight Scale (BCIS; Beck et al., 2004) which consists of two subscales: self-reflectiveness and self-certainty. A BCIS composite index score was computed by subtracting the self-certainty score from the self-reflectiveness score. All individuals performed an emotion regulation task in an FMRI scanner, during which pictures from the International Affective Picture System were used to generate negative affect (Ochsner et al., 2002). Three emotion regulation conditions were examined, in addition to a control condition in which individuals had to attend to negative pictures: (1) cognitive reappraisal to decrease negative emotions, (2) expressive suppression of negative emotions and (3) control task to induce negative emotions. In this study, the cognitive reappraisal condition to decrease negative emotions was of our main interest. Main effect analyses were performed within the entire group while regression analyses with insight only included schizophrenia patients.
T166. The effect of mentalization-based treatment in patients with first episode schizophrenia – a fMRI study
Gabriele Sachs*a, Helga Felsbergerb, Julia Furtnerb, Andreas Erfurthb
1Medical University of Vienna; 2Otto-Wagner-Spital

Background: The impairment of social cognition including mentalizing is one of the core features of the illness and has a clear impact on functional outcome.1 Several brain regions, including the medial prefrontal cortex (mPFC), bilateral temporo-parietal junction (TPJ) and precuneus have been consistently found to be activated in various mentalizing tasks. Most studies in schizophrenia report hypoactivation of the core mentalizing system and impaired mentalizing ability.2 Different treatment strategies including both treatment with atypical antipsychotics and social cognitive training3,4 can improve functional outcome in patients with schizophrenia.5

The aim of the study is to investigate the effect of a mentalization-based treatment program on the mentalizing network in the brain in patients with first episode schizophrenia.

Methods: 12 patients diagnosed with schizophrenia according to DSM-IV-TR criteria and treated with atypical antipsychotics participated in the study (6 males, mean age: 30.43, SD = 9.35 years, years of education 13.23, SD = 2.45). Patients were randomized to an add-on therapy to TAU. A subset of patients received mentalization-based therapy (MBT; n = 6) and a treatment as usual group receiving only atypical antipsychotics (n = 6; TAU). A modified treatment program for psychoses was used based on the mentalization-based therapy developed by Bateman and Fonagy for borderline personality disorder.6 Before and after the treatment fMRI analyses (fixed effects analyses) were carried out (3 Tesla, 5 blocks on/off, 36 s, TR = 3.62, SPM) using the n-back task.

Results: Preliminary results show single analyses due to the small sample size. Comparing the fMRI scans before and after treatment, increases in the activation patterns were found in first episode patients treated with MBT. In patients with TAU a reduction in the activation patterns was demonstrated (mean changes in the activation clusters in the MBT group was 5.53, SD 12.79, in the TAU group -5.80, SD 6.91).

Discussion: Mentalization-based treatment is a promising approach in the treatment of schizophrenia and can have an impact on social networks in the brain. Further studies are needed for a better understanding of social cognition and the related neural mechanism in schizophrenia.

References:
2. Eak et al. Schizophr Res. 2013; 150, 491-497.
Caudate activation for mindful choices was confirmed by ROI analysis and UHR showed least caudate activation when choosing unmindfully. mPFC was only significantly activated by controls when making unmindful choices. ROI analysis also revealed that patients recruited the ACC less than the other groups during mindful and unmindful choices. Insula was activated by all groups when making unmindful choices.

Discussion: Behaviorally, UHR resembled healthy controls, making more mindful than unmindful decisions. Differences in neural activation did not depend on symptom severity nor medication. Choosing unmindfully, controls activated mPFC more than both the patient and UHR group, possibly suggesting that controls engaged more in mentalizing activity; the fact that this finding extended to the UHR group suggests that it is part of the vulnerability to psychosis. In contrast, ACC activation was reduced in patients but not in the UHR group, possibly indicative of compensatory mechanisms. The UHR group further showed a distinct pattern of caudate activation, indicating that this region might be affected by psychosis differently than in the prodromal phase. In conclusion, SoMi seems to be still intact in the prodromal phase. This phase is especially important for interventions that aim to prevent a further decline in social functioning associated with full-blown psychosis.

T169. Choosing with others in mind: neural mechanisms of social mindfulness in health and psychosis.

Imke Lemmers-Jansen1, Anne-Kathrin Fett2, Dick Veltman3, Lydia Krabbendam2

1Vrije Universiteit Amsterdam; 2Research Institute LEARN!, VU University; 3VU Medical Center

Background: Psychosis is characterized by problems in social functioning, including social decision making. Social Mindfulness (SoMi), the ability to ‘mind other people’s interest’ and to recognize their wishes is important for smooth social interactions and could be affected in psychosis. The new SoMi paradigm requires choosing one item out of two similar categories (red and green apples) presented in a ratio 2-2 and 3-1. In the 3-1 ratio, the choice can have implications for the second player: When choosing the single item (the ‘unmindful choice’), there will be no choice left. Choosing one of the identical items is considered socially mindful. Unmindful choices activate caudate, insula and medial prefrontal cortex (mPFC)¹, key areas that have been linked to aberrant social processing in psychosis. We investigated the neural responses to the task in patients with early psychosis and patients at ultra-high risk (UHR) for psychosis to see whether any SoMi problems exist before the full-blown illness. We hypothesized that both patients and UHR show different neural activation from controls, especially in the unmindful choices.

Methods: Twenty patients with diagnosis of psychosis (16-21years), 17 UHR patients (16-31) and 47 healthy controls (16-31) performed the SoMi task in an MRI scanner. Positive and negative symptoms were measured with the CAPE, the GPTS and the PANSS. The groups were compared in choice pattern and associated brain activation. Whole brain and region of interest (ROI) analyses were conducted.

Results: Patients and UHR did not differ in symptom severity. Patients made more unmindful choices, whereas UHR and controls made more mindful choices. However, patients’ choices only differed significantly from controls, not from UHR. Symptom severity did not correlate with the choice pattern. Whole brain analysis showed that patients activated the mPFC less than the other groups, when making mindful choices. When choosing unmindfully, controls activated the mPFC more than the other groups. Caudate activation was significantly higher in controls compared to the two patient groups, when making mindful choices. For unmindful choices patients activated the caudate significantly more than the other groups.

T170. Neural correlates of reward processing in healthy siblings of patients with schizophrenia

Esther Hanssen1, Joeri Van Der Velde2, Paula Grommond3, Sukhi Shergill3, Liewe De Haan3, Richard Bruggeman4, Lydia Krabbendam3, Andre Aleman4, Nienke van Atteveldt5

1VU University Amsterdam; 2UMCG; 3Research Institute LEARN!, VU University; 4Institute of Psychiatry, Psychology and Neuroscience, King’s College London; 5AMC-Academisch Psychiatrisch Centrum; 6University Medical Centre Groningen, University Centre Psychiatry; 7Research Institute LEARN!, VU University Amsterdam; 8University of Groningen, University Medical Center Groningen

Background: Deficits in motivational behavior and psychotic symptoms often observed in schizophrenia (SZ) may be driven by dysfunctional reward processing (RP). RP can be divided in two different stages: reward anticipation and reward consumption. Aberrant processing during reward anticipation seems to be related to SZ. Studies in patients with SZ have found less activation in the ventral striatum (VS) during anticipation of reward, but these findings do not provide information on effect of the genetic load on reward processing. Therefore, this study investigated RP in healthy first-degree relatives of SZ patients.

Methods: The sample consisted of 94 healthy siblings of SZ patients and 57 healthy controls. Participants completed a classic RP task, the Monetary Incentive Delay task, during functional magnetic resonance imaging (fMRI).

Results: As expected, there were no behavioral differences between groups. In contrast to our expectations, we found no differences in any of the anticipatory reward related brain areas (region of interest analyses). Whole-brain analyses did reveal group differences during both reward anticipation and reward consumption; during reward anticipation siblings showed less deactivation in the insula, posterior cingulate cortex (PCC) and medial frontal gyrus (MFG) than controls. During reward consumption siblings showed less deactivation in the PCC and the right MFG compared to controls and activation in contrast to deactivation in controls in the precuneus and the left MFG. Exclusively in siblings, MFG activity correlated positively with subclinical negative symptoms.

Discussion: These regions are typically associated with the default mode network (DMN), which normally shows decreases in activation during task-related cognitive processes. Thus, in contrast to prior literature in patients with SZ, the results do not point to altered brain activity in classical RP brain areas, such as the VS. However, the weaker deactivation found outside the reward-related network in siblings could indicate reduced task-related suppression (i.e. hyperactivation) of the DMN. The presence of DMN hyperactivation during reward anticipation and reward consumption might indicate that siblings of patients with SZ have a higher baseline level of DMN activation and possible abnormal network functioning.
T171. Prevalence of metabolic syndrome in patients with schizophrenia in Korea: a multicenter nationwide cross-sectional study

JungSun Lee1, Yeon Ho Joo2, Korean Society for Schizophrenia Research Group3

1University of Ulsan College of Medicine; 2University of Ulsan College of Medicine, Asan Medical Center; 3Korean Society for Schizophrenia

Background: It is well known that patients with schizophrenia have a reduced life expectancy. Especially, cardiovascular disease is one of the most important causes of mortality. This increased prevalence of diabetes and hypertension and increased mortality may be partially due to metabolic syndrome. The prevalence of metabolic syndrome (MetS) in patients with schizophrenia is 2-4 times higher than healthy control. The prevalence of MetS in patients with schizophrenia varies from 20% to 40% across the studies because of using different definition of MetS and confounding factors.

To overcome these limitations, we designed the nation-wide study with limited exclusion criteria for investigation about the prevalence of MetS in Korea, and the relation between psychiatric medication and the prevalence of MetS.

Methods: This study is multi-center, cross-sectional, and observational study for patients diagnosed with schizophrenia or schizoaffective disorder according to DSM-IV TR criteria. Sixteen hospitals - three mental hospitals and thirteen university affiliated general hospitals - enrolled patients aged 18 to 65 years prescribed any antipsychotic medication for treatment of schizophrenia or schizoaffective disorder between Aug 2011 and Aug 2013. Among 892 patients consented to participate the study, we excluded 47 patients of them due to lack of information such as age, gender, blood pressure (BP), waist circumference, or blood laboratory results. The index date of each patient was defined as the date of blood sampling. Doses of major antipsychotics were converted to olanzapine equivalent dose.

The metabolic syndrome was diagnosed with the definitions by the modified National Cholesterol Education Program’s Adult Treatment Panel III (ATP III-A) for Korean (3 or more of the following 5 criteria: waist circumference ≥ 85 cm in women, ≥ 90 in men, fasting blood glucose ≥ 100 mg/dL or specific treatment for hyperglycemia, serum triglyceride (TG) ≥ 150 mg/dL or specific treatment for the lipid abnormality, HDL < 40 mg/dL in men, < 50 mg/dL in women or specific treatment for the lipid abnormality, and arterial blood pressure (≥ 130/85) or specific treatment for hypertension.

Results: The number of participants in final analysis was 845. The mean age was 40.2 ±11.2 years (min:18, max:65 ) and number of male patients was 419 (49.6%). 379 patients (monotherapy group) had metabolic syndrome. The mean age was 40.2 ±11.2 years (min:18, max:65 ) and number of male patients was 419 (49.6%). 379 patients (monotherapy group) had metabolic syndrome.

Discussion: This study showed that prevalence of MetS in patients with schizophrenia or schizoaffective disorder was 36.5% and higher in male patients than in female patients (40.8% vs. 32.2%, respectively). In addition, we found that the prevalence of MetS increased significantly with increasing age and duration of illness. It was lowest among quetiapine(18.8%) and aripiprazole (22.0%) and highest among haloperidol (39.4%) and clozapine (44.7%). The limitation of this study is that we were not able to obtain total dosage of antipsychotics prescribed more than one year before the index date.

T172. Metabolic risk factors in first episodes of psychosis: findings from the PEPS study

Miquel Bioque1, Clemente Garcia-Rizo2, M Paz Garcia-Portilla3, Bibiana Cabrera Llorca4, Antonio Lobo5, Ana González-Pinto6, Mara Parellada2, Iluminada Compió6, Adrián Llerena6, Amalia Lafuente10, Jerónimo Saiz11, Miquel Bernardo12

1Hospital Clinic Barcelona; 2Neuroscience Institute, Hospital Clinic, University of Barcelona; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM); Institut de Biomedical Research Agustí Pi i Sunyer (IDIBAPS); 3CIBERSAM, University of Oviedo; 4Barcelona Clinic Schizophrenia Unit; Hospital Clinic Barcelona; Institut Clinic Neurociencies; CIBERSAM; 5Instituto Investigación Sanitaria Arapán, University of Zaragoza; CIBERSAM; 6Hospital Santiago Apóstol de Vitona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; 7CIBERSAM, Hospital General Universitario Gregorio Marañón; Universidad Complutense de Madrid; 8Hospital Santa Creu i St. Pau; CIBERSAM; 9CICAB-CAIBER Centro de Investigación Clínica, Hospital Universitario, Servicio Externo de Salud SES, Universidad de Extremadura, CIBERSAM; 10University of Barcelona; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). CIBERSAM; 11Hospital Ramon y Cajal, Universidad de Alcala, RYCS; CIBERSAM; 12Barcelona Clinic Schizophrenia Unit; Neurosciences Institute, Hospital Clinic of Barcelona; University of Barcelona; IDIBAPS, CIBERSAM

Background: Patients with psychotic disorders often suffer from excessive medical co-morbidities and mortality when compared to the general population. Available data on antipsychotic-induced metabolic risks are often constrained by potential confounding effects due to prior antipsychotic treatment.

Methods: In this study, we assessed the baseline prevalence of metabolic abnormalities and changes following treatment with commonly-used antipsychotic drugs during two years in a cohort of 335 first episodes of psychosis (FEP) patients from the PEPS study and 253 healthy controls.

Results: At baseline, the FEP group presented statistically significant (P < 0.05) higher mean levels of total cholesterol, prolactin and diastolic arterial pressure and lower HDL cholesterol and TSH than the healthy control group. After the two years of follow-up, the FEP group showed higher mean levels of glucose, glycated hemoglobin, triglycerides, and lower HDL cholesterol, together with higher body mass index and waist circumference. The majority of FEP patients received a second generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the products specifications (87.2%).

Discussion: Our findings suggest the existence of an incremented baseline prevalence rate of individual metabolic risk factors in FEP and that worsen during the first two years of treatment.

T173. Studying cortical thinning in schizophrenia using ultra high-field MRI

Bart Ferguson*, Natalia Petridou1, Hilleke E. Hulshoff Pol1, Wiepke Cahn1, René S. Kahn1, Rene C. W. Mandl1

1Brain Center Rudolf Magnus, University Medical Center Utrecht; *Center for Image Sciences, University Medical Center Utrecht

Background: Patients diagnosed with schizophrenia show structural brain abnormalities such as ventricular enlargement and cortical (gray matter) thinning.1,2,3 Disease-related cortical thinning is primarily seen in frontal and temporal areas and to a lesser extent in the parietal lobe. This cortical thinning could be due to a different size, density, or arrangement of neurons, neuroglia and nerve fibers.4 However, it is yet unknown which of the six cortical layers are affected and to what extent they are affected.

Magnetic resonance imaging (MRI) sequences can be made sensitive to different tissue properties and contents. Recently, an ultra high-field MRI (7 T) sequence sensitive to myelin within gray matter was developed.5 As certain layers contain more myelin than others, the usage of this sequence makes it possible to (in part) distinguish between different layers in the human neocortex. Laminar information could give important insight in the underlying pathogenic and pathophysiological processes and thus may provide further support for existing hypotheses and open up new avenues of research.
Methods: Twenty patients with schizophrenia (DSM IV diagnoses schizophrenia, schizotypal disorder, schizoaffective; male and female) and 20 healthy controls (male and female) who all previously participated in the TOPFIT study were scanned (after obtaining written informed consent) on a 7 T MRI scanner (Philips, Best, NL) with various image contrasts. Sequences that are run include three 0.5 mm isotropic myelin-sensitive T1-weighted, one 0.8 mm isotropic myelin-sensitive T1-weighted, one 0.8 mm isotropic regular T1-weighted, and one 0.5 mm isotropic T2* scan. Data will be processed with the use of an in-house developed software pipeline, in which average cortical profiles per brain area are calculated. Average cortical profiles are compared between sequences.

Results: Patients and healthy controls are currently being included. Discussion: At the time of writing, 12 patients and 12 controls have been included. This data not only allow us to study the role of the different cortical layers in schizophrenia in high detail but — in combination with 3 T scans previously acquired in the TOPFIT study — allow us to study to what extent this layer information is in part present at 3 T.

References:

T174. Neuroanatomical markers of autistic traits in first episode psychosis
Renate Reniers1, Katharine Chisholm2, Ashleigh Lin3, Rachel Upthegrove1, Stephen Wood4
1University of Birmingham; 2Telethon Kids Institute

Background: Psychotic disorders and those on the autism spectrum share phenotypic similarities and have been reported to co-occur at elevated rates. On the neuroanatomical level, overlapping and distinct areas of association have been reported. The current study adopted a voxel-based morphometry (VBM) approach to identify neuroanatomical markers of autistic traits in first episode psychosis (FEP).

Methods: 31 FEP individuals (25M;6 F, mean age 25 years; SD = 5) were recruited from the Birmingham and Solihull Mental Health NHS Foundation Trust in Birmingham, UK. They underwent magnetic resonance imaging at the Birmingham University Imaging Centre and completed the Autism-Spectrum Quotient for the assessment of autistic traits (AQ; Baron-Cohen et al., 2001).

Images were analysed using the VBM8 toolbox in SPM8. Grey and white matter volumes were examined controlling for gender and age. Spatial extent threshold was determined by 10,000 Monte Carlo simulations conducted using 3dClustSim (AFNI), which yielded a cluster extent of 763 voxels for grey matter and 720 voxels for white matter at an exploratory voxel-wise threshold of P < 0.01. Cluster size threshold was corrected for non-stationarity (Hayasaka et al., 2004) with the VBM8 toolbox.

Results: Data of one male participant was excluded from analyses due to excessive movement. No significant association was found between grey matter volume (reduced or increased) and AQ score. Increased white matter volume in left postcentral/supramarginal gyrus and right middle temporal gyrus (temporo-occipital part) was associated with higher AQ scores. After applying more stringent correction (voxel-wise threshold P < 0.002 with a cluster extent of 295 voxels), only the cluster in the right middle temporal gyrus remained significant. No significant association was found between reduced white matter volume and higher AQ scores.

Discussion: The observed brain pattern highlights areas of increased white matter volume that in FEP may be associated with higher AQ scores. These findings are consistent with reports of altered fractional anisotropy in these areas and may be associated with the processing of socio-emotional information. This may inform targeted treatment in FEP individuals who present with co-occurring or co-morbid autistic traits.
functional and clinical outcome from different selections of these baseline MRI measures on a continuous scale, instead of the more typical binary classification.

Results: Six-year follow-up level of functioning as well as negative and disorganization symptoms could be predicted at the individual level with correlations up to 0.42 for baseline subcortical volumes and long-term level of functioning.

Discussion: We showed that structural magnetic resonance brain images can be used to quantitatively predict long-term functional and clinical outcome in UHR individuals, suggesting that there may be scope for predicting outcome at the individual level. Moreover, we recommend classifying individual outcome on a continuous scale, enabling the assessment of different functional and clinical scales separately without the need to set a threshold.

T177. Intrinsic connectivity of fronto-temporal networks in adolescents at ultrahigh risk for psychosis: comparison with first episode psychosis patients and controls

Gisela Sugranyes1, Cristina Solé-Padullés1, Elena De la Serna2, Vanessa Sanchez-gistau3, Olga Puig-Navarro4, Clara Espelt5, Mireia Rosà6, Josefinia Castro-Fornieles6, Inmaculada Baeza1

1IDIBAPS (August Pi i Sunyer Biomedical Research Institute); 2Centro de Investigación Biomédica En Red De Salud Mental, CIBERSAM; 3Early Intervention Service, Hospital Universitari i Politecnic; 4Child and Adolescent Psychiatry and Clinical Psychology Dept. H Clinic Barcelona; 5Fundació Clinic Recerca Biomèdica; 6Fundació Clinic Recerca Biomèdica; Hospital Clinic Barcelona

Background: Fronto-temporal functional connectivity has been reported to be altered in adults with first-episode psychosis (FEP) and at ultra-high-risk for psychosis (UHR). Fronto-temporal cortices undergo important developmental changes during adolescence; however no study so far has assessed intrinsic connectivity of fronto-temporal networks in adolescents during the early stages of psychosis. Therefore, we aimed to assess intrinsic connectivity of the salience, auditory and language networks in adolescents at UHR, in relation to adolescents with a FEP and to healthy controls.

Methods: Thirty-four UHR individuals, thirty-four FEP patients and thirty-seven healthy controls (HC) aged 12-18, were recruited from the Hospital Clinic of Barcelona, Spain. Resting-state functional magnetic resonance imaging (fMRI) and a high-resolution T1 three-dimensional image were obtained on a 3 T Siemens Magnetom Trio Tim. Subjects were included on the basis of movement above 1.5mm translation and 1.5 degrees rotation in either x, y, or z axes, detected during realignment. Following preprocessing, which included co-registration of anatomical to functional data, normalisation into standard Montreal Neurological Institute space and smoothing with an 8 mm full width at half maximum Gaussian kernel, scrubbing was applied using a framewise displacement threshold of 0.2 mm where bad points were linearly interpolated, in order to control for potential micromotion artifacts. Spatial independent component analysis (ICA) was then conducted employing the Group ICA fMRI Toolbox. Components depicting connectivity in frontal and temporal brain regions were visually inspected and networks underlying salience, language and auditory processing were determined. The salience network encompassed the bilateral insula, anterior cingulate, and superior temporal and inferior frontal gyri. The language network included the middle temporal, inferior frontal gyri and the superior medial frontal cortex, and the auditory network encompassed the superior temporal gyrus, Heschl gyri, insula and right inferior frontal gyrus. ANOVA models were conducted for each network with SPM12, controlling for age.

Results: There were no between-group differences in gender (χ² = 0.269, P = 0.874). There was, however, a trend towards an older age in FEP patients (F = 2.86, P = 0.062). An effect of group was detected for the language network (F = 14.06, P = 0.009) in a cluster encompassing the right inferior/middle frontal gyrus (MNI coordinates (45,39,-3)). Specifically, FEP patients exhibited decreased intrinsic connectivity in this region of the language network. A volume-of-interest approach was conducted so as to extract signal values for each individual within the cluster where group differences were observed. UHR subjects showed intermediate values of connectivity in this region between HC and FEP patients. Examination of grey matter volume within this cluster showed no differences between groups. No differences in intrinsic connectivity emerged for the salience or the auditory network.

Discussion: Our results suggest that functional dysconnectivity of language-related regions may be a marker of risk for psychosis, which may already be identified during adolescence. Disruption in functional connectivity in the language network may be detectable prior to the structural changes observed in these brain regions in adult samples.

T178. Hippocampal glutamate and hippocampal functional connectivity in schizophrenia

Adrienne Lahti1, Nina Kraguljac1, David White1

1University of Alabama at Birmingham

Background: Impairments in episodic memory are amongst the most robust abnormalities in schizophrenia and have been linked to hippocampal dysfunction. Using MRS we previously reported an increase in hippocampal glutamate+glutamine (Glx) in unmedicated patients with schizophrenia (SZ) (Kraguljac et al., 2013). Because elevated Glx levels might result from GABA interneuron hypofunction and hippocampal interneurons generate oscillations in the gamma frequency ranges that are thought to synchronize brain activation, elevated Glx levels could affect hippocampal functional connectivity. To further characterize hippocampal abnormalities in unmedicated SZ and their relationships to elevated Glx, we measured resting state hippocampal functional connectivity (FC). Given prior findings that hippocampal FC is predictive of better memory performance in healthy controls (HC), we explore the relationship between hippocampal FC and memory function in SZ and HC. We hypothesized that, in SZ, the correlation between resting state hippocampal FC and hippocampal Glx would be abnormal in brain regions subserving memory function.

Methods: MRS spectra were acquired in left hippocampus (PRESS; TR/ TE = 2000/80 ms) and analyzed using jMRUI. Resting state functional MRI scans were acquired during a 5-min gradient recalled EPI sequence. Using a seed-based approach and SPM 8, we examined the FC of the hippocampus, using anterior and posterior seeds. Memory performance was measured using the delayed memory score of the RBANS. Matched HC were scanned as well.

Results: Compared to HC, SZ showed abnormal FC patterns with both anterior and posterior hippocampal seeds. We identified a significant group interaction in the correlation between hippocampal FC and Glx levels: in SZ, but not in HC, hippocampal FC to posterior cingulate cortex (PCC) was significantly correlated with Glx levels. Replicating prior results (Ranganath et al., 2005), in HC, we found a significant positive correlation between correlation between hippocampal FC to PCC and memory performance. In contrast, in SZ, there was a significant positive correlation between hippocampal to anterior cingulate cortex (ACC) FC and memory performance.

Discussion: In SZ, we identified a correlation between hippocampal FC to PCC and Glx but failed to identify the correlation between hippocampal FC to PCC and memory function seen in HC. Because PCC is a region pivotal for memory function, these data suggest that elevated Glx levels in SZ might have impaired the FC between the hippocampus and PCC in a way that affected its relationship with memory performance. SZ might rely on different neural network to leverage these interventions to improve memory function.

T179. Cognitive correlates of functional connectivity in schizophrenia: a resting-state FMRI study

Dominik Kraft1, Viola Oertel-Klöcher1, Michael Stäblein1, Claudia Schmied1

1Laboratory for Neuroimaging, Goethe-University Frankfurt

Background: Schizophrenia (SZ) is a severe psychiatric disorder with heterogeneous symptoms. In addition to positive and negative
symptoms, cognitive impairments – especially working memory deficits – are among the most prominent symptoms and they play a crucial role in patients with SZ. Neuroimaging studies showed multiple structural and functional brain abnormalities, e.g. for the dorsolateral prefrontal cortex (dPFC), which is known to be an important region for working memory performance. Furthermore, functional integration between spatial discrete brain regions is known to be affected in SZ. Consequently, it has been postulated that structural and functional alterations, as well as changes in the connectivity of the dPFC, may underlie deficits in working memory performance.

Methods: In the present study, functional connectivity (FC) of the dPFC was investigated using resting-state fMRI. Via correlation analysis the association between diPFC FC and individual working memory performance was analyzed.

25 patients with paranoid SZ and 28 matched healthy controls were tested. The study consisted of an fMRI sequence (EPI) during rest, while participants were instructed to lie still and look at a white fixation cross. FC of the diPFC was computed with a seed-correlation analysis (SCA) using a Matlab script in combination with NeuroElf. Additionally, cognitive functioning was assessed employing by the Matrics Consensus Cognitive Battery (MCCB).

Results: SZ patients showed deficits in all working memory domains. In direct comparison to healthy controls, the patient group displayed altered FC patterns between the diPFC and other brain regions of the memory network, e.g. to parietal, frontal as well as limbic regions. Also, altered FC in the candidate nuclei in SZ patients was significantly correlated with verbal working memory performance and the total score of the MCCB working memory domain.

Discussion: The results are interpreted in consideration of the disconnectivity hypothesis in SZ. The assumption of a disconnectivity syndrome which may underlie cognitive deficits, e.g. working memory, in SZ is supported by findings of recent studies, which have also reported pathologic hypo- and hyperconnectivity in SZ patients during working memory tasks and rest. Thus, aberrant FC during rest might be an interesting integrative biomarker for cognitive symptoms in SZ.

T180. Relationship between abnormal gyriﬁcation and clinical variables in ﬁrst-episode schizophrenia

Daiki Sasabayashi1, Yoichiro Takayanagi1, Shimako Nishiyama1, Tsutomu Takahashi1, Atsushi Furuchi1, Mikio Kido1, Yumiko Nishikawa1, Mihoko Nakamura1, Kyo Noguchi1, Michio Suzuki1

1University of Toyama Graduate School of Medicine and Pharmaceutical Sciences

Background: The neurodevelopmental model of schizophrenia has been widely accepted in the literature. Brain gyriﬁcation is regarded as a potential marker of early neurodevelopment. However, previous neuroimaging studies of gyriﬁcation in schizophrenia have reported inconsistent results. In addition, it remains unclear whether aberrant gyriﬁcation in schizophrenia, if present, is associated with clinical symptoms or cognitive impairments.

Methods: T1-weighted structural magnetic resonance imaging (MRI) scans were obtained by 1.5-T scanner from 62 patients with ﬁrst-episode schizophrenia and 57 age- and gender- matched healthy control subjects. MR images were preprocessed using FreeSurfer version5.3. The local gyriﬁcation index (LGI) of entire cortex was continuously assessed using the method by Schaer and colleagues (Schaer et al., 2008). Clinical symptoms of the patients were rated with the Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS) at the time of scanning. Fractional anisotropy (FA) of the superior longitudinal fascicle, uncinate fascicle and corpus callosum, which connect key regions of the cerebral praxis network.

Results: Compared with the controls, the patients showed signiﬁcantly higher LGI in the bilateral superior frontal, right inferior parietal, and bilateral occipital regions. The number of WCST categories archived in schizophrenia patients was negatively correlated with LGI of the anterior cingulate and rostral medial frontal regions in the right hemisphere. In addition, total SAPS scores were positively correlated with LGI in a cluster including the temporal pole, insula, and parahippocampal gyrus in the right hemisphere.

Discussion: Our ﬁndings of increased gyriﬁcation index suggesting brain hypergyria support early neurodevelopmental abnormality in schizophrenia. Our results also suggest that lower executive function and more severe symptoms in schizophrenia may partly be related to aberrant neurodevelopment especially in the right hemisphere.

T181. Information processing speed mediates the relationship between white matter and general intelligence in schizophrenia

Clara Alloza4

1University of Edinburgh

Background: Several authors have proposed that schizophrenia is the result of impaired connectivity between speciﬁc brain regions rather than differences in local brain activity. White matter abnormalities have been suggested as the anatomical substrate for this dysconnectivity hypothesis. Information processing speed has been proposed as a key cognitive resource by facilitating higher order cognition – such as general intelligence - by allowing multiple cognitive processes to be simultaneously available. However, there are a lack of established associations between general intelligence, processing speed and structural brain parameters in schizophrenia. In this study, 28 patients with schizophrenia underwent brain diffusion tensor MRI to investigate these relationships. We hypothesised that the relationship between white matter and general intelligence would be mediated by processing speed.

Methods: White matter water diffusion parameters were studied using Tract-based Spatial Statistics and computed within regions of interest (ROIs) defined using a standard atlas. Principal component analysis (PCA) was conducted on 46 white matter ROIs for fractional anisotropy (FA) and mean diffusivity (MD), in order to extract general factors of white matter microstructure.

Results: PCA was conducted on neurocognitive subtests to extract measures of general intelligence and processing speed. We found a positive correlation (r = 0.75, p < 0.001) between general intelligence and white matter FA that was partially and signiﬁcantly mediated (60.66% CI: 0.13 to 0.74) by processing speed.

Discussion: These ﬁndings suggest a plausible model of structure-function relations in schizophrenia, where white matter structure may provide a neuroanatomical substrate for general intelligence, which is partly supported by speed of information processing within brain networks.

T182. White matter correlates of impaired gesture performance and recognition in schizophrenia

Peta Viher1, Katharina Stegmayr1, Stéphanie Giezendanner1, Andrea Federspiel1, Stephan Bohlhalter2, Tim Vanbellingen2, René Müri1, Roland West3, Werner Strik1, Sebastian Walther1

1Translational Research Center, University Hospital of Psychiatry, Bern; 2Department of Clinical Research, Inselspital, Bern; Neurology and Neurorehabilitation Center, Luzerner Kantonsspital; 3Department of Clinical Research, Inselspital, Bern; 2Support Center of Advanced Neuroimaging (SCAN), University Institute of Diagnostic and Interventional Neuroradiology, Inselspital Bern

Background: Schizophrenia is associated with defective nonverbal communication contributing to poor social skills. Previous studies have shown that schizophrenia patients are signiﬁcantly impaired in gesture performance and recognition. However, brain structural correlates of impaired gesture performance are unknown. Therefore, we investigated the relationship between white matter abnormalities and impaired gesture performance and recognition in schizophrenia. We hypothesized that gesture deﬁcits are related to reduced fractional anisotropy (FA) of the superior longitudinal fascicle, uncinate fascicle and the corpus callosum, which connect key regions of the cerebral praxis network.

Methods: In 43 patients with schizophrenia spectrum disorders, gesture performance was assessed by the comprehensive Test of Upper Limb Apraxia (TULIA) and gesture recognition by the Postural
Knowledge Task (PKT). Performance was video recorded and blindly rated for accuracy. Structural brain imaging was measured in all patients using a 3-T MR Scanner. White matter microstructure was correlated with TULIA and PKT scores using Tract-Based Spatial Statistics (TBSS) including age as a covariate.

Results: The TULIA total score correlated with white matter microstructure at $P < 0.05$ (corrected) in the superior longitudinal fascicle. Again, superior performance was associated with increased FA. The PKT total score was associated with white matter at $P < 0.05$ (corrected) in the same fibers and additionally in the superior longitudinal fascicle and internal capsule. Finally, superior performance was associated with increased FA.

Discussion: Aberrant white matter of commissural, association and projection fibers are associated with poor gesture performance and recognition in schizophrenia. Particularly, abnormalities of white matter microstructure in key fibers of the praxis network like the superior longitudinal fascicle, uncinate fascicle and the corpus callosum correlated with gesture performance. Conclusions for the pathogenesis of nonverbal communication can be drawn from these results, as they argue for a contribution of specific brain structural alterations for gesture deficits. In addition, implications for gesture trainings can be obtained in order to improve nonverbal communication in schizophrenia.


Tina Kristensen* 1

1PK Research Section

Background: Contemporary psychological treatments have developed a more integrative mindset, enriching the field by combining knowledge from neuroscientific approaches with third wave cognitive behavioral therapies. Neuroscience has provided increasing evidence of the plasticity of the brain, and consequently a possibility to affect brain networks through specified training and psychotherapy. Aberrant neurodevelopment can cause vulnerability to both psychosis and social cognitive deficits. The real-life value and clinical relevance of social cognition is indisputable. Social cognition may be the strongest predictor of functional outcome in schizophrenia, is regarded a promising early risk-indicator for schizophrenia and a high priority for preventive intervention development. However, treatment strategies remain marked by a lack of evidence and agreement on specific treatment methods and targets.

The aims of the present study are to explore potential change in brain connectivity as a result of a specialized psychological intervention (social cognitive training) in patients at ultra-high risk of psychosis. Furthermore, we aim to explore cross-sectional and longitudinal associations between the disrupted brain networks and social cognitive deficits. The question we wish to answer is whether social cognitive training can improve disrupted brain networks associated with social cognition in patients at ultra-high risk of psychosis.

Methods: The present study is an on-going large randomized, controlled and blinded parallel-group superiority clinical trial, aiming to investigate whether cognitive remediation and social cognitive training can improve neuro-cognition and social cognition in patients at UHR for psychosis: the FOCUS trial. The trial is enrolling a total of 126 help-seeking patients aged 18-40 and matched healthy controls, with repeated examinations at baseline and at 6 and 12 months’ follow-up. Patients are randomized to intensive manual based Cognitive Remediation and Social Cognitive training (SCIT) plus standard treatment or standard treatment. Primary outcome on brain connectivity will be assessed with microstructural measures such as fractional anisotropy (FA), using whole-brain voxelwise tract-based spatial statistics (TBSS), fiber-based analysis and network analyses. Outcomes on social cognitive function is assessed with SRS-2; HiSoC, CANTAB (ERT); TASS and SCSS. Psychosocial function is assessed with SOFAS, PSP and Combatt.

Results: Trial initiation was April 2014, and to date the FOCUS-trial has included 75 patients and is expected to complete inclusions in 2017.

Discussion: Even if clinical symptoms are hypothesized to be the result of structural brain deficits, the relationship between the structural networks and specific cognitive deficits remain poorly understood. Considering the complexity of social cognition, requiring a coordinated function of a widely distributed network of brain regions, it is a plausible hypothesis that social cognitive deficits may be related to disrupted connectivity between implicated regions. Neural correlates of social cognition are suggested as a promising intervention target, using biomarkers for monitoring treatment response. Including both social cognition and the specific biological markers of abnormal brain changes in patients at Ultra-High Risk for psychosis, will allow us to examine if psychological treatment could delay or even prevent some of the progressive brain changes linked to schizophrenia.

T184. Schizotypy and psychosis proneness effects in a working memory FMRI paradigm

Igor Nenadic*, 1 Alexander Rapp 2, Kerstin Langbein 1, Maren Dietzek 2, Gerd Wagner 1, Ralf Schlösser 1, Heinrich Sauer 1

1Jena University Hospital

Background: Working memory deficits are among the best validated putative endophenotypes for schizophrenia, and are known to be linked to lateral prefrontal activation differences in functional MRI studies. Recent brain structural studies have suggested that variation in levels of schizotypy, a phenotypical risk marker for schizophrenia, or psychosis proneness, might affect variation in brain structure in areas also affected by schizophrenia. We evaluated the effect of positive and negative schizotypy and positive vs. negative symptom dimensions in a non-clinical sample on a well-established Sternberg working memory test.

Methods: We studied a sample of $n = 59$ healthy control subjects with no psychiatric disorder or history thereof and no first-degree relative with a psychotic disorder. All subjects underwent functional MRI using an established Sternberg working memory task (Schlösser et al., 2008). The task included two variations: a maintenance condition (in which three letters were just memorized) and manipulation (in which three letters have to be mentally rearrange according to their position in the alphabet). All subjects complete the SPQ-G (German version of the Schizotypal Personality Questionnaire; providing subscores for positive and negative schizotypy), and the CAPE (community assessment of psychic experiences, giving a positive and negative symptom scale). FMRI analyses were carried out with SPM8, taking into account the encoding vs. the maintenance stages of the task. For the purpose of this analysis, we focused on prefrontal activation differences.

Results: For negative schizotypy (SPQ-G), we found a negative correlation with left dorsolateral/ventrolateral prefrontal activation during the encoding stage, as well as left superior prefrontal cortex for the difference between manipulation and maintenance trials. We did, however, not find similar effects for the positive symptom dimensions of CAPE, which rather showed negative correlation in anterior parietal areas. However, for the CAPE negative symptom dimension, a weak effect in the left anterior lateral prefrontal cortex in the manipulation > maintenance comparison emerged. Most effects, however, did not survive correction for multiple comparisons.

Discussion: Our results provide first support for an effect of schizotypy and psychosis proneness in healthy, non-risk volunteers on prefrontal activation during a working memory task. They are thus compatible with the notion of a continuum among biological markers of schizophrenia, but remain unclear whether these relate to potential genetic effects of other sources of variation. Also, effects were weak overall, thus necessitating replication of findings.

T185. Brain structural correlates of schizotypy in healthy subjects: cortical thickness and folding

Igor Nenadic*, 1 Alexander Rapp 2, Kerstin Langbein 1, Maren Dietzek 2, Amelie Schreier 1, Heinrich Sauer 1, C. Christoph Schultz 2

1Jena University Hospital; 2University of Tuebingen

Background: Schizotypal traits are a phenotype risk marker for schizophrenia and have been associated with brain structural variation in healthy subjects. In this study, we aimed to analyse high-resolution
T186. Structural plasticity of whole brain networks following aerobic endurance training in multi-episode schizophrenia patients and healthy controls
Joseph Kambetiz*1, Daniel Keesser1, Katriona Keller-Varady1, Peter Falki1, Berend Malchow1
1Ludwig Maximilian University; 2Psychiatric University Hospital, Munich

Background: It has been suggested that reduced connectivity between brain regions might represent a central pathophysiological process underlying the brain changes observed in patients with schizophrenia. Following this disconnectivity hypothesis, the reduced integration of brain networks might hamper cognitive processing and ultimately result in psychotic symptoms seen in schizophrenic patients. In the present study we tested the hypothesis that an exercise intervention could spatially alter these alterations in brain network architecture and in this way alleviate clinical symptoms.

Methods: In the present study multi-episode schizophrenia patients (n = 20) and healthy control subjects (n = 21) underwent a 6-week exercise intervention consisting of aerobic endurance training followed by a 6-week period of aerobic exercise combined with a cognitive training battery. A control group of multi-episode schizophrenia patients (n = 19) took part in a 12-week intervention consisting of table soccer (known as “foosball” is the US) for the same amount of time. A clinical assessment, neuropsychological testing and neuroimaging were performed at baseline, after 6 and 12 weeks. Diffusion-tensor imaging (DTI) sequences were used to reconstruct white-matter fibre tracts and to derive structural connectivity networks across the whole brain. We used graph-analytic techniques for characterizing functional connectivity measures in whole brain network architecture following the training intervention.

Results: At baseline there were no significant differences between the three groups in any of the investigated graph-analytical measures (all \( P < 0.05 \)). In the healthy individuals there was a significant increase in brain network integration following the intervention as indicated by reduced minimal path length (\( P < 0.01 \)) but no change in the clustering coefficient. In patients with schizophrenia there was no significant change in minimal path length or the clustering coefficient following either the treatment or the control intervention. Post-hoc analysis of patients in the treatment group indicated higher increase in brain network integration as measured by the minimal path length was associated with stronger decrease in clinical symptoms as measured by the PANSS scale.

Discussion: Our results demonstrate the sensitivity of structural brain network architecture to the aerobic endurance training intervention in healthy and clinical individuals. The results in patients indicate that aerobic exercise was associated with changes in network architecture. The reduced sensitivity of the patient sample to the intervention might result from the chronicity of their disorder as well as the previous antipsychotic medication.
T188. Extracellular and brain tissue related abnormalities in subjects at clinical high risk for psychosis in Shanghai

Yingying Tang1, Ofer Pasternak2, Marek Kubicki2, Yogesh Rath2, TianHong Zhang3, Junjie Wang3, HuiJun Li4, LiHua Xu3, Zhenying Qian3, Katharine O3, Martha E. Shenton1, Jijun Wang3, Larry J. Seidman8

1Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; 2Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School; 3Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School; 4Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; 5Florida A & M University; 6Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School; 7Laboratory, Brigham and Women's Hospital, Harvard Medical School; 8Vanderbilt University School of Medicine.

Background: White matter (WM) microstructural alterations, including axonal deterioration, demyelination, and neuroinflammation have been thought to be associated with schizophrenia. It is still unclear, however, whether signs of WM alterations as identified by diffusion MRI precede the onset of psychosis. With advanced diffusion imaging analyses we explored whether or not WM alterations are present in subjects at clinical high risk (CHR) for psychosis.

Methods: 50 CHR subjects (77% naive to psychotropic medications) and 30 healthy controls were recruited as part of the Boston-Shanghai project (Seidman & Wang, PIs). Subjects met criteria for clinical high risk as defined by the Structured Interview for Prodromal Syndromes (SIPS) and Scale of Prodromal Syndromes. Images were acquired on a 3 T Siemens magnet. Analyses for each subject included a measure of fractional anisotropy (FA) derived from diffusion tensor imaging (DTI), as well as two measures from free-water imaging. The first measure is extra-cellular free-water (FW) which describes water diffusion in extracellular space and may be a putative measure of neuroinflammation. The second measure is free-water corrected fractional anisotropy (described as FAT), which eliminates free water and measures water diffusion within and surrounding tissue. The latter has been viewed as associated with neurodegenerative and inflammation processes.

Results: We found widespread reductions of FA in CHR subjects. In contrast, the free-water analysis showed a limited extent of FAT decreases, but a prominent increase in FW over the entire brain. When averaging FAT over the voxels with significant group differences, mean FAT values in CHR subjects were significantly correlated with decreases in Global Assessment of Functioning (GAF) scores, whereas mean FW values were not correlated with GAF scores. In addition, we explored age effects on WM alterations by separating all subjects into adult (≥21 years) and adolescent groups (< 21 years). Whole-VM FAT values were significantly lower in adult CHR subjects than in adult HCs, whereas whole-WM FW values were significantly higher in adolescent CHR subjects than in adolescent HCs.

Discussion: These findings demonstrate WM microstructural alterations before the onset of psychosis. Similar studies conducted in first-episode and chronic cases suggest that increased FW may be attributed to neuroinflammation, whereas decreased FAT is more likely related to axonal degeneration. The current findings are consistent with the findings in first-episode and chronic patients and suggest that signs of neuroinflammation and neurodegeneration are observed even before the onset of psychosis, albeit to a lesser extent, than are observed in previous studies with psychotic subjects. The role of both neurodegenerative and inflammatory processes may thus be key to understanding the neurobiology and development of psychosis in those who are at high clinical risk for psychosis.

T189. The effects of genetic and environmental risk factors for schizophrenia on cortical thickness

Emma Neilson*1, Catherine Bois1, Jude Gibson1, Lynsey Hall1, Heather Whalley1, Andrew McIntosh1, Stephen Lawrie1

1University of Edinburgh

Background: It is now widely accepted that both genetic and environmental factors can increase the risk of Schizophrenia (SCZ) and Bipolar Disorder (BD). It is also well evidenced that there are differences in cortical thickness between SCZ or BD patients when compared to Healthy Controls (HC). It is however unknown whether environmental or genetic factors have a direct impact on cortical thickness in these populations, although there is evidence that both factors impact upon global, frontal and temporal volume reductions. We have therefore investigated the effect of PolyGenic Risk Scores (PGRS) and environmental risks for SCZ on cortical thickness. We hypothesised that PGRSs and ERSs for SCZ will be related to cortical thinning globally and in the frontal and temporal lobes.

Methods: 98 structural MRI scans of the brain were acquired at 3 T for HC (n = 41), SCZ (n = 37) and BD (n = 20). Cortical reconstructions were generated using FreeSurfer (v5.3). PGRSs, based on the latest SCZ Working Group of the Psychiatric Genomics Consortium findings (PGC-SCZ, 2014), were available for 59 participants (HC = 31, SCZ = 24; BD = 4).

Results: There was a significant effect of PGRS on global cortical thickness in both the left (F = 5.23, df = 1, P = 0.03) and right (F = 7.73, df = 1, P = 0.002) hemisphere within the whole sample. Right (r = -0.34) and left (r = -0.38) global cortical thickness was negatively associated with increased polygene scores. This was not attributable to case/control status. When investigating environmental risk within the patient group there was a significant main effect of ERS (F = 7.23, df = 1, P = 0.04) on the right temporal lobe cortical thickness which remained after FDR correction. Each additional environmental risk factor had an effect on greater cortical thinning. Environmental effects remained significant even when controlling for PGRS at the 0.1 threshold.

Discussion: Increased PGRSs for SCZ is related to global cortical thinning in HC, SCZ and BD participants. Environmental risk is related to cortical thickness loss within the right temporal lobe in patients. Genetic and environmental risk factors for SCZ appear therefore to have effects that can be differentiated. This possibly provides a mechanism by which different risk factors may contribute to the onset and severity of SCZ and BD. Further studies are needed to determine if this finding can be replicated in a larger sample.

T190. Decreased EEG spectral entropy modulation associated with cognitive impairment in schizophrenia.

Alba Lubeiro Juárez1, Javier Gómez Pilar1, Vicente Molina Rodríguez1

1University of Valladolid

Background: Functional connectivity may contribute to schizophrenia and may be assessed using electroencephalography (EEG). Spectral entropy (SE, quantifying global EEG spectral regularity) and median Frequency (MF, the frequency that divides the spectral power by a half) are useful measurements to assess connectivity using EEG. We have previously reported in a completely different sample deficits of modulation of SE and MF in schizophrenia during an odd-ball test related to clinical symptoms.

Methods: EEG was acquired in 44 schizophrenia patients (8 first-episodes) and 44 healthy controls during an odd-ball task. Cognitive data (BACS, WAIS and WCST) and PANSS scores were also collected. SE and MF values were assessed for each electrode at baseline (-300 to 0 ms previous to the stimuli) and response (150 to 450 ms after stimuli).
windows. SE and MF modulation were defined as the corresponding response minus baseline difference in these parameters. We assessed the significance of the differences in SE and MF between baseline and response separately in patients and controls. Moreover, SE and MF modulation values were compared between patients and controls, correcting for multiple comparisons. Finally, the relation between clinical and cognitive parameters and SE and MF modulation as well as the classificatory accuracy of these values were assessed.

Results: SE and MF values at baseline were significant larger in patients. There were significant SE and MF decreases from baseline to response windows in both groups. The SE and MF modulation values were significantly lower in patients at central electrodes (Fz and Cz). A similar pattern was observed in first-episode patients. In the patients, SE modulation at Fz was inversely correlated to verbal memory, motor speed, working memory, executive function, and positive symptoms. Furthermore, SE modulation at Cz was positive correlated with percentage of perseverative errors (WSTC test). Lineal discriminant analysis with a leave-one cross-validation classified correctly 63.6% of subjects.

Discussion: We replicated the deficit of EEG modulation (SE and MF) in schizophrenia patients in a completely different sample. The distribution of this modulation deficit was similar as it was in our previous report. In the present sample, that modulation deficit of the EEG was associated to an impaired cognitive performance.

T191. Hippocampal-striatal-midbrain connectivity during reward prediction in high-risk subjects for psychosis: correlations with abnormal belief formation and dopamine

André Schmidt1, Toby Winton-Brown1, Anthony Grace2, Paolo Fusar-Poli1, Philip McGuire1
1IoPPN, King's College London; 2University of Pittsburgh

Background: Animal models propose that abnormal hippocampal activity drives striatal hyperdopaminergia in psychosis that may contribute to abnormal salience processing. Although previous multimodal imaging studies indicate alterations in the relation between hippocampal activity and striatal dopamine function in subjects at high-risk for psychosis during reward prediction, no study has yet explored the relation between hippocampal-striatal-midbrain connectivity and striatal dopamine function.

Methods: We applied dynamic causal modeling to fMRI data during reward prediction in 28 at-risk mental state (ARMS) subjects for psychosis and 32 healthy controls (HC). 18 F-DOPA PET scanning was used to measure striatal dopamine function in 14 ARMS subjects and 17 HCs. Effective connectivity parameters within the hippocampal-striatal-midbrain circuit were correlated with striatal dopamine function and abnormal belief formation.

Results: ARMS subjects revealed significantly increased connectivity from the ventral striatum to the midbrain compared with HCs (t58 = 3.117, P = 0.003), the degree of connectivity in ARMS subjects correlated positively with abnormal belief formation (r = 0.488, P = 0.011). The modulation of midbrain to ventral striatum connectivity induced by rewarding cues correlated negatively with baseline dopamine function in the limbic striatum in ARMS subjects (r = 0.701, P = 0.008) but not HCs (r = 0.186, P = 0.491).

Discussion: Ventral striatum to midbrain connectivity during reward prediction is altered in high-risk subjects for psychosis and related to positive symptomatology, suggesting a prognostic marker for emerging psychosis. According to recent animal models, alterations in VS to midbrain connectivity maybe due to abnormal GABA activity that precedes striatal hyperdopaminergia, providing a potential target for early treatment interventions.

T192. Contribution of oxytocin pathway genes to amygdala activity in schizophrenia, bipolar disorder and healthy controls

Marit Haram1, Lars Tjelta Westlye1, Ole A. Andreassen1, Ingrid Melie1, Martin Tesli1
1Oslo University Hospital, NORMENT

Background: BACKGROUND Building on oxytocin’s effect on social cognition, the hormone and neuropeptide has been proposed as pharmacological therapy for several psychiatric disorders, including schizophrenia. Several studies have shown that social cognition rely on distinct neural circuits from those involved in other cognitive processes and brain imaging studies propose medial prefrontal cortex, ventrolateral prefrontal cortex, amygdala, the inferior parietal lobe and the temporal cortex as contributing areas. In particular, alterations in oxytocin pathway genes have already been associated with core symptoms in schizophrenia reliant on this particular brain region, making them important candidates for investigation. The aim of this study is to explore whether oxytocin pathway genes contribute to amygdala reactivity using functional Magnetic Resonance Imaging (fMRI) and to see if this potential effect is enhanced in patients with schizophreniaspectrum (SZ) and bipolar disorder (BP) compared to healthy controls.

Methods: METHODS Participants (n = 344, including 90 SZ cases, 103 BP cases and 151 healthy controls) take part of the TOP study, a multicenter collaboration on psychosis research in South- Eastern Norway. They all underwent the same protocol at baseline, which include a clinical and physical examination by a psychosis, structural and functional MRI, extensive neuropsychological testing by a psychologist, collection of blood samples for somatic screening and DNA analyses. DNA was genotyped using the Affymetrix Human SNP Array 6.0 (Affymetrix Inc, Santa Clara, CA, USA). SNPs relevant in previous literature from genes producing the oxytocin receptor (OXTR) will be selected as candidate polymorphism for investigation. We will use data from a fMRI Amygdala Reactivity Task. In this task participants selected which of two stimuli (displayed at the bottom of the screen) matched a target stimulus (displayed at the top). The images displayed were either human faces expressing anger or fear (faces matching task) or geometrical shapes (the sensorimotor control task). Individual contrast images were created by subtracting “faces” from “figures”. Then, the peak voxel in each hemisphere was defined as the voxel with most evidence of differential activation as measured by a t-test applied to the voxels within amygdala. The activations of these two voxels are carried forward as the phenotypes for the genetic association analysis. Statistical analyses will mostly be done using SPSS, and tools for genotype data (PLINK and custom made MatLab scripts). Task-induced amygdala activation is estimated using a specialized statistics package (SPM, FSL). Linear regression with an additive model with correction for sex, age and diagnosis will be used for comparisons of amygdala activation between individuals with different oxytocin gene polymorphisms in all three groups.

Results: To this date, all data have been collected, but the statistical analyses have not yet been performed. Results will be presented at the conference.

Discussion: To this date, all data have been collected, but the statistical analyses have not yet been performed. Results will be presented at the conference.

T193. Effects of muscarinic M1 receptor sequence variation on executive function in schizophrenia and healthy controls

Sean Carruthers1, Susan Rossell2, Caroline Gurvich2
1Swinburne University; 2The Alfred Hospital and Monash University

Background: Schizophrenia patients present with a range of debilitating cognitive impairments, with most patients performing one to two standard deviations below healthy controls on a range of neurocognitive measures. Considerable evidence has implicated that a dysfunctional muscarinic system contributes to the higher-order cognitive impairments prevalent amongst people with schizophrenia. Human and animal studies have documented that disruption to the regular functioning of the M1 muscarinic receptor subtype is associated with pronounced cognitive impairments, and that recently developed allosteric activators can improve cognitive performance through targeting this receptor. It is,
T194. A study of gene-gene interactions between genes on chromosome 22q11 in schizophrenia in Korea

Yu Sang Lee*1, Kyung Sue Hong2, Eunsoog An1
1Yongin Mental Hospital, 2Sungkyunkwan University School of Medicine, Samsung Medical Center

Background: Schizophrenia is a complex genetic disorder. In the genesis of schizophrenia, gene-gene interaction is thought to play some role. Genes such as COMT, PRODH, and ZDHHC8 located on chromosome 22q11 might have been linked to schizophrenia. We examined the effects of gene-gene interactions residing within chromosome 22q11 in patients with schizophrenia in Korea.

Methods: The gene-gene interaction analysis was done with 227 unrelated patients with schizophrenia and 292 normal controls in Korea. MTPRs 4680, PRODH 1945, PRODH 1766, ZDHHC8 v25 and ZDHHC8 v26 were genotyped. In case-control study, logistic regression and multifactor dimensionality reduction model were applied to investigate the interactions between these genotypes.

Results: Logistic regression found interactions between COMT rs4680 and ZDHHC8 v25 (P = 0.0392) in patients with schizophrenia in Korea. MDR could not find interactions between genes on chromosome 22q11 in schizophrenia.

Discussion: These results imply that gene-gene interactions between COMT and ZDHHC8 on chromosome 22q11 might be implicated in the genesis of schizophrenia in Korean populations.

T195. Gender-specific associations of the brain-derived neurotrophic factor VAL66MET polymorphism with neurocognitive functioning and clinical features in patients with schizophrenia

Sung-Wan Kim1, Yo-Han Lee2, Min Jhon1, Ju-Yeon Lee3, Hee-Ju Kang, Seon-Young Kim4, Kyung-Yeol Bae4, Jae-Min Kim5, Il-Seon Shin6, Jin-Sang Yoon6
1Chonnam National University Hospital; 2St. John Hospital; 3Chonnam National University Medical School; Gwangju Bukgu Community Mental Health Center; 4Chonnam National University Medical School

Background: To explore associations of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with cognitive functioning and psychopathology in patients with schizophrenia.

Methods: We included 133 subjects meeting the DSM-IV criteria for schizophrenia who were in the post-acute stage of the disease. BDNF Val66Met genotypes were identified via polymerase chain reaction. The computerized neurocognitive function battery, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CSS), Social and Occupational Functioning Scale (SOFAS), and the Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-K) were administered. Gender-stratified sub-analysis was also conducted to identify gender-specific patterns in the findings.

Results: In male patients, no significant difference in any measure by BDNF genotype was evident. In female patients, scores on the CSS and the total PANSS and all subscales were significantly higher in valine (Val) carriers. In addition, scores on the SOFAS and SWN-K were significantly lower in Val carriers. In terms of neurocognitive measures, female patients with the Val allele had significantly poorer reaction times and fewer correct responses on the Continuous Performance Test (CPT) and the Trail Making Test (parts A and B). After adjustment of PANSS total scores and log-transformed CDSS scores, CPT outcomes were significantly poorer in female patients with than in those without the Val allele.

Discussion: Gender-specific associations of the Val allele with poor neurocognitive function and more severe psychopathology were evident. Further studies are required to explore the mechanisms of these differences and the potential utility of the BDNF genotype as a predictor of outcome in patients with schizophrenia.

T196. Association between ZNF804A and the risk of schizophrenia and bipolar disorders across diagnostic boundaries

So Yong Yang1, Ji Hyun Baek2, Youngah Cho2, Ik Soo Huh3, Eun-Young Cho1, Taesung Park3, Kyoseob Ha2, Kyung Sue Hong2
1Sungkyunkwan University, Samsung Medical Center; 2Sungkyunkwan University School of Medicine, Samsung Medical Center; 3Seoul National University; 4Center of Clinical Research, Samsung Biomedical Research Institute; 5Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul National Hospital

Background: Zinc finger protein 804A (ZNF804A) has been reported as a candidate gene for both schizophrenia and bipolar disorder. However, few studies examined the effect of this gene on the vulnerability of the two disorders in the same study population. We investigated the genetic association between ZNF804A and schizophrenia, bipolar disorder, and psychotic symptoms in the Korean population.

Methods: A total of 582 patients with schizophrenia, 339 patients with bipolar I (BP-I) or bipolar II disorder (BP-II), and 502 healthy controls were recruited. Nineteen tag SNPs across the ZNF804A region and two additional SNPs (rs7597593 and rs1344706) showing significant associations of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with cognitive functioning and psychopathology in patients with schizophrenia.

Results: After accounting for group differences in premorbid intelligence, no significant main effects of diagnostic group or genotype were found for the Mazes task or the WCST. Preliminary data was recorded from 97 patients diagnosed with schizophrenia or schizoaffective disorder and 136 healthy controls. Participants completed the Mazes task of the MCCB, with a small subset completing the WCST. This was apart of an ongoing investigation into the association between genetic variations and cognition in schizophrenia. Whole blood or saliva samples were collected from each participant for genotyping.

Results: After accounting for group differences in premorbid intelligence, no significant main effects of diagnostic group or genotype were found for the Mazes task or the WCST. Preliminary results suggest that the effect of genotype on WCST performance is the same for healthy controls as per patients and the pattern of results in the patient group is consistent with previous research showing a performance advantage for the heterozygous C/A group. A significant group by genotype interaction was reported for the Mazes task. Again, the results resonate with previous findings, with heterozygous patients (M = 18.6, SD = 6.2) out performing homozygous patients (M = 15.3, SD = 6.6) on the Mazes task. In contrast, the opposite genotype effect was observed amongst healthy controls.

Discussion: Our preliminary findings resonate with previous research that has suggested that variations in the M1 receptor gene sequence can influence executive function capacities in patients with schizophrenia. This has now been demonstrated across a number of executive function measures, and our data suggests the MCCB executive function measure is also a reliable indicator of this effect. However, it is evident that additional research in this area is required to explore how variations in the M1 receptor gene influence other aspects of cognition in both patients and control groups.
after correcting for multiple testing. For schizophrenia, four SNPs showed a nominally significant association with the lowest P value of 0.008 at rs17617468. BP-II showed a weaker trend of association with the lowest P value of 0.022 at rs10497662. In a post-hoc analysis, psychotic symptoms in three patients groups across diagnostic boundaries did not show an association with ZNF804A. Therefore, we cannot rule out the possibility that ZNF804A may play a role in the common susceptibility of schizophrenia and bipolar disorders. However, no other trend was observed for psychotic symptoms. Further efforts are needed to identify a specific phenotype associated with this gene across the current diagnostic categories.

**Results**

We focused on providing additional evidence for previously reported schizophrenia candidate genes (genes reported to carry a de novo mutation) to further prioritize the potential schizophrenia candidate genes and to be able to distinguish between phenotype neutral and phenotype relevant mutations. Additional genetic evidence for each potential schizophrenia candidate gene is warranted. **Methods**: In total, 150 patients with schizophrenia were subjected to Exome Sequencing. The patient cohort was enriched for an early age at onset and a poor prognosis. All individuals were of German descent according to self-reported ancestry. We observed that vitamin D co-administration had no effect on the production of these inflammatory cytokines in both the Dam and foetal brain (P < 0.05). **Discussion**: This is the first study to show that vitamin D may be protective in a widely used model of psychosis. In particular, the restoration of normal locomotor sensitivity to amphetamine by vitamin D indicates developmental dopamine systems are targeted by vitamin D. However, the broad spectrum of behavioural phenotypes abolished by vitamin D indicates multiple pathways are targeted for the therapeutic actions of vitamin D during brain development. Our findings suggest the neuroprotective mechanism/s invoked by vitamin D during brain development extend well beyond its role as an anti-inflammatory factor. We are now investigating whether maternal supplementation with cholecalciferol may be just as effective.

**T197. Exome sequencing in patients with schizophrenia**

Anna Koller1, Frederic Neukirch1, Lisa Winkler1, Kerstin Ludwig1, Julian Hecker1, Jana Strohmaier2, Holger Thiele3, Marcella Rietschel2, Markus M Nöthen1, Franziska Degenhardt*

1Queensland Centre for Mental Health Research; 2ETH Zurich; 3Queensland Brain Institute

**Background**: The genetic architecture of schizophrenia is complex. The so far identified genetic risk factors include both common, low-penetrant variants and rare, high-penetrant variants. Using Exome Sequencing, an increasing number of potentially relevant high-penetrant variants are currently being identified among patients with schizophrenia. Due to the large number of mutations identified so far, it is difficult to distinguish between phenotype neutral and schizophrenia relevant mutations. Additional genetic evidence for each potential schizophrenia candidate gene is warranted. **Methods**: In total, 150 patients with schizophrenia were subjected to Exome Sequencing. The patient cohort was enriched for an early age at onset and a poor prognosis. All individuals were of German descent according to self-reported ancestry. We observed that vitamin D co-administration had no effect on the production of these inflammatory cytokines in both the Dam and foetal brain (P < 0.05). **Discussion**: This is the first study to show that vitamin D may be protective in a widely used model of psychosis. In particular, the restoration of normal locomotor sensitivity to amphetamine by vitamin D indicates developmental dopamine systems are targeted by vitamin D. However, the broad spectrum of behavioural phenotypes abolished by vitamin D indicates multiple pathways are targeted for the therapeutic actions of vitamin D during brain development. Our findings suggest the neuroprotective mechanism/s invoked by vitamin D during brain development extend well beyond its role as an anti-inflammatory factor. We are now investigating whether maternal supplementation with cholecalciferol may be just as effective.

**Results**

We focused on providing additional evidence for previously reported schizophrenia candidate genes (genes reported to carry a de novo mutation) to further prioritize the potential schizophrenia candidate genes and to be able to distinguish between phenotype neutral and phenotype relevant mutations. Additional genetic evidence for each potential schizophrenia candidate gene is warranted. **Methods**: In total, 150 patients with schizophrenia were subjected to Exome Sequencing. The patient cohort was enriched for an early age at onset and a poor prognosis. All individuals were of German descent according to self-reported ancestry. We observed that vitamin D co-administration had no effect on the production of these inflammatory cytokines in both the Dam and foetal brain (P < 0.05). **Discussion**: This is the first study to show that vitamin D may be protective in a widely used model of psychosis. In particular, the restoration of normal locomotor sensitivity to amphetamine by vitamin D indicates developmental dopamine systems are targeted by vitamin D. However, the broad spectrum of behavioural phenotypes abolished by vitamin D indicates multiple pathways are targeted for the therapeutic actions of vitamin D during brain development. Our findings suggest the neuroprotective mechanism/s invoked by vitamin D during brain development extend well beyond its role as an anti-inflammatory factor. We are now investigating whether maternal supplementation with cholecalciferol may be just as effective.

**T198. Vitamin D treatment during pregnancy prevents schizophrenia-related phenotypes in a maternal immune activation animal model**

Daryl Eyles1, Stephanie Vulliermet2, Leon Luan3, Ura Meyer2

1Queensland Centre for Mental Health Research; 2ETH Zurich; 3Queensland Brain Institute

**Background**: We have established that maternal vitamin D deficiency is a risk-factor for schizophrenia in offspring. Maternal Immune Activation (MIA) induced by a variety of infectious agents is also a known epidemiological risk factor for these conditions. Vitamin D deficiency is alarmingly common in women of childbearing age. Given vitamin D is a well known regulator of immune function we have addressed the question of whether it could ameliorate behavioural phenotypes relevant to these psychiatric disorders in a well-described MIA animal model. **Methods**: Gravid C57Bl6 mouse dams were treated with the viral mimic poly(I:C) (polyriboinosinic-polyribocytidilic acid), a synthetic analogue of double-stranded RNA at gestational day 9. Poly(I:C) induces a cytokine-associated viral-like acute phase response in both the placenta and foetal brain. MIA or vehicle exposed dams simultaneously received 400ng/kg 1,25 α(OH)2D3 (the active hormonal form of vitamin D) or corn oil vehicle. One cohort of offspring were tested as juveniles for behaviours relevant to psychiatric conditions such as amphetamine-induced locomotion, social interaction, fear conditioning, marble burying and behaviour in an elevated plus maze. Inflammatory cytokines were measured in both maternal blood and foetal brains 4 hrs after exposure to Poly(I:C). **Results**: As previously shown, Poly(I:C) increased locomotor response to amphetamine, impaired social interaction and impaired acquisition of fear learning compared with vehicle treated dams (P < 0.05). Co-administration of vitamin D however completely abolished all these phenotypes whilst having no adverse effects on vehicle treated animals. In addition Poly(I:C) also severely impaired marble burying (an ethologically normal behaviour in rodents and possible measure general anxiety) compared to vehicle treated controls (P < 0.05). Co-administration of vitamin D again completely abolished this phenotype whilst having no adverse effects on vehicle treated animals. There was no effect of poly(I:C) on elevated plus maze behaviour. **Discussion**: As previously shown Poly(I:C) treatment induced a robust elevation in the inflammatory cytokines IL-6, IL-1β and TNFα both in maternal circulation and in foetal brain (P < 0.0001). To our surprise, Vitamin D co-administration had no effect on the production of these inflammatory cytokines in both the Dam and foetal brain (P < 0.05). **Discussion**: This is the first study to show that vitamin D may be protective in a widely used model of psychosis. In particular, the restoration of normal locomotor sensitivity to amphetamine by vitamin D indicates developmental dopamine systems are targeted by vitamin D. However, the broad spectrum of behavioural phenotypes abolished by vitamin D indicates multiple pathways are targets for the therapeutic actions of vitamin D during brain development. Our findings suggest the neuroprotective mechanism/s invoked by vitamin D during brain development extend well beyond its role as an anti-inflammatory factor. We are now investigating whether maternal supplementation with cholecalciferol may be just as effective.

**T199. IL-6 is a critical factor in the hippocampus-mediated neural circuit alteration underlying psychosis-associated phenotypes**

Daisuke Fukudome*,1, Mari Kondo1, Tomoaki Tezuka1, Catherine Foss1, Martin Pomper1, Atsushi Kaniya1, Akira Sawa1

1John Hopkins University School of Medicine

**Background**: Recent studies suggest that patients with psychosis were reported to have increased blood and CSF levels of immune-associated molecules, such as inflammatory cytokines, such as IL-6. Alteration in IL-6 have also been reported in post-mortem brains of patients with schizophrenia. Nonetheless, the role of IL-6 in the brain for psychosis-associated phenotypes remain to be explored. Recent human brain imaging studies suggest that hippocampus (HP) is a critical brain region involved in psychosis phenotypes. However, a key mediator in HP involved in psychosis phenotypes remains elusive. Thus, we hypothesize IL-6 may play an important role in the altered HP-mediated neural circuit for psychosis-associated phenotypes. To address this question, we used previously reported the cuprizone short-term exposure (CSE) mouse model that elicits specific elevation of IL-6 in astrocyte in the HP and behavioral endophenotypes associated with psychosis. **Methods**: Young adult C57BL/6 J male mice were fed either a diet containing 0.2% cuprizone, the copper chelator, or a control diet consisting of standard mouse chow for one week. In order to examine the role of IL-6 for psychosis-associated phenotypes in the CSE mouse model, IL6 expression was specifically suppressed in the dorsal HP by AAV-mediated knockdown approaches, followed by neurochemical, histological and behavioral assays. In addition, ex vivo autoradiography for TSPO, a marker of activated microglia and astrocytes, was conducted using the clinically translatable [125]iodo-DPA-713 radioligand. **Results**: We found that one week short exposure to cuprizone produces psychosis-associated behavioral abnormalities without
robust demyelination. In addition to elevated IL-6 expression predominantly in hippocampal astrocytes, an increase in binding of TSPO was observed in the HP. CSE mice display a hyperlocomotor response to amphetamine and an increase in synaptic dopamine in the nucleus accumbens. The CSE mice also display a deficit in Y-maze spontaneous alternation and short term object recognition memory. Of note, knock down of IL-6 in the dorsal HP ameliorated observed behavioral abnormalities in the CSE mice.

Discussion: IL-6 in the dorsal HP is a critical factor in the HP-mediated neural circuit alteration underlying psychosis-associated phenotypes observed in the CSE mice model. The CSE mouse model may be a useful tool to study molecular mechanisms underlying HP-mediated neural circuit alteration-associated psychotic behavioral phenotypes.

T200. Perinatal asphyxia and cesarean section changes the expression of novel schizophrenia risk genes in rat
Keiko Iwata1, Alessandra Paparelli2, Tomoyasu Wakuda3, Conrad Iyegbe4, Robin Murray5, Nori Takei5
1Research Center for Child Mental Development, University of Fukui; 2Institute of Psychiatry, King’s College; 3Hamamatsu University School of Medicine; 4MRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King’s College; 5Research Center for Child Mental Development, Hamamatsu University School of Medicine; Institute of Psychiatry, King’s College

Background: Epidemiological studies suggest that obstetric complications, particularly those related to hypoxia in the offspring during labor and delivery, is a risk factor for the development of schizophrenia later in life. Impacts of perinatal asphyxia on postnatal life have been studied in a rodent model in which global hypoxia was imposed during the perinatal period (asphyxia model), and this model has been shown to manifest several abnormalities in adulthood that have relevance to schizophrenia. On the other hand, there is some evidence suggesting that cesarean section (C-section) itself is associated with schizophrenia. Therefore, we also examined the effects of C-section per se as one of potential exogenous insults. Besides, a strong genetic component is known to be involved in schizophrenia. Recently, novel schizophrenia loci, including CNNM2, CSMD1 and MMP16, have been reported by GWAS. Thus, we are intrigued to examine whether these novel schizophrenia risk genes would be altered in their expressions in our asphyxia-induced rat model as well as in the C-section rat model. However, little is known about how these gene expressions are virtually involved in the CNS in the course of neonatal, adolescence and adulthood. We analysed expression levels of these genes in the course of neural and oligodendrocytic differentiation to confirm involvement of the novel schizophrenia risk genes in the maturation of the CNS.

Methods: We analysed expressions of schizophrenia risk genes by quantitative real-time PCR. These gene expressions were measured at three periods, neonatal, adolescence and adulthood. We analysed expression levels of these genes in rat brain tissues, such as prefrontal cortex (Pfc), the striatum (Str), and the hippocampus (Hip), which are suggested to be critically involved in schizophrenia. We also analysed expressions of the genes during neuronal and oligodendrocytic differentiation using human neuronal (SK-N-SH) cells and human oligodendrocytic (MO3.13) cells.

Results: We found that the expression of Cnnm2 was elevated in rodents specifically exposed to asphyxia, whereas C-section caused altered expression in other two genes, CSMD1 and Mmp16. Time course of such alteration varied; some lasted from the neonatal period to adulthood and other occurred only after birth. Cnnm2 expression was significantly downregulated in Pfc and Str via asphyxia. In asphyxia, long-lasting altered expression was observed in Pfc, while the alteration was limited to the neonatal period in Str. On the other hand, C-section upregulated Csdm1 expression (in Str and Hip) and Mmp16 expression (in Str). The altered level of Csdm1 expression was conserved until adulthood in Str, while its alteration was transient in Hip. The Mmp16 expression was upregulated remarkably but just after C-section in Str. We then confirmed the involvement of the genes in the CNS; Cnnm2 and Mmp16 expressions were upregulated in the differentiated neuronal cell line. In the matured oligodendrocytic cell line, Cnnm2 and Mmp16 expressions were downregulated, while CSMD1 expression was upregulated.

Discussion: Long-lasting changes in gene expressions found are reminiscent of the persistent nature of the phenotype of schizophrenia. However, some alterations were observed only at the perinatal period. These alterations may affect neuro-manipulation such as neural differentiation and glial maturation early in life, and such an impact may lead to permanent CNS deficits. In addition, C-section may be related to the pathophysiology of schizophrenia via involvement of CSMD1 and MMP16. Further research elucidating the mechanisms of asphyxia and C-section for affecting CNS would help to understand the pathophysiology of schizophrenia.

T201. Overexpression of G-protein coupled receptor 85 (GPR85) in the rat hippocampus induces deficits in spatial short-term memory
Eliza Koros*1, Birgit Stierstorfer1, Roberto Arban1, Thorsten Lamla1
1Boehringer Ingelheim Pharma GmbH & Co. KG

Background: The G-protein coupled receptor 85 (GPR85) is an orphan receptor expressed abundantly in the brain that is involved in regulating neural and synaptic plasticity and modulating diverse behaviors. In addition, human findings showed that genetic variants in GPR85 have been associated with risk for schizophrenia. Previous studies in transgenic mice overexpressing GPR85 demonstrated that these animals display reduced dendritic arborization and decreased hippocampal neurogenesis as well as impaired performance in tests of short- and long-term memory. Thus, we investigated whether an increased expression of GPR85 in the hippocampus by an adenovirus vector-driven approach may regulate memory function in the hippocampal-dependent object location test in rats.

Methods: Overexpression of GPR85 was obtained by the AAV vector designed and selected for its ability to increase GPR85 levels in vitro. Wistar rats were treated with recombinant adenoviral intra-hippocampal injection of AAV9-HIV-ES-VS-GPR85 or AAV9-HIV-ES-VS-GFP in the object location task, 3 and 6 weeks later. AAV-mediated GPR85 overexpression in the hippocampus of rats was checked by immunohistochemistry.

Results: Overexpression of GPR85 restricted to the hippocampus resulted in impaired memory performance of rats in the object location task addressing spatial memory domain.

Discussion: This study shows that hippocampal overexpression of GPR85 in rats results in an impaired performance in the object location test. The effects on spatial memory observed in the present study corroborates previous findings from other studies and further support the idea that GPR85 inhibition may be a potential approach to improve cognition in schizophrenia and other psychiatric disorders.

T202. Age-dependent alterations in gabaaergic signaling, mediators of inflammatory pathways and redox homeostasis in frontal cortex of the MAM rat model
Thomas Lanz1, Nathaniel Hodgson2, Gabriel Sholder1, Simon Xi1, William Howe1, Roubia Kozak1, Takao Henisch2, Patricio O’Donnell1
1Pfizer Global R&D; 2Harvard University

Background: Schizophrenia is a neurodevelopmental disorder with risk factors of both genetic and epigenetic origins. In the methylazoxymethanol (MAM) rat model, embryos are exposed to a teratogen in utero during a critical period for the developing frontal cortex (E17). This manipulation results in a variety of behavioral and neurochemical differences in the offspring, which become evident only after puberty, mimicking the typical age of onset for schizophrenia. The present work sought to understand in greater depth the molecular alterations arising in young and aged animals.

Methods: Brains were harvested from naïve E17 MAM rats at 3, 6, and 12 months of age. Frontal cortex was split, with one half fixed for histology. From the other half, medial prefrontal cortex was collected for HPLC analysis of metabolic thiols. Plasma were collected for measurement of cytokines. Surrounding frontal cortex was frozen separately for RNA extraction and sequencing. A separate cohort of MAM rats was trained in a continuous trial-unique delayed nonmatching-to-location (CTUNL) working memory task. Tissue was
collected for RNA extraction after the rats had completed multiple testing sessions (16 months old).

Results: Initial RNAseq analysis in young MAM rats showed a large number of dysregulated transcripts that have been observed to be differentially expressed in post-mortem human brain, such as the GABAergic markers Parvalbumin (PV), CCK, and NPY. A previous report has identified a significant reduction in PV+ neurons measured by immunohistochemistry. Pathway analysis of genes in common between MAM rat and schizophrenia brain revealed several signaling pathways, inflammatory pathways and pathways suggestive of oxidative stress. The increased immunological signature in frontal cortex was not matched by changes in peripheral cytokines. Measurements of metabolites in the glutathione (GSH) synthesis pathway revealed age-dependent increases in multiple metabolites such as cystathionine and GSSG, with a resulting reduction in the GSH/GSSG ratio. Analysis of working memory showed no impairment in performance once the MAM had learned the task, but animals showed slower acquisition.

Discussion: The present dataset describes molecular and biochemical changes in the frontal cortex of the adult MAM rat arising from environmental manipulation of its developmental trajectory. Some features of schizophrenia pathology, such as a reduction in PV+ neurons, reduced GABAergic transcripts and increased inflammatory transcripts, can be observed in the MAM rat. Alterations in glutathione metabolism, which grow in magnitude with age, suggest persisting oxidative stress in the medial prefrontal cortex. Working memory, as measured by CTUNL, was not overtly impaired, but the MAM rats showed a slower learning curve than control rats. Taken together, these data add to the picture of a neurodevelopmental model that may have utility in evaluating therapeutic efficacy of novel compounds that promote central anti-oxidant systems, reduce neuroinflammation, or increase interneuron function.

T203. Transgenerational transmission and modification of behavioral deficits induced by prenatal immune activation

Ulrike Weber-Stadlbauer*1, Juliet Riccheto1, Marie Labouesse1, Urs Meyer1
1University of Zurich

Background: Maternal exposure to infectious or inflammatory insults during pregnancy increases the offspring’s risk to develop neuropsychiatric disorders, including schizophrenia. It remains unknown, however, whether the increase in disease susceptibility induced by prenatal immune challenges could be transmitted across subsequent generations without any further immune exposures. The phenomenon of non-genetic transgenerational transmission of behavioral traits has attained increasing recognition in view of its potential importance in the etiology and treatment of multi-factorial disorders. The present study is the first to examine possible transgenerational effects using a well-established model of maternal viral-like immune activation in mice.

Methods: Pregnant mice (F0) were injected with the viral mimetic poly(I:C) (5 mg/kg, i.v.) or control solution in early pregnancy (gestation day 9). Upon reaching early adulthood, F1 offspring were either allocated to behavioral testing or breeding, the latter of which served to produce subsequent (F2 and F3) generations of poly(I:C)-exposed or control ancestors. Extensive behavioral testing was then carried out in all generations. In addition, we performed genome-wide transcriptomic profiling to determine possible gene expression changes in the amygdala of F1 and F2 mice using next generation mRNA sequencing. Results: Behavioral analyses in F1, F2 and F3 offspring revealed that deficits in social interaction and cue rearing, both of which emerge in F1 poly(I:C) offspring, are also present in the F2 and F3 generation. F1 poly(I:C) offspring also showed increased sensitivity to the psychostimulant drug amphetamine. Interestingly, the F2 and F3 poly(I:C) generations displayed the opposite pattern, namely reduced amphetamine sensitivity. Behavioral despair emerged as a novel phenotype in the F2 and F3 poly(I:C) generation without being manifest in F1 offspring. Transcriptomic analyses revealed 2217 differentially expressed genes in F1 poly(I:C) offspring relative to F1 controls, and 4015 DEGs in F2 poly(I:C) offspring relative to F2 controls. A remarkable number of genes (1132) were differentially expressed in both generations. Many of these common genes are part of the dopamine- and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) signalling pathway.

Discussion: Our findings demonstrate that behavioral deficits induced by prenatal infection can be transmitted and modified across subsequent generations. The transmission of common behavioral phenotypes across generations may be linked to aberrant DARPP-32 signalling, whereas transcriptional changes in generation-specific gene sets may underlie the emergence of generation-specific behavioral abnormalities such as sensorimotor gating (F1) and behavioral despair (F2 and F3). Future experiments will examine the possibility that the behavioral abnormalities and the differences in gene expression following prenatal immune activation are transmitted to subsequent generations via modifications in the epigenetic machinery.

T204. Role of AMPA receptor deficiency in the onset of schizophrenia in an inducible genetic mouse model

Dragos Inta1*, Miriam Vogt1, Hasan Elkin1, Peter Gass1
1Central Institute of Mental Health

Background: Adolescence is characterized by important molecular and anatomical changes with relevance for the maturation of brain circuitry and cognitive function. This time period is of critical importance in the emergence of several neuropsychiatric disorders accompanied by cognitive impairments, such as affective disorders and schizophrenia. The molecular mechanisms underlying these changes at neuronal level during this specific developmental stage remains however poorly understood. GluA1-containing AMPA receptors, which are located predominantly on hippocampal neurons, are the primary molecular determinants of synaptic plasticity. We investigated here the consequences of the inducible deletion of GluA1 AMPA receptors in glutamatergic neurons during late adolescence.

Methods: We generated mutant mice with a tamoxifen-inducible deletion of GluA1 under the control of the CamKII promoter for temporally- and spatially-restricted gene manipulation. Analysis comprised a standard battery of behavioural tests for revealing schizophrenia-like abnormalities, as well as neurochemical and gene expression analysis for identifying possible changes in striatal dopamine and NMDA receptors.

Results: GluA1 ablation during late adolescence induced cognitive impairments, but also marked hyperlocomotion and sensorimotor gating deficits. Unlike the global genetic deletion of GluA1, inducible GluA1 ablation during late adolescence resulted in normal sociability. Deletion of GluA1 induced redistribution of GluA2 subunits, suggesting AMPA receptor trafficking deficits. Mutant animals showed increased hippocampal NMDA receptor expression and no change in striatal dopamine concentration.

Discussion: Our data provide new insight into the role of deficient AMPA receptors specifically during late adolescence in inducing several cognitive and behavioural alterations with possible relevance for neuropsychiatric disorders.

T205. UBE3B expression in the prefrontal cortex during development and in schizophrenia

Emily Kohlbrenner*1, Tsung-Ung Wilson Woo2
1McLean Hospital; 2McLean Hospital and Harvard Medical School

Background: The prefrontal cortex, a major site of dysfunction in schizophrenia, undergoes extensive developmental changes during adolescence, including the remodeling and pruning of circuitry in neuronal networks that eventually lead to enhanced cognitive decision making ability in adulthood. Our previous work explores gene expression regulation in normal, postnatal human development; specifically at layer 3 pyramidal cells that furnish corticocortical connections in the prefrontal cortex. We identified genes that are both developmentally regulated and differentially expressed in schizophrenia. One of these genes is the ubiquitin ligase encoding gene, UBE3B, a paralog to the widely studied UBE3A which has been previously correlated with autistic behaviors in mice. Alterations in the ubiquitination system are known to contribute to developmental neurological diseases such as Angelman Syndrome and other autism spectrum disorders. Our protein and gene expression analysis findings

© 2016 Schizophrenia International Research Society/Nature Publishing Group
suggest that UBE3B expression increases developmentally and is decreased in schizophrenic samples, and thereby could contribute to the developmental pathophysiology of schizophrenia by disturbing periadolescent synaptic refinement of prefrontal cortical circuitry. Methods: Nissl-stained homogenous populations of pyramidal neurons were extracted from layer III of the prefrontal cortex via the Arcturus XT Laser Capture Microdissection protocol from a cohort of preadolescent (n = 7) and post adolescent (n = 6) control subjects. Total mRNA was then isolated and amplified using the Picopure mRNA Isolation Kit from Arcturus. Expression profiling experiments were conducted using the Affymetrix X3P microarray chip. The generated data were normalized with MA55. Differentially expressed genes in pre- vs. post-adolescent subjects were determined using ANOVA, and filtered with an FDR-corrected P value of 0.05 and a fold change of 1.5. A pathway analysis was performed with GeneGo software to determine the biological significance of the differentially expressed genes. UBE3B protein expression levels were verified using an immunohistochemistry staining protocol with an anti-ube3b polyclonal antibody made in rabbit and an anti-rabbit secondary made in goat. Tissue was fixed in 4% paraformaldehyde and cut at 20μm (developmental cohort) and 10μM (disease cohort). Images were taken at 2.5x magnification to visualize staining. 500μM × 500μM columns were drawn to count Ube3B and Ube3b/Nissl co-localization staining through ASV prefrontal cortex layers I–V. Fold change microarray data were validated with qRT-PCR in an ongoing investigation of the genes of interest. Templates were generated from the LCM cohort cDNA and amplified using SYBR Green and normalized to GAPDH. Results: UBE3B cellular density increases developmentally and is also seen to be decreased in adult subjects with schizophrenia (SZ). The percent of total ube3b-expressing cells, specifically pyramidal neurons, is also decreased in SZ. Genetically, we found UBE3B to be upregulated in the healthy post-adolescent cohort, and downregulated in the adult SZ cohort versus the healthy adult control. Discussion: We are particularly interested in UBE3B, a gene that was found to be upregulated during periadolescent development but downregulated in subjects with SZ. Because UBE3B is involved in ubiquitination, which has been strongly implicated in the regulation of synaptic plasticity, our findings raise the hypothesis that altered expression of UBE3B could contribute to the developmental pathophysiology of SZ by disturbing periadolescent synaptic refinement of prefrontal cortical circuitry.

T206. The dopaminergic response to acute stress in health and psychopathology: a systematic review

Thomas Vaessen1, Dennis Hernaus2, Inez Myin-Germeys3, Thérèse van Amelsvoort1

1University of Leuven; 2Maastricht University; 3KU Leuven

Background: Previous work in animals has shown that dopamine (DA) in cortex and striatum plays an essential role in stress processing. We reviewed the evidence for the role of DA in the human acute stress response in both healthy individuals and those at increased risk for or diagnosed with a psychiatric disorder.

Methods: PUBMED was searched for studies published before January 8th 2015 using the following Boolean phrase: (“positron emission tomography” OR “PET” OR “single photon emission computed tomography” OR “SPECT” OR “single photon emission tomography” OR “SPECT”) AND (“dopamine”) AND (“stress” OR “pain”).

Results: All studies included (n studies = 25, n observations = 324) utilized DA D2/D3 positron emission tomography and measured DAergic activity during an acute stress challenge. The evidence in healthy volunteers (HV) suggests that physiological, but not psychological, stress consistently increases striatal DA release. Instead, increased medial prefrontal cortex (mPFC) DAergic activity in HV was observed during psychological stress. Across brain regions, stress-related DAergic activity was correlated with the physiological and psychological intensity of the stressor. The magnitude of stress-induced DA release was dependent on rearing conditions, personality traits and genetic variations in several SNPs. In psychopathology, preliminary evidence was found for stress-related dorsal striatal DAergic hyperactivity in psychosis spectrum and a blunted response in chronic cannabis use and pain-related disorders, but results were inconsistent.

Discussion: Physiological stress-induced DAergic activity in striatum in HV may reflect somatosensory properties of the stressor and readiness for active fight-or-flight behavior. DAergic activity in HV in the ventral striatum and mPFC may be more related to expectations about the stressor and threat evaluation, respectively. Future studies with increased sample size in HV and psychopathology assessing the functional relevance of stress-induced DAergic activity, the association between cortical and subcortical DAergic activity and the direct comparison of different stressors are necessary to conclusively elucidate the role of the DA system in the stress response.

T207. No link between duration of prodromal and psychotic symptoms and brain structural volumes in emerging psychosis

Charlotte Rapp1, Carlos Canela2, Erich Studerus3, Anna Liisa Walter4, Jacqueline Aston5, Stefan Borgwardt6, Anita Riecher-Rossler7

1Psychiatry Clinics Solothurn; 2Practice Doctor in Binningen; 3University Hospital of Psychiatry Basel; 4Psychiatric Outpatient Clinic; 5Psychiatric University Clinics Basel; 6University of Basel; 7Center for Gender Research and Early Detection

Background: The time period during which patients manifest psychotic or unspecific symptoms prior to treatment (duration of untreated psychosis, DUP) and the duration of untreated illness, DII has been found to be moderately associated with poor clinical and social outcome, which may amongst others be due to “neurotoxicity” of untreated psychosis. Equivocal evidence exists of an association between DUP/DUI and structural brain abnormalities, such as reduced hippocampus (HV) (Bühlmann et al., 2010), pituitary volume (PV) (Büschen et al., 2011) and grey matter volume (GMV) (Borgwardt et al., 2007). The objective of this work was to examine if DUP and DII are associated with grey matter volume abnormalities in HV, PV or GMV.

Methods: Using a region-of-interest (ROI) based approach, we present data of 39 patients from the Basel Fe Psy (Früherkennung von Psychosen) (Riecher-Rossler et al., 2007) study for which information about DUP, DII and HV, PV and GMV data could be obtained. 23 of the patients were identified as first-episode-psychosis patients (FEP), 16 as at-risk-mental-state (ARMS – T) patients, who later made the transition to frank psychosis.

Results: We found no significant association between DUP/DII and HV, PV or GMV when corrected for sex, age and antipsychotics, although we found a statistical trend for a weak negative association between DII and GMV in FEP.

Discussion: Our results do not support the hypothesis of a “toxic” effect of untreated psychosis on brain structure.

T208. Increased expression of alpha-2,8-sialyltransferase 8 (ST8SIA2) in superior temporal gyrus of elderly patients with schizophrenia

Toni Mueller1, Stefani Yates1, Yaham Haroutunian2, James Meador-Woodruff1

1University of Alabama at Birmingham; 2Mount Sinai School of Medicine

Background: The role of posttranslational protein modifications (PTMs) in the pathophysiology of schizophrenia (SCZ) is a recent target of investigation in this devastating neuropsychiatric illness. One PTM, glycosylation, has come under study due to the role glycan adomnay plays in modulating a wide variety of inter- and intracellular processes, carbohydrate active enzymes (CAzymes), glycosyltransferases and glycodies, comprise approximately 2% of the human genome and mediate this functionally important PTM. Sialyltransferases (SiaTases) and sialidases respectively attach or cleave the 9-carbon α-keto sugar, N-acetylenuraminic acid (NeuAc or sialic acid) on a substrate molecule. NeuAc is commonly found at the termini of glycan branches and is uniquely able to form extended homopolysaccharide chains. Polysialic acid (PSA) is synthesized by the addition of 8+ NeuAc units attached via an α-2,8-linkage hydrolyzed by ST8SIA2, ST8SIA4, or less efficiently by ST8SIA3. PSA and polysialylated proteins play important roles in the spatiotemporal
regulation of neurodevelopmental processes, and reduced PSA is a feature of SCZ pathophysiology. Specifically, reduced polysialylation of neural cell adhesion molecule (NCAM, PSA-NCAM), but not total NCAM expression, is evident in the hippocampus and dorsolateral prefrontal cortex (DLPFC) in SCZ.

Our lab recently investigated transcriptome of CAzymes in SCZ DLPFC and, contrary to our expectation, found increased mRNA of both SiaTases and sialidases. While reduced PSA-NCAM has been suggested to contribute to decreased neuropahtology and reduced volume of SCZ superior temporal gyrus (STG), evidence supporting this hypothesis has not been reported. To elaborate on potential deficits of NeuAc in SCZ STG, we measured the protein expression of ST8SIA2, ST8SIA3, NEU1, and NEU2. We hypothesized that, consistent with increased transcription of these CAzymes, SiaTases and sialidase protein levels are increased in SCZ.

Methods: Samples of gray matter from the full cortical thickness of the left STG (Brodman area 22) of 16 elderly SCZ and 14 comparison subjects were obtained from the Mount Sinai Medical Center brain collection. Prepared samples of total homogenate were loaded in 4-12% Bis-Tris gels and run using standard SDS-PAGE and semi-dry transfer methods. Membranes were then probed with antibodies against ST8SIA2, ST8SIA3, NEU1, NEU2, and valosin-containing protein (VCP) as a loading control. The relative abundance of proteins was determined by measuring the signal intensity of each target normalized to the signal intensity of VCP.

Results: Protein expression of ST8SIA2 is altered in schizophrenia. ST8SIA2 demonstrated a 22% increase in expression relative to COMP subjects in SCZ (t(28) = 2.75, P = 0.01). ST8SIA3, NEU1, and NEU2 expression was not found different between diagnostic groups in STG. Discussion: ST8SIA2 is the primary mediator of PSA-NCAM synthesis, and mutations of the ST8SIA2 gene have been correlated with increased SCZ susceptibility risk. These single nucleotide polymorphisms have recently been shown to functionally impair α2,8-SiaTase activity in vitro. suggesting that deficient NeuAc hydrolysis may lead to upregulated transcription and translation of a mutated ST8SIA2 gene in SCZ STG, as we report here. This may be an indication of cellular compensation in the disorder, it is noteworthy that 11 of the 16 SCZ subjects were on typical antipsychotics within 6 weeks of death and this finding may represent a medication effect rather than an inherent feature of SCZ pathophobiology. Further investigation of PSA, PSA-NCAM, and ST8SIA2 expression in SCZ STG of unmedicated patients in earlier stages of the disorder are warranted.

T209. Unravelling the role of schizophrenia risk genes in microglia: specific functions in the anti-inflammatory phenotype?

Lot de Witte1, Lynn van Olst1, Manja Litjens1, Elly Hol1, Carles Garcia-Riberas2, Greeten Velezmoro2, Javier Terriente3, Javier Joya3, Oriol Vall3, Cristina Pujades1

1University Medical Center Utrecht

Background: It is becoming more and more clear which genes are associated with schizophrenia. How these risk genes contribute to schizophrenia pathogenesis is still largely unknown. It has been shown that the expression of schizophrenia risk genes is not restricted to neurons but also enriched in immune cells. In addition, pathway analysis has revealed that the risk genes cluster not only in neuronal but also in immune pathways. Which specific immune cells and pathways are affected in schizophrenia is still unknown. The aim of the present study is to investigate the expression and function of schizophrenia risk genes in human microglia, the main population of immune cells in the brain.

Methods: From GWAS, CNV and linkage studies nineteen schizophrenia risk genes were selected for further analyses. The expression of these genes was assessed in primary human microglia isolated from post-mortem brain tissue and compared to the expression in total brain tissue. The regulation and function of microglia-enriched genes was studied in primary microglia as well as monocyte-derived macrophages in the brain.

Results: Expression of seven out of nineteen genes was enriched in microglia compared to whole brain tissue. Polarization of human primary microglia and human primary monocyte-derived macrophages with anti-inflammatory stimuli, particularly dexamethasone and TGF-β, but not pro-inflammatory stimuli, resulted in a significantly higher expression of most of the microglia enriched genes. Two of the schizophrenia risk genes were silenced in human primary monocyte-derived macrophages using small interference RNAs and the knockdown resulted in downregulation of seven out ten TGF-β target genes. Discussion: Expression of potential schizophrenia risk genes is enriched in microglia further increased after stimulation with dexamethasone and TGF-β. Moreover, knock down of one of these genes resulted in downregulation of TGF-β response. These results suggest that schizophrenia risk genes may be involved in specific functions of alternatively activated microglia cells, such as controlling inflammation, tissue repair, or in the development of microglia and that dysregulation of these functions may be involved in schizophrenia pathogenesis.

T210. Effect of clozapine and haloperidol in the morphology and neurodevelopment of zebrafish embryo.

Carles Garcia-Riberas2, Greeten Velezmoro2, Javier Terriente3, Javier Joya3, Oriol Vall3, Cristina Pujades1

1Hosp Sant Pau. GRIE-IMIM. UAB; 2Infant Dev Res Group GRIE-IMIM, 3ZeClinics. UPF; 1JUF

Background: In recent years, alterations in cognitive, motor, socio-emotional and adaptive behaviour in children exposed in utero to antipsychotic drugs has been observed. FDA places Haloperidol and Clozapine in Pregnancy Categories C and B respectively. While the lack of well-controlled safety studies. On the other hand, some data suggest antipsychotics might impact in the morphology of brain structure. In this regard, second generation antipsychotics (SGAs) show different neuroplastic effects when compared to first generation antipsychotics (FGAs). In particular, SGAs have been shown to mitigate gray matter volume reductions, common phenotype present in schizophrenia patients. This effect suggests SGAs could have a neuroplastic effect. Additional studies have reported a decrease in cortical thickness during treatment with SGA. It is not understood if these effects might be related to an effect in neurogenesis, neuronal apoptosis, or to a different reason altogether.

We aim to study the teratogenic potential and putative neuroplastic effect of haloperidol and clozapine during CNS development using zebrafish developing embryos.

Methods: Zebrafish embryos were obtained by mating adult fishes by standard procedures. All fish strains were maintained individually as inbred lines. Wild type, strain AB; Tg[Mü4127]; Tg[neurod:GFP]; Tg[Isl1: GFP]; Tg[isl3:GFP] (also called Isl2b). All procedures used have been approved by the PRBB animal care facility and Users ethical committee, and followed national and European regulations. Concentrations 0.1µM, 1µM, 10µM, 100µM and 1 mM were tested. Mortality and embryonic morphology were quantified during the assay at 3 different time-points (24, 48 and 72 hpf). In whole mount antibody staining embryos were incubated O/N at 4 °C with rabbit anti-β-tubulin (1:500), mouse anti-DsRed (1:500), rabbit anti-phosphoHistone3 (pH3) (1:500), or mouse anti-HuC. TUNEL assay was also performed.

Results: Clozapine and Haloperidol were lethal at 100 µM concentration in zebrafish embryos. Teratogenic doses of both drugs were observed in the range of 0.1 to 10 µM. No effect appeared on patterning, differentiation and apoptosis at 10 µM and below, with no significant differences when we compared average number of pH3-positive cells observed per hemisegement among control (DM501W = 10.75 ± 3.59), haloperidol (10.5 ± 3.51; P = 0.9) or clozapine (7.5 ± 3.1; P = 0.2). Neurogenesis was affected predominantly by clozapine at 10 to 100 µM concentration, and to a less extend by Haloperidol at same concentrations. Embryos exposed either drug do not exhibited significant variation in the number of differentiating neurons. 10µM Haloperidol treated embryos showed similar number of cells expressing neuroD per hemisegement (10µM = 12,16 ± 0.932) compared with controls (12,275 ± 0,941). However, exposure to clozapine reduced neurogenesis 9%. Moreover, a significant (P < 0.05) decrease in the number of neuroD-GFP+ cells was detected in embryos exposed to 100 µM for both drugs: reduction of 31.7% for clozapine and 16.8% for haloperidol.

Discussion: Teratogenic doses of both drugs are in the range of 0.1 to 10 µmicoRoM at which two phenotypes can be observed, one with...
T211. Prefrontal gray matter volume loss is associated with decreased working memory performance in adolescents with a first episode of psychosis

Marta Rapado-Castro1,2, Mara V. Arenzana3, Joost Janssen1, David Fraguas1, Josefina Castro-Fornieles1, Ana González-Pinto1, Montse Graell1, Soraya Otero4, Manuel Desco5, Christos Pantelis6, Celso Arango5
1Hospital G.U. Gregorio Marañon; 2Universidad Complutense; 3Hospital Clinic de Barcelona; 4Hospital Santiago Apóstol de Vitòria; 5Hospital Infantil Universitario Niño Jesús; 6Hospital Universitario Marqués de Valdecilla; 7The University of Melbourne and Melbourne Health

Background: Cognitive maturation during adolescence is modulated by brain maturation. High-order cognitive processes (i.e. Sustained Attention (SA), Working Memory (WM) and Executive Function (EF)) have been associated with the prefrontal cortex. In typical development, frontal lobe gray matter (GM) volume typically peaks at 11-12 years whereas gains in WM are extended up to 15-19 years of age and EF performance improves up to mid-twenties (1). SA is a basic underlying cognitive process required to complete any activity is the first one to develop. Studies examining frontal cortical changes and cognitive performance in psychosis over time lend support for an altered development of higher brain cognitive functions [2] which parallel progressive GM loss over time [3,4]. However the direct relationship between these processes has not been assessed to date in early onset psychosis. We aimed to assess the relationship between changes in GM volume in the frontal lobe and SA, WM and EF performance in adolescents with a first episode of psychosis after 2 years.

Methods: A subsample of 32 first-episode psychotic patients (mean age 15.82; range [11–17]) and 47 matched controls (mean age 15.26; range [13–17]) completed both baseline and longitudinal cognitive and neuroimaging assessments from the original CAFEPS sample (110 patients and 98 controls [5]). A structural MRI was obtained in five 1.5 T scanners. Lateral frontal lobe GM volumes were obtained using an automated method based on the Talairach’ atlas. Prefrontal cortex related abilities were assessed using subtests of SA (Digits Forwards WAIS-III, time to complete TMT-A, number of correct items from words and colors Stroop test, number of correct responses and average reaction time from the CPT); WM (Digits backwards and letter-number sequencing, WAIS-III) and EF (TMTB-A, number of errors, number of perseverative errors and categories of the WCST, Stroop Interference score, total COWAT score) (z-scores). ANCOVA was used to examine differences between groups in longitudinal change in lateral frontal GM volumes using age, scanner site, IVC at baseline and interscan IVC change at 2 years as covariates of no interest. Partial correlation analyses were performed to determine the association between changes (2-year minus baseline) in frontal GM volumes and SA, WM and EF performance (composite score) within each group. In order to analyse the predictive value of changes in frontal GM over cognitive performance, backwards stepwise regression analyses were conducted.

Results: Patients showed significantly greater loss of GM volume in the frontal lobe (left \(r = 5.825; P = 0.018\); right \(r = 7.007; P = 0.010\)) than healthy controls at 2 years follow up. Longitudinal change (decrease) GM volume was significantly associated with decreased WM performance in patients \(r = 0.484; p = 0.009\); right \(r = 0.422; P = 0.025\). No association was found in healthy controls. Results of a backwards stepwise regression model revealed that change in frontal GM volume over time predicted a significant amount (left 19%; right 16%) of the variance of change in WM, even when variance for all other variables in the final model was accounted for. No association was found between longitudinal GM volume change and SA or EF in these groups.

Discussion: Adolescents with a first episode of psychosis presented a specific decrease in GM volume in the frontal lobe during the first two years after illness onset. Within patients but not controls, progressive loss of GM volume was associated with decreased WM function. Our results suggest that during adolescence, patients seem to follow an abnormal neurodevelopmental trajectory in which progressive reduction of frontal GM volume might contribute to the observed working memory dysfunction.

T212. Why is exotropia (one specific type of strabismus) a significant risk factor for schizophrenia?

Christopher von Bartheld1, Andrea Agarwal1, Cheng-yuan Feng1, Austin Christensen1, Dan Wen2, Kellie Cassinelli3, L. Alan Johnson3, Brian Kirkpatrick4
1University of Nevada School of Medicine; 2Central South University, Xiangya Hospital, Changsha; 3Sierra Eye Associates

Background: Several recent studies have shown that children with strabismus (specifically exotropia) have a significantly increased risk of developing schizophrenia decades later (Toyota et al., 2004; Schiffman et al., 2006; Yoshitsugu et al., 2006; Mohney et al., 2008; Ndlouv et al., 2011; increased risk 3 to 185fold, median ~70fold), suggesting an overlapping pathophysiology for both diseases or a role of exotropia as a risk factor for schizophrenia. The association of schizophrenia with exotropia but not esotropia suggests that the two relevant rectus muscles (medial and lateral) differ in their susceptibility to this process. We here identified which genes known to be associated with schizophrenia have abnormal expression patterns in strabismic medial rectus extraocular muscles. Given the link between exotropia and schizophrenia, we also tested the hypothesis that seasonality of birthdates may be similar between the two groups of patients.

Methods: Samples from strabismic lateral and medial rectus muscles were obtained during corrective surgeries; normal samples were obtained from deceased organ donors. Consistent gene expression differences of 2-fold or more on targeted or customized PCR arrays were compiled from paired comparisons \(n = 4\) per condition. We selected 86 molecules of particular interest based on known risk factors for schizophrenia. Birth months of 5,847 patients with either exotropia or esotropia were normalized to geographically matched birth records, analyzed with a chi-square test, and compared with published data from cohorts of patients with schizophrenia.

Results: Among 381 genes encoding signaling molecules, 22 were consistently and significantly dysregulated in strabismic medial rectus muscles. Almost half (10) of these were known biomarkers for schizophrenia (Schwarz et al., 2011; Miller et al., 2011), including cytokines, growth factors and their receptors, and downstream signaling pathways. NRG1, VEGFA were decreased, while CTGF, CXC4, I7, TNF, NTRK2, I1L10RA, TNF and TNFR were increased. Birthdates of patients with exotropia showed a pronounced peak in summer months \(P = 0.001\), similar to the birth pattern of people with schizophrenia who have primary negative symptoms (Messias et al., 2004).

Discussion: Our gene expression data indicate a molecular link between exotropia and schizophrenia. This suggests that the gene expression profile in the medial rectus muscle may be related to the risk of developing schizophrenia. We are currently exploring whether the dysregulation of schizophrenia-related molecules is specific to strabismic medial rectus muscles (exotropia) and absent from strabismic lateral rectus muscles (esotropia). We are also exploring whether infants with very early correction of their exotropia have a reduced incidence of schizophrenia, as has been hypothesized (Korn, 2004). Neurodevelopmental abnormalities may lead to both medial rectus muscle dysfunction and brain exotropia, when it manifests early in life and compromises visual capacity, may increase the risk of the development of psychosis (Landgraf and Osterheider, 2013; Silverstein et al., 2013). The new findings may aid in the development of methods to predict the risk of schizophrenia years prior to the appearance of psychotic symptoms, and conceivably aid in the prevention of some percentage of cases of schizophrenia.
T213. Very preterm born adults experience elevated levels of psychopathology that are associated with the volumes of corticostriatal white matter tracts

Jasmin Kroll1, Sean Froud-Falson1, Jane Tseng1, Philip Brittain1, Slava Karolis1, Chiara Nosarti1
1King’s College London

Background: Very preterm birth has been associated with an increased risk of psychiatric disorder later in life. Higher rates of sub-clinical psychopathology might also be expected in preterm populations as a whole. Establishing the aetiological mechanisms underlying these sequelae is crucial in developing preventative strategies and treatments. The objective of this study is to evaluate psychopathology and its structural brain correlates in very preterm adults.

Methods: We assessed psychopathology in a cohort of 127 adults who had been born very prematurely (VPT, <33 weeks) and a group of 88 term-born controls aged 30 years, using the ‘Comprehensive Assessment of At Risk Mental States’ (CAARMS). Using Diffusion Magnetic Resonance Imaging (MRI) data we also studied possible structural alterations in corticostriatal tracts, due to their known involvement in a variety of neurodevelopmental and neuropsychiatric disorders.

Results: VPT participants had higher rates of psychopathology on two CAARMS symptom clusters: a ‘Negative-Interpersonal’ cluster (NI, P = 0.018), relating to symptoms of anhedonia, depression and anxiety and a ‘Communication-Cognitive-Behavioural Disorganization’ cluster (CCBD, P = 0.018), relating to symptoms of disorganization of a child’s behaviour, poverty of speech and cognitive and affective disturbance. The volume of five corticostriatal tracts (see below) was also significantly smaller in the VPT group (all P < 0.05). A number of negative correlations were found between the two CAARMS clusters and corticostriatal tract volumes (i.e. higher symptomatology = lower tract volume): NI cluster scores and Striatal Working Memory/Attention tract (r = -0.20, p = 0.045), Striatal Sensorimotor tract (r = -0.33, p = 0.004) and Striatal Default Mode Network tract (r = -0.30, p = 0.013); CCBD cluster scores and Striatal Frontal tract (r = -0.21, p = 0.038) and Striatum Limbic tract (r = -0.21, p = 0.033), after Benjamini-Hochberg FDR correction.

Discussion: These results demonstrate increased rates of psychopathology in a sample of adults aged 30 who survived VPT birth, which could be at least partly explained by volumetric alterations in corticostriatal tracts, involving amongst the others, the limbic and frontal cortices and the default mode network, which are crucial for emotion/salience processing.

T214. Uncovering components of cognitive behavioural case management (CBCM) in UHR individuals: what is implemented and what is effective?

Jessica A. Hartmann1, Patrick D. McGorry1, G. Paul Amminger1, Hok Pan Yuen1, Connie Markulev1, Lavoie Suzie1, Miriam R. Schäfer1, Meredith McHugh1, Barnaby Nelson1
1Queen’s Centre of Excellence in Youth Mental Health

Background: Converging evidence suggest that cognitive behavioural therapy (CBT) and cognitive behavioural case management (CBCM) may provide a safe and effective pre-emptive treatment option in people at ultra-high risk (UHR) for psychosis. However, given the broad nature of this treatment approach, it is not clear which CBCM strategies are implemented and which components should be routinely incorporated. The aim of the current study was to characterise the provided components and progression of a CBCM regimen and to analyse the relationship between these components and symptomatic and functional outcome.

Methods: As part of a larger trial comprising 304 UHR individuals (Neuropro-E study), participants were provided with a manualised intervention of CBT embedded within case management (CBCM). Participants received 6-20 CBCM sessions, depending on their need, for up to 12 months. CBCM components used were registered post-session by the clinician using a checklist. Clinical status and symptomatic/functional outcome was assessed at baseline and reassessed at 6, 9 and 12-months. Analytical methods (in progress) include descriptive analyses of the implemented CBCM components (cross sectional and over the course of the treatment period); multiple regression analysis, as well as survival analysis associating particular CBCM elements to symptomatic outcome and clinical status.

Results: CBCM data were available for 282 participants. Participants received on average 14 CBCM sessions. Over the treatment period, most prevalent implemented strategies were mental state and symptom monitoring (67%), assessment of symptoms (46%) and stress management (44%), with relapse prevention/termination (12%) and crisis management (13%) as least prevalent. Preliminary regression analyses suggest that a higher number of provided sessions, as well as CBCM component assessment of symptoms predicted higher total depression (MADRS) and general psychopathology scores (total BPRS score) at 12 months (P < 0.01).

Discussion: These preliminary results indicate that a prominent aspect of cognitive behavioural intervention for UHR patients is stress management, in line with stress-vulnerability models of psychosis onset, as well as monitoring symptom progression. The relationship between higher number of CBCM sessions and worse symptom scores at 12 month follow up was most likely driven by those patients with greater clinical need and worse symptom profile requiring a greater amount of clinical intervention. Further analyses to be presented at the conference will address whether particular components of CBCM (e.g., treatment focused on positive symptoms) relate to particular aspects of clinical outcome (e.g., reduced transition rate, improved functional outcome, etc.).

T215. Individualized metacognitive therapy for delusions: effectiveness in a pragmatic controlled trial

Christina Andreou1, Martina Fieker2, Charlotte Wittekind3, Brooke Schneider2, Steffen Moritz2
1Center for Gender Research and Early Detection, University Psychiatric Clinics, Basel, University Medical Center Hamburg-Eppendorf, 2University Medical Center Hamburg-Eppendorf

Background: Delusions constitute a hallmark symptom of psychotic disorders. Since extensive research has linked the emergence and maintenance of delusions to reasoning biases (i.e., specific distorted thinking styles), there has been an increased interest in the therapeutic efficacy of interventions that aim to improve such reasoning biases. Individualized metacognitive therapy (MCT+; free download in 10 languages at www.uke.de/mct_plus) is a short, structured and fully manualized treatment program for patients with psychosis that leans on the principles of cognitive-behavioral therapy and adopts a ‘backdoor’ approach: Through engaging exercises the patient is introduced to reasoning biases, before individual symptoms are addressed. Aim of the present study was to assess the effectiveness of MCT+ in the context of a pragmatic controlled trial.

Methods: The study was designed as a randomized, controlled, rater-blind trial. Participants were 92 patients with schizophrenia-spectrum disorders and current or past delusions. In order to ensure generalizability of results, exclusion criteria were restricted to mental retardation, major brain damage, and substance dependence. Patients were allocated to either MCT+ or a control intervention (computerized cognitive training), of which they received up to 12 twice-weekly sessions. All patients continued receiving their usual care (including therapy groups and medication) during the study. The primary outcome measures were PANSS item P1 (delusions) and PSYRATS delusions total score at 8 weeks. Results were calculated with ANCOVAs adjusting for baseline scores. Intention-to-treat (ITT) analyses included all patients who participated in at least one treatment session (control n = 32); matching data were estimated using multiple imputation. Per protocol analyses (PP) included all patients for whom follow-up data were available (MCT+ n = 40; control n = 32).

Results: The mean number of attended sessions was similar for the two groups. There were no differences in antipsychotic medication dose either at baseline or follow-up. Primary outcome analyses revealed a significant superiority for MCT+ regarding P1 (ITT P = 0.03, PP P = 0.02) and PSYRATS delusion score (ITT P = 0.02, PP P = 0.018), at a medium effect size (partial eta-squared = 0.08 in both cases). Secondary analyses revealed a numerical advantage of MCT+ for all symptom
dimensions of the PANSS which, however, did not reach significance (all P > 0.2). When analyses were repeated including only patients who attended at least 4 sessions of either intervention (MKT+ n = 39; control n = 26), all between-group effects increased in size, approaching a large effect size for delusions (partial eta-squared = 0.12) and a medium effect size in the case of PANSS positive (P = 0.06, partial eta-squared = 0.06), distress (P = 0.06, partial eta-squared = 0.06) and disinhibition symptoms (P = 0.04, partial eta-squared = 0.07). Results were not affected by the presence or absence of current clinically relevant delusions at baseline (defined as P1 score ≥ 4).

Discussion: MCT+ was more effective in reducing delusions in patients with psychotic disorders compared to a control intervention (computerized cognitive remediation training), irrespective of delusion severity at baseline. This effect was more pronounced in patients who attended more sessions.

T216. Exercise improves clinical symptoms, quality of life, global functioning and depression in schizophrenia: a systematic review and meta-analysis

Meenaksi Dauwan*, Marielle Begemann, Sophie Heringa, Iris Sommer

1University Medical Center Utrecht

Background: Physical exercise may be valuable for patients with schizophrenia spectrum disorders as it may have beneficial effect on clinical symptoms, quality of life and cognition.

Methods: A systematic search was performed using PubMed (Medline), Embase Psychinfo, and Cochrane Database of Systematic Reviews. Controlled and uncontrolled studies investigating the effect of any type of physical exercise interventions in schizophrenia spectrum disorders were included. Outcome measures were clinical symptoms, quality of life, global functioning, depression or cognition. Meta-analyses were performed using Comprehensive Meta-Analysis software. A random effects model was used to compute overall weighted effect sizes in Hedges’ g.

Results: 29 studies were included, examining 1109 patients. Exercise was superior to control conditions in improving total symptom severity (k = 14, n = 719: Hedges’ g = .39, P < .001), positive (k = 15, n = 715: Hedges’ g = .32, P < .01), negative (k = 18, n = 854: Hedges’ g = .49, P < .001), and general (k = 10, n = 475: Hedges’ g = .27, P < .05) symptoms, quality of life (k = 11, n = 770: Hedges’ g = .35, P < .001), global functioning (k = 5, n = 342: Hedges’ g = .32, P < .01), and depressive symptoms (k = 7, n = 337: Hedges’ g = .71, P < .001). Yoga, specifically, improved the cognitive subdomain long-term memory (k = 2, n = 184: Hedges’ g = .32, P < .05), while exercise in general or in any other form had no effect on cognition.

Discussion: Physical exercise is a robust add-on treatment for improving clinical symptoms, quality of life, global functioning, and depressive symptoms in patients with schizophrenia. The effect on cognition is not demonstrated, but may be present for yoga.

T217. Theta burst transcranial magnetic stimulation for auditory verbal hallucinations

Margot Slot*, Sanne Koops, Edwin van Dellen, Maya Schutte, Wendy Nieuwpoort, Sebastiaan F.W. Neggers, Iris Sommer

1University Medical Center Utrecht

Background: Auditory verbal hallucinations (AVH) are a characteristic symptom of schizophrenia. In 25% of patients, these hallucinations are irresponsive to existing treatments such as antipsychotic medication. Repetitive Transcranial Magnetic Stimulation (rTMS) to the left temporo-parietal region has been suggested to be a non-invasive treatment option for refractory hallucinations, but results up till now have been inconclusive. Recent studies with large sample sizes could not demonstrate efficacy of 1-Hz rTMS when compared to placebo. An alternative stimulation protocol using theta burst rTMS (TB-rTMS) may be a more effective treatment option.

Methods: In a double-blind sham-controlled design, seventy-one patients with AVH were randomly allocated to either TB-rTMS or placebo treatment. The TB-rTMS group received ten continuous TB-rTMS treatments over the left temporo-parietal cortex distributed over five consecutive days. The placebo group received ten treatments of sham stimulation following the same procedures as the active treatment group. Severity of AVH was assessed at baseline, after five days of treatment, and during follow-up one month later using the Positive and Negative Symptom Scale (PANSS), Auditory Hallucinations Rating Scale (AHRS) and Psychotic Symptom Rating Scale (PSYRATS). Treatment effects on AVH were analyzed using a mixed design ANOVA.

Results: The severity of AVH did not significantly reduce after TB-rTMS compared to placebo, as no significant interaction effect between time and treatment group was found. A significant improvement in AVH occurred after treatment in general as measured by the AHRS (p < .01) and the PSYRATS (n = .002). Furthermore, the total (p = .04), positive (p = .03) and general (p = .01) PANSS score decreased significantly over time, but there was no significant decrease on the negative scale, neither a significant time by group interaction on the PANSS.

Discussion: As both treatment groups showed equal improvement, the results suggest AVH improvements were due to a placebo-effect rather than treatment-specific effects of TB-rTMS.

T218. Cognitive remediation group therapy reduces persistent negative symptoms in schizophrenia outpatients: RCT results

Daniel Muellér*, Volker Roder

1University Hospital of Psychiatry and Psychotherapy Bern; 2Universitären Psychiatrischen Dienste Bern

Background: Negative symptoms often inhibit the social integration of people suffering from schizophrenia. Persistent Negative Symptoms (PNS) are consensus defined as primary negative symptoms or secondary symptoms not responding to usual treatment and interfering with patients’ ability to perform role functions in clinically stabilized patients. The treatment of PNS is increasingly considered an unmet need, as very few interventions specifically addressing PNS exist up to date. Aim of this study was to investigate whether cognitive remediation therapy (CRT) supports remission of PNS.

Methods: The Integrated Neurocognitive Therapy (INT) represents a CRT group treatment approach designed for schizophrenia outpatients. We identified PNS outpatients of a data set from an international RCT comparing INT with Treatment as Usual (TAU). A total of 53 patients met inclusion criteria for PNS. A test-battery assessed baseline, end of therapy of 15 weeks (with bi-weekly sessions) and follow-up one year after baseline. Change in outcome between INT and TAU over treatment and follow-up was compared using GLM for repeated measurements. Remission rates of the two treatment conditions were compared using Chi-square tests.

Results: Remission rates of PNS (mild or no symptom severity) after therapy were significantly higher for INT compared to TAU after therapy and at follow-up. However, symptom reduction was associated not only to the motivation factor (e.g., motivation, sociality) but not to the expression factor (e.g., blunted affect) of PNS. Furthermore, INT compared to TAU significantly increased functional outcome at follow-up. Regarding proximal outcome in cognitive domains, some significant effects were found in basic neurocognition (speed, attention, verbal memory). No effects in complex neurocognition and social cognition were evident in INT or TAU.

Discussion: INT seems to successfully reduce PNS and functional outcome deficits in PNS outpatients. To address individual deficits in specific negative symptoms such as blunted affect and alogia (expressive factor) as well as in complex cognitive functions, CRT should be combined with other therapy topics such as physical exercise and motivational techniques over a longer duration of therapy.
T219. Cognitive therapy and motivational interviewing: reducing cannabis consumption in individuals with psychosis
Henrietta Steinhart1, Uli REininghaus2, Cecile Henquet2, Tineke Latater2, Maurice Smits2, Christine Barrowclough3, Inez Myin-Germeys4
1KU Leuven, Center for Contextual Psychiatry; 2Maastricht University; 3University of Manchester; 4KU Leuven

Background: Cannabis dependence and abuse is a widely spread phenomenon among individuals with psychotic disorder. In vulnerable individuals, cannabis stimulates the development of psychotic symptoms and exerts a negative influence on the course of the disorder as well as treatment compliance. So far, only one treatment approach yielded promising results in the combined treatment of cannabis dependence and psychosis: Barrowclough’s Cognitive Therapy and Motivational Interviewing (CT+MI). The aim of the current study is to test the efficacy of CT+MI in reducing cannabis consumption in individuals with psychosis.

Methods: Sixty patients were randomly assigned to CT+MI or a control condition (treatment as usual). CT+MI consisted of 24 individual sessions (45-60 min) spread over a period of 40 weeks, complemented by two booster sessions at weeks 5 and 10 after completion of treatment. Cannabis consumption (number of days abstinent from cannabis) was measured at baseline, post treatment, and at six and twelve months follow-up using the Time Line Follow Back method. An available case analysis involving 37 cases was carried out. In this preliminary sample, linear mixed effects models with random intercept were deployed to investigate the effect of treatment on cannabis consumption. Changes in cannabis consumption were tested both within treatment group and with a treatment×time interaction using a Wald test. Group differences in cannabis consumption were analyzed for each follow-up moment.

Results: In the treatment group, number of abstinent days significantly increased over time until six months after the intervention (post treatment: β = 13.97, P = 0.002, 95% CI [5.08:22.68]; six month follow-up: β = 11.92, P = 0.014, 95% CI [2.44:21.40]; 12 month follow-up: β = 7.93; P = 0.074, 95% CI [-0.76;16.63]). The difference in the number of abstinent days was slightly higher in the treatment group at end of treatment (β = 3.29, P = 0.65, 95% CI [-11.03; 17.61]) and at six month follow-up: β = 12.36, P = 0.11, 95% CI [-2.83; 27.55]), but this difference fell short of statistical significance at conventional levels. At 12 month follow-up, cannabis consumption did not significantly differ in the two groups (β = 0.70, P = 0.93; 95% CI [-13.76;15.15]). There was no evidence of a time × group interaction (β = 2.86, P = 0.41). This suggests that, overall, group differences in cannabis consumption did not significantly vary over time.

Discussion: Initial evidence from the current data suggests that CT+MI does not reduce cannabis consumption in individuals with psychosis. Due to the small sample size, these preliminary results need to be interpreted with caution.

T220. An event-related potential EEG-neurofeedback training to treat auditory verbal hallucinations in schizophrenia patients
Kathryn Heri1*, Laura Diaz Hernandez1, Daniela Hubl1, Thomas Dierks1, Thomas Koenig1
1University Hospital of Psychiatry Bern

Background: Previous studies have shown a global reduction of the event-related potential component (ERP) N100 in schizophrenia patients, which is even more pronounced during the event of auditory verbal hallucinations (AVH). This presumably results from a dysfunctional activation of the primary auditory cortex by inner speech, which reduces its responsiveness to external stimuli. The idea of this study is to enhance the responsiveness of the primary auditory cortex to external stimuli with an upregulation of the event-related potential component N100 through neurofeedback. Our main interest stands on the behavioral level, specifically in the change of the subjective intensity of AVHs.

Methods: Therefore, 15 healthy control subjects and 8 with chronic schizophrenia or schizoaffective disorder diagnosed patients underwent a neurofeedback training. Patients with an age range between 18 - 65 years have been randomly assigned to the treatment or the placebo group. Our design was scheduled with 16 training sessions starting and ending with a collection of questionnaires.

Results: We will present preliminary data of neurofeedback-trained schizophrenia patients and healthy control subjects. In controls, we generally found an unspecific habituation effect that lowered the N100 amplitude over time. Several subjects were able to compensate for this habituation with help of the given neurofeedback. In patients, a similar picture has been seen. On the behavioral level, one of the subjects in the training group reported that the negative impact of the voices decreased even further two weeks after the training.

Discussion: The training results of the healthy subjects and patients at an important role of habituation in neurofeedback training on sensory ERP components. The patient data suggests that the chosen intervention may interact with AVH, but larger case numbers are necessary to draw well justified conclusions.

T221. Impact of psychosocial interventions on caregiver burden of schizophrenic outpatients. A systematic review of randomized controlled trials
Elaine Di Sarno1*, Mario Rodrigues Louzã Neto2
1Institute of Psychiatric, Hospital Clinics, IPQC-H-FMUSP; 2Universidade de São Paulo

Background: Schizophrenia is a chronic disease that poses an important impact the family members and caregivers. These adverse consequences have been measured in studies of family/caregiver burden and it is expected that psychosocial interventions might reduce family burden. We systematically reviewed randomized controlled trials to evaluate the effectiveness of psychosocial interventions in reducing family burden of schizophrenia.

Methods: A systematic review (following PRISMA Statement) of the main international databases, without language or period restriction, up to November 2015. Search terms: schizophrenia, caregiver, burden, outpatients, interventions, caregiving, treatment, psychoeducation. Inclusion criteria: randomized controlled trials (RCT), outpatients, use a rating scale or questionnaire designed to measure burden. Exclusion criteria: other trials (e.g., non-Randomized, observational, ongoing etc.). RCTs that used other rating scales, to indirect measure burden (e.g., quality of life scales, expressed emotion) were excluded.

Results: Sixteen trials fulfilled our inclusion/exclusion criteria. They comprised 1341 individuals, 750 in the experimental, 591 in the control group. Sample size varied between 29 and 225 caregivers. Studies were conducted in the USA (n = 1), Italy (n = 2), Spain (n = 2), China (n = 4), Iran (n = 4), Pakistan (n = 1), India (n = 1) and Chile (n = 1). The mean age of the patients varied from 25 to 35 years, they had the diagnosis of schizophrenia (with one exception, DSM-IV). Duration of disease varied between 6 and 21 years. Most of the trials included as caregiver one family member (usually the mother); their age mean varied between 32 and 55 years. Caregivers spent between 7 hours/day and 35 hours/week with the patient. Randomization was described in 11 trials and blinding, in 6 studies. Instruments used to measure burden: Burden Assessment schedule (BAS), Caregiver Burden Scale (Zarit), Experience of Caregiving Inventory (ECI), Family Burden Interview Schedule (FBIS), Social Behaviour Assessment Schedule (SBAS), Family Burden Questionnaire (FBQ), Pai and Kapur Interview Schedule and Family Problems Questionnaire (FPQ).

Different methods of psychoeducation (including lectures, videos, booklets) was used in 10 trials, 5 trials combined psychoeducation with support groups and 1 trial applied Yoga. The duration of the intervention varied from 4 weeks to 12 months, usually once a week. The design of the trials usually included a baseline measure and a second measure at the end of the trial, 5 studies did a third evaluation 12 months after the end of the intervention, 3 studies after 18 months and 2 studies after 24 months. Control group is described as ‘routine care’ (psychiatric consultation for medication control) or ‘waiting list’. In all trials, the intervention group obtained a statistically significant reduction of burden in comparison to control group.

Discussion: Our review shows that psychosocial interventions are effective in reducing the burden of caregivers in schizophrenia. This reduction of burden lasted for 12 and 18 months after the end of the intervention. Nevertheless it has to be considered that there are few RCTs on this subject and they usually are of relatively poor quality.
use of ‘routine care’ as control group creates an unfair comparator to the intervention groups. More, well designed studies are needed to evaluate the impact of interventions in family burden of schizophrenia.

T222. Comparing the efficacy of two types of cognitive remediation in schizophrenia: results from a two-site retrospective cohort study.
Bruno Biagianti1, Matteo Cellà2, Clare Reeder3, Sophia Vinogradov2, Til Wykes2
1San Francisco Veterans Affairs Medical Center; 2Institute of Psychiatry, Psychology and Neuroscience, King’s College London

Background: Cognitive remediation (CR) for schizophrenia uses a variety of methods that differ in terms of approach (computerized, paper and pencil), type of assistance (therapist-assisted, computer-assisted, unsupervised), and targeted domains. Here, we compared the impact on cognitive and clinical outcomes of two CR programs with similar duration and intensity: an unsupervised, computerized auditory targeted cognitive training (TCT) that was shown to improve global cognition and verbal learning and memory, and a therapist-assisted, paper and pencil, cognitive remediation therapy (CRT) that was shown to improve working memory, cognitive flexibility, negative and disorganized symptoms. We investigated whether these two interventions generated similar magnitudes of cognitive and clinical improvements.

Methods: Data were merged from two published RCTs. We compared 46 participants with schizophrenia who completed 50 hours of TCT, and 43 participants who completed 40 sessions of CRT. The cognitive outcome measures that could be compared between datasets were verbal fluency (Verbal Fluency Task FAS), verbal working memory (Letter Number Test), speed of processing and executive functioning (Trail Making Test A and B). Neither of the two cognitive remediation approaches was developed to specifically target these domains. For these variables, T scores were calculated using means and standard deviations from published normative data stratified by age and education. PANSS scores were coded using the Van Den Oord 6 factor solution. To determine statistically significant differences in cognitive and clinical outcomes, we conducted ANCOVAs on the post-treatment scores, with pre-treatment scores as covariates and group as an independent variable. Within-group effect sizes were computed by calculating the bias-adjusted standardized mean difference (Hedges’g). To examine whether gains between the two groups were statistically different, effect sizes were compared using Hedges’g confidence intervals.

Results: The two groups were matched on age, gender, education, and chlorpromazine equivalents. CRT participants had worse baseline speed of processing and executive functioning, compared to those in TCT. There were no statistically significant differences between cognitive improvements induced by TCT and CRT. Effect sizes were slightly larger for CRT (g = .17–.39) than for TCT (g = .13–16), but their confidence intervals significantly overlapped. There were significant differences in clinical outcomes between TCT and CRT when adjusting for the baseline covariate. Although confidence intervals for effect sizes were not significantly different between the two groups, CRT improved negative symptoms (g = .28) and amotivation (g = .37), whereas TCT did not induce significant changes.

Discussion: Unsupervised TCT and therapist-assisted CRT induced similar cognitive improvements in the domains that were available for investigation, with small-moderate effect sizes. Since pre-treatment cognitive impairments may influence the response to different CR programs, we suggest that CRT be tailored to the cognitive profile of each individual. When possible, multiple options should be offered to individuals with schizophrenia, according to their needs and goals. Therapist-assisted CRT induces improvements in negative symptoms and motivation, two critical domains for functional recovery in schizophrenia. Unsupervised TCT can be delivered remotely and implemented for individuals with schizophrenia who live in under-resourced areas and cannot reach mental health clinics, and for those who do not approach these treatment settings because of mental health stigma.

T223. Preliminary evidence for impaired object recognition as a neural correlate of visual derealisation phenomena in first episode schizophrenia patients
Daniel Nuñez1, Rieke Oelkers-Ax2, André Rupp3, Heribert Sattel1, Franz Resch4, Matthias Weisbrod5, Thomas Fuchs7
1Universidad de Talca; University of Heidelberg, 2University of Heidelberg, 3Technische Universität München, 4University of Heidelberg; Klinikum Karlsbad-Langensteinbach

Background: Perceptual closure, the ability to recognize an image based on partial information, and disturbances of self awareness (self-disorders, SDs), are important features of schizophrenia. The link between these two aspects has not been studied yet. We hypothesized that the generation of event-related potentials associated with perceptual closure (ERPs: P100, and Ncl) is impaired in first-episode schizophrenia patients (FEP), and that this deficit is associated with visual aspects of SDs in this group. The present research investigated perceptual closure in FEP, and the relationships between ERPs components and visual aspects of SDs, addressed by the Examination of Anomalous Self-Experience interview (EASE).

Methods: Nineteen FEP and twenty age and gender matched healthy controls were stimulated with images with different levels of fragmentation according to the Ascending Method of Limits (AML). Generators underlying perceptual closure were analyzed using source localization (Brain Electrical Source Analysis software: BESA). ERPs of first-episode schizophrenia patients were compared to those of healthy controls by t-test for independent groups. Relationships between SDs visual factors and ERP components were analyzed through the Spearman’s correlation coefficient.

Results: The amplitudes of P100 and Ncl components were significantly reduced in patients relative to controls (F = 4.22, P < 0.05; F = 10.28, P < 0.05 respectively), and the latency of Ncl component was significantly longer in patients (F = 4.49, P < 0.05). The EASE visual factor “distance to the world” was significantly correlated with the amplitude values of the Ncl component in patients (P < 0.05).

Discussion: The perceptual closure deficit in FEP might be associated with a subtype of derealisation phenomena characterized by visual experiences of being more distant to the world. Further research to confirm these findings is needed.

T224. Differences between patients with schizophrenia and unaffected controls in computationally derived acoustic phonetic parameters and measures of lexical variation and idea density
Luca Pauselli1, Michael Compton2, Anya Lunden3, Sean Cleary4, Yazeed Alolayan5, Brooke Halpern6, Beth Broussard7, Anthony Crisafuro8, Leslie Capulong9, Benson Ku5, Pierfrancesco Balducci6, Francesco Bernardini15, Bill Hollingsworth5, Michael Covington5
1University of Perugia, School of Psychiatry; 2Lenox Hill Hospital; 3College of William and Mary; 4The George Washington University; 5Hofstra North Shore - LI School of Medicine; 6University of Perugia; 7Università Degli Studi Di Perugia; 8University of Georgia

Background: In recent years, computerized analysis of the speech of patients with schizophrenia has shown to be a promising and objective means of evaluating both negative symptoms and language disturbances. In this study, funded by the U.S. National Institute of Mental Health (NIMH), we examined differences between patients and controls in a number of computationally derived linguistic parameters. Methods: We collected diverse audiorecordings of spoken language (i.e., first, describing a line drawing; second, talking about a “perfect, most ideal day”; third, speaking about “the scariest, most frightening experience you’ve ever had”; fourth, reading aloud a neutral text passage; and fifth, reading aloud an emotionally stimulating text passage) from 98 patients and 102 controls, drawn from diverse sites in Washington, D.C. and New York City. We also measured IQ and neurocognition, and among patients, we collected extensive clinical phenotypic data with regard to negative symptoms and disorganization.
Results: Analyses pertaining to phonetic parameters (e.g., pitch variability, mouth opening variability, tongue movement variability, and "fraction voiced" or the amount of speaking (as opposed to pauses) during the recordings) revealed differences between patients and controls in specific measures. Furthermore, measures of lexical variation (moving average type-token ratio) and idea density also uncovered significant differences between the two groups. Discussion: Patients with schizophrenia differ from unaffected controls in a number of computationally derived linguistic parameters that relate to both negative symptoms and disorganization. Research such as this could represent a step toward developing new methods for measuring and tracking negative symptom severity and disorganization using computationally derived linguistic indices.

T225. Unawareness and misattribution of symptoms in schizophrenia: relationship with symptom clusters and socio-demographic variables

Ada Ruiz*, Esther Pousa, Carles Garcia-Ribera, Carmina Massons, Susana Ochoa, Judith Usall, Jesús Cobo
1Hospital del Mar; 2Corporació Sanitària Parc Taulí; 3Hospital de S. Pau, Barcelona; 4Parc Sanitari San Joan de Déu – CIBERSAM. St Boi de Llobregat

Background: Previous studies suggest that poor insight in psychosis is not related or only modestly related to the severity of symptoms, leading to the conclusion that insight could be an independent phenomenon. The feature of schizophrenia or may have a non-linear relationship with symptoms severity. So far, little is known about insight into particular psychiatric symptoms, whereas symptoms are different in nature and might be influenced by different socio-cultural, neurobiological or psychological factors. The aim of this study is to describe and deeply explore the relationship between insight and psychopathology -considering the classical multiple dimensions of insight as well as unawareness and misattribution into particular symptoms - in a sample of schizophrenic patients.

Methods: A multicenter cross-sectional naturalistic study of 248 schizophrenic patients (180 men and 68 women) from different clinical settings was undertaken. Severity of psychopathology was assessed using Positive and Negative Syndrome Scale (PANSS) and Lindenmayer’s Factors -Positive, Negative, Cognitive, Depressive and Excitement- were obtained. The deficit of insight and its three dimensions -awareness of illness, effects of medication, of social consequences- and the awareness and attribution of each different symptom were evaluated by the Scale of Unawareness of Mental Disorders (SUMD). Functionality was measured by GAF Scale. Pre-morbid IQ was estimated by verbal subscale of WAIS. Stepwise regression models were performed including all the socio-demographic and clinical variables that were significant at the bivariate analysis.

Results: Conversion of the SUMD score of symptoms into dichotomic categories (aware or partial aware / unaware) shows that a high number of patients express some awareness of symptoms like hallucinations (62%), poor control of aggressive impulsions (62%), apathy (76%), anhedonia (62%), attention problems (76%), and poor social relationships (70%); but few patients are total or partial aware of apathy (76%), anhedonia (62%), attention problems (76%), and poor control of aggressive impulses (62%)

Discussion: Insight in schizophrenia is a multi-phased phenomenon that is more than "just psychopathology" and that the awareness of particular symptoms is the dimension most highly influenced by clinical severity. Symptoms have different degrees of opacity to awareness. The positive and cognitive psychopathological factors are the most strongly linked to the phenomenology of insight, supporting the neuropsychological view of insight. The consistently reported relationship between insight and negative symptoms does in fact refer to cognitive aspects of negative symptoms rather than to affective ones such as emotional withdrawal or blunted affect.

Our results support findings reporting a lack of relationship between insight and depressive symptoms.

T226. Stress in those at risk for psychotic disorder: a possible role for momentary stress in the exacerbation of affective and psychotic symptoms

1Maastricht University; KU Leuven; 2University of Bonn; 3KU Leuven, Centre for Contextual Psychiatry; 4Maastricht University; 5GGZ / Maastricht University; 6University of Aachen; 7Heinrich-Heine University Düsseldorf; 8University of Cologne

Background: Increased sensitivity to daily life stressors has been found in patients with psychotic disorder, as well as in individuals at (clinical high) risk for psychosis. Furthermore, recent studies with individuals at clinical high-risk for psychosis (CHR) have reported impaired tolerance and increased functional impairment in response to normal stress compared to healthy controls and higher self-reported psychosocial stress levels compared to first-episode psychosis patients, suggesting impaired stress tolerance is characteristic of CHR state. Aim of this study was to further examine the association between momentary stress and both affective and psychotic symptoms in everyday life of CHR patients, compared to chronic psychotic patients and healthy controls, in search for evidence of early stress-sensitization.

Methods: The experience sampling method (ESM) was used to measure affective and psychotic reactivity to everyday stressful activities, events and social situations in 22 CHR patients, 24 chronic psychotic patients and 26 healthy controls. The data was analyzed in STATA with multivariate multilevel models, an extension of standard hierarchical linear models when analyzing multiple (correlated) outcomes. Models were fitted separately in the three groups (i.e., psychotic patients, CHR patients, and controls). To test whether the degree of association (i.e., correlation) between two outcomes differed between the groups at the peak level, the estimated correlations with their corresponding standard errors were extracted and entered in Wald-type tests.

Results: Levels of negative affect (NA) and momentary psychotic symptoms were similar in both patient groups. Additionally, group comparisons showed the association strength between NA and activity-related stress to be larger for CHR patients than for psychotic patients (0.1558 vs. 0.2764, Z = -2.67, P = 0.008), and larger for CHR compared to controls (0.2764 vs. 0.1128, Z = 3.68, P = 0.0002). Similarly, the association strength between activity-related stress and psychotic symptoms was larger in CHR than in patients (0.1357 vs. 0.2404, Z = -2.29, P = 0.02).

Discussion: The results suggest that those at CHR for psychosis are more sensitive to daily life stressors, in particular activity-related stress, than psychotic patients. Emotional and psychotic stress sensitization seems to occur prior to the development of a full-blown psychotic state and to play a role particularly in the early phase of the illness. These findings underscore the need for early intervention in CHR patients to help them to learn how to better cope with stressors and in turn lower both emotional and psychotic reactivity to these stressors.
T227. Reliability and validity of the Korean version of the motivation and pleasure scale self-report (MAP-SR), a self-report measure of negative symptoms

Ji Sun Kim1, Seon-Kyeong Jang2, Seon-Heoli Park3, Joong-Kyu Park4, Jung Suk Lee5, Kee-Hong Choi3, Jung-Sea Yi6, Seung-Hwan Lee8
1Clinical Emotion Cognition Laboratory; 2Clinical Emotion and Cognition Research Laboratory; 3Yong-In Mental Hospital; 4Daegu University; 5National Health Insurance Service Ilsan Hospital; 6Korea University; 7Hallym University College of Medicine, Kangnam Sacred Heart Hospital; 8Inje University Ilsan Paik Hospital

Background: The Clinical Assessment Interview for Negative Symptoms (CAINS) is an empirically developed interview measure of negative symptoms in psychotic disorders. The Motivation and Pleasure Scale—Self-Report (MAP-SR) is a self-report measure that assesses the motivation and pleasure domain of negative symptoms based on the CAINS. This study examined the reliability and validity of a Korean version of the MAP-SR.

Methods: One hundred thirty nine patients with schizophrenia completed the 18-item MAP-SR, the CAINS, the Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Calgary Depression Scale for Schizophrenia (CDSS) and other measures of trait and cognitive function.

Results: Excluding poorly performed three items, the revised 15-item MAP-SR demonstrated good internal consistency and convergent validity with the clinician-rated Motivation and Pleasure scale of the CAINS as well as anhedonia/avolition subscale of the SANS. The scale also showed good discriminant validity, with little association with psychotic symptoms, agitation/mania and depression/anxiety. MAP-SR scores were related to Behavioral Activation System scales for trait measure and verbal fluency for cognitive measure.

Discussion: The Korean version of the MAP-SR is a promising self-report measure for examining severity of negative symptoms in schizophrenia.

T228. Experiences of antipsychotic treatment in clinical recovery from first episode psychosis

Jone Bjornestad1,2, Larry Davidson3,4, Inge Joa3,4, Tor Ketil Larsen4, Wenche ten Velden Hegelstad5, Johannes Langeveld6, Marius Veseth7, Ingrid Melle8, Jan Olav Johannesen9, Kolbjørn Brønnick2
1TIPS – Centre for Clinical Research in Psychosis / University of Stavanger; 2Yale University, School of Medicine and Institution for Social and Policy Studies; 3TIPS – Centre for Clinical Research in Psychosis, Stavanger University Hospital; 4University of Bergen; 5Bergen University College, Faculty of Health and Social Sciences; 6University of Oslo, Norwegian Centre for Mental Disorders Research

Background: Recent studies have raised questions about the benefits, costs, safety and effectiveness of antipsychotic drugs. Further broad exploration of these issues is required, and must include the service user perspective. This explorative study investigates the experiences of 20 service users, all in symptomatic and functional remission, of using antipsychotic medications during and after a first episode of psychosis.

Methods: Thematic analytic approach within an interpretative-phenomenological framework. Analysis followed an established meaning condensation procedure.

Results: Main themes: (1) Use of antipsychotic drugs beyond the acute phase – Considered to compromise the contribution of individual effort in recovery; (2) Non-stigmatizing environments perceived to increase likelihood of successful use; and (3) Prolonged use of antipsychotic drugs perceived to reduce likelihood of functional recovery. Minor themes: (4) Trustful relationships considered more important than antipsychotic drugs; (5) Antipsychotic drugs reduce mental chaos during the acute phase; and (6) Antipsychotic drugs regulate mood swings and prevent further episodes of psychosis in cases of affective psychosis with mood incongruent psychotic symptoms.

Discussion: In this study, participants described acute phase antipsychotic treatment as mostly advantageous, but costs were often seen as outweighing benefits with continued use beyond this stage. Echoing recent longitudinal study findings, this calls into question the position of continued maintenance treatment with antipsychotic drugs as the global, gold standard long-term treatment of psychosis. Findings clearly emphasize the need for a collaborative approach, involving service users in decisions concerning antipsychotic drug use, to be integrated across all phases of care.

T229. Paranoia and facets of self-esteem in early psychosis: associations across psychometric and real-life assessment methods

Manel Monsonet1, Paula Cristóbal-Narváez1, Tamara Sheinbaum1, Tecelli Domínguez-Martínez1, Thomas R. Kwapił2, Neus Barranites-Vidal1
1Clínica i de la Salut, Universitat Autònoma de Barcelona; 2Cátedras-CONACyT, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz; 3University of North Carolina at Greensboro

Background: Paranoia and self-esteem have been widely associated in the literature; however, the precise nature of their association remains unclear. The present study investigated in a sample of at-risk mental state (ARMS) and first episode of psychosis (FEP) patients whether (i) global and specific facets of self-esteem (positive and negative self-beliefs) show differential associations with paranoia, and (ii) whether such distinction holds for momentary (Experience Sampling Methodology; ESM) and psychometric measures of trait self-esteem and paranoia.

Methods: 53 ARMS and 33 FEP patients were administered the Rosenberg Self-Esteem Scale (RSES) and the Positive and Negative Syndromes Scale (PANSS). Participants also received personal digital assistants that signaled them randomly eight times daily for one week to complete questionnaires about their thoughts, feelings, behaviors, and psychotic-like symptoms (momentary or ESM-paranoia and self-esteem measures).

Results: ESM-paranoia was inversely associated with ESM positive self-beliefs and positively associated with ESM negative self-beliefs in both groups. It was not associated with global ESM self-esteem in either of the two groups. ESM-paranoia was also inversely associated with total RSES in FEP patients, whereas a trend was present in ARMS patients. When the RSES facets were considered separately, ESM-paranoia was inversely associated with RSES positive self-beliefs in the ARMS group (the FEP group showed a trend), and positively associated with RSES negative self-beliefs in the FEP group. Finally, paranoia as assessed by the PANSS was inversely associated with total RSES in ARMS, but not FEP, patients. Likewise, PANSS paranoia showed an inverse association with RSES positive self-beliefs and a positive association with RSES negative self-beliefs in the ARMS group.

Discussion: ESM and questionnaire assessments of self-esteem and its facets showed distinct patterns of associations with momentary paranoia and clinician ratings of paranoia. It has been proposed that different assessment methods may tap different aspects of the self (e.g., ESM assessments would tap the “experiencing self” while psychometric measures would tap the “believing self”). The findings suggest that taking into account these different aspects of the self, as well as the different facets of self-esteem, is relevant for increasing our understanding of the role of the self in paranoia. Furthermore, delineating how these constructs are associated across the psychosis continuum is relevant for identifying risk factors and targets for intervention efforts.

T230. An embedded, embodied, enactive account to psychosis

Inez Myin-Germeys1
1KU Leuven

Background: Subjective experiences are the core of psychiatry. Patients suffer from feeling depressed, anxious or paranoid, they hear voices or see things that others cannot see. In this paper, I will argue that in order to make real progress in our understanding of psychopathology and more importantly in the development of new treatments, we need to put these experiences back at the core of our research rather...
than moving away from them (for example as is being proposed in the RDQI criteria).

Methods: Within the field of Cognitive Science, an embodied, enacted approach to cognition and experience has been developed, which states that experiences can only be understood through studying how they arise out of interaction with the environment. I will apply this approach to the study of psychotic symptoms by using the Experience Sampling Method (ESM). ESM is a structured diary technique that allows assessing experiences as well as context in the realm of daily life. It is therefore ideally suited to examine psychopathological experiences from a person-environment interaction perspective.

Results: In this paper, I will discuss how interactional changes over time may be associated with moment-to-moment variation in psycho-pathology. For example, affective/subjective factors such as an increase in anxiety or the experience of subjective stress have been associated with increased levels of psychotic symptoms. Similarly, situational factors, such as social context (being with unfamiliar compared to being with familiar people) and lack of sleep have been associated with increased levels of paranoia. Secondly, I will provide two examples of newly developed real-life interventions that specifically focus on altering person-environment interactions, possibly fundamentally improving our clinical practice.

Discussion: The embedded, embodied, enacted approach may aid in improving our understanding of psychopathology. It provides a conceptual framework for a better understanding of existing data as well as for formulating new and possibly more accurate hypotheses. The picture that is emerging is that of psychopathology as a specific pattern of thoroughly context-sensitive interaction, related to but differing from non-pathological interaction. Following this approach may not only prove theoretically fruitful but might also have considerable applicable clinical benefits.

T231. The differences between individuals with persistent and non-persistent psychotic-like experiences: a follow-up study in the general population of Hong Kong

Kit Wai Lee*, Kit Wa Chan1, Wing Chung Chang1, Edwin Ho Ming Lee2, Christy Lai Ming Hui1, Jingxia Lin1, Eric Yu Hai Chen1
1The University of Hong Kong

Background: Psychotic-like experiences (PLEs) are poorly-understood phenomena referring to subclinical psychotic experiences that are reported by individuals without psychotic disorder. Most PLEs are transient, while persistent PLEs might increase the risk of developing psychosis. Examining the trajectory of PLEs and studying the differences between individuals with and without persistent PLEs could provide important insights on the development of psychosis as well as for the recognition of PLEs. Thus the current study aims to: 1. explore the trajectory of PLEs over two years in the general population of Hong Kong; and 2. examine the difference of subjects with or without persistent PLEs in terms of demographics, mental health and neurological functioning.

Methods: Current on-going study is a 2-year follow-up on the participants who reported PLEs in the Hong Kong Mental Morbidity Survey 2010 (HKMMS) - an epidemiological study carried out between 2010 and 2013 which targeted at general population aged 16-75 years old. The inclusion criteria were: 1. Participated in the HKMMS; 2. Endorsed one or more items in Psychotic Screening Questionnaire (PSQ); 3. No known psychotic disorder. 174 out of 5719 subjects of the HKMMS were eligible to take part in the current study. PLEs were assessed by PSQ, where subjects endorsing one or more items at both baseline (HKMMS) and follow-up (current study) were considered as having persistent PLEs. Depression and anxiety symptoms (Hospital Anxiety and Depression Scale), social and occupational functioning (Social and Occupational Functioning Assessment Scale) as well as perceived social support of the subjects were also measured (Multidimensional Scale of Perceived Social Support).

Results: In the first 100 subjects, 63 (63%) were female, aged from 18-72 years (mean = 45.27, SD = 14.88). Mean years of education was 13.09 (SD = 5.05). 49/100 (49%) subjects had persistent PLEs at follow-up (endorsed ≥ 1 PSQ items at baseline and follow-up). It was found that subjects with persistent PLEs (PP) at follow-up endorsed significantly more PSQ items at baseline than the non-persistent subjects (NP) (U = 950.50, P = 0.05).

Baseline demographics were compared between PP and NP subjects. PP subjects were significantly older (t = 0.98, P < 0.05) than NP subjects. No significant difference were found in years of education (t = 2.57, P = 0.25), gender (χ² = 1.16, P = 0.28) and immigrant status (χ² = 1.69, P = 0.28).

Mental health related factors were also compared between PP and NP subjects. At follow-up, there were significant differences between the two groups in social and occupational functioning (t = 1.14, P < 0.01; PP < NP), depression symptoms (t = 4.37, P < 0.05, PP > NP) and anxiety symptoms (t = 4.37, P < 0.05, PP > NP) scores. There were no significant difference found in these factors at baseline. No significant difference of social support was found between the two groups at both time points.

For neurocognitive tests, PP subjects performed significantly worse in digit-symbol coding test (U = 757.00, P < 0.01), arithmetic (U = 816.50, P < 0.05) (WAIS-III) and verbal fluency (U = 266.50, P < 0.01) at follow-up.

Discussion: The number of PSQ items endorsed seems to affect the persistence of PLEs over two years’ time. Differences in mood between PP and NP suggest potential link between mood, PLEs and development of psychosis. Also, despite being healthy, PP subjects seems to have some impairment in terms of mental health and neurological functions. Further investigation will be carried out to find out whether specific types of PLEs are more predictive of persistence than others, as well as exploring the potential relationship between persistent PLEs and impairment in mental health and neurological functioning.

T232. The course of acoustic verbal characteristics over time

Jack J.A. Jenner1, L.B. Luteijn2
1Jenner Consult; 2GGZ Midden Holland

Background: Clinicians mainly deal with negative auditory verbal hallucinations (AVH). However, the majority of voice hearers have positive and useful AVH too. Assessment of the latter two is mandatory because of their clinical implications. Useful voices need to be cherished and fearing the loss of positive voices may cause patient drop-out. Because of these implications we studied the course over time of positive and useful AVH.

Methods: During 4 months all consecutive referrals to a psychiatric Out-Patient Department (OPD) were assessed for psychiatric diagnosis (DSM-IV-TR), AVH bij means of the AVHRS and PUVI. AVH (Auditory Verbal Hallucinations Rating scale) is a structured 16-items interview. Inter-rater agreement scores (Cohen’s kappa coefficients) are 0.84 and 0.88 respectively, internal consistency scores (Cronbach’s alpha coefficients) 0.84 and 0.77).

PUVI (Positive and Useful Verbal Hallucinations Inventory) is a 53-item self-report AVH inventory designed to assess socio-demographics and psychopathology (8 items), prevalence, course and characteristics of positive and useful AVH (15 items), and emotional attribution (9 items). Its internal consistency is good (Cronbach’s alpha = 0.925 for positive and 0.889 for useful voices).

Descriptive statistics, Chi-square tests, Mann-Whitney U tests and logistic regression models were used to analyze the data. For all tests, a two-tailed significance level of P < 0.05 was used.

Results: One-hundred and sixty-six subjects (SS) were included, thirteen SS (7.8%) were excluded because of missing data leaving 153 patients for statistical analysis. Mean age was 38.41 years (S. D. = 13.3). Seventy-seven SS (50%) had ever heard voices.

- Content of voices changed over time in 52% of the voice hearers.
- Positive and negative AVH: 10% changed from positive towards negative, 20% from negative to positive, 22% changed in positive as well as negative voices.
- Useful AVH: no change occurred in 67%, voices became not-useful in 12%.
- Not-useful voices became useful in 21%.
- Voice hearing subjects attributed changes in their voices to: social circumstances (15%), voice induced circumstances (8%), and treatment (77%).
Command hallucinations commanded to: (i) commit suicidal behavior (52%), (ii) physically assault others (40%), (iii) stop talking about the voices (37.5%).

AVH had (i) a trauma (35%) or sexual abuse related content (46%), (ii) were punitive (71%), (iii) sounded like the offender’s voice or had (iv) the same gender as the offender (59%).

Discussion: This study shows that voice-characteristics change over time in a substantial number of voice hearers.

Positive voices have been reported in 35 to 75 percent of voice hearers depending on diagnosis and setting of the Ss. Assessment of positive voices is mandatory for two reasons. First, positive voices may be used against negative ones. Second, Quite a few patients fear that therapy may result in disappearance of these voices. It appeared that change in positive content occurred in 50% of the Ss.

Useful voices have been found in over forty percent of voice hearers. They may improve self-care and compliance. Changes were found in 33% of the Ss.

The clinical impact of these changes warrants further study.

T233. Quetiapine ER versus aripiprazole in children and adolescents with psychosis: the randomised, blinded clinical tolerability and efficacy of antipsychotics (TEA) trial.

Anne Katrine Pagsberg1, Piia Jeppesen1, Dea Klaber1, Karsten Gjessing Jensen1, Ditte Ruda1, Marie Stentebjerg-Olesen2, Eva Ann-Sofie Saldeen3, Niels Bilenberg4, Anne Dorte Stenstrøm5, Jesper Pedersen5, Jens Richardt Jepsen6, Birgitte Fagerlund6, Christian Gluud7, Maria Skoog8, Per Winkel8, Christoph U. Correll9, Anders Fink-Jensen10

1Child and Adolescent Mental Health Centre, Mental Health Services Capital Region of Denmark; 2Psychiatric Centre Copenhagen, University Hospital Copenhagen and Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen; 3Child and Adolescent Mental Health Centers, Lund University Hospital; 4Child and Adolescent Psychiatry, Odense University Hospital; 5Child and Adolescent Mental Health Services, Region Zealand, Denmark; 6Center for Neuropsychiatric Schizophrenia Research; 7CINS/CSR, Psychiatric Center Glostrup; 8The Copenhagen Trial Unit, Copenhagen University Hospitals; 9The Zucker Hillside Hospital, New York; 10Psychiatric Centre Copenhagen, University Hospital Copenhagen

Background: The evidence for choices between antipsychotics for children and adolescents with schizophrenia and other psychotic disorders is limited. The main objective of the TEA trial was to compare the benefits and harms of treatment with quetiapine extended release (ER) versus (vs) aripiprazole in children and adolescents with psychosis.

Trial registration: ClinicalTrials.gov: NCT01119014

Methods: The TEA trial is a Danish investigator-initiated, independently funded, multi-centre, blinded, randomised clinical trial (RCT). Patients aged 12–17 years with non-organic psychosis; antipsychotic-naïve or minimally treated were 1:1 randomised to a 12-week, double-blind intervention with quetiapine ER 600 mg/day vs aripiprazole 20 mg/day. Benefits and harms were assessed 2, 4, and 12 weeks after randomisation. The primary outcome was change in the positive symptom score of the Positive and Negative Syndrome Scale (PANSS). Key adverse outcomes were weight change; homeostatic model assessment of insulin resistance; akathisia (Barnes Akathisia Scale); and sedation (UKU (udvalget for kliniske undersøgelsesmetoder) side effects rating scale).

Results: Patients (n = 113), 82% with schizophrenia, 30% males, mean age 15.8 years (SD 1.36) were randomised, n = 55 to quetiapine ER and n = 58 to aripiprazole. There was no significant group difference on mean PANSS positive score after 12 weeks of intervention, but a significant effect of time for the whole group. The comparison on the four key adverse effect outcomes showed that the mean weight increased over time and more so with quetiapine ER than with aripiprazole. Insulin resistance was higher with quetiapine ER than with aripiprazole. Akathisia was more frequent with aripiprazole than with quetiapine ER. Frequency of sedation were similar between groups. There were no group differences on additional efficacy outcomes (PANSS negative, general, depressive or total symptoms; Global Assessment of Psychosocial Disability; Clinical Global Impression-Severity/Improvement; suicidality; or response-rates). Additional adverse outcomes showed more neurologic, autonomic, and total adverse reactions with aripiprazole than with quetiapine ER. More pronounced changes in metabolic variables were observed with quetiapine ER. There were no group differences on the counts of serious adverse reactions, serious adverse events, or adverse events. Discussion: This RCT comparing quetiapine ER versus aripiprazole for early onset psychosis found no differences on the changes of PANSS positive symptoms. Akathisia was more frequent with aripiprazole, while weight increase and insulin resistance were higher with quetiapine ER. Additional analysis showed no group differences on other psychopathology and functional outcomes, but more neurologic, autonomic and total adverse reactions with aripiprazole, while metabolic variables increased more with quetiapine ER.

T234. Adolescent cannabinoid exposure increases the susceptibility for a schizophrenia-like phenotype in a novel rodent model

David Aguilar1, Stephanie Perez2, Andrea Giuffrida1, Daniel Lodge2

1University of Texas Health Science Center San Antonio, 2UTHSCSA

Background: Schizophrenia is a debilitating disorder that affects over one percent of the population. Adolescent cannabis abuse is associated with an increased risk of developing schizophrenia. However, this is not a causal relationship as many adolescents use cannabis in a recreational setting and do not develop psychiatric illnesses. Thus, it is likely that cannabinoids increase the risk of developing schizophrenia only in individuals with an underlying predisposition. To explore this phenomenon, we have developed a model of “susceptibility” to schizophrenia-like symptoms. Specifically, the second filial (F2) generation of a developmental rodent model of schizophrenia (i.e. gestational methylazoxymethanol acetate (MAM) administration) show increased susceptibility to a schizophrenia-like phenotype. Based on the relationship between cannabinoids and schizophrenia, we hypothesized that cannabinoid exposure during adolescence would increase the proportion of “susceptible” F2 generation MAM rats displaying a schizophrenia-like phenotype while having no observable effects in control animals.

Methods: F2 MAM and F2 SAL rats were exposed in adolescence (postnatal days 35-45) to either a vehicle control or the synthetic cannabinoid WIN55,212-2 (0.2 mg/kg, i.p., 5 injections). In adulthood (postnatal days 70+) rats were tested at the behavioral (stimulant-induced hyperlocomotion), electrophysiological (extracellular dopamine recordings in the ventral tegmental area of anesthetized rats), and molecular (parvalbumin expression in the ventral hippocampus) levels.

Results: Our data shows that exposure to 0.2 mg/kg WIN55,212-2 during adolescence increases the proportion of “susceptible” F2 MAM displaying a schizophrenia-like phenotype without producing noticeable deficits in control rats. Specifically, F2 MAM rats treated with 0.2 mg/kg WIN55,212-2 in adolescence (F2 MAM x WIN) show an increase in spontaneously active dopamine cells per vertical electrode track through the ventral tegmental area. Cells per track are as follows: F2 SAL x Veh had 1.134 ± 0.008 cells per track, F2 SAL x WIN had 1.084 ± 0.09 cells per track, F2 MAM x Veh had 1.319 ± 0.14 cells per track, F2 MAM x WIN had 1.642 ± 0.12 cells per track. A locomotor test revealed F2 MAM rats exposed to WIN during adolescence are more sensitive to a low dose of amphetamine (0.5 mg/kg, i.p.) than their F2 MAM x VEH and F2 SAL counterparts. Additionally, adolescent WIN treatment caused a decrease in ventral hippocampal parvalbumin expression which we have previously demonstrated to contribute to the aberrant dopamine system function observed in rodent models. Discussion: Here we report on a novel model of schizophrenia susceptibility and demonstrate that this model is indeed sensitive to cannabinoid exposure during adolescence. Moreover, analysis of this affect may be the inhibitory parvalbumin containing interneurons in the ventral hippocampus. The F2 MAM rat may therefore be a useful model for exploring gene/environmental interactions as they pertain to schizophrenia.
Background: Schizophrenia is a mental and chronic disease with a worldwide prevalence of approximately 1%. About 20-50% of patients with schizophrenia will not respond to the antipsychotic medication. Therefore, the use of multiple antipsychotics is a common practice in schizophrenia when a single drug doesn’t relieve symptoms satisfactorily. Consequently, drug-drug interactions become inevitable. Thus, the aim of this study was to observe potential drug-drug interactions medications prescribed to Mexican schizophrenia patients.

Methods: We performed a retrospective and transversal study carried out in a clinic of the psychiatry. Only prescription of patients with schizophrenia with diagnoses based in DSM-IV was included in this study. The Drug Interactions Checker software was used in this study to analyze the potential drug-drug interactions. We also classified the potential drug-drug interactions by severity level and finally we analyzed the potential drug-drug interaction effect.

Results: Eighty six of one hundred twenty six patients were at risk of potential drug-drug interactions. Haloperidol and Biperiden was the most common drug pair of two hundred thirty two pairs observed. 13.8% of all the drug-drug interaction showed major level of severity, whereas an 83.2% was moderate. Finally, the Central nervous System depression is one of potential drug-drug interactions medications prescribed to Mexican schizophrenia patients.

Discussion: In the article, we detected a high number of patients with schizophrenia to be received two or more drugs. The potential drug-drug interactions observed in Mexican population are consistent with the prescription the concomitant use of antipsychotics, benzodiazepines and antidepressants in schizophrenia that could give a central nervous systems depression and anticholinergic effect. The drug-drug interaction could be considered when the patient with schizophrenia is prescribed.
with antipsychotic treatment response as measured with PANSS in a sample of SZ treated with olanzapine in monotherapy (N = 47) as well as in a placebo-controlled cross-over double-blind study in SZ on atypical antipsychotics (N = 40).

Results: Gene set encompassed 85 genes and included 6 genes associated with schizophrenia in the Psychiatric Genetic Consortium study (hypogeometric test, P = 0.0073). We found 8 SNPs associated with gene set co-expression (FDR < 0.25). The PGS correlated with DRD2 gene set expression in both microarray samples (discovery, R2 = 0.38, P = 3.6 x 10^-22; replication, R2 = 0.053, P = 0.05). Predicted greater DRD2 gene set co-expression was associated with greater prefrontal activity. In the discovery imaging sample on healthy subjects we detected bilateral clusters in the superior and middle frontal gyri encompassing prefrontal cortex (BA 9/10/46) serving topological FDR corrected P < 0.05. In the replication sample, we found correlation between the PGS and signal change values extracted from the same clusters (corrected P = 0.029). In patients, clusters localization largely overlaps with that found in the discovery sample. Moreover, PGS was associated with a WM efficiency index (accuracy/reaction time). ANCOVA with LOAD (1-back, 2-back) as the within factor and efficiency index as the dependent variable showed a PGS x LOAD interaction (P = 0.037). Post-hoc regression yielded a significant fit for 2-back (R2 = 0.035, P = 0.23). Finally, PGS was associated with clinical improvement in terms of PANSS total score improvement in both datasets (p = 0.39, P = 0.007; p = 0.27, P = 0.047).

Discussion: Predicted greater DRD2 co-expression was associated with greater prefrontal activity, lower WM efficiency index and greater treatment response. We successfully replicated our findings in independent datasets. This study provides evidence that gene network of DRD2 modulates schizophrenia related phenotypes at the levels of brain circuits, behavior and clinical outcome. The molecular pathway co-regulated with DRD2 suggests novel potential entry points to target treatment of systems-level phenotypes and symptoms associated with schizophrenia risk.

T238. The effect of antipsychotic type and dose changes on dyskinesia and Parkinsonism in patients with a serious mental illness (SMI)

Charlotte Mentzel1, P. Roberto Bakker2, Glen Matroos3, Hans Hoek4, Marjan Driukker5, Marina Tijssen6, Peter Van Hatten7
1GGZ Centraal, Innova; 2Maastricht University/Psychiatric Centre GGz Centraal; 3GGZ Curacao; 4Parnassia Psychiatric Institute; 5Maastricht University Medical Centre; 6Universitair Medisch Centrum Groningen; 7GGz Centraal/Maastricht University

Background: Despite the introduction of Second Generation Antipsychotics (SGAs) medication induced movement disorders are still highly prevalent. The two most common are parkinsonism and tardive dyskinesia. Current treatment recommendations for these disorders include lowering antipsychotic dose and switching to an SGA. However the efficacy of these treatments has not yet been studied in patients with severe mental illness (SMI).

Methods: An 18 year prospective study including all 223 SMI patients receiving care from the only mental-health service of the previously Dutch Antilles. Eight clinical assessments focused on movement disorders and medication use. Parkinsonism was scored on the Unified Parkinson’s Disease Rating Scale (UPDRS) and dyskinesia on the Abnormal Involuntary Movements Scale (AIMS). Antipsychotics were classified into both FGA/SGA and high/low D2 affinity categories, the effect of switching within each category on subsequent movement scores was calculated separately by using time-lag multilevel logistic regression models (hereafter: the FGA/SGA-switch model and D2-affinity switch model).

Results: At baseline, the mean age was 50 years, 72% was male, and 80% had schizophrenia as a primary diagnosis. Average antipsychotic defined daily dose (DDD) was 2.09 (1.81 - 2.32), which increased with each progressive time point. The mean prevalence of tardive dyskinesia and parkinsonism was 54 and 35%, respectively, with an average severity, for cases, of 9 points on the AIMS and 19 points on the UPDRS. Both disorders displayed a relapsing remitting course. The (time-lag multilevel) regression models yielded significant coefficients, between a reduction in dyskinesia severity and starting switching to an FGA (B = -3.54, P < 0.001), as well as starting/switching to a high D2 affinity antipsychotic (B = -2.48, P < 0.01); only in the FGA/SGA model adding an SGA to existing FGA treatment had a significant relationship with dyskinesia severity reduction (B = -2.43, P < 0.01). In the parkinsonism analyses stopping antipsychotics (B = -7.76, P < 0.01, FGA/SGA-switch model; B = -7.3, P = 0.01, D2-affinity switch model).

Discussion: The results show that switching from an FGA to an SGA does not necessarily result in a reduction of dyskinesia or parkinsonism. Our study indicates that only stopping all antipsychotics reduces (the severity of) parkinsonism, and starting an FGA or a high D2-affinity antipsychotic may reduce (the severity of) dyskinesia in the next 1 -2 years.

T239. Treatment with antipsychotics in late-life schizophrenia

Rob Kok1, Shenena Sheikhiaremi1, Nicolien Kist1, Julia Van Den Berg1
1Parnassia Psychiatric Institute

Background: Very few studies are published on the treatment of schizophrenia in older patients. The only randomised controlled trials in older patients that have been published are in early-onset schizophrenia patients (EOS). RCTs in Late Onset Schizophrenia (LOS, first symptoms after 40 years) and Very Late Onset Schizophrenia-like Psychosis (VLOS, first symptoms after 60 years) are lacking. However, case series suggest that patients with LOS and VLOS may be effectively treated with lower doses of antipsychotics than EOS with the same age.

Methods: All patients with schizophrenia, admitted to an inpatient ward for older patients (55 years and older) with psychotic disorders between March 2011 and August 2013, were asked to participate in this study. The class (typical, atypical, clozapine) and dose (haloperidol equivalents) of antipsychotic agent were the primary outcome variables.

Results: We included 44 patients; 14 with EOS (8 male and 6 female, aged 65.6 ± 7.6 years), 17 with LOS (3 male, 14 female, aged 66.4 ± 7.3 years) and 13 with VLOS (5 male, 8 female; aged 74.8 ± 12.5 years). There was no significant difference in antipsychotic class, but no VLOS patient received clozapine, in contrast to the EOS and LOS groups. The VLOS group received a lower dose of haloperidol equivalents compared to the EOS group, but this difference was not statistically significant (2.9 ± 2.4 mg versus 5.0 ± 3.1 mg; P = 0.061). There was no difference in dose between LOS and EOS patients (5.1 ± 3.9 mg versus 5.0 ± 3.1 mg; P = 0.972).

Discussion: VLOS patients were treated with a lower dose of haloperidol equivalents compared to EOS patients, but the difference of 2 mg/day was not statistically significant. This may be due to a lack of power. However, suboptimal treatment may also explain the differences in dose and in the lack of prescribing clozapine. Studies in LOS/VLOS patients that assess both efficacy (decrease in PANSS score) and side effects are necessary.

T240. Clinical and functional response to paliperidone palmitate in early schizophrenia – a retrospective observational study in newly diagnosed patients treated over a 12-month period

Ludger Hargarter1, Paul Bergmans2, Pierre Cherubin3, Andreas Schreiner1
1Janssen Cilag GmbH; 2Janssen Cilag Netherlands; 3Janssen Cilag France

Background: Data on clinical outcomes with long-acting antipsychotic treatment in young, newly diagnosed patients with schizophrenia is sparse.

Objectives: To explore hospitalization, drug utilization and clinical outcomes from medical records of newly diagnosed schizophrenia patients during the first 12 months of treatment with once-monthly paliperidone palmitate (PP).

Methods: International, multicenter, retrospective, observational study. Outcomes presented here: baseline (BL) characteristics and
demographics, clinically relevant improvements in disease severity (ie \( \geq 20\% \) decrease in PANSS or BPRS total score or CGI-S Change \( \geq -2 \) or CGI-C \( \geq 3 \), with no score showing worsening) and clinically relevant functional improvement (ie change in PSP total score \( \geq 7 \) points or change in GAF total score \( \geq +20 \) points, with no score showing worsening) from BL to last-observation-carried-forward endpoint (LOCF-EP) within 12-month documentation period, mean mode PP dose and adverse drug reactions.

Results: 84 patients analyzed: 69% male, mean age at initiation of PP was 24.1(SD2.7) years, Mean BL weight was 78.7(SD16.0)kg and 80.0 (SD14.7)kg at LOCF-EP, with a mean change of 1.2(SD3.3)kg; mean time from first psychotic episode to initiation of PP was 5.5 (SD3.3) months. At LOCF-EP 86.6% achieved a clinically relevant functional improvement (52/84, Kaplan-Meier median time from initiation of PP: 52.4 days), 63.4% achieved a clinically relevant improvement (52/84, Kaplan-Meier median time from initiation of PP: 53.1 days). PP mean mode maintenance dose was 96.4(SD19.8) mg. ADRs reported in \( \geq 5\% \) of patients were weight increase 9.1% and hyperprolactinemia 5.7%.

Discussion: Treatment with once-monthly PP was well tolerated and associated with clinically relevant improvements in disease severity and functioning in young, newly diagnosed schizophrenia patients.

T241. Effectiveness of antipsychotics used in first episode psychosis: a naturalistic cohort study
Andrew Thompson\(^1\), Michael Harris\(^2\), Gail Kavanagh\(^2\), Steven Marwaha\(^1\), Vijitha Wickramasinghe\(^3\), Ketan Jethwa\(^3\), Nirmalan Ayudara\(^3\), Richard Whale\(^2\)
1University of Warwick; 2Sussex Partnership NHS Foundation Trust; 3Coventry and Warwickshire NHS Partnership Trust

Background: Continuous antipsychotic treatment for at least one year from symptom remission is an arguable gold standard following a first episode of psychosis. Whilst a range of antipsychotics used in routine practice have demonstrated similar clinical efficacy in first episode, understanding which are most likely to be continued may better inform prescribing practice and offer comparative effectiveness evidence incorporating efficacy, tolerability and other complex qualitative factors.

Methods: A retrospective, cohort study examined the naturalistic 1-year treatment of all patients accepted by early intervention in psychosis services across 7 sites in Sussex, Coventry and Warwickshire, UK, between February 2009 and February 2012. Electronic case notes and clinical files of patients were examined from the point of treatment initiation to any cause discontinuation or for a period of one year (which ever occurred sooner). Kaplan-Meier survival analysis and a Cox-proportional hazards regression model were used to determine and compare the median survival time and rate of discontinuation at one year for the different treatment groups.

Results: Out of 460 patients prescribed treatment, 61 were prescribed Aripiprazole, 185 prescribed Olanzapine, 116 prescribed Quetiapine and 88 prescribed Risperidone. The greatest risk of treatment discontinuation was in the first 3 months of treatment for all medications. Risperidone had the longest median time to discontinuation at 165.0 days (95% CI 97.1-232.9) followed by Quetiapine with 135.0 days (95% CI 77.6-192.4), Aripiprazole with 118.0 days (95% CI 63.0-173.0), and Olanzipane with 109.0 (95% CI 85.4-132.6) days. Highest rates of discontinuation by one year were seen with Olanzipane (140/179, 78.2%) and Aripiprazole (43/56, 76.8%), followed by Quetiapine (74/107, 69.2%) and Risperidone (53/80, 66.3%), after excluding missing variables. There was only a significant difference between Risperidone and Olanzipane on log rank pairwise comparison of survival distribution between medications (\( \chi^2 = 4.34; P = 0.037 \)).

Discorssion: This inclusive study suggests that of all antipsychotics currently used clinically in the UK at this time, risperidone has greater effectiveness than olanzapine as measured by median survival time to all cause discontinuation, in the treatment of first episode psychosis. Our findings may influence clinicians’ first prescribing decisions. Reasons for discontinuation are complex but appear most frequently not clearly associated with medication properties, highlighting the importance of collaborative decision making with the patient and adherence orientated interventions.

T242. A systematic review and meta-analysis of treatments for clozapine-induced obesity and metabolic syndrome: evidence from randomised-controlled trials
Jorge Zimbron\(^1\), Golam Khandaker\(^1\), Chiara Toschi\(^2\), Peter Jones\(^3\), Emilio Fernandez-Egea\(^1\)
1University of Cambridge; 2University College London

Abstracts

Background: Average life expectancy in people with schizophrenia is about 20 years shorter than the general population – this difference is largely attributed to increased mortality from chronic physical conditions such as heart disease and diabetes mellitus (Saha et al., 2007). Cardiometabolic complications such as weight gain, obesity, metabolic syndrome and diabetes mellitus are well recognized side effects of antipsychotics particularly the atypicals which are widely used today (De Hert et al., 2011).

Clozapine is generally regarded as the most efficacious antipsychotic drug (Leucht et al., 2013), but has been associated with the highest risk for developing obesity and metabolic complications compared with other atypical antipsychotics (Allison et al., 1999; Boden et al., 2013; Gianfrancesco et al., 2002). It is estimated that the prevalence of metabolic syndrome in long-term clozapine users ranges from 28 to 45% (Bai et al., 2011; Boden et al., 2013). Clozapine is the gold standard for managing treatment-resistant schizophrenia, which comprises approximately 25% of all patients with this condition (Brenner et al., 1990). Clozapine is the only antipsychotic approved by the US Food and Drug Administration (FDA) for treatment-resistant schizophrenia (Novartis, 2002). Similarly, the UK national institute for health and care excellence (NICE) recommends clozapine as the treatment of choice for patients who do not respond to two antipsychotics (NICE, 2014). Clinicians, therefore, are faced with a difficult choice between efficacy and long-term cardiometabolic complications when choosing clozapine. We present a systematic review and meta-analysis of pharmacological and non-pharmacological treatments for clozapine-induced obesity and metabolic syndrome.

Methods: Two researchers independently searched PubMed and Embase for randomised controlled trials (RCTs) of treatments for clozapine-induced obesity or metabolic syndrome. All other types of studies were excluded. We only included RCTs where more than 50% of participants were taking clozapine.

Results: We identified 13 RCTs. Effective pharmacological treatments for clozapine-induced obesity and metabolic syndrome include metformin, aripiprazole, and Orlistat (in men only). Meta-analysis of three studies showed a robust effect of metformin in reducing body mass index and waist circumference but no effects on blood glucose, triglyceride levels, or HDL levels. In addition, there is limited evidence for combined calorie restriction and exercise as a non-pharmacological alternative for the treatment of clozapine-induced obesity, but only in an in-patient setting. Rosiglitazone, topiramate, sibutramine, phenylpropanolamine, modafinil, and atomoxetine have not shown to be beneficial, despite reports of efficacy in other populations.

Discussion: Randomised-controlled trial data supports the use of metformin, aripiprazole, and Orlistat (in men only) for treating clozapine-induced obesity. Calorie restriction in combination with an exercise programme may be effective as a non-pharmacological alternative. Findings from trials in different populations should not be extrapolated to people being treated with clozapine. Further trials focusing on clozapine-induced obesity and metabolic syndrome are needed.

Tamara Modebadze¹, Claire Gillougeley¹, Guiseppe Alvaro³, Charles Large², Fiona LeBeau¹, Mark Cunningham¹
¹Newcastle University; ²Autifony Therapeutics Limited

**Background:** Cortical networks produce synchronized fast network oscillations in the beta (20-30 Hz) and gamma (30-80 Hz) frequency band that are critical for a range of different cognitive functions. Numerous studies have shown that this neuronal network activity is orchestrated by GABAergic inhibitory mechanisms. Within this context, perisomatic targeting fast-spiking parvalbumin-containing (PV+) interneurons are capable of sustaining action potential output in the gamma frequency range. PV+ interneurons entrain the population of cortical pyramidal neurons via gamma frequency inhibition. Previous studies in patients suffering from schizophrenia (1) and putative animals models (2) of the condition demonstrate an inability of cortical networks to generate coherent gamma frequency oscillations. The Kv3-family of potassium channels, including Kv3.1, are selectively expressed in PV+ interneurons in the cortex. Kv3 channels allow fast-spiking PV+ interneurons to fire accurately at high frequencies to orchestrate the activity of cortical networks. Such high rates of firing, with high temporal accuracy, are required for the generation of gamma rhythms. Post-mortem studies using cortical tissue obtained from patients with schizophrenia report reductions in PV+ and in the expression of Kv3.1 channels in the remaining PV+ interneurons.

Methods: In vitro slice experiments from drug naïve rats slices were obtained from male Lister Hooded rats (2 months old), whereas for chronic PCP slices 60 female Lister Hooded rats were used for these experiments. Rats were housed in groups of 3 under standard laboratory conditions under a 12hr light: dark cycle, lights on at 0700hr. Behavioural testing and slice preparation were carried out in the light phase.

**Results:** Targeting Kv3 channels, and enhancing the activity of PV+ interneurons, has potential as a pharmacological treatment for schizophrenia. We have, therefore, examined the effect of a novel Kv3 modulator (AUT00206) in an established pre-clinical model of schizophrenia. We first used sub-chronic treatment of rats with phencyclidine (PCP) (2 mg/kg, i.p. twice daily for 7 days) to confirm that a significant deficit in the novel object recognition (NOR) task (n = 24 animals; P < 0.05) could be achieved. Prefrontal cortex slices containing the prefrontal (PrL) and infralimbic (IL) subregions were then prepared from PCP and vehicle treated rats that had undergone behavioural testing. Fast network oscillations were elicited by the application of carbachol (10 μM) and kainate (200 nM) in slices from PCP and vehicle treated animals. The amplitude of fast network oscillations in recordings in PCP treated PrL (n = 7) and IL (n = 6) slices were significantly increased following the application of AUT00206 (10 μM; PrL: 1.73 ± 0.72 μV2 v. 2.49 ± 1.03 μV2; IL: 0.55 ± 0.2 μV2 v. 0.74 ± 0.34 μV2). In comparison in slices taken from saline treated animals which showed no cognitive deficit (n = 22 animals; P > 0.05), in the NOR behavioural task application of AUT00206 (10 μM) had no effect on the fast network oscillation power in either the PrL (1.51 ± 0.30 μV2 v. 1.32 ± 0.5 μV2; P > 0.05, n = 6) or IL (0.25 ± 0.1 μV2 v. 0.21 ± 0.1 μV2; P > 0.05, n = 3) subregions.

**Discussion:** In summary these results demonstrate that AUT00206 significantly increases the power of fast network oscillations in the PrL and IL subregions of the rat medial prefrontal cortex only in slices obtained from sub-chronic PCP treated rats which have also shown a robust cognitive deficit in the NOR behavioural task. Our results suggest that, modulation of Kv3 channels by this novel modulator, may have the potential to correct disruptions in neuronal synchronization in schizophrenic patients by augmenting gamma frequency oscillations.
The use of clozapine is limited due to the occurrence of the rare but life threatening adverse event of agranulocytosis, an event which occurs in approximately 0.8% of clozapine users. In all cases this is preceded by a drop in neutrophil count, which triggers cessation of clozapine treatment. Further, neutropenia can occur during clozapine treatment, which can also necessitate the discontinuation of clozapine.

We currently do not know how clozapine causes these adverse reactions, but the risk appears to be greatest within the first 18 weeks of treatment. Not all risk factors are the same for agranulocytosis and neutropenia; this implies that there may be distinct mechanisms for the two.

The sociodemographic characteristics associated with CIA and neutropenia, along with their incidence is reasonably well established. However, there is little epidemiological research into clinical factors which may impact on this risk. The use of concurrent medication and the risk for the development of CIA and neutropenia has not been examined in a large cohort of patients.

Methods: The principal objective of this research is to examine and identify clinical risk factors associated with the onset of clozapine induced agranulocytosis (CIA) and neutropenia (CIA). A retrospective review of electronic health records was undertaken. The utilised the Case Register Interactive Search (CRIS) system, which has been developed to allow for the search and retrieval of anonymised electronic clinical records of patient data within SLaM.

All patients who discontinued Clozapine due to a neutropenic event were included for analysis. Patients with a reference to word “red” or “neutropenia” not in a context of a neutropenic event were excluded. A control sample was constructed from all patients with a documented Clozapine exposure at the time of the Clozapine neutropenic event of the case patient.

Results: 101 cases and 101 controls were included in this study. 44% (n=44) developed neutropenia within the first 6 months of clozapine treatment, 16% during 6-12 months of treatment, and 40% after one year of treatment.

We found significant associations between Clozapine associated neutropenia and the concurrent use of Sodium valproate when adjusted for age and ethnicity (Odds ratio (OR) 1.98, 95%CI: 1.02-3.86; P = 0.043). A dose dependent relationship between Clozapine neutropenia and the concurrent use of Sodium valproate when month of clozapine use (T = -1.642, P = 0.001). A higher risk of Clozapine associated neutropenia was seen in younger patients (OR 4.0, CI 0.09-17.29; P = 0.001) when compared to those aged > 50. The risk of neutropenia was also increased in those of black ethnicity (59.4%) compared to those of white ethnicity (31.0%) in controls (OR 2.80, CI 0.90-8.71; P = 0.04).

We found that 55% of our 55 patients those who were re-challenged were unsuccessful and had a second neutropenic event. This was more common in patients of white ethnicity (53%) compared to black ethnicity (40%)(x2 = 5.420, P = 0.026).

Discussion: This is the first case-control study, and largest study to identify an association between clozapine associated neutropenia and the concurrent use of sodium valproate. We recommend that consideration for the discontinuation of sodium valproate be made prior to the initiation of Clozapine. Patients should be also considered for re-challenge if the first neutropenic event was deemed to be sodium valproate related.

T246. Screening for antipsychotic drugs which do not interact with monoamine receptors

Eric Prinssen*1, Jean-Luc Moreau1, Thomas Mueggler1, Lucinda Steward1, Taeleen Hanania2, Dani Brunner2, Vadim Alexandrov2, Emer Leahy2, Sabine Kolczewski1

1F Hoffmann - La Roche Ltd, 2PsychoGenics Inc

Background: Phenotypic screening approaches have proven successful in delivering first-in-class drugs. The current project used SmartCube™, a state-of-the-art behavioral primary screening platform in mice, to discover new potential treatments for psychiatric indications (Alexandrov et al. 2015, Eur J Pharmacol). We used SmartCube™ as the starting point for an exploratory phenotypic screening approach in which we generate in vivo signatures of molecules without any a priori biological constraints. Instead, the criteria for compound selection were CNS drug-like properties in silico, manual selection by experienced CNS chemists, and availability of sufficient high-grade powder from our compound library. Compounds with a desired in vivo profile were then screened in vitro for absence of binding to monoamine receptors. To confirm their psychoactive profile, compounds were tested in our rodent pharmacological MRI (phMRI) platform. The pattern of brain activity induced by novel compounds was assessed by arterial spin labeling (ASL) MRI and compared to those patterns elicited by known antipsychotics chosen from our reference database (Bruns et al. 2015, Neuroimage).

Methods: Compounds were tested in C57/Taconic mice in SmartCube™ 15 min after acute i.p. dosing. The behavioral signatures were calculated by a proprietary algorithm using a reference compound database. The in vitro binding profile of the compounds was assessed for dopamine, serotonin and adrenergic receptors. For phMRI, compounds were administered acutely via the i.p. route in Sprague Dawley rats; after 30 min the animals were lightly anesthetized with isoflurane and submitted to MRI acquisition. Using continuous ASL, changes in blood perfusion, a surrogate for changes in neural activity, was measured in more than 60 brain regions-of-interest (ROI) and then compared to those elicited by typical and atypical reference antipsychotics (Bruns et al. 2015, Neuroimage) using multivariate analysis.

Results: Testing for significant behavioral activity in SmartCube gave a hit rate of approximately 20%. One of these hits was identified as a starting point for a program, because of its attractive SmartCube profile (antipsychotic-like without side-effects across a large dose range), phMRI pattern (atypical antipsychotic-like) and lack of inhibition of monoamine receptor binding. This hit was expanded into a series which was further optimized for antipsychotic-like properties using SmartCube as the primary screen. For selected compounds, the antipsychotic-like signature in SmartCube was generally confirmed in the reference system used for multivariate profiling of phMRI.

Discussion: Screening and optimizing, using the in vivo SmartCube platform as primary screen and an in vitro target panel as the secondary screen, has led to the identification of compounds with antipsychotic-like properties, in the absence of effects on monoamine receptors. Using multivariate profiling of phMRI activation patterns as a secondary unbiased platform, provided additional confidence in the antipsychotic-like properties of these compounds. This approach suggests that it is possible to engineer serendipity into phenotypic screening and to integrate this into rational drug design.

T247. Inhibition of PDE1 leads to memory improvement in animal models related to cognitive symptoms of schizophrenia via enhancement of dopamine D1 receptor signaling

Holger Rosenbrock1, Niklas Schüller1, Riccardo Giovannini1, Roland Pfau1, Birgit Stierstorfer1, Scott Hobson1, Anton Pekcec1

1Boehringer Ingelheim Pharma GmbH & Co KG

Abstracts

Background: Cognitive dysfunction in schizophrenia is believed to result at least in part - from prefrontal dopaminergic hypo-functionalitity resulting in insufficient dopamine D1 receptor signaling. D1 receptors are stimulatory Gs coupled receptors which activate adenylyl cyclase resulting in the increased synthesis of cAMP. Phosphodiesterase-1 (PDE1) hydrolyzes both cAMP and cGMP and is expressed in cortical and striatal areas of the brain at which it is suggested to play a role in D1 receptor signaling (Duinen et al., 2015). Thus, in the present study, co-localization studies by immunofluorescence and measurement of PDE1 and D1 receptor were performed using D1 and human brain section. Additionally, the impact of PDE1 inhibition on brain cAMP/cGMP elevation was studied as well as its behavioral consequences in animal cognition tasks. Further experiments are underway to evaluate the interaction of PDE1 and D1 receptor
mechanistically in prefrontal cortical slices by electrophysiology and to assess the impact of PDE1 inhibition on attentional performance. 

**Methods:** Rat and human brains tissues fixed with formalin were sliced for double immunofluorescence staining using antibodies for PDE1B, D1 receptor and pre-/post-synaptic markers. Analysis of staining was performed by confocal microscopy. Potency of the PDE1-inhibitor (PDE-I: WO2013/192556) was determined in PDE assays using recombinant human PDE1A, 1B and 1C expressed in a baculoviral system. Interaction of PDE1 and D1 receptor on neuronal transmission was assessed by using extracellular recordings from layer 5 of rat prefrontal slices. Adult male mice were administered with the PDE-I, and the increase of cAMP/cGMP was determined in prefrontal cortex via ELISA technique. Memory performance was tested in the mouse T-maze continuous alternation task after administration of the PDE-I, and attention was assessed in the rat 5-choice serial reaction time task.

**Results:** Double immunofluorescence analysis revealed co-localization of PDE1 and D1 receptors in neurons of prefrontal and other cortical areas of rat and human brain. PDE1 showed almost equally high potency on PDE1A, 1B and 1C (IC50 = 31-75 pM), and PDE-I administration to mice led to a dose-dependent increase of cAMP in prefrontal slices. Adult male mice were administered with the PDE-I, and the IC50 of cAMP/cGMP was determined in prefrontal cortex via ELISA technique. Memory performance was tested in the mouse T-maze continuous alternation task after administration of the PDE-I, and attention was assessed in the rat 5-choice serial reaction time task.

**Discussion:** As demonstrated in this study, PDE1B is co-expressed with D1 receptors in neurons of the prefrontal cortex, which indicate an involvement of PDE1B in regulating D1 receptor signaling by modulating cAMP levels. Indeed, PDE1B may also modulate cAMP levels in the prefrontal cortex and is an important target for PDE1 inhibitors, and memory performance could be improved in a working memory task (T-maze) which is related to prefrontal cortical function. Thus, our data further support the use of PDE1 inhibitors as potential approach for the treatment of disorders with cognitive dysfunction such as schizophrenia.

**References:**

**T248. Informing clinicians, patients and guidelines. Network meta-analysis on 24 antipsychotic drugs and a broad range of important outcomes for schizophrenia - a protocol**

Maximilian Huhn1, Mytro Samara1, Yi Kang Zhu2, Johannes Schneider1, Philipp Roth2, Matteo Rabaioi-Fischer, Susanne Bächter1, Stefan Leucht1

1Klinikum rechts der Isar, Technische Universität München; 2Klinik Rechts der Isar, Technical University of Munich; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine

**Background:** The evidence base concerning differences between individual neuroleptic drugs is sparse. Network meta-analysis provides the possibility to rank individual drugs for efficacy, tolerability and acceptability domains.

**Methods:** We developed a protocol to do a network meta analysis examining twelve second- and twelve first-generation antipsychotic drugs in acute treatment of schizophrenia. Included studies must be randomized and at least single blind. Data sources will be the Cochrane Schizophrenia Group’s specialized register, MEDLINE, EMBASE, CENTRAL, ClinicalTrials.gov and the FDA website, supplemented by requests to study authors. Outcomes will be overall efficacy (primary outcome), responder rates, drop-out rates, positive, negative and depressive symptoms, quality of life, and side-effects. Data extraction will be done by two persons independently.

**Results:** After elimination of duplicates or search yielded 16419 hits. Outcomes are currently extracted.

**Discussion:** Our final results will expand the evidence base for the treatment of schizophrenia. Especially the huge amount of tolerability and acceptability data presented will help to find the best drug for the individual patient.

**T249. Effects of N-acetylcysteine in schizophrenia-like behaviors induced by a progressive regimen of amphetamine sensitization in mice**

Ana Herrmann1, Roberta Andrejew2, Radharani Benvenutti1, Elaine Elisabetsky2

1Universidade Federal Do Rio Grande Do Sul; 2Universidade Federal do Rio Grande Do Sul

**Background:** A process of ‘endogenous sensitization’ is thought to drive the mesolimbic dopamine hyperfunction that underlies psychotic symptoms in schizophrenia patients. This sensitization is the basis for the enhanced striatal dopamine release in response to an acute amphetamine challenge observed in such patients. The heightened sensitivity to amphetamine can be modeled in rodents by repeated exposure to psychostimulants, resulting in a long-term sensitization where increased behavioral response to the drug is observed at a subsequent exposure. N-acetylcysteine (NAC) has been proposed as an adjunctive treatment for neuropsychiatric disorders and assessed in several clinical trials, including in patients with schizophrenia. Given the relevance of antioxidant, anti-inflammatory and glutamate-modulating properties for schizophrenia, we here explored the potential of NAC in this context. In early intervention. We used amphetamine sensitization in an escalating dose protocol to mimic the graded progression from the prodromal state to full-blown schizophrenia. This protocol leads to changes that resemble several of the neurochemical findings observed in patients with schizophrenia and at-risk subjects. **Methods:** Amphetamine was administered to adult male C57BL/6 mice three times per week during 3 weeks; the dose was weekly increased from 1 to 3 mg/kg, NAC (60 mg/kg) was given immediately before saline or amphetamine during the second and third weeks. All solutions were injected intraperitoneally. Latent inhibition (conditioned active avoidance in a two-way shuttle box) and locomotor response to amphetamine challenge were assessed after 4 weeks of washout.

**Results:** The progressive amphetamine regimen disrupted latent inhibition and induced locomotor sensitization to an amphetamine challenge. NAC disrupted latent inhibition in control animals, and failed to prevent the amphetamine-induced disruption. In sensitized animals, NAC attenuated the enhanced locomotor response to amphetamine.

**Discussion:** NAC administered along with amphetamine partially protected against the locomotor effects induced by amphetamine sensitization. Glutamate pathways are involved in the neurochemical mechanisms that underlie sensitization, since activation of NMDA receptors is required for inducing sensitization. NAC increases extrasynaptic glutamate by activating the cystine-glutamate antiporter, resulting in stimulation of metabotropic glutamate receptors 2/3 that inhibit synaptic glutamate release. This glutamate modulation mechanism might account for the protective effects of NAC against the locomotor effects of amphetamine sensitization. NAC lacks acute effects when administered before amphetamine or MK-801 challenges, which suggests that NAC is more effective in counteracting the long-term adaptations induced by repeated psychostimulant administration than as a classic antipsychotic in an animal model of positive schizophrenia symptoms. However, data from a range of doses and administration intervals is needed before a definitive conclusion can be reached. We have previously shown that NAC prevents the increased sensitivity to amphetamine in social isolation-reared mice. This study complements that data and supports the idea that NAC may be useful in preventing the neurochemical changes that are thought to precede full-blown schizophrenia. Given this protective effect is especially relevant to at-risk subjects, and considering the safety profile of NAC, clinical trials are warranted.

**T250. Pattern of antipsychotic prescription among patients with schizophrenia at a Nigerian neuropsychiatric hospital**

Babatunde Fadipe1, Timothy Adebowale2, Yetunde Fadipe3, Andrew Olagunju3

1Lagos University Teaching Hospital, Lagos; 2Neuropsychiatric Hospital, Ogun State; 3Lagos University Teaching Hospital

**Background:** Psychotropic medication have been identified as a key component in the management of patients with schizophrenia.
Several psychotropic medication as well as other medication are available for use to patients with schizophrenia both as over-the-counter and prescription. It has been widely documented that indiscriminate use of medication particularly antipsychotic medication has the potential to result in unpleasant side effects and has been implicated in poor adherence to treatment regimen. Coupled to this is the numerous complications that may arise from polypharmacy prescriptions, particularly in an environment where most of payment for healthcare is out-of-pocket. This study set out to examine the pattern of antipsychotic medication use among patients with schizophrenia at a Nigerian Neuropsychiatric hospital. Methods: The study which was part of a larger study was a descriptive cross-sectional study. Three hundred and seventy consecutive clinical attendees with a Diagnostic and Statistical Manual of mental disorders (DSM-IV) diagnosis of schizophrenia confirmed with the Structured Clinical Interview for DSM-IV axis I disorders (SCID-I) and aged between 18 and 64 years of age were recruited at the outpatient clinic of the Federal Neuropsychiatric Hospital, Yaba, Lagos. The respondents were interviewed using a questionnaire that assessed sociodemographic and clinical variables. A medication use recall questionnaire assessed medication use recall in the 24-hour period prior to data collection as a predictor of medication use behavior. Monotherapy was defined as a single antipsychotic medication, whereas polypharmacy was defined as having two or more antipsychotics. Data was analyzed using SPSS-20 to generate frequency tables. Ethical approval was sought from the health research and ethics committee of the study centre while a written informed consent was obtained from each subject that participated in the study. Results: The mean age of patients was 37.87 (SD = 11.24), with a male to female ratio of 1:1. The mean (SD) age at onset of mental illness was 26.46 (SD = 7.84) years. The average monthly cost of treatment was 19.86 US Dollars, while the median monthly income was 500 US Dollars. Only about a fifth (18.4%) of the respondents were directly responsible for paying for their treatment despite 45.7% of them being employed. The most common route of administration of antipsychotic medication was oral (52.5%). One hundred and eighty three (49.5%) of the respondents were on monotherapy, 47% were on a combination of oral and depot medication, while about a fifth (21.4%) of them were on a combination of both typical and atypical medication and 53.5% were on only typical medication. The average number of medications taken on a daily basis was 2.4 (SD = 1), while the mean medication use recall score was 69.4%. The most common depot preparation was fluphenazine decanoate. About a third (33.8%) of the respondents experienced various types of medication side effects with 15.9% of all the patients experiencing extrapyramidal side effects. Discussion: The finding in this study suggests that physicians in our environment have a slightly high preference for polypharmacy, although it is known that other factors such as response to treatment, dropouts due to any reason and due to inefficacy of treatment, and important adverse events. We also assessed the effect of potential moderator and quality variables on the primary outcome by several meta-regression, subgroup and sensitivity analyses. All analyses were performed in a Bayesian setting. Results: This was the first and large (40 RCTs, 5172 patients) meta-analysis of blind trials on treatment resistant schizophrenia applying the modern methodology of NMA. For the primary outcome, in the pairwise meta-analysis, only olanzapine was significantly better than haloperidol (SMD -0.29, 4 RCTs, n = 693). In the NMA, olanzapine was significantly more effective than quetiapine (SMD -0.29), haloperidol (-0.29) and sertindole (-0.46); clozapine was more effective than haloperidol (-0.22) and sertindole (-0.40); and risperidone was more effective than sertindole (-0.32). Few significant differences were found among antipsychotics in the remaining outcomes. Altogether, there was a certain pattern of superiority for olanzapine, clozapine and risperidone which were significantly better than other antipsychotics in various efficacy outcomes such overall and positive symptoms, response rates and drop-outs due to inefficacy, but the results were not consistent and the effect sizes were small. The most surprising finding was that clozapine was not significantly better than most other drugs in both the pairwise and the NMA. Discussion: There is at present insufficient evidence on which antipsychotic drug is more efficacious for patients with treatment-resistant schizophrenia. Clozapine’s superiority over FGAs has been repeatedly demonstrated establishing clozapine as the gold standard treatment in this specific population, but blinded randomized trials-in contrast to unblinded effectiveness studies- provide little evidence for the superiority of clozapine compared to other second generation antipsychotics. Based on the above results and given the high risk profile of clozapine, treatment attempts with olanzapine or risperidone could be warranted, before moving on to clozapine. Nevertheless, our meta-analysis is not definitive due to several limitations such as limited or no data for specific SGAs and differences in the criteria of treatment resistance and clozapine dosing between studies; thus, more trials comparing clozapine with other SGAs in more severely ill patients and using high clozapine doses are warranted.

T251. Treatment-resistant schizophrenia: simple pairwise and network meta-analysis of all antipsychotics
Myrto Samara1, Adriani Nikolakopoulou2, Georgia Salanti2, Stefan Leucht1
1Klinikum rechts der Isar, Technische Universität München; 2University of Ioannina School of Medicine
Background: Although clinicians often deal with patients suffering from refractory forms of schizophrenia, an up-to-date systematic review and meta-analysis on the effects of the various antipsychotic drugs in treatment-resistant schizophrenia is not available; the last one, already fifteen year-old, was by Chakos et al. (2001) concluding that clozapine -the drug of standard was most efficacious and was better tolerated than first-generation antipsychotics (FGAs) such as haloperidol and chlorpromazine. But given the restrictions of clozapine’s use due to its many side-effects and in light of a continuously increasing number of new randomized controlled trials (RCTs) on other antipsychotics, we decided to perform simple pairwise and network meta-analysis (NMA) of all antipsychotics in treatment-resistant schizophrenia.
Methods: We searched Medline, Embase, Biosis, PsycINFO, Pubmed, the Cochrane Central Register of Controlled Trials, WHO International Trial Registry and ClinicalTrials.gov. At least two independent reviewers selected published and unpublished blind RCTs and extracted all data. The primary outcome was efficacy as measured by mean overall change in symptoms of schizophrenia. Secondary outcomes were mean change in positive and negative symptoms, categorical response to treatment, dropouts due to any reason and due to inefficacy of treatment, and important adverse events. We also assessed the effect of potential moderator and quality variables on the primary outcome by several meta-regression, subgroup and sensitivity analyses. All analyses were performed in a Bayesian setting.
Results: This was the first and large (40 RCTs, 5,172 patients) meta-analysis of blind trials on treatment resistant schizophrenia applying the modern methodology of NMA. For the primary outcome, in the pairwise meta-analysis, only olanzapine was significantly better than haloperidol (SMD -0.29, 4 RCTs, n = 693). In the NMA, olanzapine was significantly more effective than quetiapine (SMD -0.29), haloperidol (-0.29) and sertindole (-0.46); clozapine was more effective than haloperidol (-0.22) and sertindole (-0.40); and risperidone was more effective than sertindole (-0.32). Few significant differences were found among antipsychotics in the remaining outcomes. Altogether, there was a certain pattern of superiority for olanzapine, clozapine and risperidone which were significantly better than other antipsychotics in various efficacy outcomes such overall and positive symptoms, response rates and drop-outs due to inefficacy, but the results were not consistent and the effect sizes were small. The most surprising finding was that clozapine was not significantly better than most other drugs in both the pairwise and the NMA.
Discussion: There is at present insufficient evidence on which antipsychotic drug is more efficacious for patients with treatment-resistant schizophrenia. Clozapine’s superiority over FGAs has been repeatedly demonstrated establishing clozapine as the gold standard treatment in this specific population, but blinded randomized trials-in contrast to unblinded effectiveness studies- provide little evidence for the superiority of clozapine compared to other second generation antipsychotics. Based on the above results and given the high risk profile of clozapine, treatment attempts with olanzapine or risperidone could be warranted, before moving on to clozapine. Nevertheless, our meta-analysis is not definitive due to several limitations such as limited or no data for specific SGAs and differences in the criteria of treatment resistance and clozapine dosing between studies; thus, more trials comparing clozapine with other SGAs in more severely ill patients and using high clozapine doses are warranted.

T252. Treatment strategies in case of non-response in schizophrenia: meta-analytical assessments of increasing the antipsychotic dose and switching the antipsychotic drug versus continuation of the same antipsychotic dose and drug.
Myrto Samara1, Stefan Leucht1
1Technische Universität München
Background: Many patients with schizophrenia do not reach a satisfying clinical response with a standard dose of an initially prescribed antipsychotic drug. In such cases, clinicians face the dilemma of increasing the antipsychotic dose beyond regular thresholds in order to enhance antipsychotic efficacy. Another treatment option would be to switch the initial antipsychotic drug to another compound. Nevertheless, the evidence on these two treatment strategies is scarce. Therefore, we decided to conduct two separate systematic reviews and meta-analyses; one examining whether increasing the antipsychotic dose rather than maintaining it and one examining whether switching the antipsychotic drug rather than maintaining it could benefit patients who do not respond to their initial antipsychotic treatment.
Methods: We searched the Cochrane Schizophrenia Group Trials Register up to October 2015. References of all included studies were extracted for further trials. All relevant randomized controlled trials (RCTs) were selected and all data were extracted by two independent
Background: responses depending on treatment history transcripts in antipsychotic-naïve vs. antipsychotic-exposed researchers. For dichotomous outcomes, random-effects relative risk (RR) and 95% confidence intervals (CI) were estimated. For continuous outcomes, weighted mean differences (MD) based on a random-effects model were used. Since both reviews are ongoing, hereby we could only present the results on the two primary dichotomous outcomes.

Results: In the first review comparing increasing the antipsychotic dose rather than maintaining it, nine relevant RCTs with 557 participants were included; the small sample sizes per trial limited the overall quality of the evidence. No significant difference was found between groups in terms of the number of patients who responded (7 RCTs, n = 407, RR 1.11, CI 0.78 to 1.58) or left the study early (4 RCTs, n = 250, RR 1.10, CI 0.77 to 1.57). In the second review, comparing switching the antipsychotic drug rather than maintaining it, ten relevant RCTs with 928 participants were included; the small sample sizes again limited the overall quality of the evidence. No significant difference was found between groups in terms of the number of patients who responded (5 RCTs, n = 596, RR 1.17, CI 0.94 to 1.45) or left the study early (4 RCTs, n = 437, RR 1.05, CI 0.79 to 1.39).

Discussion: There was not even a single study in favor of the dose increase strategy in case of non-response in schizophrenia. As for the switching strategy, a recent unpublished trial supports its effectiveness -but data from previous trials are not consistent. The overall quality of the meta-analytic results is low, mainly due to the limited evidence base; there is an urgent need for further trials in order to determine the optimal treatment strategy in case of non-response to the initial antipsychotic treatment in schizophrenia.

T253. A molecular imaging study of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed animals. a molecular explanation for discrepancy in treatment responses depending on treatment history

Felice Iasevoli¹, Federica Marmo¹, Elisabetta F. Buonaguro¹*, Gianmarco Latte¹, Rodolfo Rossi¹, Carmine Tomasetti¹, Andrea de Bartolomeis¹. ¹University “Federico II” of Naples; ²Lundbeck, LLC.

Background: Partial or non-response to antipsychotics, the mainstay treatment of schizophrenia, is a major concern in schizophrenia therapy. Switching from one antipsychotic to another is a common psychiatric practice, mostly in those people that are non-responders. However, no study has so far investigated whether the molecular effects of an antipsychotic are affected by a previous treatment. The aim of this study will be to evaluate whether a prolonged treatment with an atypical antipsychotic, i.e. amisulpride, has divergent molecular effects when given in antipsychotic-naïve subjects compared to subjects who had a prolonged treatment with a typical antipsychotic, i.e. haloperidol. We investigated the effects of these procedures on the expression of genes of the post-synaptic density (PSD). These molecules have been found modulated by antipsychotic treatments and have been implicated in synaptic plasticity processes and schizophrenia pathophysiology.

Methods: Male Sprague-Dawley rats were assigned to the following treatment groups: Vehicle (VEH); Haloperidol 0.25 mg/kg (HAL0.25); haloperidol 0.5 mg/kg (HAL0.5); haloperidol 0.8 mg/kg (HAL0.8); amisulpride 0.05 mg/kg (ASE0.05); amisulpride 0.1 mg/kg (ASE0.1); amisulpride 0.3 mg/kg (ASE0.3); olanzapine 2.5 mg/kg (OLA). Drugs were dissolved in saline, adjusted to physiological pH, and subcutaneously injected for 21 days (one injection/day). Ninety minutes after the last injection, animals were sacrificed and brains were processed for in situ transcript mapping and level analysis. Treatment effect on gene expression was evaluated by ANOVA. Results: Atenolol administration induced Homer1a expression in several brain regions compared to VEH. In the striatum, ASE0.1 and ASE0.3 reduced Homer1a expression only in the ventromedial caudate putamen compared to VEH. Arc expression was reduced by ASE0.1 and ASE0.3 in all cortical and striatal regions explored. Homer1b expression was increased by ASE0.05 in multiple cortical regions and in the nucleus accumbens, while OLA and HAL0.5 increased Homer1b expression in the striatum and in the nucleus accumbens compared to VEH. Shank expression was poorly affected in all treatment groups. PSD-95 expression was not significantly different between VEH and Halo.

Discussion: These results demonstrate that the molecular effects of amisulpride are strongly divergent in antipsychotic-naïve animals compared to animals that received a prolonged treatment with haloperidol. Further studies are needed to evaluate whether these observations can be generalized to the other antipsychotic compounds and to which extent can be translated to human therapy. Nonetheless, our study may shed a light on some forms of treatment resistant schizophrenia.

T254. Different receptor profile and dose of antipsychotics induce differential changes in level and topography of postsynaptic density transcripts associated to psychosis pathophysiology.

Andrea de Bartolomeis¹, Felice Iasevoli¹, Federica Marmo¹, Anna Eramo², Gianmarco Latte¹, Camilla Avagliano¹, Carmine Tomasetti¹, Elisabetta F. Buonaguro¹*. ¹University “Federico II” of Naples; ²Lundbeck, LLC.

Background: Postsynaptic density (PSD) proteins have been involved in psychosis pathophysiology and antipsychotic treatment. Antipsychotics impact differentially the expression, level and topography of PSD transcripts after acute administration, depending on receptor profile and dose administered. However, a direct head-to-head comparison of first and second-generation antipsychotics at different doses in a chronic paradigm is still lacking. To fill this gap, we evaluated the expression of key PSD transcripts, i.e. Homer1a, Arc, Homer1b, PSD-95 and Shank after chronic treatment with haloperidol and asenapine, a first and second-generation antipsychotic, respectively. Olanzapine was used also, as an internal comparator.

Methods: Male Sprague-Dawley rats were assigned to the following treatment groups: Vehicle (VEH); Haloperidol 0.25 mg/kg (HAL0.25); haloperidol 0.5 mg/kg (HAL0.5); haloperidol 0.8 mg/kg (HAL0.8); amisulpride 0.05 mg/kg (ASE0.05); amisulpride 0.1 mg/kg (ASE0.1); amisulpride 0.3 mg/kg (ASE0.3); olanzapine 2.5 mg/kg (OLA). Drugs were dissolved in saline, adjusted to physiological pH, and subcutaneously injected for 21 days (one injection/day). Ninety minutes after the last injection, animals were sacrificed, and brains were processed for in situ transcript mapping and level analysis. Treatment effect on gene expression was evaluated by ANOVA.

Results: Atenolol administration reduced Homer1a expression in several brain regions compared to VEH. In the striatum, ASE0.1 and ASE0.3 reduced Homer1a expression only in the ventromedial caudate putamen compared to VEH. Arc expression was reduced by asenapine at almost all treatments in both cortical and striatal regions explored. Homer1b expression was increased by ASE0.05 in multiple cortical regions and in the nucleus accumbens, while OLA and HAL0.5 increased Homer1b expression only in the nucleus accumbens compared to VEH. Shank expression was poorly affected in all treatment groups. PSD-95 expression was reduced by ASE0.1 in cortical areas and in the medial regions of the caudate putamen compared to VEH. Among all treatments, only OLA administration induced PSD-95 expression in the ventrolateral caudate putamen and in the nucleus accumbens.

Discussion: The expression of genes relevant to synaptic plasticity at the PSD was differentially modulated after chronic administration of typical and atypical antipsychotics compounds as well as by the same compound administered at different doses. Asenapine impacted gene expression mostly in cortical regions, haloperidol mainly in striatum.
These results are consistent with the observed effects of asenapine on the glutamatergic system (i.e. enhancement of NMDA-mediated currents in pyramidal cortical neurons and decrease NMDA receptor activity in the striatum) and with the well known action of haloperidol on the dopaminergic nigro-striatal pathway.

T255. Prevention of disability in treatment resistant schizophrenia (TRS) needs individuation of factors contributing to social impairment. Results from a pilot study using a stringent operative procedure to categorize TRS patients.

Felice Iasevoli, Maria Vittoria Formato, Raffaele Ballesta, Sara Giordano, Emiliano Prinzivalli, Gianmarco Latte, Rodolfo Rossi, Elisabetta F. Buonaguro

1University “Federico II” of Naples

**Background:** Treatment Resistant Schizophrenia (TRS) is diagnosed in patients who did not respond or respond poorly to adequate antipsychotic treatments. TRS causes severe disability in people who are affected. It has been demonstrated that TRS patients have more limited achievements in functional milestones of everyday living even compared to schizophrenia responder patients (RP). In this work, we aimed at investigating the factors that are associated with impaired global and area-specific social performances in TRS patients, with the scope of individuating a set of modifiable factors that could be addressed to prevent severe disability.

**Methods:** We included 118 psychotic and non-psychotic consecutive patients with a significant impairment on the Personal and Social Performance (PSP) scale (defined as a total score < 80). Diagnosis of TRS was made according to a multistep procedure whose main points were: 1) reliable reconstruction of pharmacological history of the patient, to confirm that he/she had already received (and did not respond) at least two adequate antipsychotic treatments; 2) evaluation of actual psychotic symptoms (patients were considered actively psychotics whether they had a Positive and Negative Syndrome Scale, PANSS, total score >70); 3) assessment of factors of pseudo-pharmacoresistance; attempts to their correction, if possible; re-categorization of the patient after correction; 4) additional prospective antipsychotic trial, to assess the condition of non-response or sustained partial response. Patients under clozapine were categorized as TRS. All patients were administered the PSP and underwent a panel of assessments exploring demographic, clinical, psychometric, social and cognitive variables. ANOVA and linear regression were used.

**Results:** PSP total score, PSP Area1 (Social Useful Activities), Area2 (Personal and Social Relationship), and Area3 (Self-Care) subscale scores were significantly different among diagnostic groups, while Area4 (Disturbing and Aggressive Behavior) subscale score was not. PSP total, Area1, and Area3 subscale scores were significantly higher in TRS than in RP and NSP, while Area2 subscale score was not significantly different compared to RP but was higher than in NSP. PSP total score in TRS patients was significantly associated to: occupation status; age at onset; adherence to therapy; PANSS negative score. These factors produced a model whose adjusted R2 was 0.57, therefore accounting for more than half of PSP total score variance in these patients. Factors associated to PSP total score were sharply different in RP and NSP and gave models that accounted for a minor part of PSP total score variance.

The same factors were significantly associated with Area1 score, providing a model whose adjusted R2 was 0.54. Area2 score significantly associated with use of first-generation antipsychotics and adherence to therapy. Area3 score significantly associated with use of first-generation antipsychotics, adherence to therapy, Verbal Fluency, and PANSS total score. In both cases, backward stepwise regression showed that adherence to therapy was the only predictor surviving the procedure. Both models showed low (≤ 0.2) adjusted R2.

**Discussion:** These results confirm previous reports on the most relevant social impairment in TRS patients compared to non-TRS patients. High levels of negative symptoms, younger age at onset, poor vocational status, and poor adherence to therapeutic advice were relevant factors of social impairment. Specifically, these factors appeared implicated in impaired social useful activities. Impairment in social relationship and self-care were only limitedly associated to poor adherence, as other factors presumably contribute to these alterations.

T256. Symptomatic remission in patients with schizophrenia treated with paliperidone palmitate (1-month and 3-month formulations)

Adam Savitz, Haiyan Xu, Srijani Gopal, Isaac Nuamah, David Hough, Maju Mathews

1Jansen Research & Development

**Background:** In this double-blind (DB), parallel-group, multicenter, phase-3 study (EudraCT no: 2011-004889-15), symptomatic remission was analyzed in patients (age 18-70 years) with schizophrenia following treatment with paliperidone palmitate (1-month [PP1M] and 3-month [PP3M] formulation).

**Methods:** Patients previously stabilized on PP1M and treated with fixed doses of PP3M (175, 263, 350, or 525 mg eq. deltoid/gluteal) or PP1M (50, 75, 100, or 150 mg eq. deltoid/gluteal) for 48 weeks were included in this analysis. Symptomatic remission was assessed according to Andreasen’s criteria (<3 score on all positive and negative symptom score [PANSS] items: P1, P2, P3, N1, N4, N6, G5, and G9 for the last 6 months of DB treatment, with no excursion allowed). Functional remission was also assessed.

**Results:** Consistent with the primary efficacy endpoint with similar relapse rates in both treatment groups (PP3M: n = 37; PP1M: n = 45; 95% difference in relapse-free rate: 1.2% [95% CI: 2.7%; 5.1%]), the percentage of patients who showed symptomatic remission was similar and >50% in both groups (PP3M: n = 243/483, 50%; PP1M: n = 260/512, 51%; relative risk of remission [95% CI]: 0.98 [0.87, 1.11]). Among the remitters at entry into DB phase, percentage of patients who met the symptomatic remission criteria was similar in both groups across 48 weeks. Proportion of patients who maintained symptomatic remission and functioning remission (PSP score >70 during the last 6 months of DB treatment) was similar between both groups (PP3M: n = 121/483, 25%; PP1M: n = 136/512; 27%).

**Discussion:** Patients treated with PP demonstrated higher symptomatic remission compared with remission rates published elsewhere (Beitinger, 2008) with similar rates in both treatment groups across all 48 weeks. PP3M can thus be considered as a unique option for symptomatic remission in patients with schizophrenia previously stabilized on PP1M.


T257. Resilience in individuals clinically at high risk for psychosis - first results from the PRONIA study


1University of Cologne; 2University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern; 3Psychiatric University Hospital Basel; 4University of Milan; 5Melbourne Neuropsychiatry Centre, University of Melbourne; 6University of Turku; 7University of Birmingham, Edgbaston; 8Ludwig-Maximilians-University of Munich

**Background:** PRONIA (‘Personalized Prognostic Tools for Early Psychosis Mangement’) is a prospective collaboration project funded by the European Union under the 7th Framework Programme (grant agreement no 602152). Considering a broad set of variables (sMRI, rsfMRI, DTI, psychopathological, life event related and sociobiographic data, neurocognition, genomics and other blood derived parameters) as well as advanced statistical methods, PRONIA aims at developing an innovative multivariate prognostic tool enabling an individualized prediction of illness trajectories and outcome. Seven university centers
in five European countries and in Australia (Munich, Basel, Birmingham, Cologne, Melbourne, Milan/Udine, Turku) participate in the evaluation of three clinical groups (subjects clinically at high risk of developing a psychosis [CHR], patients with a recent onset psychosis [ROP] and patients with a recent onset depression [ROD]) as well as healthy controls; planned sample size is $n=1,700$.

In a first interim analysis, we investigated data from the ‘Resilience Scale for Adults’ (RSA) developed by Odin Hjemdal and Oddgeir Friborg, a self-report instrument with six factors: perception of self, planned future, social competence, family cohesion, social resources and structured style.

Results: Group comparisons revealed a significant difference between patients and healthy controls. Healthy controls showed higher total scores on the RSA than CHR, ROP and ROD participants. Further, CHR patients scored significantly lower than ROD on RSA total. The ROP sample showed significantly higher scores on the RSA factor perception of self compared to ROD and CHR as well as a significant higher score on planned future than CHR participants.

Discussion: The results of the current study support the notion that lower resilience is associated with mental illness. This was already observable in a population clinically at risk for psychosis, who scored even lower than the recent onset depression group. The lower scores on the RSA factors perception of self and planned future might reflect a higher impact of depression compared to the recent onset psychosis group.

T258. Peer problems and low self-esteem mediates the schizotypy – reactive aggression relationship in adolescents
Keri Wong$^1$, Adrian Raine$^2$
$^1$University of Cambridge; $^2$University of Pennsylvania

Background: Very little prior research exists on aggressive behavior in children with schizotypal and paranoid features, and almost no research on factors that may help explain this relationship. This study assesses whether paranoid and non-paranoid features of schizotypy are particularly associated with reactive forms of aggression, and if peer problems and low self-esteem mediate this relationship.

Methods: 1,301 schoolchildren aged 8-14 years were assessed on the child version of the Schizotypal Personality Questionnaire (SPQ-C) and the Social Mistrust Scale (SMS). Aggression was assessed using the Reactive-Proactive Aggression Questionnaire (RPQ). A serial multiple mediation model was tested with a hypothesized causal flow from schizotypy / suspicious schizotypy to peer problems to low self-esteem to increased aggression.

Results: Increased schizotypy and suspicious schizotypy were both associated with increased aggression, particularly the reactive form. Peer problems and self-esteem mediated the relationships between schizotypy and reactive, but not proactive, aggression. Specifically, children with higher levels of schizotypy were more likely to have peer problems which in turn were associated with lower self-esteem which in turn was associated with reactive aggression.

Discussion: Results provide an initial explanatory model of why children with paranoid and non-paranoid schizotypy features are more likely to be reactively aggressive. Therapeutic implications to enhance self-esteem in schizotypal adolescents may help reduce their co-morbid reactive aggressive behavior.

T259. Social and role functioning in a high risk child and adolescent sample
Montserrat Dolz$^1$, Jordina Tor$^1$, Marta Pardo$^1$, Daniel Muñoz$^1$, Marta Carulla$^1$, Xavier Álvarez$^1$, Elena De la Serna$^2$, Gisela Sugranyes$^3$, Inmaculada Baexe$^4$
$^1$Hospital Sant Joan de Déu; $^2$Centro De Investigación Biomédica En Red De Salud Mental, CIBERSAM; $^3$Hospital Clinic Barcelona; $^4$Hospital Clinic de Barcelona

Background: Functioning in daily life and social functioning, as well as global functioning ability are one of the core features of psychotic illness. Early stages of psychosis are associated with poor functioning in adolescents (Grano et al 2011). Premorbid functioning, such as early adolescent social dysfunction were suggested as an early predictor of conversion (Tarabox et al, 2013). Nevertheless, there are only few studies attending to this topic in child and adolescent population, despite its importance.

Methods: A prospective, naturalistic and multicentric study from Hospital Clinic and Hospital Sant Joan de Déu of Barcelona conducted in help-seeking children and adolescents (10-17 years) and healthy controls (HC). Inclusion criteria: 1) Attention deficit or hyperactivity disorder during the follow-up visits. There were no baseline differences between converted and non-converted individuals at baseline in terms of functioning ability.

Discussion: Risk high child and adolescent samples show worse global functioning, social functioning and role functioning than healthy controls at baseline, as observed in previous literature (Grano et al., 2011). In terms of predictive value, functioning not seems to be a good discriminative between converters and non-converters, since no baseline differences were founded between these two samples.

T260. Comparing domains of functioning in clinical high risk subjects, recent onset psychosis and recent onset depression patients - first results from the PRONIA study
Marlene Rosen$^1$, Theresa Haidl$^1$, Nathalie Kaiser$^2$, Frauke Schultz-Lutter$^2$, Stefan Borgwardt$^3$, Paolo Brambilla$^4$, Christos Pantelis$^5$, Raimo K. R. Salokangas$^6$, Stephen Wood$^7$, Nikolaos Koutsoulis$^8$, Stephan Uhrmann$^1$, and the PRONIA Group$^5$
$^1$University of Cologne; $^2$University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern; $^3$Psychiatric University Hospital Basel; $^4$University of Milan; $^5$Melbourne Neuropsychiatry Centre, University of Melbourne; $^6$University of Turku; $^7$University of Birmingham, Edgbaston; $^8$Ludwig-Maximilians-Universität

Background: Decreased global functioning was reported in several studies on clinical high risk (CHR) states of developing a first psychotic episode. In a considerable proportion of CHR individuals, functional deterioration remains even after (transient) remission of symptomatic risk indicators. Moreover, low levels of functioning are predictive for a later transition to psychosis. Furthermore, intervention trials demonstrated a favorable effect on transition rates, but not on functioning. Therefore, previous studies used rather global measures of functioning. However, for evaluating the mechanisms underlying functional decline and for an improved definition of targets for intervention, a more detailed analysis of the affection of the different domains of functioning and its illness-related pattern is required.

Methods: PRONIA (‘Personalized Prognostic Tools for Early Psychosis Management’) is a prospective collaboration project funded by the European Union under the 7th Framework Programme (grant agreement n° 602152). Considering a broad set of variables (sMRI, rsMRI, DTI, psychopathological, life event related and sociobiographic data, neurocognition, genomics and other blood derived parameters) as well as advanced statistical methods, PRONIA aims at developing an innovative multivariate prognostic tool enabling an individualized prediction of illness trajectories and outcomes. Participants from university centers in five European countries and in Australia (Munich, Basel, Birmingham, Cologne, Melbourne, Milan/Udine, Turku) participate in the evaluation of three clinical groups (subjects clinically at high risk of developing a psychosis [CHR], patients with a recent onset psychosis...
reported a significantly higher subjective burden due to the bullying experience. Again, this burden was significantly more pronounced in the CHR than in the ROD and ROP group, and ROP patients got significantly more problems than ROD patients.

Discussion: Our results underline the importance of bullying prevention with regard to mental health. The fact that CHR patients reported more severe bullying experiences than the ROD and ROP groups may indicate a higher sensitivity for stressful social experiences in this group. The prospective design of PRONIA will enable us to further elucidate the impact of bullying experiences on the symptomatic and functional outcome of all three groups, including the impact on a later progression to psychosis in the CHR group.

T262. Self-stigma and its relationship with victimization, psychotic symptoms and self-esteem among people with schizophrenia spectrum disorders

Ellen Horszelenberg1, Jooske van Busschbach2, Marieke Pijnenborg3, Andre Aleman4

1GGZ Drenthe; 2RUGO/UMCG, University of Groningen; 3University of Groningen, University Medical Center Groningen

Background: Self-stigma is highly prevalent in schizophrenia and can be seen as an important factor leading to low self-esteem. It is however unclear how psychological factors and actual adverse events contribute to self-stigma. This study empirically examines how symptom severity and the experience of being victimized affect both self-stigma and self-esteem.

Methods: Persons with a schizophrenia spectrum disorder (N = 102) were assessed with a battery of self-rating questionnaires and interviews. Structural equation modelling (SEM) was subsequently applied to test the fit of three models: a model with symptoms and victimization as direct predictors of self-stigma and negative self-esteem, a model with an indirect effect for symptoms mediated by victimization, and a third model with a direct effect for negative symptoms and an indirect effect for positive symptoms mediated by victimization.

Results: Results showed good model fit for the direct effects of both symptoms and victimization: both lead to an increase of self-stigma and subsequent negative self-esteem. Negative symptoms had a direct association with self-stigma, while the relationship between positive symptoms and self-stigma was mediated by victimization.

Discussion: Our findings suggest that symptoms and victimization may contribute to self-stigma, leading to negative self-esteem in individuals with a schizophrenia spectrum disorder. Especially for patients with positive symptoms victimization seems to be an important factor in developing self-stigma. Given the burden of self-stigma on patients and the constraining effects on societal participation and service use, interventions targeting victimisation as well as self-stigma are needed.

T263. Mentalizing ability as a mediator between reported childhood abuse and non-affective psychotic disorder

Jonas Weijers1, Liesbeth Eurelings-Bontekoe2, Jean-Paul Selten3

1Maastricht University, Department of Mental Health and Neuroscience; Rivierduinen Mental Health Care Institute; 2Leiden University

Background: A number of studies have identified reported childhood abuse as an important risk factor for nonaffective psychotic disorder (NAPD). Interestingly, van Os and colleagues (Nature, 468(7321), 2010) have suggested that a reduced mentalizing ability may be one of the mechanisms underlying the effect of childhood abuse on the risk of NAPD. Indeed, there is some evidence for an association between mentalizing ability and severity of social dysfunction, positive and negative symptoms. It is therefore possible that mentalizing ability (partially) mediates the effect of childhood abuse on social functioning, negative symptoms and positive symptoms. The current study tested this hypothesis.

Methods: Sixty-two patients with NAPD were recruited from Rivierduinen mental health care institute. Participants were interviewed with the Childhood Experience of Care and Abuse, the Social Functioning Scale, and the Positive and Negative Syndrome Scale. The hinting task...
was used to measure mentalizing ability. Three mediator models were tested using a bootstrapping procedure with reported childhood abuse as independent variable, mentalizing ability as mediator and social functioning, positive symptoms and negative symptoms as dependent variables.

Results: A total of 108 individuals had a functional capacity evaluation. The mean age of the patients was 39.96 years (SD = 9.07), and 26% of the patients were female. The mean duration of illness was 17.28 years (SD = 8.14). A univariate analysis yielded statistical inverse correlations between global functioning and positive symptoms (rho = -0.58; P = 0.0001), negative symptoms (rho = -0.43; P = 0.0018), general psychopathology (rho = -0.59; P = 0.0001) and awareness of illness (rho = -0.54; P = 0.0001). In a logistic stepwise regression analysis, psychosocial functioning was significantly predicted by negative symptoms and general psychopathology (P = 0.0009).

Discussion: The negative symptoms - as well as other psychopathological features, such as a lack of insight - undermine the functional outcomes in patients with schizophrenia. In all likelihood, if psychosocial functioning and social cognition had been applied, our findings would likely have been more determinant and would have showed a stronger and more accurate correlation between these factors and global psychosocial functioning.

Higher UPSA-B scores were associated with financial independence and non-schizophrenia spectrum diagnosis but not with residential independence or with MIRECC GAF occupational or social functioning sub-scale scores (rho = 0.14 and rho = 0.10 respectively, both P = NS).

BIT severity was significantly associated with functional capacity on multiple regression analysis and at FEP presentation (beta = -0.22, P < 0.05) but not at 1 year. BIT severity was not significantly correlated with either social or occupational functioning (rho = 0.16 and rho = 0.13 respectively, P = NS). None of the FTD dimensions had a concurrent or predictive relationship with functional capacity. Functional capacity at 1 year was predicted by premorbid IQ, female gender and baseline functional but not negative symptoms. The multivariate models explained 33% and 45% of the variance in functional capacity, at baseline and 1 year respectively.

Discussion: Functional capacity was associated with BIT at FEP but not at 1 year in this study and it showed no association with FTD. The validity of functional capacity in FEP has previously been questioned and, in addition to its temporal stability, this should be considered in its future use in clinical trials. The validity and generalisability of BIT as a measure of language disturbance is questionable in FEP although this study was somewhat under-powered for some analyses.

T265. Predicting psychosocial functioning in schizophrenia: the role of clinical symptoms and the awareness of illness

Álvaro López-Díaz1, Fermín González-Higuera2, Pedro Torres-Hernández2

1Servicio Andaluz de Salud

Abstracts

Background: Schizophrenia is a disabling mental disorder with a chronic course that often leads to significant impairments in psychosocial functioning. These functional deficits are considered to be important prognosis factors whose comprehensive treatment should go beyond just the psychotic symptoms. There are many studies that link negative symptoms with their impact on the daily functioning of patients with schizophrenia but only a few include the lack of insight as a variable to analyze. This study aims to examine the concomitant relationships between psychopathological symptoms, the awareness of mental illness and the functional impairment.

Methods: Fifty adult patients meeting the ICD-10 criteria for schizophrenia were consecutively recruited for this study following their admission into a Mental Health Rehabilitation Centre. Their clinical features and psychosocial functioning data were collected with the following psychometric instruments: Brief Psychiatric Rating Scale (BPRS), Scale to assess Unawareness of Mental Disorder (SUM-D) and the Social Performance Scale (SPS). For methodological purposes, the BPRS scores were grouped into three dimensions: positive symptoms, negative symptoms and general psychopathology (which included the rest of the items). In addition, only the global scores for SPS and SUM-D were taken into account in the study. Correlation coefficients and multiple regression analysis were performed to measure the strength of association between the quantitative variables. Statistical analysis was carried out using MedCalc software and the significance level was set at P < 0.05.

Results: The mean age of the patients was 39.96 years (SD = 9.07), and 26% of the patients were female. The mean duration of illness was 17.28 years (SD = 8.14). A univariate analysis yielded statistical inverse correlations between global functioning and positive symptoms (rho = -0.58; P = 0.0001), negative symptoms (rho = -0.43; P = 0.0018), general psychopathology (rho = -0.59; P = 0.0001) and awareness of illness (rho = -0.54; P = 0.0001). In a logistic stepwise regression analysis, psychosocial functioning was significantly predicted by negative symptoms and general psychopathology (P = 0.0009).

Discussion: The negative symptoms - as well as other psychopathological features, such as a lack of insight - undermine the functional outcomes in patients with schizophrenia. In all likelihood, if psychosocial functioning and social cognition had been applied, our findings would likely have been more determinant and would have showed a stronger and more accurate correlation between these factors and global psychosocial functioning.
T266. Recovery in schizophrenia: a natural 5-year follow-up study in a private practice
Mustafa Yildiz1
1Kocaeli University

**Background:** Follow-up studies have found that a substantial number of patients with schizophrenia achieve recovery (i.e., sustained improvement in both symptoms and social/vocational functioning). The aim of this study was to determine recovery rates and related factors in schizophrenia outpatients.

**Methods:** A sample of 61 consecutive outpatients (schizophrenia = 42, schizoaffective disorder = 19) who followed-up for five years was examined in the study. Psychopathological status was evaluated by means of standardized symptomatic remission criteria based on Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression severity (CGI-S). Functionality of the patients was evaluated by means of Global Assessment of Functioning (GAF) and informations from family members. Recovery required remission of positive and negative symptoms and adequate social/vocational functioning (fulfilment of age-appropriate role expectations, performance of daily living tasks without supervision, and engagement in social interactions) for at least 24 months. Demographic and clinical variables were compared using one-way analysis of variance for continuous variables and χ2 test for dichotomous ones. Binary logistic regression was performed to find the predictors of recovery.

**Results:** After 5 years, 67.2% of the patients achieved symptomatic remission at some point, and 39.3% had adequate social functioning at least for 2 years. Only 27.9% of subjects met recovery criteria for more than 2 years. Late onset of illness (22y), being schizoaffective disorder, and being first episode were predictors of recovery. Schizophrenic and schizoaffective patients were characterized by an overlapping age at onset, mean duration of illness, mean duration of untreated psychosis and common sociodemographic characteristics. More than half of the patients were taken intramuscular injection antipsychotic drugs any time of the treatment period. The mean number of visits was 16.3 ± 5.8 that is 3-4 meeting in a year.

**Discussion:** The proportion of patients who met recovery criteria is not low. This finding might be interpreted as a result of same physician treatment, intramuscular drug applications, and regular meetings. Compared to schizophrenic patients, schizoaffective patients may be considered as a subgroup of psychotic patients displaying several specific characteristics in terms of clinical course, clinical and functional outcome and treatment.

T267. Attempts of suicide in first episode of psychosis and psychosocial functioning
Manuel Canal-Rivero1, Jorge Garcia Egea2, Jordi E. Obiols Llandrich3, Miguel Ruiz Veguilla2
1University Hospital Virgen del Rocio (Seville) Spain; 2Autonomus University of Barcelona; 3University of Groningen

**Background:** The adverse impact of attempts of suicide on psychosocial functioning and symptomatic remission hasn’t been well documented. However, the determinants and levels of psychosocial functioning and symptomatic remission remain poorly understood in people experiencing FEP. This study aimed to study the effects of attempts of suicide after first episode of psychosis on psychosocial functioning and symptomatic remission one year after first episode of psychosis.

**Methods:** Sixty-five first-episode patients participated in this study. Baseline demographic clinical data and information about suicide attempts previous at FEP were collected in the first contact with mental health services. Sociodemographic and clinical data were collected from information provided by the patients and their relatives. We used Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) to screen for psychotic symptoms which were then used for the diagnosis of suicide attempts previous at FEP was collected using Schedules for Clinical Assessment in Neuropsychiatry SCAN. This clinical interview contains a question about attempted suicide. At 12 months after first episode of psychosis WHO-DAS-S was used to assess psychosocial functioning. Is a semi-structured interview to screen psychosocial functioning in four dimensions: personal care, occupation, family and household and broader social context. This interview is recommended by OMS to evaluate difficulties caused for physical and mental problems. We defined remission according to PANS operational criteria set up by the Remission in Schizophrenia Working Group. The symptomatic criterion includes eight core PANSS items (delusion, unusual thoughts content, hallucinatory behaviour, conceptual disorganization, mannerism/posturing, blunted affect, social withdrawal, lack of spontaneity) with a score ≤ 3. The duration criterion is symptomatic remission maintenance over 6 consecutive months.

**Results:** Significant correlation (P < 0.001) was found between disability in personal care and number of attempts of suicide after first episode of psychosis (r = 0.52). Disability in family and household correlated significantly (P < 0.005) with number of attempts after first episode of psychosis (r = 0.29). Multivariable analysis were done for analyse the relationship between disability in personal care and family and household with number of attempts of suicide. In the linear regression we included covariates. These covariates were: age, gender and diagnosis. Number of attempts of suicide explaining 20% of the variance in the disability of personal care and 14% of the variance in the disability of family and household.

**Discussion:** Suicide attempts impacted negatively on personal care and family and household disability. These findings have significant implications for early, targeted interventions for this vulnerable group.
especially in people with a serious mental illness (SMI). People with an SMI should have more opportunities to take care of themselves in their own environment. Provided help should become more recovery focused.

The Individual Recovery Outcomes Counter (I.ROC), developed at Penumbra in Scotland, is a recovery focused instrument, fitting very well into the recovery vision. The I.ROC assesses recovery in twelve domains of life through twelve questions, the outcome provides starting points for recovery focused help. The psychometric properties of the I.ROC are already investigated in Scotland, with good results. The newly translated Dutch version however still needs validation. Within the Netherlands a consortium has been formed (including Phrenos, Pro Persona, GGZ Drenthe, Indigo, GGZ Friesland, Lentis Groningen, GGZ Breburg) with main aim establishing the psychometric properties of the Dutch I.ROC in various health care populations. The psychometric properties in the SMI population will be investigated by GGZ Drenthe, Lentis Groningen, GGZ Friesland and GGZ Breburg, in order to use the results of the I.ROC in mental health care, outcomes are further shaped in the HOPE toolkit, which is directly connected to the twelve measured domains. The toolkit consists of guidance plans, tools, wellbeing tips and links to other resources. If the psychometric properties of the Dutch I.ROC are sufficient, the HOPE toolkit will be implemented in several FACT teams in Drenthe, the Netherlands for an effect evaluation.

Methods: In the Netherlands, mental health care users are evaluated once every year with a standard set of instruments, during these yearly evaluations, people with an SMI using health care at GGZ Drenthe, GGZ Friesland, Lentis Groningen or GGZ Breburg will be asked to fill out the I.ROC for the first time. The inclusion will take place from January until December 2016, in this period we hope to include a minimum of 400 people with an SMI. Participants fill out an I.ROC every six months during one year, adding up to three assessments for each participant.

Several other instruments will be used to compare the results of the I.ROC to (e.g. Honos, Mansa). We will look at validity, reliability and factor structure. The effectiveness of the HOPE toolkit will be investigated in up to five FACT teams in Drenthe, with the implementation of the toolkit in some teams and care-as-usual in other teams. Participants will fill out an I.ROC every three months during at least one year. Besides that, various other instruments will be completed and interviews will be held with both participants and health care workers.

Results: If present at the time, first results will be presented at the poster. Otherwise the poster will give an overview of our I.ROC research plans.

Discussion: First results will be discussed if present at the time.

T270. Health related quality of life in schizophrenia and other psychoses: AQoL-4D findings from the second Australian National Survey of Psychosis

Amanda Neil1, Vaughan Carr2, Andrew Mackinnon3, Anna Waterreus4, Helen Stain5, Mary-Claire Hanlon6, Sam Korn7, Vera Morgan8

1Menzies Institute for Medical Research; 2University of New South Wales; 3Orygen Youth Health Research Centre, University of Melbourne; 4University of Western Australia; 5Durham University, United Kingdom; 6Calvary Mater Hospital; 7University of Melbourne; 8School of Psychiatry & Clinical Neuroscience, University of Western Australia

Background: Multi-attribute utility instruments are generic health-related quality of life (HRQoL) measures that enable valuation of health states relative to death (0.0) and full health (1.0). The usefulness of one such instrument, the AQoL-4D, was tested in a population with psychosis to confirm whether it has adequate lower end sensitivity to provide meaningful HRQoL valuations in this population, and to assess utility values across demographic, general and illness-related health categorizations.

Methods: A nationally representative sample of participants in the Second Australian National Survey of Psychosis (N=1,825) were asked to complete the AQoL-4D as one of 32 assessment modules encompassing demographic, diagnostic, clinical, cognitive, physical health, independent functioning and service use measures. A standard algorithm was applied to responses to each of 12 items in the instrument.

Results: Utility values were assessed for 1793 participants (98.2%). The AQoL-4D gave rise to no ceiling effects. Only 6.6% of participants scored in the top decile of HRQoL (0.9-1.0). In contrast, 10.8% scored in the lowest decile ([0.0, 0.10], a floor effect observed in 0.4%. The mean utility value was 0.49 (95%CI: 0.48-0.51), significantly lower than the Australian population norm of 0.81 (95%CI: 0.81-0.82). Greatest impacts on HRQoL were for diminishing independent functioning (ES: 0.68-2.24), self-rated mental health (ES: 0.15-1.65) and physical health (ES: 0.11-1.21). Strong effects were also observed for course of disorder (ES: 0.08-1.13), current suicidal ideation (ES: 0.76-1.08), and labor force participation (ES: 0.97-1.21).

Conclusion: The AQoL-4D had good lower end sensitivity in a psychosis sample and demonstrated responsiveness across subjective, objective and symptom measures. The HRQoL impacts of psychosis are profound. The greatest losses were associated with poorer independent functioning, self-rated mental and physical health, course of disorder and current suicidal ideation.

T271. Reliability and validity of the specific levels of function scale - Japanese version; relation to cognitive insight

Tomiki Sumiyoshi1, Keiichiro Nishida2, Hidehito Niimura3, Atsuhito Toyomaki1, Tetsuba Morimoto1, Masayuki Tanii4, Ken Inada7, Taka Ninomiya7, Yosuke Koshikawa6, Toshikiho Kinoshita6, Ichiro Kusumi2, Akira Iwanami10, Takefumi Ueno1, Takeshi Terao11, Kazuyuki Nakagome12

1Translational Medical Center, National Center of Neurology and Psychiatry; 2Kansai Medical University; 3Keio University School of Medicine; 4Hokkaido University, Graduate School of Medicine; 5Nara Medical University; 6Showa University School of Medicine, 7School of Medicine, Tokyo Women's Medical University; 8Kyoto University Faculty of Medicine; 9University of Occupational and Environmental Health; 10Showa university School of Medicine; 11National Hospital Organization, Hizen Psychiatric Center; 12National Institute of Mental Health, National Center of Neurology and Psychiatry

Background: Improving functional outcomes in work, residential and social issues provides ultimate goals in the treatment of psychiatric diseases, such as schizophrenia. There have been efforts to identify assessment tools adequately measuring “real-world functional outcomes” which is linked to neurocognition and daily activity skills. In this respect, the Specific Levels of Function (SLOF) has been reported to be a promising measure of social function (Harvey et al. Am J Psychiatry 2011). In addition to cognitive function, there have been suggestions that the lack of insight, a core feature of schizophrenia, also influences outcome. Therefore, the aims of this study were: 1) to determine the reliability and validity of the Japanese version of SLOF; and 2) to determine if cognitive insight, a component of metacognition, would affect social function, as measured by the SLOF.

Methods: This study was a multi-center trial involving 10 medical facilities in Japan, in which 58 Japanese patients meeting DSM-IV-R criteria for schizophrenia participated. The study protocol was approved by the ethics committees of participating institutions. The Social Functioning Scale ‘Individuals’ version modified for the MATRICS-PASS (Modified SFS for PASS) - Japanese version (Sumiyoshi et al. Schizophr Res Cogn 2015) was used as a self-report measure of social function. Neurocognition and functional capacity (daily activity skills) were evaluated by Japanese versions of the Brief Assessment of Cognition in Schizophrenia (BACS) and the UCSD Performance-based Skills Assessment-Brief (UPSA-B), respectively. We also assessed cognitive insight (metacognition) by means of the Beck Cognitive Insight Scale (BCIS). Severity of symptoms was measured by the Positive and Negative Syndrome Scale (PANSS). All of these clinical scales have been validated. The SLOF Japanese version, developed based on the original English version, was also administered. Interviewer-rated summary scores of the SLOF, based on its three domains, e.g. Interpersonal Functioning, Everyday Activities, and Vocational Functioning, were obtained (Sabbag et al. Schizophr Res 2011; Strassnig et al. Schizophr Res 2015).

Results: Cronbach alpha for the SLOF Japanese version was 0.80. The one-week test-retest reliability of the scale was acceptable (τ = 0.81,
Pearson’s correlation coefficients indicated significant relationships between scores of the SLOF vs. those of the SFS (r = 0.56, P < 0.01), BACS (r = 0.56, P < 0.01), UPSA-B (r = 0.65, P < 0.01), BCIS (r = 0.30, P < 0.05) and PANSS (r = -0.59, P < 0.001). Further analysis indicated that the correlation between performance on the UPSA-B and scores of the SLOF was significantly more robust compared to the correlation between performance on the UPSA-B and scores of the SFS (r = 0.30, P < 0.05). Similarly, the correlation between scores of the BACS and SLOF tended to be more robust than that between the BACS and SFS (r = 1.89, P = 0.059). Importantly, while the correlation between scores of the BCIS and SLOF reached significance, it was not so between scores of the BCIS and SFS (r = 0.17, P = n.s.).

Discussion: These results suggest the SLOF Japanese version, reported here, provides a valid and reliable measure of social consequences in patients with schizophrenia. The positive relationship between cognitive insight and social function evaluated by the SLOF (interviewer-rated), but not SFS (self-reported) is consistent with the observation that ratings with the former scale were more strongly associated with performances on objective functional measures (i.e. BACS and UPSA-B).

T272. What do service users want from a smartphone app for psychosis?
Sandra Buccı
t
1University of Manchester

Background: Schizophrenia affects 2% of the population. The majority of people who experience a first episode of psychosis (FEP) reach remission within 12-months of intervention. However, the early course of psychosis is characterised by repeated relapse; 80% of those experiencing a first episode of psychosis will relapse within 5-years of their initial episode, adversely impacting on their psychosocial development. National and international guidelines recommend a combination of pharmacological and psychosocial intervention in the treatment of schizophrenia. However, many service users are not compliant with their prescribed medication and a shortage of trained clinicians, resource pressures, long waiting lists, to name a few mean that of people with psychosis who could benefit, relatively few service users have access to helpful psychosocial packages, often resulting in relapse indicators being missed. Accordingly, there is an urgent need to improve access to helpful intervention packages that can be delivered in a timely manner.

Methods: Using framework analysis, this presentation will focus on the findings from two large qualitative studies carried out in the UK, whereby first episode psychosis service users (n = 20) and early intervention service clinicians (n = 40) were interviewed to elicit views about the feasibility and acceptability of mobile health (mHealth) approaches to delivery psychosocial interventions in psychosis. Data regards the necessary features of Smartphone-based apps for will be presented.

Results: Participants interviewed ranged between 16-34 years in age. Based on qualitative interviews with service users, there was an overarching view that smartphone technology is an acceptable and relevant way for service users to manage their mental health problems. Service users used technology for a variety of reasons, including help-seeking and gathering information regards their mental health problem. Participants felt that apps could overcome many of the barriers to traditional service set-up and was an easy point of access with high ecological validity, extending the reach of service delivery and circumventing waiting times. There were many important features considered necessary to app design and development, including language, the ability to personalise the app and to maximise the functionality of the app. Empowerment, control and choice and the de-stigmatising nature of apps also reinforced their importance.

Discussion: The presenter will compare and contrast service user vs clinician views and attitudes about app-based interventions and will conclude by presenting the key factors necessary first episode psychosis service users consider to be important when designing and implementing apps in early psychosis.

T273. Quality of life assessment in schizophrenia diagnosed patients with predominant negative symptoms
Daniel VIStLE*, 1, Octavian VasilIU1, Diana Gabriela VasilIU1, Florin VasiLE1
1University Emergency Military Central Hospital Bucharest

Background: Negative symptoms have a significant impact over the schizophrenia diagnosed patients overall functionality, including work performance, social interactions, self-care, academic achievements etc. Assessing the impact of the negative symptoms over the patients everyday life activities from the psychiatrists point of view, integrating caregivers opinion and the patients own perspective, could be an useful process in order to establish reintegration programs and making therapeutic decisions.

Methods: This is an observational, open-label trial, consisting in a group of 34 patients, 22 male and 12 female, diagnosed with schizophrenia (according to DSM 5 criteria), that presented predominant negative symptoms, as defined by a Positive and Negative Syndrome Scale (PANSS) Negative Subscale score higher than 25 and a PANSS Positive Subscale of maximum 20, were evaluated longitudinally for 24 weeks, using PANSS, Scale for Assessment of Negative Symptoms (SANS), Quality of Life Inventory (QoLI), Clinical Global Impression- Severity (CGI-S), Global Assessment of Functioning (GAF), Visual Analogic Scale (VAS) scored 1 to 10 for the caregiver’s perception of the patient’s overall improvement. All the psychometric scales were applied every 4 weeks. Patients included in this trial maintained their initial treatment (atypical antipsychotics- olanzapine n = 16, ziprasidone n = 8, aripiprazole n = 6, quetiapine n = 4) during 24 weeks, except for cases of psychotic decompensations, when hospitalisation and antipsychotic switch/augmentation was considered appropriate. All patients that developed acute psychotic episodes and necessitated antipsychotic changes had been eliminated from statistical processing.

Results: After 24 weeks, data from 24 patients were processed. Scales for negative psychotic symptoms recorded minor variations compared to baseline (SANS -8.9+/1.2, and PANSS- Negative Subscale -3.6+/0.9), demonstrating a high stability in time. No differences between patients’ evolution on PANSS-Negative Subscale or SANS were detected depending on the antipsychotic used. CGI-S and GAF registered variations of 1.2+/0.3, and 7.7+/1.7, respectively. QoLI evaluations detected a worsening in several dimensions: “satisfaction with social relations” (-10.5%), “satisfaction with mental and physical health” (-7.7%) and “satisfaction with life in general” (-5.2%). On VAS, the caregivers reported more frequent a deterioration of the global clinical status (58.4% versus 41.6%) of minimal (-1 to -3 points, n = 8) or moderate (-3 to -5 points, n = 6) severity.

Discussion: Evaluation of the quality of life in patients with schizophrenia and predominant negative symptoms is important because it could not be inferred from other clinical scales for psychotic symptoms, like PANSS or SANS, and neither from global functioning scales like GAF. This could be a reflection of the fact that small scale variations on clinical scales for psychosis have a high resonance both at the patient’s perception of his/her life quality, and at the caregiver’s perception of the patient’s overall functioning. This could be the base for establishing psychotherapy programs focused on enhancing the patients’ sense of self-efficacy through social reintegration and working skill training.

T274. Assessing the relevance of the subjective well-being under neuroleptics–short form in schizophrenia: patient and caregiver perspectives
Dieter Naber*, 1, Maud Beillat2, Dana B. DiBenedetti3, T. Michelle Brown3
1University Medical Center Hamburg-Eppendorf, 2Lundbeck SAS, 3RTI Health Solutions

Background: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable (LAI) antipsychotic treatment for adults with schizophrenia. In a recent 28-week, head-to-head clinical trial (the QUALIFY study) against paliperidone palmitate, patients taking AOM 400 showed superior improvements of health-related quality of life (HRQOL) and functioning (Naber et al., 2015). One of the study’s
T275. Measuring well-being in chronic schizophrenia: the significance of positive symptoms

Julia Brown¹, Gisela Mezquida², Emilio Fernandez-Egea³
¹Australian National University; ²Hosp. Clinic Barcel/Institut Clinic Neuro; ³University of Cambridge

Background: Well-being perception differs from quality of life concepts and has been less explored in schizophrenia patients. A recurrent limitation is the reduced number of tools available for assessing well-being in this population group. This cross-sectional study sought to compare subjective well-being scores in a group of chronic schizophrenia patients (N = 142) receiving clozapine treatment with those of a general population sample using a new scale, and to explore which clinically recognised factors may predict subjective well-being amongst chronic schizophrenia patients.

Methods: The Short Warwick-Edinburgh Mental Well-Being Scale (SWEMWBS) was used to measure well-being. We compared subjective well-being distribution between patients and general population using a t test, and then correlated SWEMWBS scores and 27 clinically recognised factors, spanning socio-demographics, symptom severity scores, physical health diagnosis, clozapine side effects, habits and prescribed medication. Factors with a P < 0.2 correlation were then included as a predictors in a linear regression model.

Results: Patients were found to have a significantly lower mean SWEMWBS score compared to that of the general population distribution (P < 0.0001). Ten factors were included in the linear regression model, however only positive symptom severity was a significant predictor of SWEMWBS score (P < 0.003).

Discussion: These results suggest that the SWEMWBS is an efficient tool for assessing subjective well-being in schizophrenia patients. This study also suggests that greater levels of clinical attention given to positive symptoms compared with other symptoms and aspects of well-being, during biomedical treatment for chronic schizophrenia, may partially explain the finding that only positive symptoms significantly predicted patient perceptions of low well-being in this study.

T276. Does functioning and life satisfaction differ for schizophrenia patients with co-morbid depression?

Eric Tan¹, Susan Rossell²
¹Swinburne University

Background: The negative relationship between depression and ratings of life satisfaction in schizophrenia is well established. However, the relation between depression and objective functioning in the disorder is still relatively unclear. There is evidence for this relationship in other disorders (e.g., cancer, OCD). The inherent differences between individual measures of functioning (e.g., social relationships and physical health) and their consolidation into composite objective quality of life (QoL) scores have further complicated the issue. This study sought to examine the differences in objective QoL between schizophrenia patients with (DP) and without (NDP) co-morbid depression. This was done separately for 5 subjective (e.g., functional activities and functioning (DAF), frequency of family relations (FAM) and social relations (SOCREL), safety (SAF) and health state (HEALTH). Life satisfaction ratings (subjective QoL) for these domains were also compared. We hypothesized that both objective and subjective QoL in depressed schizophrenia patients would be lower than NDP.

Methods: 57 patients with schizophrenia/schizoaffective disorder were recruited and administered the MADRS. MADRS scores were used to distinguish 31 patients with current clinical depression (M = 45.81, SD = 10.29) and 26 without (M = 40.54, SD = 11.00). Objective and subjective QoL was assessed using Lehman’s (1988) QoL Interview (QoLI) with the PANSS for current symptomatology. z-scores were created for each domain (objective and subjective) based on the responses of 44 healthy control participants (M = 39.80, SD = 13.94).

Results: Objectively, there was a trend to poorer functioning for DP to NDP patients in only the SOCREL domain (P = .02, corrected for multiple comparisons). This contrasted with significantly reduced subjective life satisfaction between groups in the DAF (P = .01), SOCREL (P = .03 - trend) and HEALTH (P = .000) domains.

Discussion: Depressive symptoms do not appear to have a broad effect on daily functioning in schizophrenia, though there is some evidence they might influence interpersonal interaction. The broad impact of depression disproportionately reducing life satisfaction is supported. The overall findings reinforce the need to address depression in schizophrenia in terms of improving their subjective experiences. On a functional level, this may help improve interpersonal interaction and facilitate efficacious re-integration into the workplace and broader society.

T277. Association of knowledge and causal explanation of schizophrenia students’ attitude towards service users: a comparison between nursing and medical undergraduates

Lucia Sideli¹, Caterina La Cascia¹, Fabio Seminierio*, Valentina Barone¹, Crocettaarchele Sartorio¹, Roberta D’agostino¹, Alice Mule¹, Laura Ferraro¹, Giada Tripoli², Michel Inguglia³, Antonio Francomano¹, Daniele La Barbera¹, Marta Di Forti², Robin Murray²
¹University of Palermo; ²King's College London; ³ASP Palermo

Background: People with severe mental disorders are prone to face negative attitudes in general health care settings, with significant implications in terms of under-diagnosis and under-treatment of physical illnesses (Thorncroft et al., 2007). Although several authors argued that a better knowledge of the disease and its biological causes and mechanisms would have led to a more positive view of patients with schizophrenia and less social distancing, studies yielded mixed findings, particularly amongst medical doctors and students (Serafini et al., 2011; Magliano, 2013, 2014). The aim of this study is to study the association of knowledge and causal explanation of schizophrenia amongst nursing and medical students.
compare the attitudes towards service users expressed by nursing and medical students and to explore the relation between knowledge of schizophrenia, causal explanation, and participants’ and perceived social view of the disorder.

Methods: The study involved 59 medical students and 161 nursing students attending the third year of their BSc who have not attended yet a Psychiatry course. Socio-demographic information was collected using an ad-hoc questionnaire, participants’ view about people affected with schizophrenia was assessed using the Opinion on Mental Illness Questionnaire (OQ, Magliano, 2004, 2011), and perceived devaluation of service users by the community was assessed using the Devaluation Consumers Scale (Struening et al., 2001). Between groups differences and associations between categorical and continuous variables were tested using Student’s t test and ANCOVA. Nursing and medical students were similar in terms of self-reported ethnicity and education, but different in terms of gender distribution, age, and father social class; therefore, these variables were used as potential confounders.

Results: Medical students were more able to identify as schizophrenia a clinical vignette of a patients affected by delusions and hallucinations (36 [61.0%] vs. 36 [22.4%], chi sq 29.306, P < 0.001). Furthermore, a greater proportion of them chose biological causes (i.e. heredity, chemical imbalance, or obstetrical complications) as more frequent cause of schizophrenia (25 [43.4%] vs. 30 [18.6%], chi sq 12.978, P < 0.001). After adjusting for potential confounders, nursing students showed a more optimistic view on recovery from schizophrenia (F 11.922, P < 0.001), effectiveness of available treatments (F 48.187, P < 0.001), and community’s attitude towards patients affected by severe mental disorders (F 5.268, P 0.0223). Among nursing students, only those who correctly identified schizophrenia reported reduced confidence in recovery (F 9.225, P 0.003) and were more conscious about community’s devaluation of patients with schizophrenia. Moreover, in the same group, psychosocial explanation of schizophrenia (i.e. stress, family conflicts, or disillusionment in love) were associated to a more optimistic view towards social equality of service users, though this relation became non-significant after adjusting for confounders.

Discussion: Our preliminary findings show that medical students express higher level of stigma against schizophrenia and perceived greater community’s devaluations against service users. On the other hand, nursing students generally showed a more optimistic view about schizophrenia, which was particularly pronounced among those who shared a psychosocial explanation of the disease. This is partially consistent with the literature and underline the relevance of education intervention and stigma-reduction programs about health science students.

T278. An audit of clozapine use in first episode psychosis
Roisin Doyle1, Donal O’Keeffe1*, Caragh Behan1, Sarah Masterson1, Aine Kelly1, Ann Sheridan1, Dolores Keating1, Caroline Hynes2, Kevin Madigan1, Elizabeth Lawlor1, Mary Clarke1
1DETECT Early Intervention in Psychosis Service; 2Saint John of God Hospital, Minster, Kilkenny, Ireland; 3School of Nursing, Midwifery and Health Systems; 4Saint John of God Hospital Ltd, Dublin, Ireland

Background: Clozapine is a second generation antipsychotic medication consistently shown to be more efficacious in treatment-resistant schizophrenia (TRS). It is estimated that 30% of people with schizophrenia will not respond to standard therapeutic treatment. Along with reducing positive and negative symptoms, Clozapine has also been reported to reduce risk of suicide and reduce hospitalisation rates. Given demographic information was collected those with TRS. The UK National Institute for Health and Care Excellence (NICE) first published guidelines for the treatment of schizophrenia in 2002. It recommends using Clozapine for treatment resistant schizophrenia. The guidelines state that Clozapine should be offered after two adequate 4-6 week trials of different antipsychotics, of which one must be an atypical. However, adherence to these guidelines have been consistently poor in the US, Canada, New Zealand and Australia.

Methods: Ethics and audit committee approval was received. Data were collected from the paper and electronic records of people who originally presented with first episode psychosis between 1995 and 1999 (N = 166). Information was gathered from paper charts and electronic records (inpatient and outpatient). Data were collected from the time of first presentation up to the end of December 2013, or until the patient was discharged or transferred to another service. Information on service use and physical health was gathered using a data collection form designed specifically for this audit.

Results: A total of 28/166 participants were prescribed Clozapine. Of this Clozapine subsample 23/28 (82%) were male. The mean age at baseline was 23.11 years for the Clozapine subsample and 29.13 for the entire sample. The most prevalent diagnosis of the cohort prescribed Clozapine was schizophrenia (82%). The mean time to first trial of clozapine was 6.7 years. The mean number of hospital admissions reduced from 6.04 per year to 0.88 per year, following the initiation of Clozapine. 11 participants (46%) had their Clozapine prescription augmented with another medication, including mood stabilisers and typical and atypical antipsychotics. 87.5% of patients had side effects as a result of Clozapine initiation. The mean number of anti-psychotics prescribed before a Clozapine trial was 4.85.

Discussion: Nearly one in five of the original cohort was considered to have asuboptimal response to trials of antipsychotic medication. Similarly to other studies we found that barriers to treatment with Clozapine exist. Clozapine for treatment resistant schizophrenia is underutilised and better understanding of this is necessary given the implications for patient’s quality of life and hospital admission rates.
T280. Five-year outcomes of FEP patients receiving integrated vs. functional mental health care. A pilot study from the PICOS

Francesco Gardellin², Mirella Ruggeri¹, Sarah Tosato¹, Chiara Bonetto¹, Gioia Zanatta¹, Silvia Zoppi¹, Sara Petterlini¹, Carla Comacchio¹, Giorgia Dimitri¹, Dario Lamonaca², Francesco Gardellin², Mirella Ruggeri¹
¹University of Verona; ²NHS Local Health Authority

Discussion: No consensus currently exists on whether mental health care should be provided through ‘functional’ (i.e., transition of patients between different psychiatric services is coordinated through a network of regulated referrals) or ‘integrated’ (the same mental health staff delivers to patients all the different interventions across in-patient and out-patient settings) systems. This study aimed to compare, in a sample of first episode psychosis (FEP) patients, integrated and functional mental health care systems with regard to a range of subjective, clinical and social outcomes at 1-, 2- and 5 years from illness onset.

Methods: This study was conducted in the context of the Psychosis Incident Cohort Outcome Study (PICOS), a multisite naturalistic research on FEP patients treated within the public psychiatric sector in the Veneto Region (Italy). Assessment was performed using a comprehensive set of standardized measures. Patients were recruited from 23 public community mental health services, which were retrospectively stratified as having provided functional or integrated care according to the definitions operationalized in the COFI (COMparing policy framework, structure, effectiveness and cost-effectiveness of Functional and Integrated systems of mental health care), a EU funded multisite research comparing functional (i.e., care is provided by different clinicians/teams in in-patient and out-patient services) and integrated (i.e., care is provided by the same responsible clinician across in-patient and out-patient services) systems across five European countries.

Results: A total of 397 FEP patients were assessed at baseline. Preliminary analysis revealed that patients treated within integrated systems had more engagement with services over time than those treated by functional ones (respectively, 100% vs. 86% at 2 years; 90% vs. 69% at 5 years). Regression analyses showed that receiving continuity of care helped in reducing the level of needs in different domains of the Camberwell Assessment of Needs (CAN) at each follow-up point and, in particular, had a significant effect in reducing the level of unmet health needs at 2 years, also after having controlled for baseline differences between groups.

Discussion: This study provides some initial empirical findings on which kind of mental health care system (functional vs. integrated) may be most beneficial for patients experiencing their first episode of psychosis. Our results indicate that integrated care is more effective in reducing patients’ levels of needs, especially needs relative to the health domain. In recent years the concept of needs for care has been proposed as a new paradigm in both planning mental health service interventions and assessing the outcome of care provided. Integrated model seems to be the most adequate service configuration to specifically address this important subjective outcome. Additional variables should be selected in future studies to detect possible differences between integrated vs. functional systems on FEP patients.

T281. Free associations as both a verbal and nonverbal phenomenon in dance/movement therapy - a case study with patients diagnosed with schizophrenia and varying degrees of related forms of psychiatric diagnoses.

Karolina Bryl¹
¹Drexel University

Background: The purpose of this paper is to explore the connection between the psychoanalytical idea and method of free associations and their kinesthetic analogues in self-expression through dance and movement, as they appear in Dance Movement Therapy (DMT) processes. The paper provides a brief theoretical review of the psychoanalytic concept of free association represented in the Christopher Bolas (2002) book “Free Association,” and a case study that analyzes a single DMT session with patients diagnosed with schizophrenia and varying degrees of related forms of psychiatric diagnoses, to demonstrate how free associations can reveal one’s unconscious and inner world through movement and within DMT sessions. The application of free association and its’ relevance to the dance movement therapy will also be demonstrated.

Methods: This case study analyzes a single session of Dance Movement Therapy (DMT) with patients diagnosed with mental disorders, especially those on the schizophrenia spectrum. Participants: 40 patients (ages 18 to 56) diagnosed with mental disorders, recovering from active psychosis into more residual stages of disability, attending Daily Psychiatric Rehabilitation Unit in one of the hospitals in Poland.

Free Association - a technique used in psychoanalysis, psychoanalytic and psychodynamic approaches to therapy - was used to analyze DMT session.

Results: - Interpreting the free associations of both the group members’ verbal and nonverbal expression allowed therapist to deepen understanding of group dynamics. Movement reflects internal processes and shed light on relational processes. - DMTs note transient body rhythms, changes in muscular tensions, and the varying shapes, postures, or body attitude that they see in their patients. They also work from the premise that movement helps to release creativity. Together, these observations show that DMTs, whether they are aware of it, or not, support free associating. Therefore, one may conclude that moving and talking freely can yield information about one’s emotional state, ability to express oneself, regulate, and identify shifts in internal self-organization.

Movement and talking freely can yield information about one’s emotional state, ability to express oneself, regulate, and identify shifts in internal self-organization. Discussion: As described in the vignette portraying a conflict between group members and dance/movement therapist, one can see that in DMT, movement serves as a relational process. Free association technique has been used as a way to encourage patients to talk freely about what was on their minds, moving from one object to another, not following any plan or hidden agenda, and later unpacking unconscious meaning, revealed and helped to explain individual and group dynamics. This was unheard not only in words, but also in movement and gesture. Patients related, unconsciously, to what was going on within them, and in their life stories - the fundamental need for secure attachments. Clients and therapists engaged in empathetic creative process using body movement and dance to assist integration of emotional, cognitive, physical, social and spiritual aspects of self (Meekums, 2002). By intentionally incorporating free associations into DMT practice, one can reveal the hidden logic of the unconscious, express deeper layers of own being, disclose mental content that has been forbidden. Such findings, for both therapist and client, including patients in psychiatric, care can result in becoming more aware of one’s own nonverbal and verbal expressions, thoughts, feelings, internal images and sensations, and, with time and increased exposure to free association, result in initiation of personal and interpersonal change.

T282. The Moray Psychosis Survey: prevalence, demographics and treatment characteristics in a rural cohort of patients diagnosed with schizophrenia

Angus MacBeth¹, Hannah Greaves²
¹University of Edinburgh; ²NHS Grampian

Abstract: There is a paucity of contemporary data on prevalence, demographics and treatment characteristics of psychotic disorders in rural areas. We identified a cohort of individuals with a lifetime diagnosis of schizophrenia on the caseload of mental health teams in rural North Scotland. We sought to estimate prevalence and to measure demographic and treatment characteristics across the natural course of the disorder.

Methods: This study used a computerized database to extract casenote data (n = 139). Demographic variables measured included employment, housing and age at onset, Treatment characteristics including admission at onset, medication changes and access to psychological therapies were also measured. Data were extracted for selected time points up to 15 years.
Results: We identified \( n = 139 \) cases. The prevalence rate for a schizophrenia diagnosis within the working age population was 2.48 cases per 1000. The gender ratio was 60.40 (M:F). The average age of onset was 28.98 years (Range = 14-54). With regard to treatment, 67% of cases were admitted to hospital at onset. The average number of medication changes was 11 (Range = 0-44). For psychological therapy 33% were offered psychological input, and 12% of the sample were offered CBT. With regard to recovery rates it was found that 15% \((n = 21)\) were employed, 1% \((n = 2)\) were in education or training and the remaining 84% of the sample were unemployed. For symptomatic recovery 33% \((n = 46)\) were in full recovery, 25% \((n = 35)\) were in partial recovery, 1% were in relapse at point of audit and 39% \((n = 55)\) presented with chronic symptoms of schizophrenia. Full symptomatic recovery was associated with being employment or training (\(Chi^2 = 17.7, P = .0001\)).

Discussion: This case-note study provides an overview of patient characteristics and treatment of schizophrenia in rural Scotland. Our data are comparable with urban datasets and can also be compared with rural Schizophrenia surveys conducted in Scotland in the early 1980’s. Findings can inform the treatment pathway for individuals with schizophrenia living in rural areas our data also highlight the need to develop interventions focused on both symptomatic and functional recovery, including employment and training pathways.

T283. Meta-analysis of oxytocin in schizophrenia: effects on social cognition
Angus MacBeth\(^*\), Andrew Gumbley\(^2\)
\(1^\)University of Edinburgh; \(2^\)University of Glasgow

Background: There is considerable evidence that affiliative and social cognitive processes are linked to oxytocin (OXT). There is evidence that oxytocergic systems are involved in psychosis and emerging evidence that synthetic OXT may represent a novel treatment paradigm. Meta-analytic findings for the relationship of OXT to symptom reduction are mixed. However, the literature on the effects of OXT on social cognition and emotion recognition has yielded promising results in non-clinical samples and where OXT has been used to enhance psychological interventions. As treatment trials of OXT in human clinical samples increase, we conducted a meta-analysis to estimate an effect size for OXT treatment on social cognition and emotional recognition.

Methods: Published trials of OXT vs. Placebo in schizophrenia were identified. Participants had a diagnosis of Schizophrenia or psychosis and the outcome variables explored the effects of OXT in relation to social cognition and emotional recognition. Effect sizes for OXT on were converted to Hedge’s ‘g’. Meta-analyses were conducted with both fixed and random effects meta-analyses, incorporating assessment of heterogeneity, publication bias and influence bias.

Results: OXT administration versus placebo was associated with a moderate effect on improved emotion recognition \(SMD = -0.36; 95\% CI = -0.80 to 0.08, P = 0.03\), a minimal non-significant effect on trust \(SMD = -0.17; 95\% CI = -0.57 to 0.22, P = 0.47\); a moderate non-significant effect on empathy \(SMD = 0.27; 95\% CI = -0.80 to 0.26; P = 0.98\); and a minimal non-significant effect on trust \(SMD = -0.17; 95\% CI = 0.53 to 0.20; P = 0.49\). Heterogeneity indicated substantial methodological variation in the studies that were analyzed.

Discussion: Preliminary evidence suggests there is currently limited evidence to support the effectiveness of OXT administration on improving social and emotional cognition in schizophrenia. Effect sizes are mainly small in magnitude and non-significant. Results suggest there may be promise in closer examination of the effects of OXT on emotion recognition. However, results are compromised by heterogeneity in study methodologies and the lack of standardized batteries for measuring social and emotional cognition.
Sample: Inclusion criteria: patients between 16-55 year-old, who were admitted in the Psychiatric acute ward of Parc Sanitari Sant Joan de Déu. First episode psychosis, drug-naïve patients. A total of 32 patients were included in the study.

- Instruments: Prolactine serum levels were obtained before starting antipsychotic treatment, within first 24 hours of hospitalisation. Catatonia was assessed by means of the Bush Francis Catatonia Rating Scale (BFCRS), during first days of hospitalisation. Duration of Untreated Psychosis was also obtained.

- Results: We did not find correlation between catatonia and prolactin serum levels. We did not find either association between catatonia and DUP. Nevertheless, we are still including patients in our sample, hence these are preliminary results. In addition, some more additional analysis will be done.

**T286. Preliminary results of the effectiveness of the MCT group in people with psychosis in rehabilitation services**

Mar García-Franco1, Gemma Prat2, Sonia Vilamala-Anton3,1, María José Escandell-Morcillo1, José Ramón Martín-Martínez1, Ingrid Tortade-Arumi1, J. Gonzalez2, R. Monreal2, Susana Ochoa3

1Parc Sanitari Sant Joan de Déu; 2Fundació Althaia; 3Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat

**Background:** The psychotic spectrum disorders course with a common feature, the presence schizophrenic-like positive symptoms. Usually, cognitive biases such as jumping to conclusions, self-service bias or close pressure, are underlying positive symptoms and, it is know that difficult the community functioning of people that show them (Garety et al, 2005; Moritz & Woodward, 2006). Metacognition training is a group standardized treatment addressed to treat specifically cognitive biases in people with positive psychotic symptoms. This tool was created by Moritz & Woodward (2007), and studies had been described to positive results compared with other cognitive programs to reduce cognitive bias or that usual treatments to reduce positive psychotic symptomatology (Moritz et al, 2011).

**Methods:** A crossed clinical trial randomized controlled with a Rehabilitation Treatment as Usual. A total of 21 persons between 18-60 years old, with diagnosis included in the spectrum psychotic disorders, with a score > 3 in the PANSS delusion, grandiosity or suspiciousness subscale and < 5 in the subscale of Hostility of the PANSS in the last year and, without any factor that affect cognition were included in the study. All participants signed an informed consent. After, they were aleatorized to control (CG) or experimental (EG) group. The intervention (module A with 8 sessions) was first done in the EG while the CG received treatment as usual in the rehabilitation services. Evaluation was done in the baseline and post-treatment (after the module A). All participants were evaluated in all assessment moments with the following instruments:

- Beck Cognitive Insight Scale (Beck et al, 2004)
- Beck Self-esteem Scale
- Beck Cognitive Insight Scale (Beck et al, 2004)

**Comparisons between groups (EG or CG) were done by the difference of means of the Student t-test implemented in the SPSS/PC (version 22).**

**Results:** A total of 21 people with psychosis were included, 8 (38.1%) women and 13 (61.9%) men. Mean age of 48 years old (SD = 10.38). Only 15 subjects completed two assessments of the study. No differences were found in the BCS [EG:-.71+/-.35; CG:1.6+/-.79]; Rosenberg self-esteem questionnaire [EG:1.33+/-.40; CG:6.5+/-.54]; total scores and in the subscales of BCS, self-certainty [EG:57+/-.37; CG:14+/-.41] and self-reflectionness [EG: 7.5+/-.5.2; CG:6.0+/-.4.3] and in the two subscales of the IPSAQ, externalized bias [EG:1.0+/-.7.3; CG:-.57+/-.5.0], personalized bias [EG:1.8+/-.1.8; CG:-1.1+/-.0] between two groups.

**Discussion:** Our preliminary results showed that the two groups did not differ in psychotic positive symptomatology and in levels of self-esteem after the completion of the module A of the metacognition programme. These are preliminary results; however these are not into agreement with other studies. Nevertheless, this is the first time that this programme was implemented in persons that received rehabilitation treatment, and our results are done in a preliminary sample. It is possible that in this case, both modules (A and B) should be carried out to find improvement in positive psychotic symptoms and metacognitive variables.

**T287. Risk of psychosis and internal migration: results from the BOLOGNA first episode psychosis study**

Ilaria Tarricone1, Jane Boydell2, Armosa Kokona3, Federico Triolo4, Lisa Gamberrini1, Enrico Sutti1, Michela Marchetta1, Marco Menchetti1, Marta Di Forti4, Robin Murray5, Craig Morgan5, Domencio Berardi6

1Bologna University; 2Institute of Psychiatry, Psychology & Neuroscience, King’s College London

**Background:** Incidence of psychotic disorders is higher in many migrant groups; however little is known about internal migrants (IM). This study aims to describe the IR in natives (NA), IM and external migrants (EM) in Bologna, North Italy

**Methods:** All patients aged 18-64 years, with First Episode Psychosis (FEP), who made contact with the Bologna West Psychiatric services, between 2002 and 2010, were included.

**Results:** 187 cases were included. Age and sex adjusted IR of psychosis per 100.000 per year were: 12.6 for NA, 25.3 for IM and 21.4 for EM. The IR was 1.93 (1.19-3.13; P = 0.007) for IM and 1.79 (1.06-3.02, P = 0.03) for EM compared to NA.

**Discussion:** Rates of psychosis were significantly elevated in IM as well as in EM. This result adds evidence as to the role of migration itself (versus ethnicity) on the risk of psychosis.

**T288. Anthropometric values in naïve first episode of non affective psychosis: the role of weight at birth**

Clemente Garcia-Rizo1, Cristina Oliveira1, Brian Kirkpatrick2, Miguel Bernardo Arroyo3, Fernandez-Egea Emilio4

1Barcelona Clinic Schizophrenia Unit, Neurosciences Institute, Hospital Clinic of Barcelona, CIBERSAM, IDIBAPS; 2Barcelona Clinical Schizophrenia Unit; 3University of Nevada; 4Barcelona Clinic Schizophrenia Unit (BCSU), Neurosciences Institute, Hospital Clinic of Barcelona, University of Barcelona, CIBERSAM, IDIBAPS; 5University of Cambridge

**Background:** Patients with schizophrenia exhibit a reduced life expectancy mainly due to medical-related pathologies, such as cardiovascular diseases or type 2 diabetes mellitus. Actual body of knowledge supports that those medical conditions might have been initiated due to stressful events during fetal development. Indeed intra-uterus growth patterns do predict anthropometric measures in adulthood, which have been described as risk factors for schizophrenia and metabolic side effects. We aim to evaluate anthropometric values in a cohort of naïve patients with non affective psychosis and correlated them with a surrogate marker of the fetal environment such as weight at birth.

**Methods:** Weight at birth and anthropometric values from 61 naïve patients with a first episode of non affective psychosis and 87 matched controls by age and gender were evaluated.

**Results:** Patients show a decreased weight at birth, weight and body mass index at onset compared with controls while no differences were found in height. In a regression model, height was significantly associated with weight at birth, gender, diagnosis and the interaction of weight at birth by diagnosis; weight with age and weight at birth while body mass index with age. Weight at birth positively correlates with height in patients. Significant differences applied to gender.
Discussion: Our results support a systemic disease concept, confirming body differences (anthropometric) values at the onset while highlighting the role of a fetal environment marker, weight at birth, as a predictor of baseline characteristics implied in future metabolic risk factors.

T289. Metabolic syndrome or glucose abnormalities in first episode of psychosis?
Clemente Garcia-Rizo*1, Emilio Fernandez-Egea2, Cristina Oliveira3, Ana Meseguer4, Bibiana Cabrera4, Gisela Mezquida3, Miquel Bioque4, Rafael Penades5, Eduard Parellada5, Miguel Bernardo Arroyo5, Brian Kirkpatrick6

1Barcelona Clinic Schizophrenia Unit, Neurosciences Institute, Hospital Clinic of Barcelona, CIBERSAM, IDIBAPS; 2University of Cambridge; Cambridgeshire and Peterborough NHS Foundation Trust; 3Barcelona Clinic Schizophrenia Unit; 4Barcelona Clinic Schizophrenia Unit, Neurosciences Institute, Hospital Clinic of Barcelona, CIBERSAM; 5Barcelona Clinic Schizophrenia Unit, Neurosciences Institute, Hospital Clinic of Barcelona, University of Barcelona, CIBERSAM, IDIBAPS; 6University of Nevada School of Medicine

Background: Patients with schizophrenia exhibit a reduced life expectancy mainly due to diverse medical conditions such as cardiovascular diseases, type 2 diabetes mellitus and metabolic syndrome. Besides pharmacological secondary side-effects and unhealthy lifestyle, studies in naïve patients reflect diverse abnormalities at the onset. Although patients with a first episode of psychosis display a wide scope of metabolic abnormalities, ranging from normality till pathological values depending on the parameters studied, metabolic syndrome is the regular evaluation investigated and might not display the biochemical complexity underlying patients.

Methods: We evaluate the metabolic syndrome and glycemic homeostasis in a subset of 84 naïve patients with a first episode of non-affective psychosis. Patients and matched controls underwent an oral glucose tolerance test after an overnight fast.

Results: Patients showed a similar metabolic syndrome prevalence compared with a matched control sample (6% vs 4% P = 0.562) while glucose homeostasis values differed significantly (14% vs 5% P = 0.034).

Discussion: Our results suggest that metabolic syndrome is not a useful marker in patients before pharmacological treatment as glucose abnormalities are not detected. Abnormal glycemic homeostasis at the onset of the disease requires specific preventive measures in order to avoid future cardiovascular events. New strategies must be implemented in order to evaluate the cardiovascular risk and subsequent morbidity in patients at the onset of the disease.

Acknowledgments
The publication of this supplement was funded by the Schizophrenia International Research Society.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/